bao_format,curated_by,assay_test_type,cell_id,src_id,assay_category,assay_tissue,assay_cell_type,tissue_id,chembl_id,variant_id,assay_id,description,assay_tax_id,tid,assay_subcellular_fraction,assay_organism,confidence_score,doc_id,assay_strain,src_assay_id,relationship_type,assay_type
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615117,,1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,12052,,,8,11087,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL615118,,2,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,22226,,,0,684,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615119,,3,,,22226,,,0,15453,,,U,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL615120,,4,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,9913.0,104729,,Bos taurus,4,17841,,,H,B
BAO_0000219,Intermediate,,163.0,1,,,143B,,CHEMBL615121,,5,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),9606.0,80001,,Homo sapiens,1,17430,,,N,F
BAO_0000219,Intermediate,,163.0,1,,,143B,,CHEMBL615122,,6,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),9606.0,80001,,Homo sapiens,1,17430,,,N,F
BAO_0000219,Intermediate,,163.0,1,,,143B,,CHEMBL615123,,7,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,10090.0,80001,,Mus musculus,1,13799,,,N,F
BAO_0000219,Expert,,163.0,1,,,143B,,CHEMBL615124,,8,In vitro cell cytotoxicity was determined against 143B cell line,9606.0,80001,,Homo sapiens,1,17774,,,N,F
BAO_0000219,Intermediate,,163.0,1,,,143B,,CHEMBL615125,,9,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,9606.0,80001,,Homo sapiens,1,3801,,,N,F
BAO_0000219,Intermediate,,163.0,1,,,143B,,CHEMBL615126,,10,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,9606.0,80001,,Homo sapiens,1,17430,,,N,F
BAO_0000219,Intermediate,,163.0,1,,,143B,,CHEMBL615127,,11,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,9606.0,80001,,Homo sapiens,1,17430,,,N,F
BAO_0000219,Expert,,163.0,1,,,143B,,CHEMBL615128,,12,In vitro cell cytotoxicity was determined against 143B-LTK cell line,9606.0,80001,,Homo sapiens,1,17774,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL857900,,13,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1280.0,50185,,Staphylococcus aureus,1,11324,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL615129,,14,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1280.0,50185,,Staphylococcus aureus,1,11324,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL615130,,15,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1280.0,50185,,Staphylococcus aureus,1,11324,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL615131,,16,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1280.0,50185,,Staphylococcus aureus,1,11324,,,N,F
BAO_0000357,Expert,,,1,,,,,CHEMBL884521,,17,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,10116.0,100122,,Rattus norvegicus,9,11347,,,D,A
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615132,,18,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,12054,,,8,16474,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615133,,19,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,12054,,,8,10091,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615134,,20,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,12054,,,8,16474,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615135,,21,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,12054,,,8,16474,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615136,,22,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,12054,,,8,16474,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615137,,23,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,12054,,,8,16474,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615138,,24,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,12054,,,8,16474,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL836324,,25,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,22226,,,0,14352,,,U,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615139,,26,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,9986.0,12054,,Oryctolagus cuniculus,8,5646,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615140,,27,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),9986.0,12054,,Oryctolagus cuniculus,8,5646,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL615141,,28,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,12426,,,8,10997,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615142,,29,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,3847.0,12054,,soya bean,8,6309,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615143,,30,Inhibitory activity against soybean 15-lipoxygenase was evaluated,3847.0,12054,,Glycine max,8,167,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615144,,31,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,3847.0,12054,,Glycine max,8,167,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872867,,32,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,3847.0,12054,,Glycine max,8,11087,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615145,,33,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,3847.0,12054,,Glycine max,8,11087,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615146,,34,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,3847.0,12054,,Glycine max,8,13622,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615147,,35,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,3847.0,12054,,Glycine max,8,13622,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615148,,36,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,10116.0,22226,,Rattus norvegicus,0,11347,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615149,,37,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,562.0,22226,,Escherichia coli,0,5926,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615150,,38,Dissociation constant with dimeric 16S rRNA RNA construct B,,22226,,,0,4567,,,U,B
BAO_0000225,Intermediate,,,1,,,,,CHEMBL615151,,39,Dissociation constant towards 16S rRNA construct A,,22222,,,3,3782,,,M,B
BAO_0000225,Intermediate,,,1,,,,,CHEMBL615152,,40,Dissociation constant towards 16S rRNA construct B,,22222,,,3,3782,,,M,B
BAO_0000225,Expert,,,1,,,,,CHEMBL615153,,41,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,562.0,100263,,Escherichia coli,3,4466,,,M,B
BAO_0000225,Expert,,,1,,,,,CHEMBL615154,,42,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,562.0,100263,,Escherichia coli,3,6592,,,M,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615155,,43,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,13053,,,8,898,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615156,,44,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,13053,,,8,898,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615157,,45,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,9606.0,20001,,Homo sapiens,8,13163,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615158,,46,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,9606.0,20001,,Homo sapiens,8,13163,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615159,,47,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",10116.0,12971,,Rattus norvegicus,9,10691,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615172,,48,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",10116.0,12971,,Rattus norvegicus,9,10691,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615173,,49,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",10116.0,12971,,Rattus norvegicus,9,10691,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615174,,50,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",10116.0,12971,,Rattus norvegicus,9,10691,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL884518,,51,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,13053,,,8,898,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615175,,52,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,11512,,,8,912,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615176,,53,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,11512,,,8,912,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615177,,54,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,11512,,,8,912,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL615178,,55,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,10116.0,104740,Membranes,Rattus norvegicus,5,15103,,,D,B
BAO_0000219,Intermediate,,506.0,1,,,1A9,,CHEMBL615179,,56,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,9606.0,80002,,Homo sapiens,1,5116,,,N,F
BAO_0000219,Autocuration,,,1,,,Oocytes,,CHEMBL615180,,57,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,10116.0,104835,,Rattus norvegicus,7,14578,,,D,F
BAO_0000219,Autocuration,,,1,,,Oocytes,,CHEMBL615181,,58,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,10116.0,104821,,Rattus norvegicus,7,14578,,,D,F
BAO_0000219,Autocuration,,,1,,,Oocytes,,CHEMBL615182,,59,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,10116.0,104848,,Rattus norvegicus,7,14578,,,D,F
BAO_0000219,Expert,,506.0,1,,,1A9,,CHEMBL615183,,60,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,9606.0,80002,,Homo sapiens,1,4787,,,N,F
BAO_0000219,Intermediate,,506.0,1,,,1A9,,CHEMBL615184,,61,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,9606.0,80002,,Homo sapiens,1,4787,,,N,F
BAO_0000219,Intermediate,,506.0,1,,,1A9,,CHEMBL615185,,62,Cytotoxic activity against human ovarian cancer (1A9) cell line,9606.0,80002,,Homo sapiens,1,3547,,,N,F
BAO_0000219,Intermediate,,506.0,1,,,1A9,,CHEMBL615186,,63,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,9606.0,80002,,Homo sapiens,1,3547,,,N,F
BAO_0000219,Intermediate,,506.0,1,,,1A9,,CHEMBL615187,,64,Effective dose of compound against replication of 1A9 cell line was evaluated,9606.0,80002,,Homo sapiens,1,6726,,,N,F
BAO_0000219,Expert,,506.0,1,,,1A9,,CHEMBL885343,,65,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,9606.0,80002,,Homo sapiens,1,3455,,,N,F
BAO_0000219,Intermediate,,506.0,1,,,1A9,,CHEMBL615188,,66,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),9606.0,80002,,Homo sapiens,1,5726,,,N,F
BAO_0000219,Intermediate,,506.0,1,,,1A9,,CHEMBL615189,,67,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,9606.0,80002,,Homo sapiens,1,5726,,,N,F
BAO_0000219,Intermediate,,506.0,1,,,1A9,,CHEMBL615190,,68,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,9606.0,80002,,Homo sapiens,1,5726,,,N,F
BAO_0000219,Intermediate,,506.0,1,,,1A9,,CHEMBL615191,,69,Inhibitory activity against Taxol resistant 1A9 cell lines,9606.0,80002,,Homo sapiens,1,3395,,,N,F
BAO_0000219,Expert,,506.0,1,,,1A9,,CHEMBL615192,,70,Cytotoxicity against human ovarian cancer (1A9) cell lines.,9606.0,80002,,Homo sapiens,1,3415,,,N,F
BAO_0000219,Expert,,506.0,1,,,1A9,,CHEMBL827083,,71,Percentage inhibition of human ovarian cancer (1A9) cell lines.,9606.0,80002,,Homo sapiens,1,3415,,,N,F
BAO_0000219,Expert,,506.0,1,,,1A9,,CHEMBL615193,,72,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,9606.0,80002,,Homo sapiens,1,17099,,,N,F
BAO_0000219,Intermediate,,506.0,1,,,1A9,,CHEMBL615194,,73,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,9606.0,80002,,Homo sapiens,1,17099,,,N,F
BAO_0000219,Intermediate,,506.0,1,,,1A9,,CHEMBL615195,,74,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,9606.0,80002,,Homo sapiens,1,17099,,,N,F
BAO_0000219,Intermediate,,506.0,1,,,1A9,,CHEMBL615196,,75,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,9606.0,80002,,Homo sapiens,1,17099,,,N,F
BAO_0000219,Intermediate,,503.0,1,,,Jurkat,,CHEMBL615197,,76,Inhibitory concentration against Jurkat cells,9606.0,81072,,Homo sapiens,1,17721,,,N,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL615198,,77,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,22226,,,0,1229,,,U,F
BAO_0000357,Expert,,,1,,,,,CHEMBL615199,,78,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,10116.0,100121,,Rattus norvegicus,9,11347,,,D,A
BAO_0000357,Expert,,,1,,,,,CHEMBL615200,,79,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,11231,,,8,17117,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615201,,80,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,11231,,,8,17117,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615202,,81,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,11231,,,8,17117,,,H,B
BAO_0000251,Autocuration,,,1,,,,,CHEMBL615203,,82,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",5476.0,11231,Microsomes,Candida albicans,8,11375,,,H,B
BAO_0000251,Autocuration,,,1,,,,,CHEMBL615204,,83,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",5476.0,11231,Microsomes,Candida albicans,8,11375,,,H,B
BAO_0000251,Autocuration,,,1,,,,,CHEMBL615205,,84,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",4932.0,11231,Microsomes,Saccharomyces cerevisiae,8,11375,,,H,B
BAO_0000251,Autocuration,,,1,,,,,CHEMBL615206,,85,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",4932.0,11231,Microsomes,Saccharomyces cerevisiae,8,11375,,,H,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615207,,86,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",9823.0,12083,Microsomes,Sus scrofa,8,11375,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL827084,,87,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",10116.0,11231,,Rattus norvegicus,8,791,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615208,,88,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",10116.0,11231,,Rattus norvegicus,8,791,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615209,,89,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",10116.0,11231,,Rattus norvegicus,8,791,,,H,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615210,,90,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",10116.0,12083,Microsomes,Rattus norvegicus,9,11375,,,D,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615211,,91,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",10116.0,12083,Microsomes,Rattus norvegicus,9,11375,,,D,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615212,,92,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",10116.0,12083,Microsomes,Rattus norvegicus,9,153,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615213,,93,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,11377,,,8,8269,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615273,,94,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,11377,,,8,8269,,,H,B
BAO_0000219,Expert,,726.0,1,,,HepG2,,CHEMBL615274,,95,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,9606.0,81020,,Homo sapiens,1,17653,,,N,F
BAO_0000219,Intermediate,,726.0,1,,,HepG2,,CHEMBL615275,,96,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,9606.0,81020,,Homo sapiens,1,14277,,,N,F
BAO_0000219,Intermediate,,726.0,1,,,HepG2,,CHEMBL615276,,97,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,9606.0,81020,,Homo sapiens,1,1717,,,N,F
BAO_0000219,Intermediate,,726.0,1,,,HepG2,,CHEMBL615277,,98,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,9606.0,81020,,Homo sapiens,1,14091,,,N,F
BAO_0000219,Intermediate,,726.0,1,,,HepG2,,CHEMBL615326,,99,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,9606.0,81020,,Homo sapiens,1,14091,,,N,F
BAO_0000218,Expert,,,1,,,,,CHEMBL883130,,100,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,10407.0,50606,,Hepatitis B virus,1,17653,,,N,F
BAO_0000219,Intermediate,,726.0,1,,,HepG2,,CHEMBL884519,,101,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,9606.0,81020,,Homo sapiens,1,13105,,,N,F
BAO_0000219,Intermediate,,726.0,1,,,HepG2,,CHEMBL615327,,102,Concentration required to inhibit 50% of 2.2.15 cell line,9606.0,81020,,Homo sapiens,1,1717,,,N,F
BAO_0000219,Intermediate,,726.0,1,,,HepG2,,CHEMBL615328,,103,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,9606.0,81020,,Homo sapiens,1,13105,,,N,A
BAO_0000218,Intermediate,,,1,,,2.2.15,,CHEMBL615329,,104,Cytotoxic activity of compound against uninfected 2.2.15 cells.,9606.0,50587,,Homo sapiens,1,13600,,,N,F
BAO_0000218,Intermediate,,,1,,,2.2.15,,CHEMBL615330,,105,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,9606.0,50587,,Homo sapiens,1,13467,,,N,F
BAO_0000218,Expert,,,1,,,2.2.15,,CHEMBL615331,,106,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",10407.0,50606,,Hepatitis B virus,1,17477,,,N,F
BAO_0000218,Intermediate,,,1,,,2.2.15,,CHEMBL615332,,107,In vitro anti-HBV activity in 2.2.15 cells,9606.0,50587,,Homo sapiens,1,1593,,,N,F
BAO_0000218,Intermediate,,,1,,,2.2.15,,CHEMBL615333,,108,In vitro anti-HBV activity in 2.2.15 cells; Not determined,9606.0,50587,,Homo sapiens,1,1593,,,N,F
BAO_0000218,Intermediate,,,1,,,2.2.15,,CHEMBL615334,,109,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,9606.0,50587,,Homo sapiens,1,15089,,,N,F
BAO_0000218,Intermediate,,,1,,,2.2.15,,CHEMBL615335,,110,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,9606.0,50587,,Homo sapiens,1,15089,,,N,F
BAO_0000218,Intermediate,,,1,,,2.2.15,,CHEMBL615336,,111,Cytotoxicity in 2.2.15 cells,9606.0,50587,,Homo sapiens,1,1593,,,N,F
BAO_0000218,Intermediate,,,1,,,2.2.15,,CHEMBL615337,,112,Cytotoxicity in 2.2.15 cells; Not determined,9606.0,50587,,Homo sapiens,1,1593,,,N,F
BAO_0000218,Intermediate,,,1,,,2.2.15,,CHEMBL615338,,113,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,9606.0,50587,,Homo sapiens,1,13600,,,N,F
BAO_0000218,Intermediate,,,1,,,2.2.15,,CHEMBL615339,,114,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,9606.0,50587,,Homo sapiens,1,13467,,,N,F
BAO_0000218,Intermediate,,,1,,,2.2.15,,CHEMBL615340,,115,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,9606.0,50587,,Homo sapiens,1,13467,,,N,F
BAO_0000219,Intermediate,,726.0,1,,,HepG2,,CHEMBL615341,,116,Antiviral activity against HBV was determined in 2.215 cell line,9606.0,81020,,Homo sapiens,1,14764,,,N,F
BAO_0000251,Autocuration,,,1,,,,,CHEMBL615342,,117,Inhibition of 20-HETE synthesis in human renal microsomes,9606.0,22226,Microsomes,Homo sapiens,0,6531,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615343,,118,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,22226,,,0,17322,,,U,B
BAO_0000219,Intermediate,,388.0,1,,,2008,,CHEMBL615344,,119,Inhibitory concentration against 2008 (ovarian) cells,9606.0,80612,,Homo sapiens,1,17072,,,N,F
BAO_0000219,Intermediate,,388.0,1,,,2008,,CHEMBL615345,,120,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,9606.0,80612,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,388.0,1,,,2008,,CHEMBL615346,,121,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),9606.0,80612,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,388.0,1,,,2008,,CHEMBL615347,,122,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,9606.0,80612,,Homo sapiens,1,17146,,,N,F
BAO_0000219,Intermediate,,388.0,1,,,2008,,CHEMBL615348,,123,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,9606.0,80612,,Homo sapiens,1,17146,,,N,F
BAO_0000219,Intermediate,,561.0,1,,,2008/R,,CHEMBL827085,,124,In vitro inhibition of 2008/R ovarian cancer cell line,9606.0,80613,,Homo sapiens,1,10797,,,N,F
BAO_0000219,Intermediate,,561.0,1,,,2008/R,,CHEMBL615349,,125,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,9606.0,80613,,Homo sapiens,1,10797,,,N,F
BAO_0000219,Intermediate,,389.0,1,,,2008/S,,CHEMBL615350,,126,In vitro inhibition of 2008/S ovarian cancer cell line,9606.0,80614,,Homo sapiens,1,10797,,,N,F
BAO_0000219,Intermediate,,389.0,1,,,2008/S,,CHEMBL615351,,127,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,9606.0,80614,,Homo sapiens,1,10797,,,N,F
BAO_0000220,Expert,,,1,,,,,CHEMBL615352,,128,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,9606.0,100256,,Homo sapiens,2,4823,,,S,B
BAO_0000220,Intermediate,,,1,,,,,CHEMBL615353,,129,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,9606.0,100256,,Homo sapiens,2,12912,,,S,B
BAO_0000220,Expert,,,1,,,,,CHEMBL615354,,130,Inhibition of chymotrypsin-like activity of 20S proteasome,,100256,,,2,2957,,,S,B
BAO_0000220,Expert,,,1,,,,,CHEMBL615355,,131,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,100256,,,2,2957,,,S,B
BAO_0000220,Intermediate,,,1,,,,,CHEMBL615356,,132,Inhibitory activity against 20S proteosome,,100256,,,2,3260,,,S,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615357,,133,Compound was tested for inhibitory activity against tryptase,9606.0,22226,,Homo sapiens,0,3451,,,U,B
BAO_0000219,Intermediate,,726.0,1,,,HepG2,,CHEMBL615358,,134,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,9606.0,81020,,Homo sapiens,1,13885,,,N,F
BAO_0000219,Intermediate,,726.0,1,,,HepG2,,CHEMBL827086,,135,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,9606.0,81020,,Homo sapiens,1,13885,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615359,,136,Compound was tested for the inhibition of Alpha-glucosidase,,22226,,,0,3676,,,U,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615360,,137,Inhibitory concentration against human neutrophil elastase (HNE),,235,,,8,6043,,,H,B
BAO_0000218,Autocuration,,,1,,Heart,,948.0,CHEMBL615361,,138,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,10116.0,22226,,Rattus norvegicus,0,11140,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615362,,139,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,19640,,,8,10543,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615363,,140,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,19640,,,8,10543,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615364,,141,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,19640,,,8,10543,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615365,,142,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,19640,,,8,10543,,,H,F
BAO_0000219,Intermediate,,524.0,1,,,P338,,CHEMBL615366,,143,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,10090.0,80360,,Mus musculus,1,11365,,,N,F
BAO_0000219,Intermediate,,524.0,1,,,P338,,CHEMBL615367,,144,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,10090.0,80360,,Mus musculus,1,11365,,,N,F
BAO_0000219,Intermediate,,554.0,1,,,PBL,,CHEMBL615368,,145,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,9606.0,80384,,Homo sapiens,1,11803,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615369,,146,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,9940.0,22226,,Ovis aries,0,11803,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615370,,147,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,9940.0,22226,,Ovis aries,0,11803,,,U,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615673,,148,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,191,,,8,12278,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615674,,149,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,9606.0,22226,,Homo sapiens,0,8249,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615675,,150,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,9606.0,22226,,Homo sapiens,0,8249,,,U,F
BAO_0000219,Autocuration,,635.0,1,,,CCRF-CEM,,CHEMBL615676,,151,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,9606.0,22226,,Homo sapiens,0,8249,,,U,F
BAO_0000219,Autocuration,,635.0,1,,,CCRF-CEM,,CHEMBL615677,,152,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,9606.0,22226,,Homo sapiens,0,8249,,,U,F
BAO_0000219,Autocuration,,635.0,1,,,CCRF-CEM,,CHEMBL615678,,153,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,9606.0,22226,,Homo sapiens,0,8249,,,U,F
BAO_0000219,Autocuration,,635.0,1,,,CCRF-CEM,,CHEMBL615679,,154,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,9606.0,22226,,Homo sapiens,0,8249,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615680,,155,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,9606.0,22226,,Homo sapiens,0,8249,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615681,,156,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,9606.0,22226,,Homo sapiens,0,8249,,,U,F
BAO_0000249,Autocuration,,,1,,,,,CHEMBL857972,,157,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,104290,,,6,16992,,,H,B
BAO_0000218,Intermediate,,,1,,,,,CHEMBL857899,,158,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,1314.0,50264,,Streptococcus pyogenes,1,10543,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL615371,,159,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),10335.0,50527,,Human herpesvirus 3,1,17833,,,N,F
BAO_0000218,Expert,,468.0,1,,,HEL,,CHEMBL615372,,160,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,10335.0,50527,,vericilla zoster virus,1,17290,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL615373,,161,Antiviral activity against 07/1 strain of VZV; ND: No data,10335.0,50527,,vericilla zoster virus,1,17290,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL615374,,162,Antiviral activity against 07/1 strain of VZV; ND=No data,10335.0,50527,,vericilla zoster virus,1,17290,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL615375,,163,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",561.0,50145,,escherichia cloac,1,10932,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615376,,164,Ratio of Ki at A2 to Ki at A1 receptors,,22226,,,0,9707,,,U,B
BAO_0000249,Expert,,,1,,,,,CHEMBL615377,,165,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",5476.0,11143,,Candida albicans,8,2346,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615378,,166,"Inhibition of 1,3-beta-glucan synthase",284593.0,18077,,Candida glabrata CBS 138,8,2205,,,H,B
BAO_0000219,Intermediate,,832.0,1,,,1-87 tumor cell line,,CHEMBL615379,,167,Inhibition of growth of 1-87 human tumor cell line,9606.0,80609,,Homo sapiens,1,11900,,,N,F
BAO_0000219,Expert,,,1,,,,,CHEMBL615380,,168,Inhibition of 1-lipoxygenase (LOX)in RBL cells,10116.0,12166,,Rattus norvegicus,9,14864,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615381,,169,Inhibitory activity against soybean 1-lipoxygenase (SLO),3847.0,100171,,Glycine max,9,16474,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615382,,170,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,3847.0,100171,,Glycine max,9,16474,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615383,,171,% inhibition against soybean 1-lipoxygenase (SLO),3847.0,100171,,Glycine max,9,16474,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615384,,172,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,3847.0,100171,,Glycine max,9,16474,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615385,,173,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,3847.0,100171,,Glycine max,9,3094,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615386,,174,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,3847.0,100171,,Glycine max,9,3094,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615387,,175,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,3847.0,100171,,Glycine max,9,3094,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615388,,176,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,3847.0,100171,,Glycine max,9,3094,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615214,,177,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,3847.0,100171,,Glycine max,9,3094,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL827087,,178,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,3847.0,100171,,Glycine max,9,3094,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615215,,179,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,3847.0,100171,,Glycine max,9,3094,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615216,,180,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,3847.0,100171,,Glycine max,9,3094,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615217,,181,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,3847.0,100171,,Glycine max,9,3094,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615218,,182,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,3847.0,100171,,Glycine max,9,3094,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615219,,183,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,3847.0,100171,,Glycine max,9,3094,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615220,,184,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,10090.0,22226,,Mus musculus,0,10413,,,U,B
BAO_0000219,Intermediate,,294.0,1,,,C3H 10T1/2,,CHEMBL615221,,185,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),10090.0,80049,,Mus musculus,1,16929,,,N,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL615222,,186,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,22226,,,0,1229,,,U,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615223,,187,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,11489,,,8,16587,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615224,,188,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,11862,,,8,16587,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615225,,189,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,11862,,,8,16587,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615226,,190,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,11489,,,8,16587,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615227,,191,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,11862,,,8,16587,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615228,,192,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,9913.0,12347,,Bos taurus,9,8058,,,D,F
BAO_0000357,Expert,,,1,,,,,CHEMBL615229,,193,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,10116.0,100120,,Rattus norvegicus,9,9065,,,D,B
BAO_0000357,Expert,,,1,,Adrenal gland,,2369.0,CHEMBL615230,,194,Inhibition of 11 beta-hydroxylase from rat adrenal gland,10116.0,100120,,Rattus norvegicus,9,8865,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615231,,195,Inhibition of rat adrenal 11-beta-hydroxylase,10116.0,100120,,Rattus norvegicus,9,9066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL884520,,196,Inhibition of rat adrenal 11-beta-hydroxylase,10116.0,100120,,Rattus norvegicus,9,8394,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615232,,197,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,10116.0,100120,,Rattus norvegicus,9,8394,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615233,,198,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,10328,,,8,6431,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL827088,,199,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,11490,,,8,6431,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615234,,200,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,11490,,,8,6431,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615235,,201,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,11134,,,8,9295,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615236,,202,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,12052,,,8,10193,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615237,,203,Compound was tested in vitro for inhibition of 12-LO human platelet,,11134,,,8,13622,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615238,,204,Inhibitory concentration against human platelet 12-lipoxygenase,,11134,,,8,12079,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615239,,205,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,11134,,,8,13622,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615240,,206,Inhibitory concentration against human platelet 12-lipoxygenase,9606.0,11134,,Homo sapiens,9,12079,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615241,,207,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,11835,,,8,13500,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615242,,208,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,11601,,,8,13723,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615243,,209,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,11134,,,8,16474,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615244,,210,Inhibitory activity against human platelet 12-lipoxygenase,,11134,,,8,1630,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615245,,211,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,11134,,,8,167,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615246,,212,% inhibition against human platelet 12-lipoxygenase (12-HLO),,11134,,,8,16474,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615247,,213,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,11134,,,8,167,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615248,,214,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,11134,,,8,16474,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615249,,215,Inhibitory activity towards porcine 12-lipoxygenase,,11601,,,8,10091,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615250,,216,Tested for inhibition against porcine 12-LO,,11601,,,8,11966,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615251,,217,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,12052,,,8,951,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615252,,218,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,12052,,,8,10997,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL828340,,219,In vitro inhibition of rat platelet 12-lipoxygenase,,12052,,,8,10193,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615253,,220,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,12052,,,8,10193,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615254,,221,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,12052,,,8,10193,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615255,,222,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,12052,,,8,10193,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615256,,223,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,12052,,,8,10193,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615257,,224,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,12052,,,8,10193,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615258,,225,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,12052,,,8,11087,,,H,B
BAO_0000219,Intermediate,,621.0,1,,,41M,,CHEMBL615259,,226,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,9606.0,80007,,Homo sapiens,1,15569,,,N,F
BAO_0000219,Expert,,621.0,1,,,41M,,CHEMBL615260,,227,In vitro antitumor activity against 41M cell line.,9606.0,80007,,Homo sapiens,1,12989,,,N,F
BAO_0000219,Intermediate,,621.0,1,,,41M,,CHEMBL615261,,228,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,9606.0,80007,,Homo sapiens,1,16745,,,N,F
BAO_0000219,Intermediate,,621.0,1,,,41M,,CHEMBL615262,,229,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,9606.0,80007,,Homo sapiens,1,15569,,,N,F
BAO_0000219,Expert,,621.0,1,,,41M,,CHEMBL615263,,230,In vitro antitumor activity against 41McisR cell line.,9606.0,80007,,Homo sapiens,1,12989,,,N,F
BAO_0000219,Expert,,621.0,1,,,41M,,CHEMBL838393,,231,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,9606.0,80007,,Homo sapiens,1,12989,,,N,F
BAO_0000219,Intermediate,,621.0,1,,,41M,,CHEMBL615264,,232,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,9606.0,80007,,Homo sapiens,1,16745,,,N,F
BAO_0000357,Expert,,,1,,,,,CHEMBL615265,,233,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),9606.0,84,,Homo sapiens,9,6210,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615266,,234,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),9606.0,68,,Homo sapiens,9,6210,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615267,,235,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,68,,,8,6226,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615268,,236,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,10201,,,8,17855,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615269,,237,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,10201,,,8,17855,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615270,,238,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,10201,,,8,17855,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615271,,239,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,12220,,,8,10413,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615272,,240,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",562.0,11303,,Escherichia coli,8,10413,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615103,,241,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",562.0,11303,,Escherichia coli,8,10413,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615104,,242,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",562.0,11303,,Escherichia coli,8,10413,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615105,,243,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,12220,,,8,10413,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872866,,244,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,12220,,,8,10413,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615106,,245,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",9823.0,11303,,Sus scrofa,8,7587,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615107,,246,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",9823.0,11303,,Sus scrofa,8,7587,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615108,,247,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",9823.0,11303,,Sus scrofa,8,7587,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615109,,248,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",9823.0,11303,,Sus scrofa,8,7587,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615110,,249,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",9823.0,11303,,Sus scrofa,8,7587,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL840105,,250,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",9823.0,11303,,Sus scrofa,8,7587,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615111,,251,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",9823.0,11303,,Sus scrofa,8,7587,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615112,,252,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",9823.0,11303,,Sus scrofa,8,7587,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615113,,253,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",9823.0,11303,,Sus scrofa,8,7587,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615114,,254,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",9823.0,11303,,Sus scrofa,8,7587,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615115,,255,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",9823.0,11303,,Sus scrofa,8,7587,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615116,,256,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",9823.0,11303,,Sus scrofa,8,7587,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615698,,257,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,11303,,,8,7323,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615699,,258,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",9823.0,22226,,Sus scrofa,0,7587,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615700,,259,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",9823.0,22226,,Sus scrofa,0,7587,,,U,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615701,,260,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,4932.0,100249,,Saccharomyces cerevisiae,8,13750,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615702,,261,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,10116.0,22226,,Rattus norvegicus,0,7662,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615703,,262,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,10116.0,22226,,Rattus norvegicus,0,7662,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615704,,263,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",10116.0,22226,,Rattus norvegicus,0,7662,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615705,,264,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,104698,,,6,12211,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615706,,265,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,104698,,,6,12211,,,H,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL615707,,266,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,10141.0,20033,,Cavia porcellus,9,12211,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615708,,267,Stimulatory activity of intragastric pressure was tested in the rat,,10623,,,8,12211,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615709,,268,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,121,,,8,15453,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615710,,269,Dose to reduce neuronal firing against 5-HT cells in rats (iv),10116.0,22226,,Rattus norvegicus,0,11884,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615711,,270,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,12688,,,8,7185,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL615712,,271,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,9606.0,121,,Homo sapiens,9,6876,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL836325,,272,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,9606.0,121,,Homo sapiens,9,6876,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615713,,273,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,12198,,,8,11863,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615714,,274,Inhibition constant of high-affinity 5-HT uptake,,12198,,,8,11863,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615715,,275,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,12198,,,8,11863,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615716,,276,Maximum rate was determined for high affinity transport of 5-HT,,12198,,,8,11863,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615717,,277,Compound was tested for agonistic activity against 5-HT uptake,,104714,,,4,4639,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL881818,,278,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,10577,,,8,15796,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL884540,,279,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,9913.0,105,,Bos taurus,8,15796,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615718,,280,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,10116.0,104744,,Rattus norvegicus,5,12801,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615719,,281,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,104744,,,4,12801,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL615720,,282,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,104744,Membranes,,4,12120,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL615721,,283,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,104744,Membranes,,4,12120,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615722,,284,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,104744,,,4,11963,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615723,,285,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,51,,,8,11701,,,H,F
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615724,,286,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615725,,287,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615726,,288,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615727,,289,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,10576,,,8,16394,,,H,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL615728,,290,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,10141.0,105570,,Cavia porcellus,9,11574,,,D,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL857971,,291,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,279,,,8,15779,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615729,,292,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,107,,,8,15363,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615730,,293,Efficacy against 5-hydroxytryptamine 2A receptor,10116.0,12687,,Rattus norvegicus,9,15363,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615731,,294,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,12687,,,8,15329,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615732,,295,Relative potency towards 5-HT2A receptor of rat tail artery,,12687,,,8,15329,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615733,,296,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,12687,,,8,15329,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615734,,297,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,12687,,,8,15329,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615735,,298,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,12687,,,8,15329,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615736,,299,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,12687,,,8,15329,,,H,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL615737,,300,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,10141.0,20033,,Cavia porcellus,9,273,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL615738,,301,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),10141.0,20033,,Cavia porcellus,9,273,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL615739,,302,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,10141.0,20033,,Cavia porcellus,9,273,,,D,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615278,,303,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,10623,,,8,12092,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615279,,304,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10116.0,10623,,Rattus norvegicus,9,1317,,,D,F
BAO_0000357,Expert,,,1,,,,,CHEMBL615280,,305,Binding affinity against 5-hydroxytryptamine 4 receptor,,168,,,8,12409,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615281,,306,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,9031.0,22226,,Gallus gallus,0,11126,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615282,,307,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,9606.0,22226,,Homo sapiens,0,11126,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615283,,308,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,9606.0,22226,,Homo sapiens,0,11126,,,U,F
BAO_0000219,Autocuration,,649.0,1,,,HL-60,,CHEMBL615284,,309,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,9606.0,80156,,Homo sapiens,1,11126,,,N,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615285,,310,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,9606.0,22226,,Homo sapiens,0,11126,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615286,,311,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,9606.0,22226,,Homo sapiens,0,11126,,,U,B
BAO_0000219,Autocuration,,,1,,,Oocytes,,CHEMBL615287,,312,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,9606.0,104703,,Homo sapiens,7,17807,,,D,B
BAO_0000220,Intermediate,,,1,,,,,CHEMBL615288,,313,Chymotryptic inhibitory activity against 26S proteasome,,100256,,,2,16575,,,S,F
BAO_0000220,Intermediate,,,1,,,,,CHEMBL615289,,314,Inhibitory activity against 26S proteasome degradation of IkB,,100256,,,2,15407,,,S,B
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL615290,,315,In vitro inhibition of 2780/DOX ovarian cancer cell line,9606.0,81034,,Homo sapiens,1,10797,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL884522,,316,In vitro inhibition of 2780/S ovarian cancer cell line,9606.0,81034,,Homo sapiens,1,10797,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615291,,317,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,9606.0,22226,,Homo sapiens,0,3469,,,U,F
BAO_0000225,Intermediate,,,1,,,,,CHEMBL615292,,318,Association constant for binding to AATT 28-mer AATT hairpin,,22222,,,3,16037,,,M,B
BAO_0000225,Intermediate,,,1,,,,,CHEMBL615293,,319,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,22222,,,3,16037,,,M,B
BAO_0000225,Intermediate,,,1,,,,,CHEMBL615294,,320,Reaction Rate Parameter for 28-mer AATT hairpin,,22222,,,3,16037,,,M,B
BAO_0000225,Intermediate,,,1,,,,,CHEMBL615295,,321,Reaction Rate Parameter for 28-mer AATT hairpin,,22222,,,3,16037,,,M,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL825021,,322,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),9606.0,22226,,Homo sapiens,0,16524,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615296,,323,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),9606.0,22226,,Homo sapiens,0,16524,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615297,,324,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,9606.0,22226,,Homo sapiens,0,16524,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615298,,325,Cytotoxicity against cell line 2SC/20 determined by MTT test,10029.0,22226,,Cricetulus griseus,0,16758,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615299,,326,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,10029.0,22226,,Cricetulus griseus,0,16758,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615300,,327,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,10029.0,22226,,Cricetulus griseus,0,16758,,,U,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615301,,328,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,241,,,8,14360,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615302,,329,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,9606.0,241,,Homo sapiens,9,14360,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615303,,330,Selectivity ratio of ID50 in liver and heart,10116.0,22226,,Rattus norvegicus,0,9964,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615304,,331,"Selectivity, ratio of relative ID50 in liver and heart",,12132,,,8,9964,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615305,,332,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,12132,,,8,9964,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615306,,333,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132,,,8,9964,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615307,,334,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132,,,8,9964,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615308,,335,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132,,,8,9964,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615309,,336,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132,,,8,9964,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615310,,337,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,22226,,,0,9964,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615311,,338,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,12132,,,8,9964,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615312,,339,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",9606.0,22226,,Homo sapiens,0,9964,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615313,,340,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,12132,,,8,9964,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615314,,341,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,12132,,,8,9964,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615315,,342,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,12132,,,8,9964,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615316,,343,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",10116.0,22226,,Rattus norvegicus,0,9964,,,U,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615317,,344,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,12132,,,8,9964,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615318,,345,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,12132,,,8,9964,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615319,,346,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",10116.0,22226,,Rattus norvegicus,0,9964,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615320,,347,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,12132,,,8,9964,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615321,,348,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,12132,,,8,9964,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615322,,349,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",10116.0,22226,,Rattus norvegicus,0,3796,,,U,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615323,,350,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,562.0,19690,,Escherichia coli,8,4251,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615407,,351,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,562.0,19690,,Escherichia coli,8,4251,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL857267,,352,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,562.0,19690,,Escherichia coli,8,4251,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615408,,353,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,562.0,19690,,Escherichia coli,8,4251,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615409,,354,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,19690,,,8,166,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615410,,355,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,19690,,,8,17861,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615411,,356,Inhibition constant against 3-dehydroquinate synthase,,19690,,,8,166,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615412,,357,Association rate constant against 3-dehydroquinate synthase,,19690,,,8,166,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615413,,358,Rate constant against 3-dehydroquinate synthase,,19690,,,8,166,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615414,,359,Inhibitory activity against fuc-TVII,,22226,,,0,3548,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615415,,360,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,10116.0,12236,Microsomes,Rattus norvegicus,9,9877,,,D,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615416,,361,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,10116.0,12236,Microsomes,Rattus norvegicus,9,9877,,,D,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615417,,362,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,10116.0,12236,Microsomes,Rattus norvegicus,9,9877,,,D,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615418,,363,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,10116.0,12236,Microsomes,Rattus norvegicus,9,9877,,,D,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615419,,364,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,10116.0,12236,Microsomes,Rattus norvegicus,9,9877,,,D,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615420,,365,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,10116.0,12236,Microsomes,Rattus norvegicus,9,9877,,,D,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615421,,366,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,10116.0,12236,Microsomes,Rattus norvegicus,9,9877,,,D,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615422,,367,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,10116.0,12236,Microsomes,Rattus norvegicus,9,9877,,,D,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615423,,368,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,10116.0,12236,Microsomes,Rattus norvegicus,9,9877,,,D,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL872868,,369,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,10116.0,12236,Microsomes,Rattus norvegicus,9,9877,,,D,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL615424,,370,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,10116.0,12236,Microsomes,Rattus norvegicus,9,9877,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL825022,,371,Inhibitory activity against 3-phosphoglycerate kinase.,,104832,,,4,3003,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615425,,372,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,104832,,,4,3003,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615426,,373,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,104832,,,4,3003,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615427,,374,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,9606.0,10612,,Homo sapiens,9,17185,,,D,B
BAO_0000219,Intermediate,,844.0,1,,,3677 melanoma cell line,,CHEMBL615428,,375,Cytotoxicity on 3677 melanoma cells,9606.0,80616,,Homo sapiens,1,6072,,,N,F
BAO_0000219,Intermediate,,844.0,1,,,3677 melanoma cell line,,CHEMBL615429,,376,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,9606.0,80616,,Homo sapiens,1,6072,,,N,F
BAO_0000219,Intermediate,,700.0,1,,,MC-38,,CHEMBL615430,,377,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,10090.0,80617,,Mus musculus,1,5018,,,N,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL615431,,378,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,9606.0,22226,,Homo sapiens,0,2852,,,U,F
BAO_0000218,Autocuration,,798.0,1,,,B16,,CHEMBL615432,,379,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,22226,,,0,8663,,,U,F
BAO_0000218,Autocuration,,798.0,1,,,B16,,CHEMBL615433,,380,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,22226,,,0,8663,,,U,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615434,,381,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,12131.0,12464,,Human rhinovirus 14,9,3245,,,D,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL615435,,382,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,169066.0,50085,,Human rhinovirus sp.,1,3245,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL615436,,383,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,169066.0,50679,,human rhinovirus type 14,1,3877,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL615437,,384,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,169066.0,50679,,human rhinovirus type 14,1,3877,,,N,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615438,,385,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12131.0,12464,,Human rhinovirus 14,9,5861,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615439,,386,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12131.0,12464,,Human rhinovirus 14,9,5861,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615440,,387,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12131.0,12464,,Human rhinovirus 14,9,5861,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615441,,388,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,12131.0,12464,,Human rhinovirus 14,9,5861,,,D,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL615641,,389,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,12059.0,50665,,Enterovirus,1,13748,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL872065,,390,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,12059.0,50665,,Enterovirus,1,13748,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL825023,,391,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,12059.0,50665,,Enterovirus,1,13748,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL615642,,392,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,12059.0,50665,,Enterovirus,1,13748,,,N,F
BAO_0000357,Expert,,,1,,,,,CHEMBL615643,,393,Inhibition of human rhinovirus 3C protease,147712.0,12464,,Human rhinovirus B,8,13748,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615644,,394,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,9606.0,22226,,Homo sapiens,0,17699,,,U,B
BAO_0000218,Intermediate,,833.0,1,,,3EM 37,,CHEMBL615645,,395,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),10090.0,80619,,Mus musculus,1,7145,,,N,F
BAO_0000218,Intermediate,,833.0,1,,,3EM 37,,CHEMBL615646,,396,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),10090.0,80619,,Mus musculus,1,7145,,,N,F
BAO_0000218,Intermediate,,833.0,1,,,3EM 37,,CHEMBL615647,,397,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),10090.0,80619,,Mus musculus,1,7145,,,N,F
BAO_0000218,Intermediate,,833.0,1,,,3EM 37,,CHEMBL615648,,398,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),10090.0,80619,,Mus musculus,1,7145,,,N,F
BAO_0000218,Intermediate,,833.0,1,,,3EM 37,,CHEMBL615649,,399,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,10090.0,80619,,Mus musculus,1,7145,,,N,F
BAO_0000218,Intermediate,,833.0,1,,,3EM 37,,CHEMBL615650,,400,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,10090.0,80619,,Mus musculus,1,7145,,,N,F
BAO_0000218,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615651,,401,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,10090.0,80620,,Mus musculus,1,5325,,,N,F
BAO_0000218,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615652,,402,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,10090.0,80620,,Mus musculus,1,5325,,,N,F
BAO_0000218,Expert,,847.0,1,,,3LL cell line,,CHEMBL615653,,403,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,10090.0,80620,,Mus musculus,1,5325,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615654,,404,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615655,,405,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL825024,,406,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615656,,407,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615657,,408,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615658,,409,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615659,,410,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615660,,411,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615661,,412,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615662,,413,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615663,,414,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615664,,415,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615665,,416,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615666,,417,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615667,,418,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615668,,419,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615669,,420,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615670,,421,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL836739,,422,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615671,,423,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615672,,424,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615791,,425,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615792,,426,spermine levels in 3LL cells after the treatment of 1 uM of Compound,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615793,,427,spermine levels in 3LL cells after the treatment of 10 uM of Compound,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615794,,428,spermine levels in 3LL cells after the treatment of 250 uM of Compound,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,847.0,1,,,3LL cell line,,CHEMBL615795,,429,spermine levels in 3LL cells after the treatment of 50 uM of Compound,10090.0,80620,,Mus musculus,1,16169,,,N,F
BAO_0000219,Intermediate,,971.0,1,,,3LLD122,,CHEMBL615590,,430,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,9606.0,80621,,Homo sapiens,1,15547,,,N,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615591,,431,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,22226,,,0,8663,,,U,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615592,,432,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,22226,,,0,8663,,,U,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615593,,433,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,22226,,,0,8663,,,U,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615594,,434,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,22226,,,0,8663,,,U,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615595,,435,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,10090.0,80951,,Mus musculus,1,4504,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615596,,436,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,10090.0,80951,,Mus musculus,1,4504,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615597,,437,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,11169,,,8,12695,,,H,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615598,,438,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,10090.0,80951,,Mus musculus,1,12695,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615599,,439,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,10090.0,80951,,Mus musculus,1,12695,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615600,,440,Effective dose against murine 3T3 fibroblasts cells,10090.0,80951,,Mus musculus,1,17642,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615601,,441,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,10090.0,80951,,Mus musculus,1,17642,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615602,,442,Cytotoxic effect on 3T3 cells,10090.0,80951,,Mus musculus,1,12340,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615603,,443,Cytotoxic effect on 3T3 cells,10090.0,80951,,Mus musculus,1,12340,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615604,,444,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,10090.0,80951,,Mus musculus,1,12716,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615605,,445,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,10090.0,80951,,Mus musculus,1,6277,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615606,,446,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,10090.0,80951,,Mus musculus,1,6277,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL884526,,447,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,10090.0,80951,,Mus musculus,1,6277,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615607,,448,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,10090.0,80951,,Mus musculus,1,6277,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615608,,449,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,10090.0,80951,,Mus musculus,1,6277,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615609,,450,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,10090.0,80951,,Mus musculus,1,6277,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615682,,451,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,10090.0,80951,,Mus musculus,1,6277,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615683,,452,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,10090.0,80951,,Mus musculus,1,6277,,,N,F
BAO_0000218,Expert,,723.0,1,,,NIH3T3,,CHEMBL615684,,453,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,10090.0,80951,,Mus musculus,1,17780,,,N,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL615685,,454,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,10090.0,104860,,Mus musculus,7,12751,,,D,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615686,,455,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,10090.0,80951,,Mus musculus,1,12380,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615687,,456,Inhibitory activity against 3T3 cell line,10090.0,80951,,Mus musculus,1,14892,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL884523,,457,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,10090.0,80951,,Mus musculus,1,12695,,,N,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615688,,458,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,11169,,,8,12695,,,H,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615689,,459,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,10090.0,80951,,Mus musculus,1,12695,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615690,,460,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,10090.0,80951,,Mus musculus,1,12695,,,N,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615691,,461,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,11169,,,8,12695,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615692,,462,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,11169,,,8,12695,,,H,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615693,,463,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,10090.0,80951,,Mus musculus,1,6277,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615324,,464,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,10090.0,80951,,Mus musculus,1,6277,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615325,,465,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,9606.0,9,,Homo sapiens,9,4959,,,D,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615490,,466,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),9606.0,9,,Homo sapiens,9,4959,,,D,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615491,,467,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,9606.0,188,,Homo sapiens,9,4959,,,D,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615492,,468,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),9606.0,188,,Homo sapiens,9,4959,,,D,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615493,,469,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,10090.0,80951,,Mus musculus,1,12082,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615494,,470,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,10090.0,80951,,Mus musculus,1,12082,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615495,,471,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,10090.0,80951,,Mus musculus,1,12082,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615496,,472,Inhibitory concentration was calculated on 3T3 cells by using growth assay,10090.0,80951,,Mus musculus,1,12082,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615497,,473,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,10090.0,80951,,Mus musculus,1,2643,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615498,,474,Inhibition of Swiss 3T3 mouse fibroblast proliferation,10090.0,80951,,Mus musculus,1,11926,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615499,,475,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,10090.0,80951,,Mus musculus,1,15204,,,N,A
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL835522,,476,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,10090.0,80951,,Mus musculus,1,15992,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615500,,477,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,10090.0,80951,,Mus musculus,1,16279,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615501,,478,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),10090.0,80951,,Mus musculus,1,16279,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615502,,479,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),10090.0,80951,,Mus musculus,1,16279,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615503,,480,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),10090.0,80951,,Mus musculus,1,16279,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615504,,481,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),10090.0,80951,,Mus musculus,1,16279,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615505,,482,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),10090.0,80951,,Mus musculus,1,16279,,,N,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL615506,,483,Inhibition of swiss 3T3 mouse fibroblast proliferation,10090.0,80951,,Mus musculus,1,12831,,,N,F
BAO_0000219,Intermediate,,723.0,1,,,NIH3T3,,CHEMBL615507,,484,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,10090.0,80951,,Mus musculus,1,13497,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615508,,485,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615509,,486,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,10090.0,80006,,Mus musculus,1,13618,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615510,,487,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,10090.0,80006,,Mus musculus,1,11902,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615511,,488,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,10090.0,80006,,Mus musculus,1,11902,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615512,,489,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,10090.0,80006,,Mus musculus,1,11902,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615513,,490,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",10090.0,80006,,Mus musculus,1,14840,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615514,,491,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",10090.0,80006,,Mus musculus,1,14840,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615515,,492,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,80006,,,1,13715,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615516,,493,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,80006,,,1,13715,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615517,,494,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,80006,,,1,13715,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615518,,495,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,80006,,,1,13715,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615519,,496,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,80006,,,1,13715,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615520,,497,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615521,,498,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615522,,499,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615523,,500,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Expert,,620.0,1,,,3T3-L1,,CHEMBL615524,,501,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Expert,,620.0,1,,,3T3-L1,,CHEMBL615525,,502,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615526,,503,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615527,,504,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615528,,505,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Expert,,620.0,1,,,3T3-L1,,CHEMBL615529,,506,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Expert,,620.0,1,,,3T3-L1,,CHEMBL615530,,507,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Expert,,620.0,1,,,3T3-L1,,CHEMBL615531,,508,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615532,,509,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,80006,,,1,13715,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615533,,510,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,80006,,,1,13715,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615534,,511,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,80006,,,1,13715,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615535,,512,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615536,,513,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615537,,514,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615538,,515,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000218,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL836166,,516,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,80006,,,1,13715,,,N,F
BAO_0000219,Expert,,620.0,1,,,3T3-L1,,CHEMBL615539,,517,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,11214,,,8,6411,,,H,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615540,,518,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,10090.0,80006,,Mus musculus,1,6411,,,N,F
BAO_0000219,Expert,,620.0,1,,,3T3-L1,,CHEMBL615541,,519,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,11214,,,8,6411,,,H,F
BAO_0000219,Expert,,620.0,1,,,3T3-L1,,CHEMBL615542,,520,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,10090.0,80006,,Mus musculus,1,3966,,,N,F
BAO_0000219,Intermediate,,620.0,1,,,3T3-L1,,CHEMBL615543,,521,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,10090.0,80006,,Mus musculus,1,3966,,,N,F
BAO_0000219,Expert,,620.0,1,,,3T3-L1,,CHEMBL615544,,522,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,10090.0,80006,,Mus musculus,1,15556,,,N,F
BAO_0000219,Expert,,620.0,1,,,3T3-L1,,CHEMBL615545,,523,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,10090.0,80006,,Mus musculus,1,5845,,,N,F
BAO_0000219,Expert,,620.0,1,,,3T3-L1,,CHEMBL615546,,524,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,10090.0,80006,,Mus musculus,1,14422,,,N,F
BAO_0000219,Expert,,620.0,1,,,3T3-L1,,CHEMBL615547,,525,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,10090.0,80006,,Mus musculus,1,5845,,,N,F
BAO_0000219,Expert,,620.0,1,,,3T3-L1,,CHEMBL615548,,526,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,10090.0,80006,,Mus musculus,1,14508,,,N,F
BAO_0000219,Expert,,620.0,1,,,3T3-L1,,CHEMBL615549,,527,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,10090.0,80006,,Mus musculus,1,14508,,,N,F
BAO_0000219,Expert,,620.0,1,,,3T3-L1,,CHEMBL615550,,528,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,10090.0,80006,,Mus musculus,1,14508,,,N,F
BAO_0000219,Intermediate,,1118.0,1,,,3Y1 cell line,,CHEMBL615551,,529,Inhibitory activity against rat fibroblast (3Y1) cell line,10116.0,80622,,Rattus norvegicus,1,6349,,,N,F
BAO_0000219,Expert,,1118.0,1,,,3Y1 cell line,,CHEMBL615552,,530,Mean concentration causing inhibition of cell growth in 3Y1 cells.,10116.0,80622,,Rattus norvegicus,1,15899,,,N,F
BAO_0000219,Expert,,1118.0,1,,,3Y1 cell line,,CHEMBL615553,,531,Cytotoxicity in 3Y1 cells.,10116.0,80622,,Rattus norvegicus,1,15899,,,N,F
BAO_0000219,Expert,,1118.0,1,,,3Y1 cell line,,CHEMBL615554,,532,Cytostatic effect in 3Y1 cells.,10116.0,80622,,Rattus norvegicus,1,15899,,,N,F
BAO_0000219,Intermediate,,1118.0,1,,,3Y1 cell line,,CHEMBL615555,,533,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",10116.0,80622,,Rattus norvegicus,1,15899,,,N,F
BAO_0000219,Expert,,1118.0,1,,,3Y1 cell line,,CHEMBL615556,,534,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,10116.0,80622,,Rattus norvegicus,1,17038,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615557,,535,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,22226,,,0,12421,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615558,,536,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,22226,,,0,12947,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872066,,537,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,22226,,,0,12947,,,U,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615559,,538,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,9823.0,11607,,Sus scrofa,9,4896,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615560,,539,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,11607,,,8,6148,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615561,,540,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,11607,,,8,16432,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL857062,,541,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,11607,,,8,4978,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615562,,542,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,11607,,,8,4978,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615563,,543,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,11607,,,8,3723,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615564,,544,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,11607,,,8,3518,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615565,,545,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,11607,,,8,4164,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615566,,546,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,11607,,,8,3518,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615567,,547,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,9823.0,11607,,Sus scrofa,9,4164,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615568,,548,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,11607,,,8,3518,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615569,,549,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,11607,,,8,3518,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615570,,550,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,11607,,,8,4978,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615571,,551,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,11607,,,8,4978,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615572,,552,Binding affinity against melatonin (MT1) receptor (pC1),,104733,,,4,6455,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615573,,553,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,22226,,,0,2222,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615574,,554,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,22226,,,0,13020,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615575,,555,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,22226,,,0,13021,,,U,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615576,,556,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,10619,,,8,14532,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615577,,557,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,10619,,,8,14118,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615578,,558,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,51,,,8,11884,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615579,,559,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,51,,,8,13969,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615580,,560,Binding affinity for 5-hydroxytryptamine 1A receptor,,51,,,8,13392,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615581,,561,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,51,,,8,14430,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615582,,562,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51,,,8,12248,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615583,,563,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51,,,8,12249,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615584,,564,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL833691,,565,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615585,,566,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615586,,567,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL884524,,568,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615587,,569,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51,,,8,12249,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615588,,570,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,51,,,8,11799,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL615589,,571,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,10116.0,10576,Membranes,Rattus norvegicus,9,14331,,,D,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615442,,572,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,9913.0,51,,Bos taurus,8,11884,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615443,,573,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,51,,,8,14331,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615444,,574,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,51,,,8,11701,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615445,,575,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,51,,,8,11701,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615446,,576,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,51,,,8,12248,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615447,,577,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,51,,,8,12248,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615448,,578,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51,,,8,12248,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615449,,579,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,51,,,8,12249,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615450,,580,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,51,,,8,12248,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615451,,581,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,51,,,8,11799,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615452,,582,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,51,,,8,634,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615453,,583,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615454,,584,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615455,,585,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615456,,586,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615457,,587,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,51,,,8,9995,,,H,B
BAO_0000218,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615458,,588,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,51,,,8,12210,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615459,,589,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,,8,13311,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615460,,590,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",9606.0,51,,Homo sapiens,9,2331,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615461,,591,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,10141.0,51,,Cavia porcellus,8,1375,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615462,,592,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,10141.0,51,,Cavia porcellus,8,1375,,,H,F
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615463,,593,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,10141.0,51,,Cavia porcellus,8,11574,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL615464,,594,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,10141.0,51,,Cavia porcellus,8,12867,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL615465,,595,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,10141.0,51,,Cavia porcellus,8,12867,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL615466,,596,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,10141.0,51,,Cavia porcellus,8,12867,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL615467,,597,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,10141.0,51,,Cavia porcellus,8,12867,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL615468,,598,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,10141.0,51,,Cavia porcellus,8,12867,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL615469,,599,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,10141.0,51,,Cavia porcellus,8,12867,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615470,,600,Binding affinity against 5-hydroxytryptamine 1A receptor,10141.0,51,,Cavia porcellus,8,11574,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615471,,601,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,10141.0,51,,Cavia porcellus,8,13114,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615472,,602,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,10141.0,51,,Cavia porcellus,8,13181,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL883242,,603,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10141.0,106,,Cavia porcellus,8,10639,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615473,,604,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10141.0,106,,Cavia porcellus,8,10639,,,H,F
BAO_0000218,Autocuration,,449.0,1,,,CHO,,CHEMBL615474,,605,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),10029.0,11863,,Cricetulus griseus,8,11883,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615475,,606,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,51,,,8,17785,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL615476,,607,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,51,,,8,1558,,,H,F
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL615477,,608,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,51,,,8,1558,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615478,,609,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,51,,,8,15740,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615160,,610,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,51,,,8,17624,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615161,,611,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,51,,,8,17624,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615162,,612,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,51,,,8,17624,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615163,,613,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,51,,,8,17624,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615164,,614,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,51,,,8,17624,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615165,,615,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,51,,,8,17624,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615166,,616,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,51,,,8,17624,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL615167,,617,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,51,,,8,14256,,,H,F
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL615168,,618,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,9606.0,51,,Homo sapiens,9,3445,,,D,B
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL615169,,619,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,9606.0,51,,Homo sapiens,9,3445,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615170,,620,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,9606.0,51,,Homo sapiens,9,17200,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615171,,621,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,9606.0,51,,Homo sapiens,9,17200,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615694,,622,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,51,,,8,15180,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615695,,623,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,51,,,8,15180,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615696,,624,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,51,,,8,16026,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615697,,625,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,51,,,8,2759,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL859410,,626,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),9606.0,51,,Homo sapiens,9,2759,,,D,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615841,,627,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,51,,,8,2759,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615842,,628,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),9606.0,51,,Homo sapiens,9,2759,,,D,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL835003,,629,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,51,,,8,2759,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615843,,630,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,51,,,8,2759,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615979,,631,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),9606.0,51,,Homo sapiens,9,2759,,,D,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615980,,632,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,51,,,8,2759,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615981,,633,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),9606.0,51,,Homo sapiens,9,2759,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615982,,634,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,9606.0,51,,Homo sapiens,9,3445,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615983,,635,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615984,,636,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615985,,637,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615986,,638,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,51,,,8,17624,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615987,,639,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,51,,,8,17624,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615988,,640,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,51,,,8,17624,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615989,,641,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,51,,,8,17624,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615990,,642,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,51,,,8,17624,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615991,,643,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,51,,,8,17624,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615992,,644,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,51,,,8,17624,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615993,,645,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,51,,,8,17624,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615994,,646,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,51,,,8,17624,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615995,,647,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,51,,,8,17624,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615996,,648,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,51,,,8,17624,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615997,,649,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,51,,,8,17624,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615998,,650,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51,,,8,6563,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615999,,651,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51,,,8,6563,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616000,,652,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,51,,,8,6563,,,H,F
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616001,,653,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,51,,,8,17296,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616002,,654,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",9606.0,51,,Homo sapiens,9,6876,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616003,,655,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,51,,,8,6876,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616004,,656,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616005,,657,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616006,,658,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,51,,,8,5548,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616007,,659,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,51,,,8,5548,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616008,,660,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,51,,,8,5548,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616009,,661,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,51,,,8,5548,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616010,,662,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,51,,,8,5929,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616011,,663,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",9606.0,51,,Homo sapiens,9,5929,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615740,,664,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",9606.0,51,,Homo sapiens,9,5929,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615741,,665,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,51,,,8,16245,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615742,,666,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,51,,,8,5640,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615743,,667,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,51,,,8,5640,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615744,,668,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,51,,,8,14509,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615745,,669,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,51,,,8,14509,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615746,,670,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,51,,,8,15331,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615747,,671,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,51,,,8,15331,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615748,,672,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51,,,8,6563,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615749,,673,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,51,,,8,6563,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615750,,674,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,51,,,8,6563,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616259,,675,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,9606.0,51,,Homo sapiens,9,6563,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616260,,676,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51,,,8,6563,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616261,,677,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616262,,678,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616263,,679,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616264,,680,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616265,,681,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616266,,682,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616267,,683,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616268,,684,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,9606.0,51,,Homo sapiens,9,5272,,,D,F
BAO_0000357,Expert,,,1,,,,,CHEMBL616269,,685,Inhibition of human 5-hydroxytryptamine 1A receptor,9606.0,51,,Homo sapiens,9,16146,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL884528,,686,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,51,,,8,17624,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL616270,,687,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,105,,,9,13706,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616271,,688,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,51,,,8,15250,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616272,,689,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,51,,,8,17624,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL616273,,690,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,51,,,8,6861,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616274,,691,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,9606.0,51,,Homo sapiens,9,17200,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616275,,692,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,51,,,8,17624,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616276,,693,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,51,,,8,17624,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616277,,694,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616278,,695,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616279,,696,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616280,,697,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616281,,698,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616282,,699,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616283,,700,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616284,,701,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616285,,702,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616286,,703,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616287,,704,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616288,,705,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616289,,706,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615610,,707,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615611,,708,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615612,,709,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615613,,710,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615614,,711,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615615,,712,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,10116.0,22226,,Rattus norvegicus,0,12058,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615616,,713,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,105093,,,4,11440,,,H,B
BAO_0000249,Autocuration,,,1,,Hypothalamus,,1898.0,CHEMBL615617,,714,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,11923,,,8,6238,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615618,,715,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,10577,,,8,10046,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615619,,716,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,10577,,,8,10046,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615620,,717,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,10577,,,8,10046,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615621,,718,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,55,,,8,167,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615622,,719,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,55,,,8,167,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615623,,720,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,12166,,,8,11520,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615624,,721,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,12166,,,8,11520,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615625,,722,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,12166,,,8,11520,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL767045,,723,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,12166,,,8,11520,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615626,,724,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,10141.0,55,,Cavia porcellus,8,135,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615627,,725,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,10141.0,55,,Cavia porcellus,8,135,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615628,,726,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,10141.0,55,,Cavia porcellus,8,11311,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615629,,727,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,10141.0,55,,Cavia porcellus,8,10193,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615630,,728,Inhibitory concentration against 5-lipoxygenase from human whole blood,9606.0,55,,Homo sapiens,9,12281,,,D,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL615631,,729,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,55,,,8,11311,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615632,,730,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,17087,,,8,12576,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615633,,731,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,17087,,,8,12281,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615634,,732,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,17087,,,8,12576,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615635,,733,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,9823.0,55,,Sus scrofa,8,11089,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615636,,734,In vitro inhibition of rat 5-Lipoxygenase,,12166,,,8,11006,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615637,,735,Inhibitory activity against 5-Lipoxygenase,10116.0,12166,,Rattus norvegicus,9,11481,,,D,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL615638,,736,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,12166,,,8,10864,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL615639,,737,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,12166,,,8,3595,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL615640,,738,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,12166,,,8,11311,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615796,,739,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,12166,,,8,11311,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL615845,,740,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,12166,,,8,11311,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615846,,741,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,12166,,,8,11006,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL615847,,742,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,12166,,,8,3595,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615848,,743,The compound was tested for inhibition of isolated 5-Lipoxygenase,,12166,,,8,11311,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615849,,744,Ratio of IC50 against 5-LO and COX,10116.0,22226,,Rattus norvegicus,0,11481,,,U,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615850,,745,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,12166,,,8,11006,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615851,,746,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,12166,,,8,11006,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL615852,,747,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,12166,,,8,11311,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615853,,748,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,12166,,,8,11006,,,H,F
BAO_0000357,Autocuration,,,1,,Prostate gland,,2367.0,CHEMBL884527,,749,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,120,,,8,4288,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872871,,750,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,8932.0,22226,,Columba livia,0,7587,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615854,,751,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,8932.0,22226,,Columba livia,0,7587,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL767046,,752,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,8932.0,22226,,Columba livia,0,7587,,,U,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615855,,753,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,10732,,,8,11249,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615856,,754,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,10116.0,12198,,Rattus norvegicus,9,8003,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615857,,755,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),10116.0,12198,,Rattus norvegicus,9,8003,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615858,,756,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),10116.0,12198,,Rattus norvegicus,9,8003,,,D,F
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615859,,757,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,10576,,,8,12416,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615860,,758,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,51,,,8,16293,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615861,,759,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,9986.0,22226,,Oryctolagus cuniculus,0,13047,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615862,,760,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,9986.0,22226,,Oryctolagus cuniculus,0,13047,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615863,,761,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,9986.0,22226,,Oryctolagus cuniculus,0,13047,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615864,,762,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,9986.0,22226,,Oryctolagus cuniculus,0,13047,,,U,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615865,,763,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,104744,,,4,10085,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615866,,764,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,104744,,,4,10085,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615867,,765,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,104744,,,4,10085,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL615868,,766,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,104744,Membranes,,4,9841,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL615869,,767,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,10116.0,104744,,Rattus norvegicus,5,8822,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615870,,768,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,10116.0,104744,,Rattus norvegicus,5,9806,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615871,,769,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,10116.0,104744,,Rattus norvegicus,5,9806,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615872,,770,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,104744,,,4,8868,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL833492,,771,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,104744,,,4,9036,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615873,,772,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,104744,,,4,11374,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615479,,773,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,104744,,,4,10881,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615480,,774,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,104744,,,4,8822,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL615481,,775,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,10116.0,104744,,Rattus norvegicus,5,9806,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872869,,776,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,104744,,,4,15463,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615482,,777,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,104744,,,4,15463,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL615483,,778,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,104744,,,4,14542,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL615484,,779,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,104744,,,4,14542,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615485,,780,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,104744,,,4,8569,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615486,,781,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,10116.0,104744,,Rattus norvegicus,5,10062,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615487,,782,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,104744,,,4,4771,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615488,,783,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,104744,,,4,10062,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615489,,784,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,104744,,,4,10062,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615389,,785,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,104744,,,4,10062,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615390,,786,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,104744,,,4,15463,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615391,,787,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,104744,,,4,15463,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615392,,788,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,104744,,,4,9098,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615393,,789,Affinity for 5-hydroxytryptamine 1 receptor,10116.0,22226,,Rattus norvegicus,0,3070,,,U,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL615394,,790,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,104744,,,4,14542,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL615395,,791,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,104744,,,4,14542,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL615396,,792,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,104744,,,4,6398,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL615397,,793,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,104744,,,4,1344,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615398,,794,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,104744,,,4,11963,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615399,,795,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,10116.0,22226,,Rattus norvegicus,0,8908,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615400,,796,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,104744,,,4,9098,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615401,,797,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,10116.0,104744,,Rattus norvegicus,5,8841,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615402,,798,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,10116.0,22226,,Rattus norvegicus,0,8814,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615403,,799,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,104744,,,4,11752,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL615404,,800,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,104744,,,4,11642,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615781,,801,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,104744,,,4,11642,,,H,B
BAO_0000220,Autocuration,,,1,,Brain,,955.0,CHEMBL615782,,802,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,104744,,,4,9231,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL615783,,803,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,104744,,,4,11351,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL873481,,804,Compound was tested for binding affinity against 5-HT1 receptor,,22226,,,0,4639,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615784,,805,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,22226,,,0,1205,,,U,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615785,,806,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,10576,,,8,10025,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL615786,,807,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,10576,,,8,13241,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615787,,808,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,10576,,,8,16245,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615788,,809,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,10576,,,8,16245,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL767044,,810,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,10576,,,8,12438,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615789,,811,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,10576,,,8,16245,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615790,,812,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,10576,,,8,16245,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615813,,813,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,10576,,,8,15740,,,H,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL615814,,814,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,10576,,,8,15535,,,H,F
BAO_0000219,Expert,,,1,,,,,CHEMBL615815,,815,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,51,,,8,15535,,,H,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL615816,,816,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,10576,,,8,15535,,,H,F
BAO_0000249,Expert,,,1,,,,,CHEMBL615817,,817,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,10576,,,8,9888,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615818,,818,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,10576,,,8,10085,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615819,,819,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,10576,,,8,10085,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL615820,,820,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,10576,Membranes,,8,17331,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615821,,821,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10116.0,10576,,Rattus norvegicus,9,10845,,,D,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615822,,822,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10116.0,10576,,Rattus norvegicus,9,10845,,,D,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615823,,823,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,10576,,,8,10845,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615824,,824,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10116.0,10576,,Rattus norvegicus,9,10845,,,D,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615825,,825,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10116.0,10576,,Rattus norvegicus,9,10845,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615826,,826,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,10576,,,8,13730,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL615827,,827,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,10576,,,8,13508,,,H,B
BAO_0000249,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615828,,828,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,10576,,,8,13508,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615829,,829,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,,8,12073,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615830,,830,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,10576,,,8,4671,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615831,,831,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,10576,,,8,13631,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615832,,832,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,10576,,,8,12438,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615833,,833,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,10576,,,8,10483,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615834,,834,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,10576,,,8,10483,,,H,B
BAO_0000249,Intermediate,,,1,,,,,CHEMBL615835,,835,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,10576,,,8,12352,,,H,B
BAO_0000249,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615836,,836,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,10576,,,8,14732,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615837,,837,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,10116.0,10576,,Rattus norvegicus,9,11049,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615838,,838,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,10116.0,10576,,Rattus norvegicus,9,11049,,,D,B
BAO_0000249,Expert,,,1,,,,,CHEMBL615839,,839,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,10576,,,8,13657,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL884525,,840,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,10576,,,8,11473,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL615840,,841,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,10576,,,8,2014,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615405,,842,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,,8,3086,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615406,,843,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,10576,,,8,15854,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615900,,844,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,10576,,,8,10922,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615901,,845,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,10576,,,8,13346,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615902,,846,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,10576,,,8,15311,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615903,,847,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,10576,,,8,10922,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615904,,848,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,10576,,,8,10025,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615905,,849,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,10576,,,8,10025,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615906,,850,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,10576,,,8,9742,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615907,,851,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,10576,,,8,9742,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL615908,,852,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,10576,,,8,12304,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615909,,853,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,10576,,,8,15789,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615910,,854,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,10576,,,8,9912,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615911,,855,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,10576,,,8,9912,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615912,,856,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,10576,,,8,9912,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615913,,857,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,10576,,,8,16693,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615914,,858,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,10576,,,8,13276,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615915,,859,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,10576,,,8,12678,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615916,,860,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,10576,,,8,11825,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615917,,861,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,10576,,,8,12443,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615918,,862,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,10576,,,8,13830,,,H,B
BAO_0000249,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615919,,863,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,10576,,,8,14286,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615920,,864,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10116.0,10576,,Rattus norvegicus,9,14356,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615921,,865,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,10576,,,8,15306,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615922,,866,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,10576,,,8,15306,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL881290,,867,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10116.0,10576,,Rattus norvegicus,9,16616,,,D,F
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615923,,868,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,10576,,,8,3651,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615924,,869,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,,8,14331,,,H,F
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615925,,870,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,,8,14331,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL615926,,871,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,10116.0,10576,,Rattus norvegicus,9,14178,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615927,,872,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,10116.0,10576,,Rattus norvegicus,9,10639,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615928,,873,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576,,,8,12306,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615929,,874,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,10116.0,10576,,Rattus norvegicus,9,1348,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615930,,875,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,10576,,,8,13605,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615931,,876,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,51,,,8,17624,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615932,,877,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,51,,,8,17624,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615933,,878,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,51,,,8,17624,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615934,,879,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,51,,,8,15267,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615935,,880,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,51,,,8,16532,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615936,,881,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,51,,,8,6563,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615937,,882,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,51,,,8,4751,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615938,,883,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,51,,,8,15463,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615797,,884,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,51,,,8,3805,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615798,,885,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,,8,5640,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872870,,886,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,51,,,8,6563,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615799,,887,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,51,,,8,5548,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615800,,888,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,51,,,8,6347,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL615801,,889,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,51,,,8,17296,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615802,,890,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,51,,,8,13047,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615803,,891,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,51,,,8,15740,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL835002,,892,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,51,,,8,5640,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615804,,893,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,51,,,8,5640,,,H,F
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL615805,,894,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,51,,,8,17211,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615806,,895,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,51,,,8,4751,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615807,,896,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,9606.0,51,,Homo sapiens,9,6491,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615808,,897,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,51,,,8,4707,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615809,,898,Binding affinity against 5-hydroxytryptamine 1A receptor,9606.0,51,,Homo sapiens,9,13910,,,D,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL615810,,899,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,51,,,8,16190,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615811,,900,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,,8,16633,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615812,,901,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,51,,,8,11898,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615751,,902,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,51,,,8,11898,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615752,,903,Binding affinity against human 5-hydroxytryptamine 1A receptor,,51,,,8,14331,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615753,,904,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,51,,,8,17624,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL615754,,905,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,51,,,8,17624,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615755,,906,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,51,,,8,3307,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615756,,907,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,9606.0,51,,Homo sapiens,9,6563,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615757,,908,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,51,,,8,14165,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615758,,909,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,51,,,8,5732,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615759,,910,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,51,,,8,13366,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615760,,911,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,51,,,8,17626,,,H,B
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL615761,,912,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,51,,,8,6588,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872104,,913,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,51,,,8,16209,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615762,,914,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,51,,,8,15463,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615763,,915,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,51,,,8,15463,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615764,,916,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,51,,,8,14770,,,H,B
BAO_0000219,Autocuration,,1167.0,1,,,Cell line,,CHEMBL615765,,917,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,51,,,8,16245,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615766,,918,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,51,,,8,16245,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615767,,919,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,51,,,8,5548,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615768,,920,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,,8,5548,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615769,,921,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,,8,5548,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615770,,922,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,51,,,8,6876,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615771,,923,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,,8,2598,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615772,,924,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,51,,,8,17785,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615773,,925,Binding affinity towards 5-hydroxytryptamine 1A receptor,,51,,,8,6013,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615774,,926,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,51,,,8,5929,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615775,,927,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,,8,16633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615776,,928,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,51,,,8,1558,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615777,,929,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,,8,16026,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL615778,,930,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,51,,,8,12469,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615779,,931,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,9606.0,51,,Homo sapiens,9,15874,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615780,,932,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,51,,,8,15874,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616298,,933,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,51,,,8,3935,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616299,,934,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,51,,,8,15818,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL616300,,935,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,51,,,8,13706,,,H,B
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL616301,,936,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,51,,,8,13729,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616302,,937,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,51,,,8,15413,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616117,,938,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,51,,,8,15413,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616118,,939,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,51,,,8,15413,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616119,,940,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,51,,,8,15413,,,H,B
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL616120,,941,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,9606.0,51,,Homo sapiens,9,3445,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616121,,942,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,51,,,8,15740,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616122,,943,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,51,,,8,15740,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616123,,944,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,51,,,8,17626,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616124,,945,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,9606.0,51,,Homo sapiens,9,4234,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616125,,946,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,51,,,8,5640,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616126,,947,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,10116.0,51,,Rattus norvegicus,8,5272,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616127,,948,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,51,,,8,4622,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616128,,949,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,51,,,8,17085,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616129,,950,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,51,,,8,3025,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616130,,951,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,51,,,8,15315,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616131,,952,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,51,,,8,15267,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL616132,,953,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,51,,,8,17158,,,H,B
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL616133,,954,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,9606.0,51,,Homo sapiens,9,14214,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616134,,955,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,,8,17133,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616135,,956,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,51,,,8,16532,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616136,,957,Affinity for 5-hydroxytryptamine 1A receptor subtype,9606.0,51,,Homo sapiens,9,2391,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616137,,958,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,51,,,8,14447,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872105,,959,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,51,,,8,14447,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616138,,960,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,51,,,8,15086,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616139,,961,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,9606.0,51,,Homo sapiens,9,13051,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616140,,962,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,51,,,8,16026,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616141,,963,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,51,,,8,17085,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616142,,964,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,,8,17133,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616143,,965,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,51,,,8,17133,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL616144,,966,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,51,,,8,17211,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL616145,,967,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,51,,,8,17211,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL616012,,968,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,51,,,8,17211,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL616013,,969,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,51,,,8,17211,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616014,,970,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,51,,,8,16394,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616015,,971,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,51,,,8,16394,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616016,,972,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,51,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616017,,973,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,51,,,8,16394,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616018,,974,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,51,,,8,16394,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616019,,975,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,51,,,8,15740,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616020,,976,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,51,,,8,15740,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL858018,,977,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,51,,,8,15740,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616021,,978,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,51,,,8,17296,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616022,,979,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,51,,,8,5640,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616023,,980,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,51,,,8,5640,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616024,,981,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,51,,,8,5640,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616025,,982,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,51,,,8,5640,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616026,,983,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,51,,,8,2759,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616027,,984,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,51,,,8,16394,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616028,,985,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",9606.0,51,,Homo sapiens,9,16394,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616029,,986,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,9606.0,51,,Homo sapiens,9,3445,,,D,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616030,,987,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,51,,,8,4316,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616031,,988,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,51,,,8,4316,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616032,,989,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,9606.0,51,,Homo sapiens,9,15180,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616033,,990,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,9606.0,51,,Homo sapiens,9,15180,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616034,,991,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51,,,8,15042,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616035,,992,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51,,,8,15042,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616036,,993,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,51,,,8,15042,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616037,,994,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51,,,8,15042,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616038,,995,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51,,,8,15042,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616039,,996,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,51,,,8,15042,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616040,,997,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,51,,,8,15042,,,H,F
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL616041,,998,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,9606.0,51,,Homo sapiens,9,15180,,,D,F
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL616042,,999,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,9606.0,51,,Homo sapiens,9,15180,,,D,F
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL616043,,1000,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,9606.0,51,,Homo sapiens,9,15180,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616044,,1001,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,51,,,8,16245,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616045,,1002,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,51,,,8,16026,,,H,F
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616046,,1003,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,51,,,8,17296,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616047,,1004,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,51,,,8,2759,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616048,,1005,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,51,,,8,2759,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616049,,1006,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),9606.0,51,,Homo sapiens,9,2759,,,D,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616050,,1007,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,51,,,8,2759,,,H,F
BAO_0000219,Expert,,,1,,,,,CHEMBL616051,,1008,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,51,,,8,15419,,,H,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL616212,,1009,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,51,,,8,15419,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616213,,1010,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,51,,,8,16026,,,H,F
BAO_0000219,Expert,In vitro,,1,,,,,CHEMBL616214,,1011,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,51,,,8,1414,,,H,B
BAO_0000219,Expert,In vitro,,1,,,,,CHEMBL616215,,1012,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,51,,,8,1414,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616216,,1013,Binding activity radioligand.,,51,,,8,12861,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616217,,1014,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,51,,,8,12861,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616218,,1015,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,51,,,8,5104,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616219,,1016,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,51,,,8,5105,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616220,,1017,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,51,,,8,16312,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL833493,,1018,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,9606.0,51,,Homo sapiens,9,15180,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616221,,1019,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,51,,,8,5033,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616222,,1020,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,9606.0,51,,Homo sapiens,9,16909,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616223,,1021,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,51,,,8,2590,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616224,,1022,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,51,,,8,2590,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616225,,1023,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,51,,,8,16394,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL616226,,1024,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,9606.0,51,,Homo sapiens,9,4540,,,D,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616227,,1025,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,51,,,8,17296,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616228,,1026,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,51,,,8,17296,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616229,,1027,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,51,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616230,,1028,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,51,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616231,,1029,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,51,,,8,15779,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616232,,1030,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,51,,,8,6166,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616233,,1031,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,51,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL857973,,1032,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,51,,,8,4199,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL616234,,1033,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,51,,,8,15316,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616235,,1034,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,51,,,8,14875,,,H,B
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL616236,,1035,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,51,,,8,14727,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616237,,1036,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,51,,,8,14727,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616238,,1037,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,51,,,8,15146,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616239,,1038,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,51,,,8,5213,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL616240,,1039,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,51,,,8,16429,,,H,B
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL616241,,1040,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,9606.0,51,,Homo sapiens,9,15042,,,D,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616242,,1041,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,51,,,8,14818,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616243,,1042,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,51,,,8,4829,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616244,,1043,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,51,,,9,17200,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616245,,1044,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,9606.0,51,,Homo sapiens,9,13051,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616246,,1045,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,106,,,8,5486,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616247,,1046,Binding affinity against 5-HT1D receptor,,105,,,8,5254,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616248,,1047,Binding affinity against 5-hydroxytryptamine 1A receptor,,105,,,8,5254,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616249,,1048,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,107,,,8,15331,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616250,,1049,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,9606.0,10576,,Homo sapiens,8,13506,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616251,,1050,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,51,,,8,15267,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616252,,1051,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,11863,,,8,16616,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616253,,1052,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,11863,,,8,16616,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616254,,1053,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,11863,,,8,16616,,,H,F
BAO_0000218,Expert,,,1,,,,,CHEMBL616255,,1054,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,10090.0,11863,,Mus musculus,9,16616,,,D,F
BAO_0000218,Expert,,,1,,,,,CHEMBL832872,,1055,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,10090.0,11863,,Mus musculus,9,16616,,,D,F
BAO_0000218,Expert,,,1,,,,,CHEMBL616256,,1056,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,10090.0,11863,,Mus musculus,9,16616,,,D,F
BAO_0000218,Expert,,,1,,,,,CHEMBL616257,,1057,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,10090.0,11863,,Mus musculus,9,16616,,,D,F
BAO_0000218,Expert,,,1,,,,,CHEMBL616258,,1058,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,10090.0,11863,,Mus musculus,9,16616,,,D,F
BAO_0000218,Expert,,,1,,,,,CHEMBL616384,,1059,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,10090.0,11863,,Mus musculus,9,16616,,,D,F
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616385,,1060,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,11863,,,8,10297,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616386,,1061,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,11863,,,8,13704,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616387,,1062,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10090.0,11863,,Mus musculus,9,10297,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616388,,1063,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,11863,,,8,10297,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616389,,1064,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10090.0,11863,,Mus musculus,9,10297,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616390,,1065,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,11863,,,8,10297,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616391,,1066,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,11863,,,8,217,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616392,,1067,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,10090.0,11863,,Mus musculus,9,10297,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616393,,1068,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,9823.0,51,,Sus scrofa,8,4921,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616394,,1069,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,9823.0,51,,Sus scrofa,8,4921,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616395,,1070,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,9823.0,51,,Sus scrofa,8,4996,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616396,,1071,Compound was evaluated for the binding affinity at 5- HT1A receptor,9823.0,51,,Sus scrofa,8,12918,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872907,,1072,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,9823.0,51,,Sus scrofa,8,5333,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616397,,1073,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,9823.0,51,,Sus scrofa,8,4437,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616398,,1074,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,9823.0,51,,Sus scrofa,8,1742,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616399,,1075,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,9823.0,51,,Sus scrofa,8,16688,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL857065,,1076,Binding activity radioligand.,9823.0,51,,Sus scrofa,8,12861,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616400,,1077,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,9823.0,51,,Sus scrofa,8,12861,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616401,,1078,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,9823.0,51,,Sus scrofa,8,12861,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616402,,1079,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,10624,,,8,12490,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616403,,1080,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,9823.0,51,,Sus scrofa,8,11828,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616404,,1081,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,9823.0,51,,Sus scrofa,8,11866,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616405,,1082,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,9823.0,51,,Sus scrofa,8,12827,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616406,,1083,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,9823.0,51,,Sus scrofa,8,12918,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616407,,1084,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,9823.0,51,,Sus scrofa,8,12919,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616408,,1085,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,9986.0,51,,Oryctolagus cuniculus,8,13047,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616409,,1086,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,10116.0,10576,,Rattus norvegicus,9,15796,,,D,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616410,,1087,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",10116.0,10576,,Rattus norvegicus,9,3651,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616411,,1088,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,10576,,,8,188,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616412,,1089,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10116.0,10576,Membranes,Rattus norvegicus,9,16616,,,D,F
BAO_0000249,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616413,,1090,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10116.0,10576,Membranes,Rattus norvegicus,9,16616,,,D,F
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616414,,1091,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576,,,8,12306,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616415,,1092,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,10116.0,10576,,Rattus norvegicus,9,17167,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616416,,1093,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,10576,,,8,14776,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616417,,1094,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,10576,,,8,12158,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616418,,1095,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,10576,,,8,13481,,,H,B
BAO_0000219,Autocuration,In vitro,,1,,,,,CHEMBL616419,,1096,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,10576,,,8,13427,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616420,,1097,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,10576,,,8,10210,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616421,,1098,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,10576,Membranes,,8,10205,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616422,,1099,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,10576,Membranes,,8,10205,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616423,,1100,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,10576,Membranes,,8,10205,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616424,,1101,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,10116.0,10576,,Rattus norvegicus,9,12280,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616425,,1102,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,10576,,,8,17386,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616426,,1103,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,10576,,,8,13654,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616427,,1104,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,10576,,,8,14423,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616428,,1105,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,10576,,,8,15412,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616290,,1106,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,,8,12073,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616052,,1107,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,10116.0,10576,,Rattus norvegicus,9,4101,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616053,,1108,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,10576,,,8,10062,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616054,,1109,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,10576,,,8,6238,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616055,,1110,Binding affinity towards 5-hydroxytryptamine 1A receptor,,10576,,,8,16273,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616056,,1111,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,10576,,,8,11139,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616057,,1112,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,10576,,,8,16796,,,H,B
BAO_0000221,Expert,,,1,,Brain,,955.0,CHEMBL616058,,1113,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10116.0,10576,,Rattus norvegicus,9,9548,,,D,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL616059,,1114,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,10576,,,8,10381,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616060,,1115,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,10576,,,8,13408,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616061,,1116,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,10116.0,10576,,Rattus norvegicus,9,13825,,,D,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616062,,1117,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,10576,,,8,11147,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616063,,1118,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,10576,,,8,10552,,,H,B
BAO_0000249,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616064,,1119,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,10576,,,8,10552,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616065,,1120,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,10116.0,10576,Membranes,Rattus norvegicus,9,17136,,,D,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616066,,1121,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,10116.0,10576,Membranes,Rattus norvegicus,9,5778,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616067,,1122,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,10576,,,8,13481,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616068,,1123,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,10576,,,8,13481,,,H,B
BAO_0000221,Intermediate,,,1,,Hippocampus,,10000000.0,CHEMBL616069,,1124,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,10576,,,8,13630,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616070,,1125,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,10576,,,8,16245,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616071,,1126,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,10576,,,8,14509,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616072,,1127,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,10576,,,8,14509,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616073,,1128,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,10576,,,8,14509,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616074,,1129,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,10576,,,8,14509,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616075,,1130,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,10576,,,8,14256,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616076,,1131,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,10576,,,8,11139,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616077,,1132,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,10116.0,10576,,Rattus norvegicus,9,11047,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616078,,1133,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,10116.0,10576,,Rattus norvegicus,9,11047,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616079,,1134,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,10116.0,10576,,Rattus norvegicus,9,11047,,,D,B
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL616080,,1135,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10116.0,10576,,Rattus norvegicus,9,2395,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616081,,1136,Binding affinity towards 5-hydroxytryptamine 1A receptor,,10576,,,8,9699,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616082,,1137,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,10116.0,10576,,Rattus norvegicus,9,12028,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616083,,1138,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,10576,,,8,12028,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616084,,1139,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,10576,,,8,5815,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616085,,1140,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,10576,,,8,16616,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616086,,1141,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,10576,,,8,5815,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616087,,1142,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,10576,,,8,2761,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616088,,1143,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,10576,,,8,13133,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616089,,1144,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,10576,,,8,10444,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616090,,1145,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,10116.0,10576,,Rattus norvegicus,9,13278,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616091,,1146,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,10576,,,8,15874,,,H,B
BAO_0000249,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616092,,1147,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,10576,Membranes,,8,10552,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616093,,1148,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,10576,,,8,11130,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616094,,1149,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,10576,,,8,11130,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL616095,,1150,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,10576,,,8,14542,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616096,,1151,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10116.0,10576,,Rattus norvegicus,9,13670,,,D,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616097,,1152,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,10576,,,8,9888,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616098,,1153,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,10116.0,10576,Membranes,Rattus norvegicus,9,3678,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616099,,1154,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,10576,,,8,11332,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616100,,1155,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,10576,,,8,11332,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616101,,1156,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,10576,,,8,1185,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616102,,1157,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,10576,,,8,2014,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616103,,1158,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,10576,,,8,1185,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616104,,1159,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,10576,,,8,14429,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616105,,1160,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,10576,,,8,16288,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616106,,1161,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,10116.0,10576,,Rattus norvegicus,9,5432,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616107,,1162,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,10576,,,8,14429,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616108,,1163,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,10576,,,8,13672,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616109,,1164,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,10576,,,8,11296,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616110,,1165,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,10576,,,8,11296,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616111,,1166,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,10576,,,8,14749,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616112,,1167,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,10576,,,8,15086,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616113,,1168,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,10576,,,8,13462,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616114,,1169,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,10576,,,8,15363,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616115,,1170,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,10576,,,8,15363,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616116,,1171,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,10576,,,8,10796,,,H,B
BAO_0000221,Expert,,,1,,Brain,,955.0,CHEMBL615844,,1172,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,10576,,,8,12816,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615939,,1173,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,10576,,,8,13542,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615940,,1174,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,10576,,,8,13308,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615941,,1175,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,10576,,,8,13541,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615942,,1176,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615943,,1177,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615944,,1178,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615945,,1179,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615946,,1180,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615947,,1181,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615948,,1182,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615949,,1183,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615950,,1184,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615951,,1185,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615952,,1186,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615953,,1187,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615954,,1188,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,10576,,,8,10058,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL615955,,1189,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10116.0,10576,,Rattus norvegicus,9,10058,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615956,,1190,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL615957,,1191,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,10576,,,8,10058,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615958,,1192,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,10576,,,8,12879,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615959,,1193,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,10576,,,8,11964,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615960,,1194,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,10576,,,8,11964,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615961,,1195,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,10576,,,8,11964,,,H,B
BAO_0000221,Expert,,,1,,Brain,,955.0,CHEMBL615962,,1196,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,10576,,,8,9548,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615963,,1197,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,10576,,,8,9098,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615964,,1198,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,10576,,,8,9098,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615965,,1199,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,10576,,,8,9098,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615966,,1200,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,10576,,,8,13248,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL615967,,1201,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,10576,,,8,3147,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615968,,1202,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,10576,,,8,13949,,,H,B
BAO_0000218,Autocuration,,449.0,1,,,CHO,,CHEMBL615969,,1203,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,10576,,,8,11883,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL615970,,1204,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,10576,,,8,11883,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615971,,1205,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,10116.0,10576,,Rattus norvegicus,9,11883,,,D,B
BAO_0000249,Expert,,,1,,,,,CHEMBL615972,,1206,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,10576,Membranes,,8,15535,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL615973,,1207,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,10576,,,8,15535,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL615974,,1208,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,10576,,,8,15535,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL615975,,1209,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,9606.0,51,,Homo sapiens,9,16372,,,D,B
BAO_0000249,Expert,,,1,,,,,CHEMBL615976,,1210,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,10576,,,8,14608,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL872106,,1211,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,10116.0,10576,,Rattus norvegicus,9,4795,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615977,,1212,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615978,,1213,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616166,,1214,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616167,,1215,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616168,,1216,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616169,,1217,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616170,,1218,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616171,,1219,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616172,,1220,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616173,,1221,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616174,,1222,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616175,,1223,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616176,,1224,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616177,,1225,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616178,,1226,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,10576,,,8,13863,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616179,,1227,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,10576,,,8,9742,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616180,,1228,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,10576,,,8,12073,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616181,,1229,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,10576,,,8,4101,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616182,,1230,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,10576,,,8,15360,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616183,,1231,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,10576,,,8,11576,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615874,,1232,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,10576,,,8,5834,,,H,B
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL615875,,1233,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10116.0,10576,,Rattus norvegicus,9,2395,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615876,,1234,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,10576,,,8,1375,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615877,,1235,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,10576,,,8,1375,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL615878,,1236,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,10576,,,8,3967,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615879,,1237,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,10576,,,8,12884,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL615880,,1238,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,10576,,,8,2343,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615881,,1239,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,10576,,,8,11511,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL615882,,1240,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10116.0,10576,,Rattus norvegicus,9,11511,,,D,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615883,,1241,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615884,,1242,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615885,,1243,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615886,,1244,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615887,,1245,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615888,,1246,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615889,,1247,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615890,,1248,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615891,,1249,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615892,,1250,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615893,,1251,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615894,,1252,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615895,,1253,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615896,,1254,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,10576,,,8,16394,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL615897,,1255,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,10576,,,8,16394,,,H,F
BAO_0000249,Expert,,,1,,,,,CHEMBL615898,,1256,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10116.0,10576,Membranes,Rattus norvegicus,9,16616,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL615899,,1257,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,10576,,,8,16796,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616291,,1258,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,10576,,,8,16796,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616292,,1259,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,10576,,,8,15629,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616293,,1260,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,10576,,,8,13241,,,H,F
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616294,,1261,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,,8,12073,,,H,B
BAO_0000249,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616295,,1262,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,10576,,,8,14286,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL616296,,1263,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,10576,,,8,14542,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616297,,1264,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616605,,1265,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616606,,1266,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616607,,1267,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,10576,,,8,13630,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616608,,1268,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616609,,1269,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616610,,1270,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,10116.0,10576,,Rattus norvegicus,9,13630,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616611,,1271,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616612,,1272,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616613,,1273,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616614,,1274,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616615,,1275,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616616,,1276,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616617,,1277,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616618,,1278,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616619,,1279,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616620,,1280,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616621,,1281,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616622,,1282,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,10576,,,8,13630,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616146,,1283,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL832873,,1284,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616147,,1285,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872872,,1286,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616148,,1287,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,10576,,,8,13630,,,H,F
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616149,,1288,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,10576,,,8,9783,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616150,,1289,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,10576,,,8,9783,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616151,,1290,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,10116.0,10576,Membranes,Rattus norvegicus,9,14331,,,D,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL872873,,1291,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,10576,,,8,15260,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616670,,1292,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,10576,,,8,15260,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616671,,1293,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,10576,,,8,15260,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL884861,,1294,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10116.0,10576,,Rattus norvegicus,9,16616,,,D,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616672,,1295,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,10576,,,8,15629,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616673,,1296,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,10576,,,8,15086,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616674,,1297,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,10576,,,8,5717,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616675,,1298,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,10576,,,8,12652,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616676,,1299,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,10576,,,8,14608,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616677,,1300,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576,,,8,12306,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616678,,1301,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576,,,8,12306,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616679,,1302,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10116.0,10576,,Rattus norvegicus,9,15247,,,D,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616680,,1303,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,10576,,,8,17529,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616681,,1304,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,,8,14826,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616682,,1305,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,,8,14826,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616683,,1306,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,10576,,,8,13241,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616684,,1307,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,10576,,,8,14093,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616685,,1308,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,10576,,,8,14093,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL616686,,1309,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,10576,,,8,14442,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616687,,1310,Affinity for 5-hydroxytryptamine 1A receptor site,,10576,,,8,9919,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616688,,1311,Affinity for 5-hydroxytryptamine 1A receptor site,,10576,,,8,9919,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616689,,1312,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,10576,,,8,11440,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616690,,1313,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,10576,,,8,11257,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616691,,1314,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,10576,,,8,10330,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616692,,1315,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,10116.0,10576,,Rattus norvegicus,9,17331,,,D,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616693,,1316,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,10576,,,8,16567,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616694,,1317,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10116.0,10576,,Rattus norvegicus,9,12058,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616695,,1318,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,10576,,,8,9699,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616696,,1319,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,10576,,,8,9547,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616697,,1320,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,10576,,,8,10330,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616698,,1321,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,10576,,,8,14331,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616949,,1322,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,10116.0,10576,,Rattus norvegicus,9,14060,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616950,,1323,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,10576,,,8,14744,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL832875,,1324,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,10576,,,8,13506,,,H,B
BAO_0000221,Expert,,,1,,Brain,,955.0,CHEMBL616951,,1325,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10576,,,8,10862,,,H,B
BAO_0000221,Expert,,,1,,Brain,,955.0,CHEMBL616952,,1326,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10576,,,8,10862,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616953,,1327,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,10576,,,8,10062,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616954,,1328,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,10576,,,8,12073,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616955,,1329,GTPgammaS radioligand binding assay,,106,,,8,14875,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616956,,1330,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,106,,,8,2391,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616957,,1331,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,106,,,8,2391,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616958,,1332,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,106,,,8,2391,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616959,,1333,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,106,,,8,2391,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616960,,1334,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,106,,,8,2391,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616961,,1335,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,106,,,8,2391,,,H,F
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL616962,,1336,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,106,,,8,17211,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL616963,,1337,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,106,,,8,17211,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616524,,1338,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,9606.0,106,,Homo sapiens,9,6491,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616525,,1339,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,106,,,8,16190,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872908,,1340,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,106,,,8,14165,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616526,,1341,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,106,,,8,14165,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616527,,1342,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,9606.0,106,,Homo sapiens,9,4234,,,D,B
BAO_0000219,Expert,,,1,,,,,CHEMBL616528,,1343,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,106,,,8,6328,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616529,,1344,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,106,,,8,14770,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616530,,1345,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,106,,,8,2598,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616531,,1346,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,106,,,8,6897,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616532,,1347,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,106,,,8,6897,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616533,,1348,Binding affinity towards 5-hydroxytryptamine 1B receptor,,106,,,8,6013,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616534,,1349,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,106,,,8,5843,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616535,,1350,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,106,,,8,14454,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616536,,1351,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,106,,,8,16209,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616537,,1352,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,106,,,8,3935,,,H,B
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL616538,,1353,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,106,,,8,13729,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616539,,1354,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,106,,,8,14251,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616540,,1355,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,106,,,8,17085,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616429,,1356,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,106,,,8,3025,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616430,,1357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,106,,,8,15315,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL616431,,1358,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,9606.0,106,,Homo sapiens,9,14214,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616432,,1359,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,9606.0,106,,Homo sapiens,9,3804,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616433,,1360,Affinity for 5-hydroxytryptamine 1B receptor subtype,9606.0,106,,Homo sapiens,9,2391,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616434,,1361,Binding affinity for human 5-hydroxytryptamine 1B receptor,9606.0,106,,Homo sapiens,9,4175,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616435,,1362,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,106,,,8,17296,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616436,,1363,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,106,,,8,17085,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL616437,,1364,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,106,,,8,17211,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL616438,,1365,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,106,,,8,17211,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL616439,,1366,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,106,,,8,17211,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616440,,1367,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,9606.0,106,,Homo sapiens,9,15926,,,D,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL616441,,1368,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,106,,,8,16312,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616442,,1369,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,106,,,8,5843,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616443,,1370,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,106,,,8,5843,,,H,B
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL616444,,1371,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,106,,,8,16312,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616445,,1372,Binding activity against human 5-hydroxytryptamine 1B receptor,9606.0,106,,Homo sapiens,9,15926,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616446,,1373,Binding activity against human 5-hydroxytryptamine 1B receptor,9606.0,106,,Homo sapiens,9,15926,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616447,,1374,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,9606.0,106,,Homo sapiens,9,4540,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616448,,1375,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,106,,,8,6166,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616449,,1376,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,106,,,8,17296,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616450,,1377,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,106,,,8,17296,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL857974,,1378,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,106,,,8,17296,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616451,,1379,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,106,,,8,15779,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616452,,1380,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,106,,,8,15779,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616453,,1381,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,106,,,8,15779,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616454,,1382,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,106,,,8,4199,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616455,,1383,Binding affinity for human 5-hydroxytryptamine 1B receptor,9606.0,106,,Homo sapiens,9,14875,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616456,,1384,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,106,,,8,15146,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616457,,1385,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,106,,,8,5213,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616458,,1386,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,106,,,8,14818,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616459,,1387,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,106,,,8,4829,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616460,,1388,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,106,,,8,14454,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616461,,1389,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,106,,,8,14454,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616462,,1390,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,106,,,8,14875,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616463,,1391,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,106,,,8,14875,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616464,,1392,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,105,,,8,15250,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616465,,1393,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,105,,,8,15250,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL832874,,1394,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,17105,,,8,15086,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616184,,1395,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,9986.0,106,,Oryctolagus cuniculus,8,3025,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616185,,1396,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,9986.0,106,,Oryctolagus cuniculus,8,14998,,,H,B
BAO_0000019,Intermediate,,,1,,,,,CHEMBL616186,,1397,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",9986.0,106,,Oryctolagus cuniculus,8,14998,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616187,,1398,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,9986.0,106,,Oryctolagus cuniculus,8,14998,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616188,,1399,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,10577,,,8,13969,,,H,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL873475,,1400,Binding affinity for 5-hydroxytryptamine 1B receptor,,10577,,,9,13392,,,D,B
BAO_0000019,Expert,,,1,,Striatum,,2435.0,CHEMBL616189,,1401,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,10116.0,10577,,Rattus norvegicus,9,3651,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616190,,1402,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,10577,,,8,10025,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616191,,1403,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616192,,1404,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616193,,1405,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616194,,1406,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616195,,1407,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,10576,,,8,13863,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616196,,1408,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,10576,,,8,13863,,,H,B
BAO_0000249,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616197,,1409,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,10576,,,8,4622,,,H,B
BAO_0000019,Intermediate,,,1,,,,,CHEMBL616198,,1410,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,10576,,,8,14911,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616199,,1411,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,10576,,,8,12678,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616200,,1412,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,10576,,,8,12678,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616201,,1413,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,10576,,,8,14235,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616202,,1414,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,10576,,,8,14949,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616203,,1415,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,10576,,,8,14949,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616204,,1416,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,10576,,,8,14949,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616205,,1417,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,10576,,,8,14949,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616206,,1418,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,10576,,,8,14949,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616207,,1419,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,10576,,,8,16118,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616208,,1420,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,10576,,,8,3268,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616209,,1421,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,10576,,,8,3268,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616210,,1422,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,10576,,,8,16117,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616211,,1423,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,10576,,,8,9783,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616504,,1424,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,10576,,,8,9783,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616505,,1425,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10116.0,10576,,Rattus norvegicus,9,14356,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616506,,1426,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,10576,,,8,15740,,,H,F
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL872107,,1427,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,10576,,,8,12306,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616507,,1428,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,10116.0,10576,,Rattus norvegicus,9,13348,,,D,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616303,,1429,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,10576,,,8,10394,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616304,,1430,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,10576,,,8,15260,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616305,,1431,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10576,,,8,10046,,,H,B
BAO_0000221,Intermediate,,,1,,Hippocampus,,10000000.0,CHEMBL616306,,1432,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,10576,,,8,15260,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616307,,1433,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,10576,,,8,12851,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL881829,,1434,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,10116.0,10576,,Rattus norvegicus,9,2148,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616308,,1435,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,10576,,,8,13134,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616309,,1436,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,10576,,,8,12462,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616310,,1437,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,10576,,,8,12462,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616311,,1438,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,10576,,,8,12462,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616312,,1439,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,10576,,,8,11933,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616313,,1440,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,10576,,,8,11933,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616314,,1441,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10116.0,10576,,Rattus norvegicus,9,403,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616315,,1442,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,,8,15538,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616567,,1443,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,10576,,,8,15538,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616568,,1444,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,10576,,,8,15538,,,H,B
BAO_0000019,Intermediate,,,1,,,,,CHEMBL616569,,1445,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,10576,,,8,12464,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616570,,1446,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,10576,,,8,1455,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616571,,1447,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,10576,,,8,12652,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616572,,1448,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,10576,,,8,12639,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616573,,1449,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,10576,,,8,13949,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616574,,1450,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,10116.0,10576,,Rattus norvegicus,9,12463,,,D,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616575,,1451,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,10576,,,8,14829,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL872108,,1452,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,10576,,,8,14829,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616576,,1453,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,10576,,,8,12092,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616577,,1454,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,10576,,,8,403,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616578,,1455,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,10576,,,8,403,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616579,,1456,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,10576,,,8,3967,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616580,,1457,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,10116.0,10576,,Rattus norvegicus,9,12771,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616581,,1458,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,10576,,,8,15086,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616582,,1459,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,,8,14909,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616583,,1460,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,10576,,,8,14949,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616584,,1461,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,10116.0,10576,,Rattus norvegicus,9,2309,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616585,,1462,Binding affinity towards 5-hydroxytryptamine 1A receptor,,10576,,,8,4170,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616586,,1463,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,10116.0,10576,,Rattus norvegicus,9,11642,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616587,,1464,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,10576,,,8,11642,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616588,,1465,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,10576,,,8,12953,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616589,,1466,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,10576,,,8,12953,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616590,,1467,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,10576,,,8,12953,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616591,,1468,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,10576,,,8,12903,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616592,,1469,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,10576,,,8,12536,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616593,,1470,The inhibition activity of 5-HT1A at 1 uM,,10576,,,8,10058,,,H,B
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL616594,,1471,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,10576,,,8,12902,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616595,,1472,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,10576,,,8,14057,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616596,,1473,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,10576,,,8,11296,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616597,,1474,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,10576,,,8,11296,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616598,,1475,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,10576,,,8,11296,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616599,,1476,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,10116.0,10576,Membranes,Rattus norvegicus,9,16616,,,D,F
BAO_0000249,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616600,,1477,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10116.0,10576,Membranes,Rattus norvegicus,9,16616,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616601,,1478,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,10576,,,8,16567,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616602,,1479,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,10576,,,8,16567,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616603,,1480,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,10576,,,8,16567,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616604,,1481,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,10576,,,8,16567,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616316,,1482,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,10576,,,8,17136,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616317,,1483,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,10576,,,8,17136,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616318,,1484,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,10116.0,10576,,Rattus norvegicus,9,16616,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616319,,1485,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,10576,,,8,17331,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616320,,1486,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,10576,,,8,17331,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616321,,1487,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,10116.0,10576,,Rattus norvegicus,9,17167,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616322,,1488,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,10576,,,8,15740,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616323,,1489,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,10576,,,8,15740,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616324,,1490,Ratio of binding affinity to 5-HT 1A and D2 receptor,,10576,,,8,4671,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616325,,1491,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616326,,1492,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,10576,,,8,10058,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616327,,1493,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,10576,,,8,10058,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616328,,1494,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,10576,,,8,12073,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL858110,,1495,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,10576,,,8,2759,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616329,,1496,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,10576,,,8,2759,,,H,F
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616330,,1497,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,10576,,,8,2759,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616331,,1498,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,10576,,,8,2759,,,H,F
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616332,,1499,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,10576,,,8,2759,,,H,F
BAO_0000249,Autocuration,,,1,,Brain,,955.0,CHEMBL857063,,1500,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,10576,,,8,9737,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616333,,1501,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,10576,,,8,9737,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616334,,1502,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,10576,,,8,5717,,,H,F
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616335,,1503,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,10576,,,8,12253,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616336,,1504,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,10576,,,8,14025,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616337,,1505,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,10576,,,8,10425,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616338,,1506,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,10576,,,8,14998,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616339,,1507,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,10576,,,8,13694,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616340,,1508,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,10576,,,8,13694,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616341,,1509,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,10576,,,8,4342,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616342,,1510,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10116.0,10576,,Rattus norvegicus,9,12936,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616343,,1511,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,10116.0,10576,,Rattus norvegicus,9,13144,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616344,,1512,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,10576,,,8,13343,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616345,,1513,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,10576,,,8,12132,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616346,,1514,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,10576,,,8,15419,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616347,,1515,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,10576,,,8,1479,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616348,,1516,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,10576,,,8,14287,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616349,,1517,Binding affinity at 5-hydroxytryptamine 1A receptor,,10576,,,8,13116,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616152,,1518,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,10116.0,10576,Membranes,Rattus norvegicus,9,2759,,,D,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616153,,1519,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,10576,,,8,2759,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616154,,1520,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,10576,,,8,14748,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616155,,1521,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,10576,,,8,12304,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616156,,1522,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,10116.0,10576,,Rattus norvegicus,9,12409,,,D,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL616157,,1523,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,10116.0,10576,,Rattus norvegicus,9,12409,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616158,,1524,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,10576,,,8,13267,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616159,,1525,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,10576,,,8,15194,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616160,,1526,pKi value against rat 5-hydroxytryptamine 1A receptor.,,10576,,,8,14256,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616161,,1527,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,10576,,,8,16567,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616162,,1528,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,10576,,,8,15740,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL616163,,1529,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,10116.0,12687,,Rattus norvegicus,9,13278,,,D,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616164,,1530,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,10626,Membranes,,8,1970,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL616165,,1531,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,10576,,,8,10034,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616355,,1532,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,10116.0,51,,Rattus norvegicus,8,13348,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616356,,1533,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,10576,,,8,13630,,,H,F
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL616357,,1534,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10576,,,8,10862,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616358,,1535,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,10576,,,8,12058,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616359,,1536,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,51,,,8,4639,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616360,,1537,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,51,,,8,15453,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616361,,1538,Binding affinity towards 5-hydroxytryptamine 1A receptor,,51,,,8,4820,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616362,,1539,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,51,,,8,1089,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616363,,1540,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,51,Brain membranes,,8,386,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616364,,1541,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,51,,,8,6011,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616365,,1542,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,51,,,8,5014,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616366,,1543,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,51,,,8,4402,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL872906,,1544,Binding affinity towards 5-hydroxytryptamine 1A receptor,,51,,,8,17066,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616367,,1545,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,51,,,8,17515,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616368,,1546,Binding affinity against 5-hydroxytryptamine 1A receptor,,51,,,8,2474,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616369,,1547,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,51,,,8,4775,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616370,,1548,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,9606.0,51,,Homo sapiens,9,14294,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616371,,1549,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,9606.0,51,,Homo sapiens,9,14294,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616372,,1550,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,51,,,8,12249,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL616373,,1551,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,51,,,8,11376,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616374,,1552,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,51,,,8,2474,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL616375,,1553,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,51,,,8,13311,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616376,,1554,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,51,,,8,4373,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL857064,,1555,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,51,,,8,1633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616377,,1556,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,51,,,8,11866,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616378,,1557,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,51,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616379,,1558,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,51,,,8,4687,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616380,,1559,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,11863,,,8,16946,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616381,,1560,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,11863,,,8,13291,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616382,,1561,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,11863,,,8,14159,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616383,,1562,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,11863,,,8,10812,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616350,,1563,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,10090.0,11863,,Mus musculus,9,3032,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616351,,1564,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,11863,,,8,16655,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616352,,1565,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,11863,,,8,14532,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616353,,1566,Binding affinity against 5-hydroxytryptamine 1A receptor,,11863,,,8,13944,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616354,,1567,Binding affinity against serotonergic 5-HT1a receptor,,11863,,,8,13033,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616508,,1568,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,11863,,,8,10321,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616559,,1569,Binding affinity for 5-hydroxytryptamine 1A receptor,10090.0,11863,,Mus musculus,9,2968,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616560,,1570,Binding affinity at 5-hydroxytryptamine 1A receptor,,11863,,,8,13964,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616561,,1571,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,11863,,,8,15527,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616562,,1572,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,11863,,,8,12248,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616563,,1573,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,11863,,,8,12249,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616564,,1574,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,11863,,,8,15120,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616565,,1575,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,11863,,,8,13313,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL616566,,1576,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,11863,,,8,2613,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616989,,1577,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,11863,,,8,16700,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL857975,,1578,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,11863,,,8,2201,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616990,,1579,Binding affinity against 5-hydroxytryptamine 1A receptor,10090.0,11863,,Mus musculus,9,1274,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616991,,1580,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,11863,,,8,1317,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616992,,1581,Tested against 5-hydroxytryptamine 1A receptor,,11863,,,8,12146,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616993,,1582,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,11863,,,8,14059,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616994,,1583,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,9986.0,106,,Oryctolagus cuniculus,8,14025,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616995,,1584,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,9986.0,106,,Oryctolagus cuniculus,8,14025,,,H,B
BAO_0000219,Intermediate,,722.0,1,,,HEK293,,CHEMBL616996,,1585,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,9593.0,105571,,Gorilla gorilla,9,14447,,,D,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616997,,1586,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,10141.0,106,,Cavia porcellus,8,3025,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL616998,,1587,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,10141.0,106,,Cavia porcellus,8,3025,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616999,,1588,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,10141.0,106,,Cavia porcellus,8,15329,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617000,,1589,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,10141.0,106,,Cavia porcellus,8,15329,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617001,,1590,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,10141.0,106,,Cavia porcellus,8,15847,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL858111,,1591,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,10141.0,106,,Cavia porcellus,8,15847,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617002,,1592,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,106,,,8,14165,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617003,,1593,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,106,,,8,14214,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617004,,1594,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,106,,,8,14214,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL617005,,1595,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,9606.0,106,,Homo sapiens,9,14214,,,D,F
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL616623,,1596,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,9606.0,106,,Homo sapiens,9,13729,,,D,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616624,,1597,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,106,,,8,3025,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL883243,,1598,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,106,,,8,2391,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616625,,1599,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,106,,,8,2391,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616626,,1600,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,106,,,8,14956,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616627,,1601,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,106,,,8,2598,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616628,,1602,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,106,,,8,2598,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616629,,1603,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,106,,,8,2598,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616630,,1604,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,106,,,8,2598,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616631,,1605,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,106,,,8,14956,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616632,,1606,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,106,,,8,14956,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL616633,,1607,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,9606.0,106,,Homo sapiens,9,14214,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616634,,1608,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,106,,,8,3463,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616635,,1609,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,106,,,8,15331,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL885358,,1610,Binding affinity against 5-hydroxytryptamine 1B receptor,9606.0,106,,Homo sapiens,9,16146,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616636,,1611,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,9606.0,106,,Homo sapiens,9,14159,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616637,,1612,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,106,,,8,14158,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616638,,1613,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,106,,,8,14159,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616639,,1614,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,106,,,8,15250,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616640,,1615,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,106,,,8,15250,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616641,,1616,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,106,,,8,15331,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616642,,1617,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,106,,,8,15332,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616643,,1618,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,106,,,8,14956,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616644,,1619,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,106,,,8,3805,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616645,,1620,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,106,,,8,14875,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616646,,1621,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),9986.0,105,,Oryctolagus cuniculus,8,14454,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616647,,1622,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),9986.0,105,,Oryctolagus cuniculus,8,14454,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616509,,1623,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,105,,,8,16288,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616510,,1624,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,105,,,8,16288,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616511,,1625,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,105,,,8,16312,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616512,,1626,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,9913.0,105,,Bos taurus,8,1348,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616513,,1627,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,9913.0,105,,Bos taurus,8,5834,,,H,B
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616514,,1628,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,9913.0,105,,Bos taurus,8,13366,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616515,,1629,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,9913.0,105,,Bos taurus,8,1414,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616516,,1630,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,9913.0,105,,Bos taurus,8,14998,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616517,,1631,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,9913.0,105,,Bos taurus,8,11473,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616518,,1632,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,9913.0,105,,Bos taurus,8,11473,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616519,,1633,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,9913.0,105,,Bos taurus,8,10639,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616520,,1634,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,9913.0,105,,Bos taurus,8,10639,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616521,,1635,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,9913.0,105,,Bos taurus,8,1375,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616522,,1636,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,9913.0,105,,Bos taurus,8,1375,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL884531,,1637,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,9913.0,105,,Bos taurus,8,16532,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616523,,1638,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,9913.0,105,,Bos taurus,8,11147,,,H,B
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616731,,1639,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,9913.0,105,,Bos taurus,8,13366,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616732,,1640,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,9913.0,105,,Bos taurus,8,10444,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616733,,1641,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,9913.0,105,,Bos taurus,8,16532,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616734,,1642,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,9913.0,105,,Bos taurus,8,16532,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616735,,1643,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,9913.0,105,,Bos taurus,8,12827,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616736,,1644,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,9913.0,105,,Bos taurus,8,12827,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616737,,1645,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,9913.0,105,,Bos taurus,8,12919,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616738,,1646,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,9913.0,105,,Bos taurus,8,14025,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616739,,1647,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,9913.0,105,,Bos taurus,8,12919,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616740,,1648,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,9913.0,105,,Bos taurus,8,12919,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616741,,1649,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,9913.0,105,,Bos taurus,8,12919,,,H,F
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616742,,1650,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,9593.0,105,,Gorilla gorilla,8,14447,,,H,B
BAO_0000019,Intermediate,,,1,,,,,CHEMBL616743,,1651,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,10141.0,105570,,Cavia porcellus,9,1375,,,D,B
BAO_0000019,Intermediate,,,1,,,,,CHEMBL616744,,1652,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,10141.0,105570,,Cavia porcellus,9,1375,,,D,B
BAO_0000019,Intermediate,,,1,,,,,CHEMBL616745,,1653,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,10141.0,105570,,Cavia porcellus,9,12409,,,D,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL616746,,1654,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,10141.0,105570,,Cavia porcellus,9,12409,,,D,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL616747,,1655,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,10141.0,105570,,Cavia porcellus,9,12409,,,D,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL616748,,1656,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,10141.0,105570,,Cavia porcellus,9,12409,,,D,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL616648,,1657,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,10141.0,105570,,Cavia porcellus,9,12409,,,D,F
BAO_0000357,Intermediate,,,1,,,,,CHEMBL616649,,1658,Binding affinity against 5-hydroxytryptamine 1D receptor,10141.0,105570,,Cavia porcellus,9,11574,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL616650,,1659,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,10141.0,105570,,Cavia porcellus,9,1558,,,D,B
BAO_0000218,Intermediate,,,1,,,,,CHEMBL616651,,1660,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,10141.0,105570,,Cavia porcellus,9,12409,,,D,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL616652,,1661,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,10141.0,105570,,Cavia porcellus,9,12409,,,D,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL616653,,1662,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,10141.0,105570,,Cavia porcellus,9,12409,,,D,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL616654,,1663,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,10141.0,105570,,Cavia porcellus,9,12409,,,D,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL616655,,1664,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,10141.0,105570,,Cavia porcellus,9,12253,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL616656,,1665,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,10141.0,105570,,Cavia porcellus,9,12936,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616657,,1666,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,10141.0,105,,Cavia porcellus,8,13181,,,H,B
BAO_0000357,Intermediate,,,1,,Striatum,,2435.0,CHEMBL616658,,1667,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,10141.0,105570,,Cavia porcellus,9,12409,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL616659,,1668,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,10141.0,105570,,Cavia porcellus,9,10639,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616660,,1669,Binding affinity against 5-hydroxytryptamine 1D receptor,,51,,,8,5254,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616661,,1670,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,106,,,8,13051,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616662,,1671,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,105,,,8,3463,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616663,,1672,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,105,,,8,15315,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616664,,1673,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,105,,,8,6011,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL881820,,1674,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",9606.0,105,,Homo sapiens,9,14159,,,D,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616665,,1675,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,105,,,8,14159,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616666,,1676,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,105,,,8,15250,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616667,,1677,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,105,,,8,15250,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616668,,1678,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,105,,,8,15331,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616669,,1679,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",9606.0,105,,Homo sapiens,9,15332,,,D,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617040,,1680,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,105,,,8,15332,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617041,,1681,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,105,,,8,3294,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617042,,1682,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,105,,,8,14158,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617043,,1683,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,105,,,8,14956,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617044,,1684,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,105,,,8,12469,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617045,,1685,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,105,,,8,3463,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617046,,1686,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",9606.0,105,,Homo sapiens,9,15250,,,D,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617047,,1687,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",9606.0,105,,Homo sapiens,9,15250,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL617048,,1688,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,105,,,8,14956,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616897,,1689,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,105,,,8,14159,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616898,,1690,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",9606.0,105,,Homo sapiens,9,14159,,,D,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL858201,,1691,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,9606.0,105,,Homo sapiens,9,14499,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616899,,1692,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,105,,,8,15315,,,H,F
BAO_0000219,Autocuration,In vitro,,1,,,,,CHEMBL616900,,1693,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,105,,,8,3294,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616901,,1694,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,105,,,8,3463,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616902,,1695,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,105,,,8,15331,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616903,,1696,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,9606.0,105,,Homo sapiens,9,14159,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616904,,1697,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,105,,,8,14158,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616905,,1698,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,105,,,8,14159,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616906,,1699,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,105,,,8,15250,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616907,,1700,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,105,,,8,15250,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616908,,1701,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,105,,,8,15331,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616909,,1702,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,9606.0,105,,Homo sapiens,9,15332,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616910,,1703,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,9606.0,105,,Homo sapiens,9,14499,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616911,,1704,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,105,,,8,15332,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616912,,1705,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,105,,,8,14956,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616913,,1706,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,105,,,8,3805,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616914,,1707,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,9606.0,105,,Homo sapiens,9,6011,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616915,,1708,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,105,,,8,16190,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616916,,1709,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,105,,,8,14165,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616917,,1710,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,9606.0,105,,Homo sapiens,9,4234,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616918,,1711,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,105,,,8,15527,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL616919,,1712,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,105,,,8,6328,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616920,,1713,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,105,,,8,16209,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872914,,1714,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,105,,,8,14770,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616921,,1715,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,105,,,8,2598,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616922,,1716,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,105,,,8,6897,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616923,,1717,Binding affinity towards 5-hydroxytryptamine 1D receptor,,105,,,8,6013,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616924,,1718,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,105,,,8,5843,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL875909,,1719,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,105,,,8,14454,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616925,,1720,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,105,,,8,14454,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616926,,1721,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,105,,,8,14454,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616927,,1722,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,105,,,8,15818,,,H,B
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL616928,,1723,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,105,,,8,13729,,,H,F
BAO_0000219,Expert,In vitro,,1,,,,,CHEMBL616929,,1724,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),9606.0,105,,Homo sapiens,9,6011,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616930,,1725,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,9606.0,105,,Homo sapiens,9,4234,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616931,,1726,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,105,,,8,17085,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616932,,1727,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,105,,,8,3025,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616933,,1728,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,105,,,8,15315,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL616934,,1729,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,9606.0,105,,Homo sapiens,9,14214,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616935,,1730,Binding affinity for human 5-hydroxytryptamine 1D receptor,9606.0,105,,Homo sapiens,9,3804,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616936,,1731,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,105,,,8,16700,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616937,,1732,Affinity for 5-hydroxytryptamine 1D receptor subtype,9606.0,105,,Homo sapiens,9,2391,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616938,,1733,Binding affinity for human 5-hydroxytryptamine 1D receptor,9606.0,105,,Homo sapiens,9,4175,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616939,,1734,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,105,,,8,17085,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616940,,1735,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,105,,,8,17085,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616941,,1736,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,9606.0,105,,Homo sapiens,9,15926,,,D,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL616942,,1737,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,105,,,8,16312,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL616943,,1738,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,105,,,8,16312,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616944,,1739,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,104802,,,4,14956,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616945,,1740,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,105,,,8,3294,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616946,,1741,Binding activity radioligand.,,105,,,8,12861,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616947,,1742,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,105,,,8,12861,,,H,B
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL616948,,1743,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,105,,,8,16312,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616851,,1744,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,105,,,8,5104,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616852,,1745,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,105,,,8,5105,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616853,,1746,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,105,,,8,14499,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616854,,1747,Binding activity against human 5-hydroxytryptamine 1D receptor,9606.0,105,,Homo sapiens,9,15926,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616855,,1748,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,9606.0,105,,Homo sapiens,9,4540,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616856,,1749,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,105,,,8,15779,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616857,,1750,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,105,,,8,15779,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616858,,1751,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,105,,,8,6166,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616859,,1752,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,105,,,8,15779,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616860,,1753,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,105,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616861,,1754,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,105,,,8,17451,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616541,,1755,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,105,,,8,17451,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616542,,1756,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,105,,,8,17451,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616543,,1757,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,105,,,8,4199,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616544,,1758,Binding affinity for human 5-hydroxytryptamine 1D receptor,9606.0,105,,Homo sapiens,9,14875,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616545,,1759,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,105,,,8,15146,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616546,,1760,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,105,,,8,5213,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616547,,1761,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,105,,,8,14818,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616548,,1762,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,105,,,8,4829,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616549,,1763,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,105,,,8,14454,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616550,,1764,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,105,,,8,14454,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL857066,,1765,Binding affinity against 5-HT2C receptor,,108,,,8,5254,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616551,,1766,Binding affinity against 5-hydroxytryptamine 1D receptor,,108,,,8,5254,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616552,,1767,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,10577,,,8,10639,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL832876,,1768,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,10577,,,8,10639,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616553,,1769,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,10577,,,8,12352,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616554,,1770,Binding affinity towards 5-HT1B was determined,,10577,,,8,9098,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616555,,1771,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,10577,,,8,14430,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616556,,1772,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,10577,,,8,13657,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616557,,1773,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,10577,,,8,13657,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616558,,1774,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,10577,,,8,15854,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616749,,1775,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,10116.0,10577,,Rattus norvegicus,9,10639,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616750,,1776,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,10577,,,8,10025,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616751,,1777,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,10577,,,8,10025,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616752,,1778,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,10577,,,8,14286,,,H,B
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616753,,1779,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,10577,,,8,3651,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616754,,1780,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,10116.0,10577,,Rattus norvegicus,9,14178,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616755,,1781,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,10577,,,8,10639,,,H,B
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616756,,1782,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,10577,,,8,13605,,,H,B
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616757,,1783,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,10577,,,8,5834,,,H,B
BAO_0000357,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616758,,1784,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,10577,,,8,10922,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616759,,1785,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,10577,,,8,14286,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616760,,1786,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,10577,,,8,11825,,,H,B
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616761,,1787,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,10577,,,8,14826,,,H,B
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616762,,1788,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,10577,,,8,9699,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616763,,1789,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,10577,,,8,14423,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL872909,,1790,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,10577,,,8,10062,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616764,,1791,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,10577,,,8,10062,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616765,,1792,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,10116.0,10577,,Rattus norvegicus,9,12280,,,D,B
BAO_0000357,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616766,,1793,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,10577,,,8,15412,,,H,B
BAO_0000357,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616767,,1794,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,10577,,,8,15412,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616768,,1795,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,10577,,,8,10062,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616769,,1796,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,10577,,,8,11147,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616770,,1797,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,10577,,,8,9547,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616771,,1798,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,10577,,,8,10444,,,H,B
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL616772,,1799,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,10577,,,8,12469,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616773,,1800,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,10577,,,8,9098,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616774,,1801,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,10577,,,8,9098,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616775,,1802,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,10577,,,8,9699,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616776,,1803,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,10577,,,8,10394,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616777,,1804,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,10577,,,8,12092,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616778,,1805,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,10577,,,8,16700,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616779,,1806,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,10116.0,10577,,Rattus norvegicus,9,403,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616780,,1807,Binding affinity towards 5-hydroxytryptamine 1B receptor,10116.0,10577,,Rattus norvegicus,9,12771,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616781,,1808,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,10577,,,8,11642,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616782,,1809,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,10577,,,8,12953,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616783,,1810,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,10577,,,8,12953,,,H,B
BAO_0000019,Expert,,,1,,Striatum,,2435.0,CHEMBL616784,,1811,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,10577,,,8,12953,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616785,,1812,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,10577,,,8,12953,,,H,B
BAO_0000249,Autocuration,,,1,,Brain,,955.0,CHEMBL857067,,1813,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,10577,,,8,9737,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616786,,1814,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,10577,,,8,9737,,,H,B
BAO_0000249,Autocuration,,,1,,Brain,,955.0,CHEMBL616787,,1815,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,10577,,,8,9737,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616788,,1816,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,10577,,,8,12827,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616789,,1817,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,10577,,,8,5033,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616790,,1818,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,10116.0,10577,,Rattus norvegicus,9,9786,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616791,,1819,Binding affinity at 5-hydroxytryptamine 1B receptor,,10577,,,8,13116,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616792,,1820,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,10577,,,8,16429,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL616793,,1821,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,10116.0,10577,,Rattus norvegicus,9,12409,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616794,,1822,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,10577,,,8,15194,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616795,,1823,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,10577,,,8,15194,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616796,,1824,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,104686,,,4,5486,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616797,,1825,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,106,,,8,4639,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616798,,1826,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,106,Brain membranes,,8,386,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616799,,1827,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,106,,,8,2474,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616800,,1828,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,106,,,8,6011,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616801,,1829,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,106,,,8,5014,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616802,,1830,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,106,,,8,17515,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616803,,1831,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,106,,,8,4373,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL857068,,1832,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,106,,,8,1633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616804,,1833,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,106,,,8,1633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616805,,1834,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,106,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616806,,1835,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,106,,,8,4687,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616807,,1836,Binding affinity against 5-hydroxytryptamine 1B receptor,,106,,,8,11574,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616808,,1837,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,106,,,8,10321,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616809,,1838,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,106,,,8,15527,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616810,,1839,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,106,,,8,17200,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616811,,1840,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,104802,,,4,14423,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616812,,1841,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,9913.0,108,,Bos taurus,8,5834,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616813,,1842,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,9823.0,108,,Sus scrofa,8,11473,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616814,,1843,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,9823.0,108,,Sus scrofa,8,11473,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616815,,1844,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,9823.0,108,,Sus scrofa,8,10639,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616816,,1845,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,9823.0,108,,Sus scrofa,8,10639,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616817,,1846,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,9823.0,108,,Sus scrofa,8,14331,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616818,,1847,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,9823.0,108,,Sus scrofa,8,10796,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616819,,1848,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,9823.0,108,,Sus scrofa,8,9098,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616820,,1849,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,9823.0,108,,Sus scrofa,8,14331,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616821,,1850,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,9823.0,108,,Sus scrofa,8,11828,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616822,,1851,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,9823.0,108,,Sus scrofa,8,11866,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616823,,1852,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,9986.0,108,,Oryctolagus cuniculus,8,13047,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616824,,1853,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,10116.0,12689,,Rattus norvegicus,9,188,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616825,,1854,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,10116.0,12689,,Rattus norvegicus,9,11825,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616826,,1855,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,10116.0,12689,,Rattus norvegicus,9,11825,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616827,,1856,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,10116.0,12689,,Rattus norvegicus,9,11624,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616828,,1857,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,10116.0,12689,,Rattus norvegicus,9,11139,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616829,,1858,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,10116.0,12689,,Rattus norvegicus,9,11147,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616830,,1859,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,10116.0,12689,,Rattus norvegicus,9,10444,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616831,,1860,Binding affinity against 5-hydroxytryptamine 1C receptor,10116.0,12689,,Rattus norvegicus,9,11624,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616832,,1861,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",10116.0,12689,,Rattus norvegicus,9,11662,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616833,,1862,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",10116.0,12689,,Rattus norvegicus,9,11662,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616834,,1863,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",10116.0,12689,,Rattus norvegicus,9,11662,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL829595,,1864,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",10116.0,12689,,Rattus norvegicus,9,11662,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616835,,1865,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,10116.0,12689,,Rattus norvegicus,9,9098,,,D,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL872910,,1866,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,10116.0,12689,,Rattus norvegicus,9,10394,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616836,,1867,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,12689,,,8,11933,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616837,,1868,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,10116.0,12689,,Rattus norvegicus,9,12092,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616466,,1869,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,10116.0,12689,,Rattus norvegicus,9,12253,,,D,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616467,,1870,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,10116.0,12689,,Rattus norvegicus,9,12253,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616468,,1871,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,108,,,8,1558,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616469,,1872,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,108,,,8,2474,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616470,,1873,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,108,,,8,2474,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616471,,1874,Binding affinity against 5-hydroxytryptamine 1C receptor,,12689,,,8,11574,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616472,,1875,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,12689,,,8,1558,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616473,,1876,Binding affinity against 5-hydroxytryptamine 1C receptor,,12689,,,8,13944,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616474,,1877,Binding affinity against serotonergic 5-HT1c receptor,,12689,,,8,13033,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616475,,1878,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,12689,,,8,10321,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616476,,1879,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,12689,,,8,11866,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616477,,1880,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),9986.0,105,,Oryctolagus cuniculus,8,14454,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616478,,1881,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,104686,,,4,11574,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616479,,1882,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,104686,,,4,11574,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616480,,1883,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,104686,,,4,13631,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616481,,1884,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,10116.0,104686,,Rattus norvegicus,5,9630,,,D,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616482,,1885,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,10116.0,104686,,Rattus norvegicus,5,8822,,,D,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL884713,,1886,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,10116.0,104686,,Rattus norvegicus,5,9064,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616483,,1887,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,104686,,,4,8868,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616484,,1888,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,104686,,,4,9064,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616485,,1889,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,104686,,,4,9806,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616486,,1890,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,104686,,,4,9098,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616487,,1891,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,104686,,,4,8868,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616488,,1892,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,104686,,,4,12765,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616489,,1893,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686,,,4,11049,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616490,,1894,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686,,,4,11049,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616491,,1895,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,104686,,,4,11049,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616492,,1896,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,104686,,,4,11049,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616493,,1897,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686,,,4,11049,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616494,,1898,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,104686,,,4,11473,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616495,,1899,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,104686,,,4,11473,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616496,,1900,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,104686,,,4,3086,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616497,,1901,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686,,,4,11049,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616498,,1902,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,104686,,,4,11049,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616499,,1903,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,104686,,,4,10639,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616500,,1904,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,104686,,,4,10922,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL616501,,1905,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,10116.0,104686,,Rattus norvegicus,5,9064,,,D,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL616502,,1906,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,104686,,,4,10748,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL884529,,1907,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,104686,Membranes,,4,11614,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616503,,1908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,104686,Membranes,,4,11615,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616964,,1909,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,104686,,,4,11615,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616965,,1910,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,104686,Membranes,,4,11614,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616966,,1911,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,104686,,,4,11702,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616967,,1912,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,104686,,,4,11702,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616968,,1913,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,10116.0,104686,,Rattus norvegicus,5,11702,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616969,,1914,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,104686,,,4,11702,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL884530,,1915,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,104686,,,4,13346,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616970,,1916,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,104686,,,4,10025,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616971,,1917,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,104686,,,4,10025,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616972,,1918,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,104686,,,4,10025,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616973,,1919,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,104686,,,4,9036,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616974,,1920,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,104686,,,4,9036,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616975,,1921,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616976,,1922,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,104686,,,4,12304,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616977,,1923,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,104686,,,4,13276,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616978,,1924,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,104686,,,4,11825,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616979,,1925,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,104686,,,4,12443,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616980,,1926,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,104686,,,4,13830,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616981,,1927,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,104686,Membranes,,4,9592,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL616982,,1928,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,104686,Membranes,,4,9592,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616983,,1929,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,104686,,,4,10881,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616984,,1930,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,104686,,,4,13605,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616985,,1931,Inhibitory activity against 5-hydroxytryptamine 2 receptor,10116.0,104686,,Rattus norvegicus,5,11624,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616986,,1932,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,104686,,,4,4101,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL616987,,1933,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,104686,,,4,4101,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616988,,1934,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,104686,,,4,15360,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617243,,1935,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,104686,,,4,11576,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617244,,1936,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,104686,,,4,5834,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL617245,,1937,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,10116.0,104686,,Rattus norvegicus,5,2395,,,D,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617246,,1938,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,104686,Membranes,,4,11965,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617546,,1939,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,104686,,,4,3967,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617547,,1940,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,104686,Brain membranes,,4,11130,,,H,B
BAO_0000219,Autocuration,In vitro,,1,,,,,CHEMBL617548,,1941,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,104686,,,4,13427,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617549,,1942,Binding affinity towards 5-hydroxytryptamine 2 receptor,,104686,,,4,9443,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617550,,1943,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,104686,,,4,9443,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617551,,1944,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,104686,,,4,11825,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617552,,1945,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,104686,Membranes,,4,12120,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617553,,1946,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,104686,Membranes,,4,12120,,,H,B
BAO_0000019,Autocuration,,,1,,Thoracic aorta,,1515.0,CHEMBL617554,,1947,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,104686,,,4,11963,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617555,,1948,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,104686,,,4,9069,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617556,,1949,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,104686,,,4,8868,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617557,,1950,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,10624,,,8,17200,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617558,,1951,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,10624,,,8,17200,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617559,,1952,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,17106,,,8,13969,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617560,,1953,Binding affinity for 5-hydroxytryptamine 1D receptor,,17106,,,9,13392,,,D,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617561,,1954,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,17106,,,8,1742,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617562,,1955,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,17106,,,8,1742,,,H,B
BAO_0000357,Autocuration,,,1,,Striatum,,2435.0,CHEMBL617563,,1956,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,17106,,,8,14331,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617564,,1957,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,17106,,,8,12861,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL617565,,1958,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,17106,,,8,12861,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL856076,,1959,Binding activity radioligand.,,17106,,,8,12861,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617566,,1960,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,17106,,,8,12861,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL875911,,1961,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,17106,,,8,12861,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617567,,1962,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,17106,,,8,12861,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617568,,1963,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,17106,,,8,675,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617569,,1964,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,17106,,,8,12490,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL617570,,1965,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,17106,,,8,11828,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617571,,1966,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,17106,,,8,11866,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617572,,1967,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,9823.0,105,,Sus scrofa,8,773,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617573,,1968,The compound was tested for intrinsic activity against 5-HT1D receptor,9986.0,105,,Oryctolagus cuniculus,8,13047,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617574,,1969,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,9986.0,105,,Oryctolagus cuniculus,8,13047,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617575,,1970,The compound was tested for binding affinity against 5-HT1D receptor,9986.0,105,,Oryctolagus cuniculus,8,13047,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617576,,1971,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,10578,,,8,188,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617577,,1972,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,10578,,,8,10639,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617578,,1973,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,10578,,,8,12438,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617579,,1974,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,10578,,,8,12438,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617580,,1975,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,10578,,,8,15854,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617581,,1976,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,10578,,,8,10394,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617582,,1977,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,10578,,,8,12092,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617583,,1978,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,10578,,,8,3389,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617584,,1979,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,105,,,8,6011,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617585,,1980,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,105,,,8,4639,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL875912,,1981,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,105,,,8,2474,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617586,,1982,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,105,,,8,5014,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617587,,1983,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,105,,,8,17515,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617588,,1984,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,105,,,8,11866,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL857980,,1985,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,105,,,8,4687,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617589,,1986,Tested against 5-hydroxytryptamine 1D receptor,,105,,,8,12146,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617590,,1987,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,105,,,8,10321,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617591,,1988,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,105,,,8,13267,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617592,,1989,Binding affinity against 5-Hydroxytryptamine 1D receptor,9606.0,105,,Homo sapiens,9,1274,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617593,,1990,,,105,,,8,15250,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL617594,,1991,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,106,,,8,13706,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL617595,,1992,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,105,,,8,13706,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617596,,1993,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,105,,,8,13706,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617597,,1994,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,105,,,8,13706,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617598,,1995,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,105,,,8,13047,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872916,,1996,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,105,,,8,13366,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617599,,1997,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,105,,,8,13366,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617091,,1998,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,105,,,8,1558,,,H,B
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL617092,,1999,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,105,,,8,12902,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL617093,,2000,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,105,,,8,13706,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617094,,2001,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,105,,,8,13706,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617095,,2002,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,105,,,8,13706,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617096,,2003,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,105,,,8,14251,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617097,,2004,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,105,,,8,14251,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617098,,2005,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,105,,,8,14251,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617301,,2006,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,105,,,8,13313,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617302,,2007,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,105,,,8,13313,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617303,,2008,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,105,,,8,13366,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617304,,2009,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,105,,,8,13051,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617305,,2010,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,105,,,8,12903,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617306,,2011,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,9606.0,105,,Homo sapiens,9,12469,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617307,,2012,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,17106,,,8,5619,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617308,,2013,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,9986.0,105,,Oryctolagus cuniculus,8,13047,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617309,,2014,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,105,,,8,16633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617310,,2015,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,105,,,8,16633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617311,,2016,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,105,,,8,16633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617312,,2017,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,105,,,8,16633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617313,,2018,Affinity against 5-hydroxytryptamine 1D receptor alpha,,105,,,8,3269,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617314,,2019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,105,,,8,12409,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617315,,2020,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,106,,,8,13706,,,H,F
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617316,,2021,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,106,,,8,13706,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617317,,2022,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,106,,,8,13706,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617318,,2023,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,106,,,8,12903,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617319,,2024,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,106,,,8,13047,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617320,,2025,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,106,,,9,13366,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617321,,2026,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,106,,,9,13366,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617322,,2027,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,106,,,9,13366,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616862,,2028,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,106,,,8,13366,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616863,,2029,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,106,,,8,13366,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616864,,2030,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,106,,,8,12469,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL616865,,2031,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,106,,,8,13706,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL616866,,2032,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,106,,,8,13706,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616867,,2033,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,106,,,8,13706,,,H,F
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL616868,,2034,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,106,,,8,12902,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616869,,2035,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,105,,,8,13051,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616870,,2036,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,106,,,8,12903,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL616871,,2037,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,105,,,8,1558,,,H,F
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL616872,,2038,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,105,,,8,1558,,,H,F
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL616873,,2039,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,105,,,8,1558,,,H,F
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL616838,,2040,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,105,,,8,1558,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616839,,2041,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,105,,,8,1558,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616840,,2042,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,9986.0,106,,Oryctolagus cuniculus,8,13047,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616841,,2043,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,105,,,8,13313,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616842,,2044,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,105,,,8,13313,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL857976,,2045,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,105,,,8,12409,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616843,,2046,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,10618,,,8,15250,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616844,,2047,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,9606.0,10618,,Homo sapiens,9,1348,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616845,,2048,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,10618,,,8,1348,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616846,,2049,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,9606.0,10618,,Homo sapiens,9,4234,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616847,,2050,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,10618,,,8,16209,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616848,,2051,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,10618,,,8,10444,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616849,,2052,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,10618,,,8,3935,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872911,,2053,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,10618,,,8,15818,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616850,,2054,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,10618,,,8,17085,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616699,,2055,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,9606.0,10618,,Homo sapiens,9,12936,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616700,,2056,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,10618,,,8,6166,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616701,,2057,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,10618,,,8,15779,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616702,,2058,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,10618,,,8,15779,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616703,,2059,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,10618,,,8,15779,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616704,,2060,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,10618,,,8,13181,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616705,,2061,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,10618,,,8,4199,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616706,,2062,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,10618,,,8,14875,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616707,,2063,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,10618,,,8,15146,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616708,,2064,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,10618,,,8,5213,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616709,,2065,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,10618,,,8,12146,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616710,,2066,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,10618,,,8,13267,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616711,,2067,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,10618,,,8,14818,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616712,,2068,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,10618,,,8,4829,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616713,,2069,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,10618,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616714,,2070,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,10618,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616715,,2071,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,10618,,,8,14159,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616716,,2072,Binding affinity towards 5-hydroxytryptamine 1E receptor,,10618,,,8,16633,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616717,,2073,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,279,,,8,17085,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616718,,2074,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,279,,,8,17085,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL875905,,2075,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,279,,,8,16209,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616719,,2076,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,279,,,8,16209,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL616720,,2077,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,279,,,8,17085,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616721,,2078,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,279,,,8,14159,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616722,,2079,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,279,,,8,15250,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616723,,2080,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,279,,,8,3805,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL616724,,2081,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,279,,,8,16190,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616725,,2082,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,279,,,8,16190,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616726,,2083,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,279,,,8,16209,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616727,,2084,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,279,,,8,16209,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616728,,2085,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,279,,,8,16209,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL616729,,2086,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,279,,,8,6866,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL616730,,2087,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,279,,,8,17085,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617125,,2088,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,279,,,8,16312,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL857977,,2089,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,279,,,8,6166,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617126,,2090,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,279,,,8,15779,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617127,,2091,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,279,,,8,4199,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617128,,2092,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,279,,,8,14875,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617129,,2093,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,279,,,8,15146,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617130,,2094,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,279,,,8,5213,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617131,,2095,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,279,,,8,14818,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617132,,2096,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,279,,,8,4829,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617133,,2097,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,279,,,8,4829,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617134,,2098,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,279,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617135,,2099,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,279,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617136,,2100,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,279,,,8,5014,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617137,,2101,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,104686,,,4,11662,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617138,,2102,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,104686,,,4,11662,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617139,,2103,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,104686,,,4,11662,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617140,,2104,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,12687,,,8,14093,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617141,,2105,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,104686,,,4,11200,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL858112,,2106,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686,,,4,11200,,,H,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL617142,,2107,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,17005,,,8,12352,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617143,,2108,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",9913.0,22226,,Bos taurus,0,13657,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617144,,2109,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,9913.0,22226,,Bos taurus,0,14331,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617145,,2110,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,9913.0,22226,,Bos taurus,0,14331,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617146,,2111,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,22226,,,0,14331,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617147,,2112,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,10141.0,104784,,Cavia porcellus,4,12685,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617148,,2113,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,10141.0,104784,,Cavia porcellus,4,14389,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617149,,2114,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,10141.0,104784,,Cavia porcellus,4,14386,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617150,,2115,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,104784,,,4,5732,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617151,,2116,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,104784,,,4,16293,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617201,,2117,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,104784,,,4,2078,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617202,,2118,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,10209,,,8,5486,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617203,,2119,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,104826,,,4,11820,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617204,,2120,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,104826,,,4,10297,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617205,,2121,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,104826,,,4,13704,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617206,,2122,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,10090.0,104826,,Mus musculus,5,10297,,,D,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617207,,2123,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,104826,,,4,11820,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617208,,2124,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,10090.0,104826,,Mus musculus,5,10297,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617209,,2125,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,104826,,,4,11555,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617210,,2126,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,104826,,,4,11555,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617211,,2127,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,104826,,,4,11555,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617212,,2128,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,10090.0,104826,,Mus musculus,5,10297,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617213,,2129,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,9823.0,104784,,Sus scrofa,4,16688,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617214,,2130,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,9823.0,104784,,Sus scrofa,4,16688,,,H,B
BAO_0000221,Autocuration,,,1,,,,,CHEMBL617215,,2131,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,22226,,,0,5333,,,U,B
BAO_0000221,Autocuration,,,1,,,,,CHEMBL617216,,2132,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,22226,,,0,4437,,,U,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617217,,2133,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,9823.0,17005,,Sus scrofa,8,5033,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617218,,2134,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,104686,,,4,15267,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872913,,2135,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,104686,,,4,15267,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617219,,2136,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,104826,,,4,11820,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL873482,,2137,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,104686,,,4,9069,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617220,,2138,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,10116.0,104686,,Rattus norvegicus,5,9162,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617221,,2139,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,104686,,,4,9162,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617222,,2140,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,104686,,,4,9162,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL875906,,2141,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,104686,,,4,10428,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617223,,2142,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,104686,,,4,9628,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617224,,2143,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,104686,,,4,12704,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617225,,2144,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,10116.0,104686,,Rattus norvegicus,5,15453,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617226,,2145,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,104686,,,4,188,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617227,,2146,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,104686,,,4,10349,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617228,,2147,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,104686,,,4,10349,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617229,,2148,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,104686,,,4,8868,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617230,,2149,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,104686,,,4,10025,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617231,,2150,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,104686,,,4,10025,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617232,,2151,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,104686,,,4,11702,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617233,,2152,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,104686,,,4,11702,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617234,,2153,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,104686,,,4,11702,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617235,,2154,Compound was tested for the inhibition of quipazine induced head twitches in rats,,104686,,,4,11702,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617236,,2155,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,104686,,,4,11702,,,H,F
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL617237,,2156,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,104686,,,4,10085,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL617238,,2157,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,104686,,,4,10085,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL617239,,2158,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,10116.0,104686,,Rattus norvegicus,5,9630,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617240,,2159,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,104686,,,4,11070,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617241,,2160,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,104686,Membranes,,4,9841,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL875907,,2161,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,104686,Membranes,,4,9841,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617242,,2162,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,104686,,,4,13291,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617152,,2163,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,104686,,,4,10590,,,H,F
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL617153,,2164,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,10116.0,104686,,Rattus norvegicus,5,9064,,,D,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617154,,2165,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,10116.0,104686,Membranes,Rattus norvegicus,5,12268,,,D,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL617155,,2166,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,104686,,,4,13508,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617156,,2167,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,104686,,,4,11279,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617157,,2168,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,104686,,,4,11200,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617158,,2169,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686,,,4,11200,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617159,,2170,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,104686,,,4,11200,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617160,,2171,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,104686,,,4,11200,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL858113,,2172,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686,,,4,11200,,,H,F
BAO_0000220,Autocuration,,,1,,Brain,,955.0,CHEMBL617247,,2173,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,104686,,,4,9231,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617248,,2174,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,104686,,,4,9737,,,H,B
BAO_0000249,Autocuration,,,1,,Brain,,955.0,CHEMBL617249,,2175,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,104686,,,4,9737,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617250,,2176,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,104686,,,4,9737,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617251,,2177,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,104686,,,4,9737,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617252,,2178,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,10116.0,104686,,Rattus norvegicus,5,11828,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617006,,2179,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,104686,,,4,12253,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617007,,2180,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,104686,,,4,12253,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617008,,2181,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,104686,,,4,11279,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617009,,2182,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,104686,,,4,11866,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617010,,2183,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,10116.0,104686,,Rattus norvegicus,5,14424,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL857978,,2184,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,10116.0,104686,,Rattus norvegicus,5,15180,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617011,,2185,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,10116.0,104686,,Rattus norvegicus,5,15180,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617012,,2186,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,10116.0,104686,,Rattus norvegicus,5,9786,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617013,,2187,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,104686,,,4,12132,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617014,,2188,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,104686,,,4,5486,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617015,,2189,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,104686,,,4,15316,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617016,,2190,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,104686,,,4,16429,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617017,,2191,pKi value for 5-hydroxytryptamine 2 receptor binding site,,104686,,,4,14617,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL617018,,2192,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,104686,,,4,11351,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617019,,2193,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,104686,,,4,11279,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617020,,2194,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,105075,,,4,9523,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617021,,2195,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,105075,,,4,9523,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617022,,2196,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,105075,,,4,9523,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617023,,2197,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,105075,,,4,9523,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617024,,2198,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,105075,,,4,9523,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617025,,2199,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,105075,,,4,9523,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617026,,2200,Hill coefficient of compound was determined,,105075,,,4,9523,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617027,,2201,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,22226,,,0,4771,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617028,,2202,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,10116.0,104686,,Rattus norvegicus,5,5033,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617029,,2203,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,12687,,,8,10845,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL875908,,2204,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,12687,,,8,10845,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617030,,2205,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,12687,,,8,16288,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617031,,2206,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,12687,,,8,16288,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617032,,2207,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,12687,,,8,16190,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617033,,2208,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,10116.0,104686,,Rattus norvegicus,5,12463,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617034,,2209,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,104686,,,4,9699,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617035,,2210,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,104686,,,4,9699,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617036,,2211,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,104686,,,4,11662,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617037,,2212,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,104784,,,4,1205,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617038,,2213,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,22226,,,0,11376,,,U,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617039,,2214,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,104784,,,4,11376,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617161,,2215,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,104784,,,4,4639,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617162,,2216,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,104784,,,4,2222,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617163,,2217,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,104784,,,4,1558,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617164,,2218,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,104784,,,4,1089,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617165,,2219,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,104784,Brain membranes,,4,386,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617166,,2220,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,104784,,,4,2474,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617167,,2221,Binding affinity towards 5-HT2 receptor,,104784,,,4,17066,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL872912,,2222,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,104784,,,4,959,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617168,,2223,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,104784,,,4,6398,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617169,,2224,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,104686,,,4,11889,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617170,,2225,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,104784,,,4,4221,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617171,,2226,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,104784,,,4,11026,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617172,,2227,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,104784,,,4,11866,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617173,,2228,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,104784,,,4,4221,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617174,,2229,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,22226,,,0,13950,,,U,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617175,,2230,5-hydroxytryptamine 2 receptor binding affinity,,104784,,,4,1263,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617176,,2231,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,17005,,,8,13291,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617177,,2232,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,17005,,,8,10812,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617178,,2233,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,104784,,,4,13020,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617179,,2234,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,104784,,,4,13021,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617180,,2235,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,104784,,,4,13020,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617181,,2236,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,17005,,,8,14532,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617182,,2237,Binding affinity against 5-hydroxytryptamine 2 receptor,,17005,,,8,13944,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617183,,2238,Binding affinity against 5-hydroxytryptamine 2 receptor,,17005,,,8,14331,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617184,,2239,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,17005,,,8,14118,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617185,,2240,Binding affinity against serotonergic 5-HT2 receptor,,17005,,,8,13033,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617186,,2241,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,17005,,,8,10321,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617187,,2242,Compound was evaluated for the binding affinity at 5- HT2 receptor,,17005,,,8,12918,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617188,,2243,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,17005,,,8,15120,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL617189,,2244,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,17005,,,8,2613,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617190,,2245,Inhibitory activity against cloned human 5-HT2 receptor,9606.0,104784,,Homo sapiens,5,13378,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617191,,2246,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",9606.0,104784,,Homo sapiens,5,2331,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617192,,2247,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",9606.0,104784,,Homo sapiens,5,2331,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617193,,2248,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",9606.0,104784,,Homo sapiens,5,2331,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617194,,2249,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",9606.0,104784,,Homo sapiens,5,2331,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617195,,2250,Binding affinity towards 5-hydroxytryptamine 2 receptor,,104784,,,4,4170,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL881830,,2251,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,104784,,,4,15453,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617196,,2252,Binding affinity towards 5-hydroxytryptamine 2 receptor,,17005,,,8,1479,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617197,,2253,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,104686,,,4,11139,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617198,,2254,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,17005,,,8,13969,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL873476,,2255,Binding affinity towards 5-hydroxytryptamine 2A receptor,,17005,,,8,13392,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617199,,2256,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,17005,,,8,14430,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617200,,2257,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,10141.0,107,,Cavia porcellus,8,13181,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617484,,2258,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,51,,,8,17200,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617485,,2259,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,107,,,8,17200,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617486,,2260,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,51,,,8,17200,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL858022,,2261,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,107,,,8,13463,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617049,,2262,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,107,,,8,6347,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617050,,2263,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,9606.0,107,,Homo sapiens,9,6857,,,D,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617051,,2264,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,107,,,8,4176,,,H,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617052,,2265,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,107,,,8,4176,,,H,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617053,,2266,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,107,,,8,4176,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617054,,2267,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,107,,,8,6347,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617055,,2268,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,107,,,8,6347,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL882924,,2269,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,107,,,8,15331,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617056,,2270,Inhibition of human 5-hydroxytryptamine 2A receptor,9606.0,107,,Homo sapiens,9,16146,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617057,,2271,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,107,,,8,15250,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL617058,,2272,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,107,,,8,13631,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617059,,2273,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,107,,,8,3805,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617060,,2274,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,107,,,8,4011,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617061,,2275,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,107,,,8,4012,,,H,B
BAO_0000219,Expert,,307.0,1,,,L929,,CHEMBL617062,,2276,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,107,,,8,6366,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617063,,2277,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,107,,,8,15949,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617064,,2278,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,107,,,8,14093,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617065,,2279,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,107,,,8,13481,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617066,,2280,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,107,,,8,6347,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617067,,2281,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,107,,,8,6347,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617068,,2282,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,107,,,8,14093,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617069,,2283,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,107,,,8,14093,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617070,,2284,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,107,,,8,13481,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617071,,2285,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,107,,,8,14442,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872915,,2286,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,107,,,8,14442,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617072,,2287,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,107,,,8,14755,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617073,,2288,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,107,,,8,16441,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617074,,2289,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,107,,,8,14744,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617075,,2290,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,107,,,8,16659,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617076,,2291,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,107,,,8,3307,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617077,,2292,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,9606.0,107,,Homo sapiens,9,6857,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617078,,2293,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,107,,,8,5635,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617079,,2294,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,9606.0,107,,Homo sapiens,9,4234,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617080,,2295,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,107,,,8,15527,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617081,,2296,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,107,,,8,6588,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL617082,,2297,Binding affinity towards human 5-HT2A receptor in BEK cells,,107,,,8,13631,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617083,,2298,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,107,,,8,17723,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617084,,2299,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,107,,,8,14770,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617085,,2300,Binding affinity for human 5-hydroxytryptamine 2A receptor,9606.0,107,,Homo sapiens,9,16293,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617086,,2301,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,107,,,8,16209,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617087,,2302,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,107,,,8,12469,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617088,,2303,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,107,,,8,15363,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617089,,2304,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,107,,,8,15363,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617090,,2305,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,107,,,8,16441,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617513,,2306,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,107,,,8,8,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617514,,2307,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,107,,,8,4176,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617515,,2308,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,107,,,8,17085,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617516,,2309,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,107,,,8,17200,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617517,,2310,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,9606.0,107,,Homo sapiens,9,17200,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617518,,2311,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,9606.0,107,,Homo sapiens,9,4013,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617519,,2312,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,107,,,8,5088,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617520,,2313,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,9606.0,107,,Homo sapiens,9,5088,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617521,,2314,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,107,,,8,5088,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617522,,2315,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,9606.0,107,,Homo sapiens,9,5088,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617523,,2316,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,107,,,8,5088,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617524,,2317,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,107,,,8,5088,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617525,,2318,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,104686,,,4,9786,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617526,,2319,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,10116.0,104686,,Rattus norvegicus,5,9205,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617527,,2320,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,104686,,,4,11257,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617528,,2321,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,104686,,,4,9362,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617529,,2322,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,104686,,,4,9362,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617530,,2323,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,104686,,,4,10590,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617531,,2324,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,104686,,,4,10468,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617532,,2325,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,104686,,,4,13050,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617533,,2326,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,104686,,,4,11624,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617534,,2327,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,104686,,,4,10468,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617535,,2328,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,104686,,,4,10330,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617536,,2329,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,104686,,,4,10062,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617537,,2330,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,104686,,,4,11642,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617538,,2331,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,104686,,,4,10062,,,H,B
BAO_0000219,Autocuration,In vitro,,1,,,,,CHEMBL617539,,2332,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,104686,,,4,13427,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617540,,2333,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,10116.0,104686,,Rattus norvegicus,5,12280,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617541,,2334,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,10116.0,104686,,Rattus norvegicus,5,4101,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617542,,2335,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,104686,,,4,10062,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617543,,2336,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,104686,,,4,11147,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL617544,,2337,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,10116.0,104686,,Rattus norvegicus,5,2395,,,D,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL617545,,2338,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,10116.0,104686,,Rattus norvegicus,5,2395,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617413,,2339,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,10116.0,104686,,Rattus norvegicus,5,9098,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617414,,2340,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,104686,,,4,9098,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617415,,2341,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,10116.0,104686,,Rattus norvegicus,5,9098,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617416,,2342,Binding affinity towards 5-hydroxytryptamine 2 receptor,,104686,,,4,9443,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617417,,2343,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,104686,,,4,9443,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617418,,2344,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,104686,,,4,9699,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617419,,2345,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,104686,,,4,9699,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617420,,2346,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,104686,,,4,9098,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617421,,2347,Affinity for 5-hydroxytryptamine 2 receptor,10116.0,104686,,Rattus norvegicus,5,3070,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617422,,2348,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,104686,,,4,9547,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617423,,2349,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,104686,,,4,10444,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617424,,2350,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,104686,,,4,14617,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617425,,2351,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,104686,,,4,14617,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617426,,2352,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,104686,,,4,11130,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617427,,2353,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,104686,,,4,11130,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL617428,,2354,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,104686,,,4,14542,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617429,,2355,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,104686,,,4,2797,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617430,,2356,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,104686,,,4,11332,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617431,,2357,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,104686,,,4,11332,,,H,B
BAO_0000019,Autocuration,,,1,,Frontal cortex,,1870.0,CHEMBL617432,,2358,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,104686,,,4,10752,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617433,,2359,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,104686,,,4,1185,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617434,,2360,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,104686,,,4,1185,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617435,,2361,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,10116.0,104686,,Rattus norvegicus,5,11624,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617436,,2362,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,104686,,,4,1344,,,H,B
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL617437,,2363,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,10116.0,104686,,Rattus norvegicus,5,15453,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617438,,2364,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,104686,,,4,11662,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617439,,2365,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,104686,,,4,11662,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617440,,2366,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,104686,,,4,10796,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617441,,2367,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,104686,,,4,9069,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872918,,2368,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,10116.0,104686,,Rattus norvegicus,5,8814,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617442,,2369,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,10116.0,104686,,Rattus norvegicus,5,8908,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617443,,2370,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,104686,,,4,9098,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617444,,2371,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,104686,,,4,9098,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617445,,2372,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,104686,,,4,9098,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617446,,2373,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,104686,,,4,9098,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617447,,2374,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,104686,,,4,9098,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617448,,2375,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,104686,,,4,9098,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617449,,2376,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,104686,,,4,9098,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617450,,2377,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617451,,2378,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617452,,2379,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617453,,2380,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617660,,2381,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617661,,2382,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617662,,2383,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872919,,2384,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617663,,2385,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617664,,2386,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617665,,2387,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617666,,2388,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,104686,,,4,9161,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617667,,2389,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,104686,,,4,12094,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617668,,2390,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,104686,,,4,12018,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617669,,2391,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,104686,,,4,10394,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617670,,2392,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,104686,,,4,15260,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617671,,2393,Inhibitory constant against 5-hydroxytryptamine 2 receptor,10116.0,104686,,Rattus norvegicus,5,11624,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617672,,2394,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,104686,,,4,13654,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617673,,2395,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,104686,,,4,9541,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617674,,2396,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,104686,,,4,11933,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617675,,2397,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,104686,,,4,15538,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617676,,2398,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,104686,,,4,15538,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617677,,2399,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,104686,,,4,15538,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617678,,2400,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,104686,,,5,8841,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617679,,2401,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,104686,,,4,1455,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617680,,2402,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,104686,,,4,1455,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617681,,2403,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,104686,,,4,11752,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL617682,,2404,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,104686,,,4,11642,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617683,,2405,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,104686,,,4,12092,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617684,,2406,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,104686,,,4,3967,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617685,,2407,Binding affinity towards 5-hydroxytryptamine 2 receptor,10116.0,104686,,Rattus norvegicus,5,12771,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617686,,2408,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,104686,,,4,11642,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617687,,2409,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,104686,,,4,11628,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617688,,2410,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,104686,,,4,13654,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617689,,2411,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686,,,4,11200,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617690,,2412,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,104686,,,4,11200,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617691,,2413,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,104686,,,4,11200,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617692,,2414,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,104686,,,4,11200,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617693,,2415,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,104686,,,4,11200,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617694,,2416,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,104686,,,4,11200,,,H,F
BAO_0000221,Expert,,,1,,Brain,,955.0,CHEMBL857985,,2417,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,12687,,,8,15436,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617695,,2418,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,10116.0,12687,,Rattus norvegicus,9,15436,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617696,,2419,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,12687,,,8,14025,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617697,,2420,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,12687,,,8,4342,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617257,,2421,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,10116.0,12687,,Rattus norvegicus,9,13735,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617258,,2422,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,10116.0,12687,,Rattus norvegicus,9,5816,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617259,,2423,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,12687,,,8,14287,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617260,,2424,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,12687,,,8,15738,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617261,,2425,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,10116.0,12687,,Rattus norvegicus,9,15738,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617262,,2426,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,12687,,,8,15026,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617263,,2427,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,12687,,,8,16647,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617264,,2428,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,12687,,,8,16647,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617265,,2429,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,10116.0,12687,,Rattus norvegicus,9,13345,,,D,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617266,,2430,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,12687,Membranes,,8,1543,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617267,,2431,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,12687,,,8,12444,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617268,,2432,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,12687,,,8,16404,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617269,,2433,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,12687,,,8,16404,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617323,,2434,Kinetic inhibition constant evaluated by measuring serotonergic activity,,12687,,,8,15577,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617324,,2435,Serotonergic activity of the compound.,,12687,,,8,15577,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617325,,2436,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,12687,,,8,2495,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617326,,2437,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,10116.0,12687,,Rattus norvegicus,9,15042,,,D,B
BAO_0000249,Expert,,,1,,,,,CHEMBL617327,,2438,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,12687,,,8,15026,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617328,,2439,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,10116.0,12687,,Rattus norvegicus,9,12919,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL617329,,2440,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,10116.0,12687,,Rattus norvegicus,9,12919,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL617330,,2441,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,10116.0,12687,,Rattus norvegicus,9,12919,,,D,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617331,,2442,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,12687,,,8,15194,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617332,,2443,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,12687,,,8,15194,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617333,,2444,Binding affinity towards 5-hydroxytryptamine 2A receptor,,107,,,8,4820,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617334,,2445,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,107,,,8,6736,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617335,,2446,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,107,,,8,5163,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617336,,2447,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,107,,,8,5163,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617337,,2448,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,107,,,8,6011,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617338,,2449,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,9606.0,107,,Homo sapiens,9,14294,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617339,,2450,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,107,,,8,5014,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617340,,2451,Binding affinity towards 5-hydroxytryptamine 2A receptor,,107,,,8,17066,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617341,,2452,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,107,,,8,17515,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617342,,2453,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,107,,,8,6736,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617343,,2454,Affinity for 5-hydroxytryptamine 2A receptor,,107,,,8,5163,,,H,B
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL617344,,2455,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,107,,,8,16911,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617345,,2456,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,107,,,8,6841,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617346,,2457,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,107,,,8,6119,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617347,,2458,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,107,,,8,3962,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617348,,2459,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,107,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617349,,2460,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,107,,,8,4373,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617350,,2461,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,107,,,8,3962,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL872339,,2462,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,107,,,8,1633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617351,,2463,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,107,,,8,4373,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617352,,2464,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,107,,,8,6576,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617353,,2465,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,107,,,8,4687,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617354,,2466,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,107,,,8,16946,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617355,,2467,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,107,,,8,14159,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617356,,2468,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,10090.0,107,,Mus musculus,8,3032,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617357,,2469,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,107,,,8,16655,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617358,,2470,Binding affinity at 5-hydroxytryptamine 2A receptor,,107,,,8,13964,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617359,,2471,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,107,,,8,16989,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617360,,2472,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,107,,,8,16117,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL875913,,2473,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,107,,,8,16700,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617361,,2474,Affinity against 5-hydroxytryptamine 2A receptor,,107,,,8,3269,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617362,,2475,Binding affinity against 5-Hydroxytryptamine 2A receptor,9606.0,107,,Homo sapiens,9,1274,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617363,,2476,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,107,,,8,1317,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617364,,2477,Tested against 5-hydroxytryptamine 2A receptor,,107,,,8,12146,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617365,,2478,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,105075,,,4,12652,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617366,,2479,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,105075,,,4,12652,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617367,,2480,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,105075,,,4,12652,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617368,,2481,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,105075,,,4,12652,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617369,,2482,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,107,,,8,16647,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617370,,2483,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,9606.0,227,,Homo sapiens,9,15851,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617371,,2484,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,9606.0,227,,Homo sapiens,9,6857,,,D,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617372,,2485,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,227,,,8,3805,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617373,,2486,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,9606.0,227,,Homo sapiens,9,6491,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617374,,2487,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,227,,,8,14093,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617375,,2488,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,227,,,8,13481,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617376,,2489,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,227,,,8,14093,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617377,,2490,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,227,,,8,14093,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617378,,2491,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,227,,,8,14093,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617379,,2492,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,227,,,8,13481,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617380,,2493,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,227,,,8,14442,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617381,,2494,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,227,,,8,14442,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617382,,2495,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,227,,,8,14442,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617383,,2496,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,107,,,8,12369,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617384,,2497,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,107,,,8,12369,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617385,,2498,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,107,,,8,12369,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617386,,2499,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,107,,,8,14447,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617387,,2500,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,107,,,8,14447,,,H,B
BAO_0000219,Autocuration,,723.0,1,,,NIH3T3,,CHEMBL617388,,2501,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,107,,,8,17451,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617389,,2502,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,107,,,8,6857,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617390,,2503,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9606.0,107,,Homo sapiens,9,6857,,,D,F
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617391,,2504,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,104817,,,4,5635,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617392,,2505,Binding activity radioligand.,,107,,,8,12861,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617393,,2506,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,107,,,8,12861,,,H,B
BAO_0000219,Autocuration,,307.0,1,,,L929,,CHEMBL617394,,2507,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,107,,,8,5105,,,H,B
BAO_0000219,Expert,,307.0,1,,,L929,,CHEMBL617395,,2508,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,107,,,8,5104,,,H,B
BAO_0000219,Expert,,307.0,1,,,L929,,CHEMBL617396,,2509,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,107,,,8,5105,,,H,B
BAO_0000219,Autocuration,,307.0,1,,,L929,,CHEMBL617397,,2510,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,107,,,8,5105,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617398,,2511,Binding affinity against 5-HT2A receptor,,107,,,8,5254,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617399,,2512,Binding affinity against 5-hydroxytryptamine 2A receptor,,107,,,8,5254,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617400,,2513,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,107,,,8,13267,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617401,,2514,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,107,,,8,13267,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617402,,2515,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,9606.0,107,,Homo sapiens,9,14157,,,D,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617403,,2516,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9606.0,107,,Homo sapiens,9,12936,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617404,,2517,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,107,,,8,14068,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL857981,,2518,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9606.0,107,,Homo sapiens,9,12936,,,D,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617405,,2519,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9606.0,107,,Homo sapiens,9,12936,,,D,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617253,,2520,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,9606.0,107,,Homo sapiens,9,4540,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617254,,2521,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,107,,,8,6166,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617255,,2522,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,107,,,8,17296,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617256,,2523,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,107,,,8,17296,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616874,,2524,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,107,,,8,17296,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL616875,,2525,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,9606.0,107,,Homo sapiens,9,15779,,,D,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL616876,,2526,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,107,,,8,14391,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL616877,,2527,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,107,,,8,15851,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL616878,,2528,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,9606.0,107,,Homo sapiens,9,15851,,,D,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL616879,,2529,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,107,,,8,3832,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL616880,,2530,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,107,,,8,3833,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL616881,,2531,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9606.0,107,,Homo sapiens,9,12936,,,D,B
BAO_0000219,Autocuration,,723.0,1,,,NIH3T3,,CHEMBL616882,,2532,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,107,,,8,17451,,,H,B
BAO_0000219,Autocuration,,723.0,1,,,NIH3T3,,CHEMBL616883,,2533,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,107,,,8,17451,,,H,B
BAO_0000219,Autocuration,,723.0,1,,,NIH3T3,,CHEMBL616884,,2534,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,107,,,8,17451,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616885,,2535,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,107,,,8,4199,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL616886,,2536,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,107,,,8,1883,,,H,B
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL616887,,2537,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,107,,,8,1883,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL616888,,2538,Binding affinity for human 5-hydroxytryptamine 2A receptor,9606.0,107,,Homo sapiens,9,14875,,,D,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616889,,2539,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,107,,,8,15146,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616890,,2540,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,107,,,8,5213,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL616891,,2541,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,9606.0,107,,Homo sapiens,9,16404,,,D,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616892,,2542,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,107,,,8,14818,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL616893,,2543,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,107,,,8,4829,,,H,B
BAO_0000219,Autocuration,,723.0,1,,,NIH3T3,,CHEMBL616894,,2544,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,10620,,,8,12652,,,H,F
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL616895,,2545,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,107,,,8,4682,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL616896,,2546,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,10620,,,8,12652,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617099,,2547,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,10621,,,8,4921,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617100,,2548,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,10621,,,8,4921,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL884532,,2549,Binding affinity against rabbit aorta 5-HT2A receptor,9986.0,107,,Oryctolagus cuniculus,8,16312,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617101,,2550,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,9986.0,107,,Oryctolagus cuniculus,8,14998,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617102,,2551,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,9986.0,107,,Oryctolagus cuniculus,8,14025,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617103,,2552,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,9986.0,107,,Oryctolagus cuniculus,8,13047,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617104,,2553,The compound was tested for binding affinity against 5-HT2A receptor,9986.0,107,,Oryctolagus cuniculus,8,13047,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL857979,,2554,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,10576,,,8,1883,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL857502,,2555,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,12687,,,8,13463,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617105,,2556,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,12687,,,8,13463,,,H,B
BAO_0000019,Autocuration,,,1,,Stomach,,945.0,CHEMBL858021,,2557,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,12687,,,8,13463,,,H,B
BAO_0000019,Expert,,,1,,Stomach,,945.0,CHEMBL875910,,2558,Binding affinity for 5-HT 2A in rat stomach fundus,10116.0,12687,,Rattus norvegicus,9,13463,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617106,,2559,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,12687,,,8,13463,,,H,B
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL617107,,2560,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,12687,,,8,16326,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617108,,2561,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,12687,,,8,14093,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617109,,2562,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,12687,,,8,14093,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617110,,2563,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,12687,,,8,15740,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617111,,2564,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,12687,,,8,16633,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617112,,2565,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,10116.0,12687,,Rattus norvegicus,9,17200,,,D,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617113,,2566,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,12687,,,8,17133,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617114,,2567,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,12687,,,8,17133,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617115,,2568,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,12687,,,8,17133,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617116,,2569,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,12687,,,8,17200,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617117,,2570,Efficacy at 5-hydroxytryptamine 2A receptor,,12687,,,8,15363,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617118,,2571,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,12687,,,8,17200,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617119,,2572,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),10116.0,12687,,Rattus norvegicus,9,17200,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617120,,2573,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),10116.0,12687,,Rattus norvegicus,9,17200,,,D,B
BAO_0000219,Expert,,,1,,,,,CHEMBL617121,,2574,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,10116.0,12687,,Rattus norvegicus,9,17200,,,D,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617122,,2575,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,12687,,,8,17200,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617123,,2576,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,12687,,,8,17211,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617124,,2577,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,12687,,,8,17331,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL617600,,2578,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,12687,,,8,13565,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617601,,2579,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,12687,,,8,13730,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL882923,,2580,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,12687,,,8,12416,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617602,,2581,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,12687,,,8,15295,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617603,,2582,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,12687,,,8,1742,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617604,,2583,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,12687,,,8,15295,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617605,,2584,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,12687,,,8,14970,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617606,,2585,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,12687,,,8,16693,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617607,,2586,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,10116.0,12687,,Rattus norvegicus,9,14776,,,D,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617455,,2587,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687,,,8,14286,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617456,,2588,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,10116.0,12687,,Rattus norvegicus,9,17200,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617457,,2589,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,12687,,,8,15306,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617458,,2590,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,10116.0,12687,,Rattus norvegicus,9,14178,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617459,,2591,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,10116.0,12687,,Rattus norvegicus,9,14229,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617460,,2592,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,12687,,,8,12884,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617461,,2593,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,12687,,,8,13149,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617462,,2594,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,10116.0,12687,,Rattus norvegicus,9,15295,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617463,,2595,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,12687,,,8,15740,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617464,,2596,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,12687,,,8,15185,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617465,,2597,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,12687,,,8,15185,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617466,,2598,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,12687,,,8,17529,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617467,,2599,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,12687,,,8,14826,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617468,,2600,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,12687,,,8,17211,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617469,,2601,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,12687,,,8,14826,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617470,,2602,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,12687,,,8,14093,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617471,,2603,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,12687,,,8,14093,,,H,B
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL617472,,2604,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,12687,,,8,13246,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617473,,2605,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,12687,,,8,13246,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617474,,2606,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,10116.0,12687,,Rattus norvegicus,9,15436,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617475,,2607,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,10116.0,12687,,Rattus norvegicus,9,15436,,,D,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL617476,,2608,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,12687,,,8,14442,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617477,,2609,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,12687,,,8,12457,,,H,B
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL617478,,2610,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,12687,,,8,12457,,,H,B
BAO_0000221,Autocuration,,,1,,,,,CHEMBL617479,,2611,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,12687,,,8,14755,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617480,,2612,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,12687,,,8,4707,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617481,,2613,Binding affinity against 5-hydroxytryptamine 2A receptor,,12687,,,8,13297,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617482,,2614,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,12687,,,8,17331,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617483,,2615,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,12687,,,8,4664,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621528,,2616,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,12687,,,8,16633,,,H,B
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL621529,,2617,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,10116.0,12687,,Rattus norvegicus,9,4664,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621530,,2618,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,12687,,,8,16133,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621531,,2619,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,12687,,,8,16133,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL621532,,2620,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,10116.0,12687,,Rattus norvegicus,9,14060,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621533,,2621,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,12687,,,8,16326,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL621534,,2622,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,12687,,,8,16659,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621535,,2623,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,12687,,,8,14776,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621536,,2624,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,12687,,,8,13481,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621537,,2625,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,12687,,,8,17386,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621538,,2626,Binding affinity for 5-hydroxytryptamine 2A receptor,10116.0,12687,,Rattus norvegicus,9,6611,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621539,,2627,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,12687,,,8,14423,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621540,,2628,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,12687,,,8,15412,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621541,,2629,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,12687,,,8,15412,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621542,,2630,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,12687,,,8,6238,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621543,,2631,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,12687,,,8,6648,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621544,,2632,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,12687,,,8,5667,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621545,,2633,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,10116.0,12687,,Rattus norvegicus,9,6611,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621546,,2634,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,12687,,,8,13481,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621547,,2635,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,12687,,,8,13481,,,H,B
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL618692,,2636,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,12687,,,8,15558,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618693,,2637,Binding affinity towards 5-hydroxytryptamine 2A receptor,,12687,,,8,6013,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872922,,2638,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,12687,,,8,16633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618694,,2639,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,12687,,,8,6013,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618695,,2640,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,10116.0,12687,,Rattus norvegicus,9,6013,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618696,,2641,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,12687,,,8,6013,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618697,,2642,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,12687,,,8,6013,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618892,,2643,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,12687,,,8,6013,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618893,,2644,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,12687,,,8,6013,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618894,,2645,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,12687,,,8,16293,,,H,B
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL618895,,2646,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,12687,,,8,17175,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618896,,2647,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,10116.0,12687,,Rattus norvegicus,9,13278,,,D,B
BAO_0000019,Autocuration,,,1,,Caudate-putamen,,5383.0,CHEMBL618897,,2648,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,12687,,,8,3682,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618898,,2649,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,12687,,,8,2014,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618899,,2650,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,12687,,,8,2014,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618900,,2651,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,12687,,,8,4932,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618901,,2652,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,12687,,,8,4932,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618902,,2653,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,12687,,,8,3935,,,H,B
BAO_0000221,Expert,,,1,,Hippocampus,,10000000.0,CHEMBL618903,,2654,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,10116.0,12687,,Rattus norvegicus,9,5432,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618904,,2655,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,12687,,,8,15818,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618905,,2656,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,12687,,,8,13672,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618906,,2657,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,12687,,,8,13672,,,H,B
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL618907,,2658,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,12687,,,8,14749,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618908,,2659,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,12687,,,8,13462,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617909,,2660,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,12687,,,8,15740,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617910,,2661,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,12687,,,8,16647,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL617911,,2662,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,12687,,,8,13345,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL872923,,2663,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687,,,8,16740,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617912,,2664,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687,,,8,16740,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617913,,2665,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,10116.0,12687,,Rattus norvegicus,9,15535,,,D,B
BAO_0000249,Expert,,,1,,,,,CHEMBL617914,,2666,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687,,,8,16740,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617915,,2667,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687,,,8,16740,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617916,,2668,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,12687,,,8,16740,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617917,,2669,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,10116.0,12687,,Rattus norvegicus,9,4795,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617918,,2670,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,12687,,,8,8,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617919,,2671,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,12687,,,8,8,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617920,,2672,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,10116.0,12687,,Rattus norvegicus,9,17200,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617921,,2673,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,10116.0,12687,,Rattus norvegicus,9,2148,,,D,B
BAO_0000224,Expert,,,1,,,,,CHEMBL617922,,2674,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",10116.0,105102,,Rattus norvegicus,5,13345,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617923,,2675,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,12687,,,8,5088,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617924,,2676,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,12687,,,8,5088,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617925,,2677,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,12687,,,8,17133,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617926,,2678,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,10116.0,12687,,Rattus norvegicus,9,17133,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617927,,2679,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,12687,,,8,16532,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617928,,2680,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,12687,,,8,15086,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617929,,2681,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,10116.0,12687,,Rattus norvegicus,9,2309,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617930,,2682,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,12687,,,8,12953,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617931,,2683,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,12687,,,8,12953,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617932,,2684,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,12687,,,8,12953,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617933,,2685,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,12687,,,8,16659,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617934,,2686,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,12687,,,8,16740,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617935,,2687,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,12687,,,8,16740,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617936,,2688,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,12687,,,8,17133,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617937,,2689,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,12687,,,8,17211,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617938,,2690,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,12687,,,8,17331,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL617939,,2691,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,12687,,,8,16633,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL617940,,2692,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,12687,,,8,16633,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL617941,,2693,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,12687,,,8,16633,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617942,,2694,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,12687,,,8,15026,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617943,,2695,Ratio of pKi of 5-HT2A to that of D2 receptor,,12687,,,8,15026,,,H,B
BAO_0000224,Expert,,,1,,,,,CHEMBL617944,,2696,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,105093,,,4,16404,,,H,B
BAO_0000224,Expert,,,1,,,,,CHEMBL617945,,2697,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,105093,,,4,16404,,,H,B
BAO_0000224,Expert,,,1,,,,,CHEMBL617946,,2698,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,105075,,,4,16404,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617947,,2699,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,12687,,,8,16404,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617948,,2700,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,12687,,,8,16326,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL858116,,2701,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,12687,,,8,15847,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617949,,2702,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,12687,,,8,15847,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617950,,2703,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,12687,,,8,15329,,,H,F
BAO_0000019,Expert,,,1,,Thoracic aorta,,1515.0,CHEMBL617951,,2704,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,12687,,,8,16404,,,H,F
BAO_0000019,Expert,,,1,,Thoracic aorta,,1515.0,CHEMBL617952,,2705,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,12687,,,8,16404,,,H,F
BAO_0000019,Autocuration,,,1,,Thoracic aorta,,1515.0,CHEMBL617953,,2706,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,12687,,,8,16404,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617954,,2707,Binding activity radioligand.,,12687,,,8,12861,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617955,,2708,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,12687,,,8,12861,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL857071,,2709,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,12687,,,8,12861,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617270,,2710,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,12687,,,8,12490,,,H,B
BAO_0000219,Autocuration,,339.0,1,,,N1E-115,,CHEMBL617271,,2711,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,12687,,,8,12827,,,H,B
BAO_0000219,Autocuration,,339.0,1,,,N1E-115,,CHEMBL617272,,2712,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,12687,,,8,12827,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617273,,2713,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,12687,,,8,12918,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617274,,2714,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,10116.0,12687,,Rattus norvegicus,9,12919,,,D,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617275,,2715,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,108,,,8,17723,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617276,,2716,Binding affinity towards 5-hydroxytryptamine 2C receptor,,108,,,8,6013,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617277,,2717,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,108,,,8,16293,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617278,,2718,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,108,,,8,3857,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617279,,2719,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,108,,,8,3857,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617280,,2720,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,108,,,8,3857,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617281,,2721,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,108,,,8,15363,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617282,,2722,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,108,,,8,15363,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617283,,2723,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,108,,,8,16441,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617284,,2724,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,108,,,8,16441,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617285,,2725,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,108,,,8,4176,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617286,,2726,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,108,,,8,17085,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617287,,2727,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,9606.0,108,,Homo sapiens,9,17200,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617288,,2728,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,108,,,8,5088,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617289,,2729,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,108,,,8,5088,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872917,,2730,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,108,,,8,5088,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617290,,2731,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,108,,,8,5088,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617291,,2732,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,108,,,8,16659,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617292,,2733,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,108,,,8,16659,,,H,B
BAO_0000219,Autocuration,,723.0,1,,,NIH3T3,,CHEMBL617293,,2734,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,108,,,8,17451,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617294,,2735,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9606.0,108,,Homo sapiens,9,6857,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL617295,,2736,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,108,,,8,3857,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617296,,2737,Binding activity radioligand.,,108,,,8,12861,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617297,,2738,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,108,,,8,12861,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617298,,2739,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,108,,,8,5104,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617299,,2740,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,108,,,8,5105,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617300,,2741,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,108,,,8,5105,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617454,,2742,Binding affinity against 5-HT2C receptor,,108,,,8,5254,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617505,,2743,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,108,,,8,13267,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617506,,2744,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,9606.0,108,,Homo sapiens,9,14157,,,D,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617507,,2745,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,9606.0,108,,Homo sapiens,9,12936,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617508,,2746,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,108,,,8,14068,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL857982,,2747,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,9606.0,108,,Homo sapiens,9,12936,,,D,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617509,,2748,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,9606.0,108,,Homo sapiens,9,4540,,,D,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617510,,2749,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,9606.0,108,,Homo sapiens,9,4540,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617511,,2750,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,108,,,8,6166,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617512,,2751,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,108,,,8,17296,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617749,,2752,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,108,,,8,17296,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617750,,2753,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,108,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617751,,2754,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,108,,,8,15779,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617752,,2755,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,108,,,8,14391,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617753,,2756,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,108,,,8,15779,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617754,,2757,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,108,,,8,15851,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617755,,2758,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,9606.0,108,,Homo sapiens,9,15851,,,D,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617756,,2759,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,108,,,8,15779,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617757,,2760,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,108,,,8,3832,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617758,,2761,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,108,,,8,3833,,,H,B
BAO_0000219,Autocuration,,723.0,1,,,NIH3T3,,CHEMBL617759,,2762,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,108,,,8,17451,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617760,,2763,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,108,,,8,4199,,,H,B
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL617761,,2764,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,108,,,8,1883,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617762,,2765,Binding affinity against 5-hydroxytryptamine 2C receptor,9606.0,108,,Homo sapiens,9,4321,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617763,,2766,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,108,,,8,14875,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL857983,,2767,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,108,,,8,15146,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617764,,2768,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,108,,,8,5213,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL617765,,2769,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,108,,,8,16404,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617766,,2770,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,108,,,8,13267,,,H,F
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL617767,,2771,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,108,,,8,13267,,,H,F
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617768,,2772,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,108,,,8,14818,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617769,,2773,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,108,,,8,4829,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL858023,,2774,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,11864,,,8,13463,,,H,B
BAO_0000019,Autocuration,,,1,,Stomach,,945.0,CHEMBL617770,,2775,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,11864,,,8,13463,,,H,B
BAO_0000019,Autocuration,,,1,,Stomach,,945.0,CHEMBL617771,,2776,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,11864,,,8,13463,,,H,B
BAO_0000219,Autocuration,,625.0,1,,,A9,,CHEMBL617772,,2777,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,11864,,,8,12652,,,H,F
BAO_0000219,Autocuration,,723.0,1,,,NIH3T3,,CHEMBL617773,,2778,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,11864,,,8,4682,,,H,B
BAO_0000219,Autocuration,,723.0,1,,,NIH3T3,,CHEMBL617850,,2779,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,11864,,,8,4682,,,H,B
BAO_0000219,Autocuration,,723.0,1,,,NIH3T3,,CHEMBL617851,,2780,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,11864,,,8,4682,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617852,,2781,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,11864,,,8,12652,,,H,F
BAO_0000019,Autocuration,,,1,,Stomach,,945.0,CHEMBL858024,,2782,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,10090.0,12689,,Mus musculus,8,13463,,,H,B
BAO_0000019,Expert,,,1,,Stomach,,945.0,CHEMBL617853,,2783,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,10116.0,12689,,Rattus norvegicus,9,13463,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617854,,2784,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,108,,,8,13969,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL873477,,2785,Binding affinity for 5-hydroxytryptamine 2C receptor,9823.0,108,,Sus scrofa,8,13392,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617855,,2786,Binding affinity towards 5-hydroxytryptamine 2C receptor,,108,,,8,13392,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617856,,2787,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,108,,,8,14430,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617857,,2788,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,108,,,8,1742,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617858,,2789,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,108,,,8,14286,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617859,,2790,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,108,,,8,5619,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617860,,2791,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,108,,,8,15086,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617861,,2792,Binding activity radioligand.,,108,,,8,12861,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617862,,2793,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,108,,,8,12861,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617863,,2794,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,108,,,8,12861,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617864,,2795,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,108,,,8,12827,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617649,,2796,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,108,,,8,12827,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617650,,2797,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,9823.0,108,,Sus scrofa,8,12919,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL617651,,2798,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,9823.0,108,,Sus scrofa,8,12919,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617652,,2799,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,9823.0,108,,Sus scrofa,8,16429,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL857072,,2800,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,9823.0,108,,Sus scrofa,8,773,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617653,,2801,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,9823.0,108,,Sus scrofa,8,5033,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617654,,2802,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,12687,,,8,12861,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617655,,2803,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,12689,,,8,14093,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL617656,,2804,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,12689,,,8,14970,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617657,,2805,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,12689,,,8,14970,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617658,,2806,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,12689,,,8,14970,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617659,,2807,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,10116.0,12689,,Rattus norvegicus,9,14178,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617838,,2808,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,10116.0,12689,,Rattus norvegicus,9,14178,,,D,B
BAO_0000249,Expert,,,1,,,,,CHEMBL617839,,2809,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,10116.0,12689,Brain membranes,Rattus norvegicus,9,14229,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617840,,2810,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,12689,,,8,16532,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617841,,2811,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,12689,,,8,14826,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL875915,,2812,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,12689,,,8,17211,,,H,B
BAO_0000219,Expert,In vitro,,1,,,,,CHEMBL617842,,2813,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,12689,,,8,17211,,,H,B
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL617843,,2814,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,12689,,,8,13246,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617844,,2815,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,12689,,,8,13246,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617845,,2816,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,12689,,,8,12457,,,H,B
BAO_0000219,Expert,,723.0,1,,,NIH3T3,,CHEMBL617846,,2817,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,12689,,,8,12457,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617847,,2818,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,12689,,,8,4707,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617848,,2819,Binding affinity against 5-hydroxytryptamine 2C receptor,,12689,,,8,13297,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617849,,2820,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,12689,,,8,16633,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621507,,2821,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,12689,,,8,16133,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621508,,2822,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,12689,,,8,16326,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621509,,2823,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,12689,,,8,14423,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621510,,2824,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,12689,,,8,15412,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621511,,2825,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,12689,,,8,15412,,,H,B
BAO_0000219,Expert,,625.0,1,,,A9,,CHEMBL621512,,2826,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,12689,,,8,15558,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621513,,2827,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,12689,,,8,16633,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621514,,2828,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,12689,,,8,6013,,,H,B
BAO_0000219,Expert,In vitro,,1,,,,,CHEMBL621515,,2829,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,12689,,,8,17175,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL621516,,2830,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,12689,,,8,12469,,,H,B
BAO_0000019,Autocuration,,,1,,Caudate-putamen,,5383.0,CHEMBL621517,,2831,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,12689,,,8,3682,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621518,,2832,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,12689,,,8,4932,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621519,,2833,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,12689,,,8,4932,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621520,,2834,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,12689,,,8,3935,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621521,,2835,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,12689,,,8,15818,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621522,,2836,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,12689,,,8,15818,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL621523,,2837,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,12689,,,8,14749,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621524,,2838,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,12689,,,8,15740,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621525,,2839,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,10116.0,12689,,Rattus norvegicus,9,17133,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872921,,2840,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,12689,,,8,16532,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621526,,2841,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,12689,,,8,12369,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL621527,,2842,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,12689,,,8,12369,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617865,,2843,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,10116.0,12689,,Rattus norvegicus,9,2309,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617866,,2844,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,12689,,,8,12953,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617867,,2845,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,12689,,,8,12953,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617487,,2846,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,12689,,,8,12953,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617488,,2847,Binding affinity for 5-hydroxytryptamine 2C receptor,,12689,,,8,12953,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617489,,2848,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,12689,,,8,17133,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617490,,2849,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,12689,,,8,17211,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617491,,2850,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,12689,,,8,17211,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617492,,2851,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,12689,,,8,14025,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617493,,2852,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,12689,,,8,14998,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617494,,2853,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,12689,,,8,4342,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617495,,2854,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,10116.0,12689,,Rattus norvegicus,9,13735,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617496,,2855,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,12689,,,8,13181,,,H,B
BAO_0000219,Autocuration,,485.0,1,,,CHO-K1,,CHEMBL617497,,2856,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,12689,,,8,1883,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617498,,2857,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,12689,,,8,15194,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617499,,2858,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,12689,,,8,15194,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617500,,2859,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,12689,,,8,14579,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617501,,2860,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,108,,,8,4639,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617502,,2861,Binding affinity towards 5-hydroxytryptamine 2C receptor,,108,,,8,4820,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617503,,2862,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,227,,,8,14442,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617504,,2863,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,227,,,8,14755,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617406,,2864,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,227,,,8,14744,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617407,,2865,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,9606.0,227,,Homo sapiens,9,6857,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617408,,2866,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,227,,,8,16209,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617409,,2867,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,227,,,8,15363,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617410,,2868,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,227,,,8,15363,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617411,,2869,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,227,,,8,15363,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617412,,2870,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,227,,,8,17085,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617774,,2871,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,9606.0,227,,Homo sapiens,9,17200,,,D,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617775,,2872,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,9606.0,227,,Homo sapiens,9,15851,,,D,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617776,,2873,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,9606.0,227,,Homo sapiens,9,15851,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617777,,2874,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9606.0,227,,Homo sapiens,9,6857,,,D,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617778,,2875,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9606.0,227,,Homo sapiens,9,6857,,,D,F
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617779,,2876,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,227,,,8,15779,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617780,,2877,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,227,,,8,15851,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617781,,2878,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,227,,,8,15779,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617782,,2879,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,9606.0,227,,Homo sapiens,9,14157,,,D,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617783,,2880,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,9606.0,227,,Homo sapiens,9,4540,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617784,,2881,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,227,,,8,6166,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617785,,2882,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,227,,,8,15779,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL857984,,2883,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,227,,,8,14391,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617786,,2884,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,227,,,8,3832,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617787,,2885,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,227,,,8,3833,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617788,,2886,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,9606.0,227,,Homo sapiens,9,15851,,,D,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL617789,,2887,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,9606.0,227,,Homo sapiens,9,15851,,,D,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617790,,2888,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,227,,,8,4199,,,H,B
BAO_0000219,Expert,,485.0,1,,,CHO-K1,,CHEMBL617791,,2889,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,227,,,8,1883,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617608,,2890,Binding affinity against 5-hydroxytryptamine 2B receptor,,227,,,8,4321,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617609,,2891,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,227,,,8,15146,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617610,,2892,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,227,,,8,5213,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617611,,2893,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,227,,,8,14818,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617612,,2894,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,227,,,8,4829,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL617613,,2895,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,227,,,8,4829,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617614,,2896,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,9986.0,227,,Oryctolagus cuniculus,8,14025,,,H,B
BAO_0000019,Expert,,,1,,Stomach,,945.0,CHEMBL617615,,2897,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,12688,,,8,13463,,,H,B
BAO_0000357,Expert,,,1,,Stomach,,945.0,CHEMBL858114,,2898,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,12688,,,8,7259,,,H,B
BAO_0000357,Autocuration,,,1,,Stomach,,945.0,CHEMBL617616,,2899,Affinity against serotonergic receptor in the isolated rat stomach fundus,,12688,,,8,7259,,,H,B
BAO_0000019,Expert,,,1,,Stomach,,945.0,CHEMBL617617,,2900,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,10116.0,12688,,Rattus norvegicus,9,7185,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL875914,,2901,Antagonistic against 5-hydroxytryptamine 2B receptor,10116.0,12688,,Rattus norvegicus,9,7185,,,D,F
BAO_0000019,Autocuration,,,1,,Stomach,,945.0,CHEMBL617618,,2902,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,12688,,,8,13267,,,H,F
BAO_0000357,Expert,,,1,,Stomach,,945.0,CHEMBL617619,,2903,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,10116.0,12688,,Rattus norvegicus,9,13735,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617620,,2904,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,12688,,,8,15738,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617621,,2905,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,12688,,,8,15738,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617622,,2906,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,12688,,,8,15738,,,H,F
BAO_0000357,Expert,,,1,,Stomach,,945.0,CHEMBL617623,,2907,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,10116.0,12688,,Rattus norvegicus,9,12936,,,D,B
BAO_0000357,Expert,,,1,,Stomach,,945.0,CHEMBL617624,,2908,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,10116.0,12688,,Rattus norvegicus,9,12936,,,D,B
BAO_0000357,Expert,,,1,,Stomach,,945.0,CHEMBL617625,,2909,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,10116.0,12688,,Rattus norvegicus,9,12936,,,D,B
BAO_0000357,Expert,,,1,,Stomach,,945.0,CHEMBL617626,,2910,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,10116.0,12688,,Rattus norvegicus,9,12936,,,D,B
BAO_0000019,Autocuration,,,1,,Stomach,,945.0,CHEMBL617627,,2911,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,12688,,,8,16404,,,H,F
BAO_0000019,Expert,,,1,,Stomach,,945.0,CHEMBL617628,,2912,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,12688,,,8,16404,,,H,F
BAO_0000019,Autocuration,,,1,,Stomach,,945.0,CHEMBL617629,,2913,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,12688,,,8,16404,,,H,F
BAO_0000019,Autocuration,,,1,,Stomach,,945.0,CHEMBL858115,,2914,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,12688,,,8,16404,,,H,F
BAO_0000019,Expert,,,1,,Stomach,,945.0,CHEMBL617630,,2915,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,10116.0,12688,,Rattus norvegicus,9,16404,,,D,F
BAO_0000019,Autocuration,,,1,,Thoracic aorta,,1515.0,CHEMBL617631,,2916,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,12688,,,8,16404,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617632,,2917,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,12688,,,8,7483,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617633,,2918,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,12688,,,8,7483,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617634,,2919,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,12688,,,8,7483,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617635,,2920,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,12688,,,8,7483,,,H,B
BAO_0000019,Autocuration,,,1,,Stomach,,945.0,CHEMBL617637,,2922,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,10116.0,12688,,Rattus norvegicus,9,16404,,,D,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617638,,2923,Binding affinity against 5-hydroxytryptamine 1A receptor,,227,,,8,6347,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617639,,2924,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,227,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617640,,2925,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,227,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617641,,2926,Evaluated for the binding affinity to 5-HT 2B receptor,,227,,,8,4687,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617642,,2927,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,227,,,8,16946,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617643,,2928,Binding affinities against 5-hydroxytryptamine 2B receptor,,227,,,8,16633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617644,,2929,Binding affinities towards 5-hydroxytryptamine 2B receptor,,227,,,8,16633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617645,,2930,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,227,,,8,16633,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617646,,2931,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,108,,,8,15026,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617647,,2932,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,9913.0,108,,Bos taurus,8,15738,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617648,,2933,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,9913.0,108,,Bos taurus,8,15738,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617875,,2934,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,9913.0,108,,Bos taurus,8,15738,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617876,,2935,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,9913.0,108,,Bos taurus,8,15738,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617877,,2936,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,9913.0,108,,Bos taurus,8,16404,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617878,,2937,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,9913.0,108,,Bos taurus,8,15026,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617879,,2938,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,9913.0,108,,Bos taurus,8,15738,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617880,,2939,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,10141.0,108,,Cavia porcellus,8,16312,,,H,B
BAO_0000357,Intermediate,,,1,,Striatum,,2435.0,CHEMBL617881,,2940,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,10141.0,20033,,Cavia porcellus,9,5486,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL857073,,2941,Binding affinity against 5-HT1A receptor,,51,,,8,5254,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617882,,2942,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,108,,,8,3857,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617883,,2943,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,9606.0,108,,Homo sapiens,9,6857,,,D,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617884,,2944,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,108,,,8,4176,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617885,,2945,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,108,,,8,6347,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617886,,2946,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,108,,,8,6347,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617887,,2947,Inhibition of human 5-hydroxytryptamine 2C receptor,9606.0,108,,Homo sapiens,9,16146,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617888,,2948,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,108,,,8,3805,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617889,,2949,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,108,,,8,3857,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617890,,2950,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,108,,,8,5635,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617891,,2951,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,108,,,8,5635,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617892,,2952,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,108,,,8,5635,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617893,,2953,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,108,,,8,4012,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617894,,2954,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,108,,,8,6366,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617895,,2955,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,108,,,8,15949,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617896,,2956,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,108,,,8,17211,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL617897,,2957,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,9606.0,108,,Homo sapiens,9,6491,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617898,,2958,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,108,,,8,14093,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617899,,2959,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,108,,,8,13481,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL617900,,2960,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,10116.0,108,,Rattus norvegicus,8,6347,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617901,,2961,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,108,,,8,14093,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617902,,2962,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,108,,,8,14093,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617903,,2963,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,108,,,8,13481,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617904,,2964,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,108,,,8,14442,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617905,,2965,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,108,,,8,14442,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617906,,2966,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,108,,,8,14442,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617907,,2967,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,108,,,8,14755,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617908,,2968,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,108,,,8,14744,,,H,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL620617,,2969,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,108,,,8,16659,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL620618,,2970,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,9606.0,108,,Homo sapiens,9,6857,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620619,,2971,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,108,,,8,5635,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620620,,2972,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,9606.0,108,,Homo sapiens,9,4234,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620621,,2973,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,108,,,8,16209,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL872920,,2974,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,10116.0,104698,Membranes,Rattus norvegicus,7,5778,,,D,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620622,,2975,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,104698,,,6,5094,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620623,,2976,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,10116.0,104698,,Rattus norvegicus,7,809,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620624,,2977,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,104698,,,6,1578,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620625,,2978,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,104698,,,6,809,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL620626,,2979,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,104698,,,6,12469,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621307,,2980,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,104698,,,6,14290,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621308,,2981,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,104698,,,6,14290,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL621309,,2982,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,104698,,,6,10609,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL621310,,2983,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,104698,,,6,10609,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL621311,,2984,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,104698,,,6,10609,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL621502,,2985,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,104698,,,6,15253,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL621503,,2986,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,104698,,,6,15253,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL621504,,2987,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,104698,Membranes,,6,11683,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL621505,,2988,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,104698,,,6,12092,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621506,,2989,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,104698,,,6,1946,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619781,,2990,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,104698,,,6,11623,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619782,,2991,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,104698,,,6,11623,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619783,,2992,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,104698,,,6,14788,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619784,,2993,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,10116.0,104698,,Rattus norvegicus,7,5432,,,D,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL619785,,2994,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,104698,,,6,14826,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619786,,2995,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,104698,,,6,2222,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619787,,2996,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,104698,,,6,11963,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872925,,2997,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,104698,,,6,14145,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619788,,2998,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,104698,,,6,17819,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL619789,,2999,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,104698,,,6,10394,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL619790,,3000,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,104698,,,6,10394,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619791,,3001,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,104698,,,6,15034,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619792,,3002,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,104698,,,6,691,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL619793,,3003,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,104698,Membranes,,6,12092,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619794,,3004,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,10116.0,104698,,Rattus norvegicus,7,11752,,,D,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL619795,,3005,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,104698,,,6,11752,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619796,,3006,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,104698,,,6,301,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620448,,3007,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,104698,,,6,16532,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620449,,3008,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,104698,,,6,16532,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620450,,3009,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,104698,,,6,12092,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620451,,3010,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,104698,,,6,11684,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620631,,3011,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,104698,,,6,11684,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620632,,3012,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,104698,,,6,12953,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620633,,3013,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,104698,,,6,12953,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620634,,3014,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,104698,,,6,12953,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620635,,3015,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,104698,,,6,12861,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620636,,3016,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620637,,3017,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620638,,3018,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620639,,3019,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620640,,3020,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620641,,3021,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620642,,3022,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620643,,3023,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620644,,3024,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620645,,3025,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620646,,3026,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620647,,3027,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620648,,3028,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620649,,3029,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620650,,3030,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620651,,3031,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL872875,,3032,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620652,,3033,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620653,,3034,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,104698,,,6,10609,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL857076,,3035,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,104698,,,6,12861,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620654,,3036,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,10116.0,104698,,Rattus norvegicus,7,12861,,,D,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620655,,3037,Binding activity radioligand.,,104698,,,6,12861,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL620656,,3038,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,104698,Brain membranes,,6,10728,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL620657,,3039,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,104698,Brain membranes,,6,10728,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620658,,3040,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,108,,,8,5163,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620659,,3041,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,108,,,8,5163,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620660,,3042,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,108,,,8,6011,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620661,,3043,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,108,,,8,5014,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620662,,3044,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,108,,,8,5635,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620663,,3045,Affinity for 5-hydroxytryptamine 2C receptor,,108,,,8,5163,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620664,,3046,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,108,,,8,6841,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620665,,3047,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,108,,,8,6119,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620666,,3048,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,108,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620667,,3049,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,108,,,8,1633,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620668,,3050,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,108,,,8,1633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620669,,3051,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,108,,,8,4373,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620670,,3052,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,108,,,8,6576,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620671,,3053,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,108,,,8,4687,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620672,,3054,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,108,,,8,12146,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620673,,3055,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,108,,,8,12146,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620674,,3056,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,108,,,8,16946,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620675,,3057,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,108,,,8,14159,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620676,,3058,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,108,,,8,16700,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621382,,3059,Affinity against 5-hydroxytryptamine 2C receptor,,108,,,8,3269,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621383,,3060,Binding affinity against 5-hydroxytryptamine 2C receptor,9606.0,108,,Homo sapiens,9,1274,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621384,,3061,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,108,,,8,1317,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621385,,3062,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,9913.0,144,,Bos taurus,8,5834,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617989,,3063,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,9913.0,144,,Bos taurus,8,11147,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL617990,,3064,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,10141.0,104714,,Cavia porcellus,4,14145,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL875085,,3065,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,10141.0,104714,,Cavia porcellus,4,10561,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617991,,3066,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,10141.0,104714,,Cavia porcellus,4,15847,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617992,,3067,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,10141.0,104714,,Cavia porcellus,4,15847,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617993,,3068,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,10141.0,104714,,Cavia porcellus,4,10561,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617994,,3069,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,10141.0,104714,,Cavia porcellus,4,11454,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617995,,3070,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617996,,3071,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617997,,3072,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617998,,3073,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617999,,3074,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618000,,3075,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617815,,3076,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",10141.0,104714,,Cavia porcellus,4,15253,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617816,,3077,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",10141.0,104714,,Cavia porcellus,4,15253,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617817,,3078,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,10141.0,104714,,Cavia porcellus,4,11963,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617818,,3079,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,10141.0,104714,,Cavia porcellus,4,1946,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617819,,3080,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,10141.0,104714,,Cavia porcellus,4,1946,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL617820,,3081,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,10141.0,104714,,Cavia porcellus,4,12045,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617821,,3082,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,10141.0,104714,,Cavia porcellus,4,1559,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617822,,3083,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),10141.0,104714,,Cavia porcellus,4,273,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617823,,3084,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),10141.0,104714,,Cavia porcellus,4,273,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617824,,3085,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,10141.0,104714,,Cavia porcellus,4,188,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617825,,3086,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,10141.0,104714,,Cavia porcellus,4,12919,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617826,,3087,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,10141.0,104714,,Cavia porcellus,4,12918,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617827,,3088,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,10141.0,104714,,Cavia porcellus,4,1559,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617828,,3089,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),10141.0,104714,,Cavia porcellus,4,273,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617829,,3090,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,10141.0,104714,,Cavia porcellus,4,1559,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617830,,3091,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,10141.0,104714,,Cavia porcellus,4,1559,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617831,,3092,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,10141.0,104714,,Cavia porcellus,4,1559,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617832,,3093,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,10141.0,104714,,Cavia porcellus,4,14424,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617833,,3094,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,10141.0,22226,,Cavia porcellus,0,13181,,,U,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617834,,3095,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,51,,,8,5486,,,H,B
BAO_0000223,Expert,,,1,,,,,CHEMBL617835,,3096,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,9606.0,104714,,Homo sapiens,5,6491,,,D,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL617836,,3097,Binding affinity towards 5-HT3 receptor,,104714,,,4,6013,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL617837,,3098,Binding activity radioligand.,,104714,,,4,12861,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620392,,3099,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,104714,,,4,12861,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620393,,3100,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,104714,,,4,5104,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620394,,3101,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,104714,,,4,5105,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620395,,3102,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,104714,,,4,5104,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620396,,3103,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,22226,,,0,3935,,,U,B
BAO_0000219,Expert,,433.0,1,,,NG108-15,,CHEMBL620582,,3104,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,105030,,,4,13657,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620583,,3105,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,105030,,,4,10369,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620584,,3106,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,105030,,,4,10369,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL620585,,3107,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,105030,,,4,12918,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL620586,,3108,Compound was evaluated for the binding affinity at 5- HT3 receptor,,105030,,,4,12918,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620587,,3109,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,105030,,,4,10369,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620588,,3110,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,105030,,,4,773,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620589,,3111,5-hydroxytryptamine 3 receptor agonism in mouse,,105030,,,4,12918,,,H,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL620590,,3112,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,105030,,,4,10561,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617956,,3113,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,105030,,,4,12827,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617957,,3114,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,105030,,,4,12827,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617958,,3115,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,105030,,,4,12918,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617959,,3116,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,105030,,,4,273,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617960,,3117,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,105030,,,4,273,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL617961,,3118,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,105030,,,4,10561,,,H,B
BAO_0000219,Autocuration,In vitro,,1,,,,,CHEMBL617962,,3119,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,105030,,,4,5033,,,H,B
BAO_0000219,Autocuration,,339.0,1,,,N1E-115,,CHEMBL617963,,3120,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,105030,,,4,16429,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617964,,3121,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,11765,,,8,10322,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL617965,,3122,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,11765,,,8,14331,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617966,,3123,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,10090.0,10630,,Mus musculus,9,13462,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL857074,,3124,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,17106,,,8,12861,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617967,,3125,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,9823.0,144,,Sus scrofa,8,15086,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617968,,3126,Binding activity radioligand.,9823.0,144,,Sus scrofa,8,12861,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL617969,,3127,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,9986.0,104714,,Oryctolagus cuniculus,4,10561,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL617970,,3128,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,9986.0,104714,,Oryctolagus cuniculus,4,10561,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL617971,,3129,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,9986.0,104714,,Oryctolagus cuniculus,4,10561,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617972,,3130,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,9986.0,104714,,Oryctolagus cuniculus,4,10561,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617973,,3131,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),9986.0,104714,,Oryctolagus cuniculus,4,273,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617974,,3132,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),9986.0,104714,,Oryctolagus cuniculus,4,273,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL617975,,3133,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),9986.0,104714,,Oryctolagus cuniculus,4,273,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617976,,3134,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),9986.0,104714,,Oryctolagus cuniculus,4,273,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617977,,3135,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),9986.0,104714,,Oryctolagus cuniculus,4,273,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617978,,3136,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),9986.0,104714,,Oryctolagus cuniculus,4,273,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617979,,3137,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),9986.0,104714,,Oryctolagus cuniculus,4,273,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL617980,,3138,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,9986.0,104714,,Oryctolagus cuniculus,4,13047,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617981,,3139,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,10116.0,104698,,Rattus norvegicus,7,1650,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617982,,3140,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,12020,,,8,16288,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL617983,,3141,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,12020,,,8,16288,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617984,,3142,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,10116.0,104698,,Rattus norvegicus,7,10254,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617985,,3143,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,104698,,,6,14532,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,Heart,,948.0,CHEMBL617986,,3144,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,104698,,,6,13392,,,H,F
BAO_0000019,Autocuration,,,1,,Heart,,948.0,CHEMBL617987,,3145,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,104698,,,6,13392,,,H,F
BAO_0000019,Autocuration,,,1,,Heart,,948.0,CHEMBL617988,,3146,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,104698,,,6,13392,,,H,F
BAO_0000019,Autocuration,,,1,,Heart,,948.0,CHEMBL617792,,3147,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,104698,,,6,13392,,,H,F
BAO_0000019,Autocuration,,,1,,Heart,,948.0,CHEMBL617793,,3148,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,104698,,,6,13392,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617794,,3149,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,104698,,,6,13392,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617795,,3150,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,104698,,,6,13392,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617796,,3151,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,104698,,,6,13392,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617797,,3152,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,104698,,,6,13392,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617798,,3153,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),10116.0,104698,,Rattus norvegicus,7,1089,,,D,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617799,,3154,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,104698,,,6,1089,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617800,,3155,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,10116.0,104698,,Rattus norvegicus,7,11454,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617801,,3156,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,10116.0,104698,,Rattus norvegicus,7,11454,,,D,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617802,,3157,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,10116.0,104698,,Rattus norvegicus,7,12205,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617803,,3158,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),10116.0,104698,,Rattus norvegicus,7,1089,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617804,,3159,Binding affinity towards 5-HT3 receptor in rat was evaluated,,104698,,,6,5094,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617805,,3160,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,10116.0,104698,,Rattus norvegicus,7,2622,,,D,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL617806,,3161,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,104698,,,6,245,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617807,,3162,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,104698,,,6,14788,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617808,,3163,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,104698,,,6,14788,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617809,,3164,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,104698,,,6,3020,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617810,,3165,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,104698,,,6,1742,,,H,B
BAO_0000249,Autocuration,,,1,,Brain,,955.0,CHEMBL617811,,3166,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,104698,,,6,17394,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL617812,,3167,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,104698,,,6,17394,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617813,,3168,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,104698,,,6,17394,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617814,,3169,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,104698,,,6,14286,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617698,,3170,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,104698,,,6,14178,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617699,,3171,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,10116.0,104698,,Rattus norvegicus,7,14178,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617700,,3172,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,10116.0,104698,,Rattus norvegicus,7,14178,,,D,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL617701,,3173,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,10116.0,104698,,Rattus norvegicus,7,14178,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617702,,3174,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,104698,,,6,15034,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL617703,,3175,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,104698,Membranes,,6,1089,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617704,,3176,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,10116.0,104698,,Rattus norvegicus,7,1089,,,D,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL617705,,3177,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,104698,,,6,16532,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL617706,,3178,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,10116.0,104698,,Rattus norvegicus,7,12801,,,D,B
BAO_0000219,Autocuration,,433.0,1,,,NG108-15,,CHEMBL617707,,3179,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,104698,,,6,15194,,,H,B
BAO_0000219,Autocuration,,433.0,1,,,NG108-15,,CHEMBL617708,,3180,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,104698,,,6,15194,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617709,,3181,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,104698,,,6,15194,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617710,,3182,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,104698,,,6,15194,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL882925,,3183,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,104698,,,6,15194,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617711,,3184,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,104698,,,6,15194,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617712,,3185,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,104698,,,6,10610,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617713,,3186,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,10116.0,104698,,Rattus norvegicus,7,10355,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL617714,,3187,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,104698,,,6,691,,,H,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL617715,,3188,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,104698,,,6,10611,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617716,,3189,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,104698,,,6,12801,,,H,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL617717,,3190,Inhibition of 5-HT evoked reflex bradycardia in rat.,,104698,,,6,10609,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617718,,3191,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617719,,3192,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617720,,3193,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617721,,3194,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,10116.0,104698,,Rattus norvegicus,7,11454,,,D,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617722,,3195,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617723,,3196,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617724,,3197,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617725,,3198,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617726,,3199,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617727,,3200,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617728,,3201,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617729,,3202,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617730,,3203,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617731,,3204,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617732,,3205,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617733,,3206,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617734,,3207,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL872874,,3208,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617735,,3209,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617736,,3210,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617737,,3211,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617738,,3212,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617739,,3213,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617740,,3214,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617741,,3215,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617742,,3216,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617743,,3217,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617744,,3218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617745,,3219,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,104698,,,6,11454,,,H,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL617746,,3220,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,104698,,,6,670,,,H,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL617747,,3221,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,104698,,,6,670,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL617748,,3222,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,104698,,,6,10321,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618909,,3223,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,104698,,,6,10321,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618910,,3224,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,104698,,,6,10321,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618911,,3225,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,104698,,,6,10321,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618912,,3226,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,104698,,,6,10321,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618913,,3227,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,104698,,,6,10322,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618914,,3228,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,104698,,,6,15412,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618915,,3229,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,104698,,,6,15412,,,H,F
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618916,,3230,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,10116.0,104698,,Rattus norvegicus,7,15412,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618917,,3231,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,104698,,,6,15412,,,H,F
BAO_0000221,Intermediate,,,1,,Hippocampus,,10000000.0,CHEMBL618918,,3232,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,104698,,,7,15412,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618919,,3233,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,10116.0,104698,,Rattus norvegicus,7,15412,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618920,,3234,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,10116.0,104698,,Rattus norvegicus,7,17394,,,D,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618921,,3235,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,104698,,,6,12457,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618922,,3236,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,104698,,,6,12457,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618923,,3237,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,104698,,,6,12205,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618924,,3238,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,104698,,,6,14532,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618925,,3239,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,104698,,,6,1122,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618926,,3240,Binding affinity towards 5-HT3 receptor in rat was evaluated,,104698,,,6,5094,,,H,B
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL618927,,3241,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,10141.0,20033,,Cavia porcellus,9,809,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL618928,,3242,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,10141.0,20033,,Cavia porcellus,9,809,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL618929,,3243,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",10141.0,20033,,Cavia porcellus,9,14290,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL618930,,3244,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",10141.0,20033,,Cavia porcellus,9,14290,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL618931,,3245,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",10141.0,20033,,Cavia porcellus,9,14290,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619594,,3246,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",10141.0,20033,,Cavia porcellus,9,14290,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619595,,3247,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",10141.0,20033,,Cavia porcellus,9,14290,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619596,,3248,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,10141.0,20033,,Cavia porcellus,9,13961,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619755,,3249,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,10141.0,20033,,Cavia porcellus,9,13961,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619756,,3250,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,10141.0,20033,,Cavia porcellus,9,809,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619757,,3251,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,10141.0,20033,,Cavia porcellus,9,809,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619758,,3252,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,10141.0,20033,,Cavia porcellus,9,809,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619759,,3253,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",10141.0,20033,,Cavia porcellus,9,14290,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619760,,3254,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",10141.0,20033,,Cavia porcellus,9,14290,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619761,,3255,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",10141.0,20033,,Cavia porcellus,9,14290,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619762,,3256,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,10141.0,20033,,Cavia porcellus,9,14290,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619763,,3257,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",10141.0,20033,,Cavia porcellus,9,14290,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL617868,,3258,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",10141.0,20033,,Cavia porcellus,9,14290,,,D,F
BAO_0000357,Intermediate,,,1,,,,,CHEMBL617869,,3259,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,10141.0,20033,,Cavia porcellus,9,15034,,,D,B
BAO_0000249,Intermediate,,,1,,Striatum,,2435.0,CHEMBL882926,,3260,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,10141.0,20033,,Cavia porcellus,9,5094,,,D,B
BAO_0000249,Intermediate,,,1,,Striatum,,2435.0,CHEMBL617870,,3261,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,10141.0,20033,,Cavia porcellus,9,5094,,,D,B
BAO_0000357,Intermediate,,,1,,Striatum,,2435.0,CHEMBL617871,,3262,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,10141.0,20033,,Cavia porcellus,9,5399,,,D,B
BAO_0000357,Intermediate,,,1,,Striatum,,2435.0,CHEMBL617872,,3263,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,10141.0,20033,,Cavia porcellus,9,17394,,,D,B
BAO_0000357,Intermediate,,,1,,Striatum,,2435.0,CHEMBL617873,,3264,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,10141.0,20033,,Cavia porcellus,9,17394,,,D,B
BAO_0000357,Intermediate,,,1,,Striatum,,2435.0,CHEMBL617874,,3265,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,10141.0,20033,,Cavia porcellus,9,17394,,,D,B
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619067,,3266,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,10141.0,20033,,Cavia porcellus,9,13961,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619068,,3267,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,10141.0,20033,,Cavia porcellus,9,13961,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619069,,3268,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,10141.0,20033,,Cavia porcellus,9,13961,,,D,F
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619070,,3269,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,10141.0,20033,,Cavia porcellus,9,16946,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619071,,3270,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,10141.0,20033,,Cavia porcellus,9,16946,,,D,B
BAO_0000019,Intermediate,,,1,,,,,CHEMBL619072,,3271,Agonistic activity against 5-hydroxytryptamine 4 receptor,10141.0,20033,,Cavia porcellus,9,15034,,,D,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL619073,,3272,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,10141.0,20033,,Cavia porcellus,9,15034,,,D,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL619074,,3273,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,10141.0,20033,,Cavia porcellus,9,12918,,,D,F
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619075,,3274,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,10141.0,20033,,Cavia porcellus,9,16946,,,D,B
BAO_0000357,Intermediate,,,1,,Striatum,,2435.0,CHEMBL619076,,3275,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,10141.0,20033,,Cavia porcellus,9,17394,,,D,B
BAO_0000357,Intermediate,,,1,,Striatum,,2435.0,CHEMBL619077,,3276,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,10141.0,20033,,Cavia porcellus,9,15034,,,D,B
BAO_0000249,Intermediate,,,1,,Striatum,,2435.0,CHEMBL619078,,3277,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,10141.0,20033,,Cavia porcellus,9,5094,,,D,B
BAO_0000249,Intermediate,,,1,,Striatum,,2435.0,CHEMBL619079,,3278,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,10141.0,20033,,Cavia porcellus,9,5094,,,D,B
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619080,,3279,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,10141.0,20033,,Cavia porcellus,9,17358,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619081,,3280,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,10141.0,20033,,Cavia porcellus,9,12953,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619082,,3281,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,10141.0,20033,,Cavia porcellus,9,12953,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619083,,3282,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,10141.0,20033,,Cavia porcellus,9,12953,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619084,,3283,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,10141.0,20033,,Cavia porcellus,9,12953,,,D,B
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL859397,,3284,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,10141.0,20033,,Cavia porcellus,9,273,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619085,,3285,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,10141.0,20033,,Cavia porcellus,9,12918,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619086,,3286,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,10141.0,20033,,Cavia porcellus,9,12919,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619087,,3287,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,10141.0,20033,,Cavia porcellus,9,273,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619088,,3288,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,10141.0,20033,,Cavia porcellus,9,273,,,D,F
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619089,,3289,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,10141.0,20033,,Cavia porcellus,9,13181,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619090,,3290,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,10141.0,168,,Cavia porcellus,8,13181,,,H,B
BAO_0000019,Intermediate,,,1,,,,,CHEMBL619091,,3291,Antagonistic activity against 5-hydroxytryptamine 4 receptor,10141.0,20033,,Cavia porcellus,9,15034,,,D,F
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619092,,3292,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,10141.0,20033,,Cavia porcellus,9,5033,,,D,B
BAO_0000019,Intermediate,,,1,,,,,CHEMBL619093,,3293,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,10141.0,20033,,Cavia porcellus,9,1980,,,D,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL619094,,3294,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,10141.0,168,,Cavia porcellus,8,13181,,,H,B
BAO_0000019,Intermediate,,,1,,,,,CHEMBL619095,,3295,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,10141.0,20033,,Cavia porcellus,9,14287,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL857988,,3296,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,10141.0,20033,,Cavia porcellus,9,1317,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619096,,3297,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,10141.0,20033,,Cavia porcellus,9,15316,,,D,B
BAO_0000357,Intermediate,,,1,,Striatum,,2435.0,CHEMBL619097,,3298,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,10141.0,20033,,Cavia porcellus,9,16429,,,D,B
BAO_0000221,Intermediate,,,1,,Hippocampus,,10000000.0,CHEMBL619098,,3299,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,10141.0,20033,,Cavia porcellus,9,14818,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619751,,3300,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,10141.0,20033,,Cavia porcellus,9,15194,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619752,,3301,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,10141.0,20033,,Cavia porcellus,9,15194,,,D,B
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL875096,,3302,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,10141.0,20033,,Cavia porcellus,9,13961,,,D,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619004,,3303,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,108,,,8,5486,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619005,,3304,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,168,,,8,16209,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619006,,3305,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,168,,,8,17085,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL619007,,3306,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,168,,,8,4199,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619008,,3307,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,168,,,8,15146,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619009,,3308,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,168,,,8,5213,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL619010,,3309,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,168,,,8,4829,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619011,,3310,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,10622,,,8,17358,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619012,,3311,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,10622,,,8,17358,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL619013,,3312,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,10622,,,8,16946,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619014,,3313,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,10622,,,8,17358,,,H,B
BAO_0000019,Autocuration,,,1,,Cardiac atrium,,2081.0,CHEMBL857503,,3314,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,11249,,,8,268,,,H,F
BAO_0000019,Autocuration,,,1,,Cardiac atrium,,2081.0,CHEMBL619015,,3315,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,11249,,,8,268,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619016,,3316,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,11249,,,8,15086,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL619017,,3317,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,11249,,,8,14875,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL619018,,3318,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,9823.0,168,,Sus scrofa,8,13267,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619019,,3319,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,9986.0,168,,Oryctolagus cuniculus,8,13047,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619020,,3320,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,10116.0,10623,,Rattus norvegicus,9,1650,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619021,,3321,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,10623,,,8,567,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619022,,3322,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,10623,,,8,17358,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619023,,3323,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,10623,,,8,188,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619024,,3324,lntrinsic activity relative to 5-HT receptor,,10623,,,8,670,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619025,,3325,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,10623,,,8,204,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL619026,,3326,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,10623,,,8,1946,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619027,,3327,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,10623,,,8,6398,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619028,,3328,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,10623,,,8,6398,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619029,,3329,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,10623,,,8,17358,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619030,,3330,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,10623,,,8,6398,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL619031,,3331,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,10623,,,8,11752,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619032,,3332,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,10623,,,8,809,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL619033,,3333,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,10116.0,10623,,Rattus norvegicus,9,14178,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619034,,3334,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,10623,,,8,567,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619035,,3335,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,10623,,,8,1946,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619036,,3336,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,10623,,,8,1946,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619037,,3337,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,10116.0,10623,,Rattus norvegicus,9,13961,,,D,B
BAO_0000249,Autocuration,,,1,,Striatum,,2435.0,CHEMBL619038,,3338,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,10623,,,8,6238,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL619039,,3339,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,10623,,,8,14290,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL619040,,3340,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,10623,,,8,14290,,,H,B
BAO_0000019,Expert,,,1,,Striatum,,2435.0,CHEMBL619041,,3341,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10116.0,10623,,Rattus norvegicus,9,809,,,D,B
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL619042,,3342,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,10623,,,8,1578,,,H,B
BAO_0000249,Expert,,,1,,Striatum,,2435.0,CHEMBL619043,,3343,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,10623,,,8,16709,,,H,B
BAO_0000019,Expert,,,1,,Striatum,,2435.0,CHEMBL619044,,3344,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,10623,,,8,1946,,,H,B
BAO_0000249,Expert,,,1,,Striatum,,2435.0,CHEMBL619045,,3345,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,10623,,,8,15253,,,H,B
BAO_0000249,Expert,,,1,,Striatum,,2435.0,CHEMBL619046,,3346,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,10623,,,8,4535,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL619047,,3347,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,10623,,,8,13961,,,H,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL619048,,3348,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,10623,,,8,17358,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL859398,,3349,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,10623,,,8,15847,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619049,,3350,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,10623,,,8,15847,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL857886,,3351,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,10623,,,8,670,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619050,,3352,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,10623,,,8,670,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620591,,3353,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,10623,,,8,1317,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL620592,,3354,Binding affinity against rat 5-hydroxytryptamine 4 receptor,10116.0,10623,,Rattus norvegicus,9,12936,,,D,B
BAO_0000249,Expert,,,1,,Striatum,,2435.0,CHEMBL620593,,3355,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,10623,,,8,4535,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL620594,,3356,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,10116.0,10623,,Rattus norvegicus,9,14424,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL875079,,3357,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,10623,,,8,14424,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL620595,,3358,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,10623,,,8,14424,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL620596,,3359,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,10116.0,10623,,Rattus norvegicus,9,14424,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620597,,3360,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,10623,,,8,14424,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL620598,,3361,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,10623,,,8,14424,,,H,F
BAO_0000218,Expert,,,1,,,,,CHEMBL620599,,3362,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,10623,,,8,14424,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620600,,3363,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,10623,,,8,14424,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620601,,3364,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,10116.0,168,,Rattus norvegicus,8,1980,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620602,,3365,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,168,,,8,4639,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620603,,3366,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,168,,,8,17358,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620604,,3367,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,168,,,8,17358,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620605,,3368,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,168,,,8,17358,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620606,,3369,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,168,,,8,1558,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620607,,3370,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,168,,,8,17358,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620608,,3371,In vitro binding affinity towards 5-HT4 receptor was determined,,168,,,8,16117,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620609,,3372,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,168,,,8,17358,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620610,,3373,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,168,,,8,17358,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620611,,3374,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,168,,,8,17358,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620612,,3375,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,168,,,8,17358,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620613,,3376,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,168,,,8,17358,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620614,,3377,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,168,,,8,17358,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620615,,3378,Binding affinity against 5-Hydroxytryptamine 4 receptor,,168,,,8,1274,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL857075,,3379,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,104698,Brain membranes,,6,10728,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL620616,,3380,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,104698,Brain membranes,,6,11695,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL619411,,3381,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,104698,Brain membranes,,6,11695,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619412,,3382,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,104698,,,6,12490,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619413,,3383,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,10116.0,104698,,Rattus norvegicus,7,11828,,,D,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL619414,,3384,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,104698,,,6,12253,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619415,,3385,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,104698,,,6,10561,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619416,,3386,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,104698,,,6,10561,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619417,,3387,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,104698,,,6,14432,,,H,F
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619418,,3388,Binding affinity against rat 5-hydroxytryptamine 3 receptor,10116.0,104698,,Rattus norvegicus,7,12936,,,D,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619419,,3389,Binding affinity against 5-Hydroxytryptamine 3 receptor,10116.0,104698,,Rattus norvegicus,7,1274,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619420,,3390,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,104698,,,6,1980,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL619421,,3391,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,104698,,,6,670,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619422,,3392,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,10116.0,104698,,Rattus norvegicus,7,968,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619423,,3393,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,104698,,,6,14287,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL875080,,3394,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,104698,,,6,567,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619424,,3395,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,104698,,,6,13267,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL619425,,3396,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,104698,,,6,14826,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619426,,3397,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,104698,,,6,15194,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619427,,3398,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,104698,,,6,15194,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619645,,3399,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,10116.0,104698,,Rattus norvegicus,7,10394,,,D,B
BAO_0000249,Expert,,,1,,,,,CHEMBL619646,,3400,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,10576,,,9,13657,,,D,B
BAO_0000221,Autocuration,,,1,,Brain,,955.0,CHEMBL619647,,3401,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,12020,,,8,1879,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619648,,3402,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,12020,,,8,1879,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619165,,3403,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,12020,,,8,1879,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620719,,3404,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,12020,,,8,204,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872924,,3405,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,12020,,,8,1879,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620720,,3406,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,12020,,,8,1879,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620721,,3407,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,12020,,,8,1879,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620722,,3408,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,12020,,,8,1879,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620723,,3409,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,104698,,,6,10641,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620724,,3410,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,12020,,,8,773,,,H,B
BAO_0000249,Autocuration,,,1,,,,,CHEMBL620725,,3411,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,104698,,,6,11952,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620726,,3412,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,10116.0,12020,,Rattus norvegicus,9,14145,,,D,F
BAO_0000357,Expert,,,1,,,,,CHEMBL620727,,3413,Binding affinity towards 5-hydroxytryptamine 3 receptor,,144,,,8,17066,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620728,,3414,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,104714,,,4,6398,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620729,,3415,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,22226,,,0,10321,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL858288,,3416,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,104714,,,4,511,,,H,F
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620730,,3417,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,104714,,,4,4639,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL620731,,3418,Binding affinity towards 5-hydroxytryptamine 3 receptor,,104714,,,4,4639,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620732,,3419,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618042,,3420,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618043,,3421,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618044,,3422,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,104714,,,4,1558,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618045,,3423,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,104714,,,4,268,,,H,F
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618046,,3424,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,104714,,,4,2474,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618047,,3425,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,104714,,,4,5067,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL875084,,3426,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,104714,,,4,5067,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618048,,3427,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,104714,,,4,5067,,,H,F
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618049,,3428,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,104714,,,4,5067,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619764,,3429,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,104714,,,4,5067,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619765,,3430,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,104714,,,4,5067,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619766,,3431,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,104714,,,4,5067,,,H,F
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619767,,3432,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,104714,,,4,5067,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619768,,3433,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,104714,,,4,5067,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619769,,3434,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,104714,,,4,5067,,,H,F
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619770,,3435,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,104714,,,4,5067,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619771,,3436,Binding affinity towards 5-hydroxytryptamine 3 receptor,,104714,,,4,5067,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL619772,,3437,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,104714,,,4,14331,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619773,,3438,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,104714,,,4,5067,,,H,B
BAO_0000219,Autocuration,,433.0,1,,,NG108-15,,CHEMBL619774,,3439,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,104714,,,4,6179,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL875083,,3440,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,104714,,,4,4265,,,H,B
BAO_0000219,Autocuration,,433.0,1,,,NG108-15,,CHEMBL620718,,3441,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,104714,,,4,4265,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618127,,3442,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,104714,,,4,17358,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618128,,3443,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,104714,,,4,17358,,,H,B
BAO_0000219,Autocuration,In vitro,,1,,,,,CHEMBL618129,,3444,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,104714,,,4,13628,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618130,,3445,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,104714,,,4,4612,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618131,,3446,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,104714,,,4,17358,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618132,,3447,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618133,,3448,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618134,,3449,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618135,,3450,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618136,,3451,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,104714,,,4,511,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618137,,3452,Binding affinity towards 5-hydroxytryptamine 3 receptor,,104714,,,4,1479,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618138,,3453,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,104714,,,4,1317,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618139,,3454,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,104714,,,4,12146,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618140,,3455,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,104714,,,4,12146,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618141,,3456,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,104714,,,4,13969,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL873478,,3457,Binding affinity for 5-hydroxytryptamine 2C receptor,,108,,,8,13392,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618142,,3458,Binding affinity towards 5-hydroxytryptamine 3 receptor,,104698,,,6,13392,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618143,,3459,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,144,,,8,14159,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618144,,3460,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,144,,,8,1558,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618145,,3461,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,144,,,8,16655,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618146,,3462,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,104714,,,4,13020,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618147,,3463,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,104714,,,4,13021,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618148,,3464,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,104714,,,4,13020,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618149,,3465,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,144,,,8,10321,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872927,,3466,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,144,,,8,15818,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618150,,3467,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,144,,,8,15818,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618151,,3468,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,144,,,8,17358,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL875094,,3469,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,144,,,8,2222,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618152,,3470,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,144,,,8,10322,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618153,,3471,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,144,,,8,16117,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618888,,3472,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,144,,,8,17200,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618889,,3473,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,144,,,8,17358,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618890,,3474,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,144,,,8,16700,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618891,,3475,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,144,,,8,1980,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619054,,3476,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,144,,,8,1980,,,H,B
BAO_0000223,Autocuration,,,1,,,,,CHEMBL619055,,3477,Binding affinity against the 5-hydroxytryptamine 3 receptor,,104714,,,4,12409,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619056,,3478,Binding affinity against human 5-hydroxytryptamine 3A receptor,,144,,,8,4365,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619057,,3479,Percent efficacy against 5-hydroxytryptamine 3A receptor,,144,,,8,4365,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619058,,3480,Binding affinity against human 5-hydroxytryptamine 3A receptor,,144,,,8,4365,,,H,B
BAO_0000219,Expert,,,1,,,Oocytes,,CHEMBL619059,,3481,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,10116.0,12020,,Rattus norvegicus,9,6769,,,D,F
BAO_0000219,Expert,,,1,,,Oocytes,,CHEMBL619060,,3482,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,10116.0,12020,,Rattus norvegicus,9,6769,,,D,F
BAO_0000219,Expert,,,1,,,Oocytes,,CHEMBL875095,,3483,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,10116.0,12020,,Rattus norvegicus,9,6769,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619061,,3484,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,10141.0,20033,,Cavia porcellus,9,809,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619062,,3485,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,10141.0,20033,,Cavia porcellus,9,809,,,D,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL619063,,3486,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,10141.0,20033,,Cavia porcellus,9,14290,,,D,F
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619064,,3487,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,10141.0,20033,,Cavia porcellus,9,17358,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619065,,3488,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,10141.0,20033,,Cavia porcellus,9,17358,,,D,B
BAO_0000221,Intermediate,,,1,,Ileum,,2116.0,CHEMBL619066,,3489,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,10141.0,20033,,Cavia porcellus,9,17358,,,D,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL619775,,3490,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,10209,,,8,17386,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619776,,3491,Affinity against 5-hydroxytryptamine 7 receptor,,10209,,,8,3269,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619777,,3492,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,10141.0,104841,,Cavia porcellus,4,7721,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619778,,3493,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,10141.0,104841,,Cavia porcellus,4,7721,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL619779,,3494,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,10141.0,104841,,Cavia porcellus,4,9117,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619780,,3495,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",10141.0,104841,,Cavia porcellus,4,7721,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619166,,3496,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",10141.0,104841,,Cavia porcellus,4,7721,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619167,,3497,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,10141.0,104841,,Cavia porcellus,4,15796,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619168,,3498,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,10141.0,104841,,Cavia porcellus,4,15796,,,H,F
BAO_0000219,Expert,,,1,,Cardiac atrium,,2081.0,CHEMBL619169,,3499,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,9606.0,168,,Homo sapiens,9,15650,,,D,B
BAO_0000219,Expert,,,1,,Cardiac atrium,,2081.0,CHEMBL619170,,3500,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,9606.0,168,,Homo sapiens,9,15650,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619171,,3501,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",9606.0,104841,,Homo sapiens,5,6866,,,D,F
BAO_0000219,Expert,,,1,,Cardiac atrium,,2081.0,CHEMBL619172,,3502,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",9606.0,168,,Homo sapiens,9,15650,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619173,,3503,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,10090.0,22226,,Mus musculus,0,10063,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619174,,3504,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,10090.0,22226,,Mus musculus,0,12665,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619175,,3505,5-hydroxytryptamine receptor binding affinity was determined in rats,,104705,,,4,7504,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619176,,3506,Binding affinity at rat 5-hydroxytryptamine receptor.,,104705,,,4,7504,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619177,,3507,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,104705,,,4,7038,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619178,,3508,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,104705,,,4,7626,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619179,,3509,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,104705,,,4,7626,,,H,B
BAO_0000019,Autocuration,,,1,,Stomach,,945.0,CHEMBL619180,,3510,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,104705,,,4,7185,,,H,F
BAO_0000019,Autocuration,,,1,,Stomach,,945.0,CHEMBL619181,,3511,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,104705,,,4,7185,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619182,,3512,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,104705,,,4,7185,,,H,F
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619183,,3513,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,104705,,,4,6960,,,H,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619184,,3514,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,104705,,,4,6960,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL619185,,3515,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,10576,,,8,12416,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619186,,3516,Binding affinity for rat 5-hydroxytryptamine transporter.,,12198,,,8,15753,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619187,,3517,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,104705,,,4,8062,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619188,,3518,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,10116.0,104705,,Rattus norvegicus,5,9036,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619189,,3519,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,10116.0,104705,,Rattus norvegicus,5,15067,,,D,B
BAO_0000019,Expert,,,1,,Brain,,955.0,CHEMBL619190,,3520,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,10116.0,12198,,Rattus norvegicus,9,15753,,,D,F
BAO_0000221,Expert,,,1,,Cerebellum,,2037.0,CHEMBL619191,,3521,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,10116.0,12198,,Rattus norvegicus,9,15753,,,D,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619192,,3522,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,10116.0,104705,,Rattus norvegicus,5,15295,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619193,,3523,Percent binding affinity against 5-hydroxytryptamine receptor,10116.0,104705,,Rattus norvegicus,5,6347,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619194,,3524,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,22226,,,0,6763,,,U,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619195,,3525,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,10116.0,104705,,Rattus norvegicus,5,12092,,,D,B
BAO_0000224,Autocuration,,,1,,,,,CHEMBL619196,,3526,Affinity against 5-hydroxytryptamine receptor was determined,10116.0,104705,,Rattus norvegicus,5,1579,,,D,B
BAO_0000019,Autocuration,,,1,,Stomach,,945.0,CHEMBL619197,,3527,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,10116.0,104705,,Rattus norvegicus,5,1579,,,D,B
BAO_0000219,Expert,In vitro,,1,,,,,CHEMBL619198,,3528,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,9606.0,121,,Homo sapiens,9,5963,,,D,B
BAO_0000219,Expert,In vitro,,1,,,,,CHEMBL875081,,3529,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,9606.0,121,,Homo sapiens,9,5963,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL884712,,3530,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,18065,,,8,5030,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL884710,,3531,Inhibition of 5-hydroxytryptamine reuptake,,121,,,8,15796,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619199,,3532,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,18065,,,8,15413,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619200,,3533,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,18065,,,8,15413,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619201,,3534,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,18065,,,8,15413,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619202,,3535,Tested for 5-hydroxytryptamine receptor uptake,,18065,,,8,12409,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL619203,,3536,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,9606.0,51,,Homo sapiens,9,16909,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619204,,3537,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,9606.0,51,,Homo sapiens,9,16909,,,D,F
BAO_0000249,Autocuration,,,1,,,,,CHEMBL619205,,3538,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,9606.0,10576,,Homo sapiens,8,15629,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619206,,3539,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,10576,,,8,15629,,,H,B
BAO_0000249,Expert,,,1,,,,,CHEMBL619207,,3540,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,10576,,,8,15629,,,H,B
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL619208,,3541,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL619209,,3542,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL619210,,3543,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL619211,,3544,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL619212,,3545,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL620681,,3546,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL620682,,3547,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL620683,,3548,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL620684,,3549,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL620685,,3550,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL620686,,3551,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Limbic system,,349.0,CHEMBL620687,,3552,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Limbic system,,349.0,CHEMBL620688,,3553,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Limbic system,,349.0,CHEMBL620689,,3554,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Limbic system,,349.0,CHEMBL620690,,3555,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Limbic system,,349.0,CHEMBL620691,,3556,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Limbic system,,349.0,CHEMBL620692,,3557,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Limbic system,,349.0,CHEMBL620693,,3558,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL620694,,3559,Binding affinity against 5-hydroxytryptamine 4 receptor,,168,,,8,1274,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL857986,,3560,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,168,,,8,17358,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620695,,3561,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,168,,,8,14532,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620696,,3562,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,168,,,8,16989,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620697,,3563,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,168,,,8,17200,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620698,,3564,Binding affinity towards 5-hydroxytryptamine 4 receptor,,168,,,8,15779,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620699,,3565,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,168,,,8,15779,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620700,,3566,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,168,,,8,15779,,,H,B
BAO_0000219,Autocuration,,643.0,1,,,COS-7,,CHEMBL620701,,3567,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,168,,,8,15650,,,H,B
BAO_0000219,Autocuration,,643.0,1,,,COS-7,,CHEMBL875082,,3568,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,168,,,8,15650,,,H,B
BAO_0000219,Autocuration,,643.0,1,,,COS-7,,CHEMBL620702,,3569,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,168,,,8,15650,,,H,B
BAO_0000219,Autocuration,,643.0,1,,,COS-7,,CHEMBL620703,,3570,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,168,,,8,15650,,,H,B
BAO_0000219,Autocuration,,673.0,1,,,C6,,CHEMBL620704,,3571,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,168,,,8,17046,,,H,B
BAO_0000219,Expert,,673.0,1,,,C6,,CHEMBL620705,,3572,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,168,,,8,17046,,,H,B
BAO_0000219,Expert,,673.0,1,,,C6,,CHEMBL620706,,3573,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,168,,,8,15650,,,H,B
BAO_0000219,Expert,,673.0,1,,,C6,,CHEMBL620707,,3574,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,168,,,8,17046,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620708,,3575,Binding affinity towards 5-hydroxytryptamine 5 receptor,,10624,,,8,17066,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620709,,3576,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,105,,,8,17200,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620710,,3577,Binding affinity against 5-hydroxytryptamine 5A receptor,9606.0,10624,,Homo sapiens,9,16146,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620711,,3578,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,10624,,,8,15250,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620712,,3579,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,9606.0,10624,,Homo sapiens,9,6491,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620713,,3580,Binding affinity towards human 5-hydroxytryptamine 5A receptor,9606.0,10624,,Homo sapiens,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620714,,3581,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,9606.0,10624,,Homo sapiens,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620715,,3582,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,9606.0,10624,,Homo sapiens,9,4234,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620716,,3583,Binding affinity towards 5-HT5A receptor,,10624,,,8,6013,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620717,,3584,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,10624,,,8,17175,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618072,,3585,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,10624,,,8,15818,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL857987,,3586,Binding affinity towards cloned human 5-HT5A receptor was determined,,10624,,,8,6166,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL618073,,3587,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,10624,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL618074,,3588,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,10624,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL618075,,3589,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,10624,,,8,5213,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618076,,3590,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,10090.0,10625,,Mus musculus,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618077,,3591,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,10090.0,10625,,Mus musculus,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618078,,3592,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,10090.0,10625,,Mus musculus,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL881821,,3593,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,10090.0,10625,,Mus musculus,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618079,,3594,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,10090.0,10625,,Mus musculus,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618080,,3595,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,10625,,,8,17175,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL618081,,3596,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,10576,,,8,16190,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL618082,,3597,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,10626,,,8,16190,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618083,,3598,Binding affinity towards 5-HT5a receptor,,10624,,,8,4820,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618084,,3599,Binding affinity towards 5-hydroxytryptamine 5A receptor,9606.0,10624,,Homo sapiens,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618085,,3600,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,10624,,,8,17066,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618086,,3601,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,10624,,,8,17175,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL875092,,3602,Binding affinities against 5-hydroxytryptamine 5A receptor,,10624,,,8,16633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618087,,3603,Binding affinities towards 5-hydroxytryptamine 5A receptor,,10624,,,8,16633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872926,,3604,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,10624,,,8,16700,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618088,,3605,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,10141.0,104714,,Cavia porcellus,4,4639,,,H,F
BAO_0000223,Autocuration,,,1,,,,,CHEMBL618089,,3606,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,104714,,,4,5486,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618090,,3607,Inhibition of human 5-hydroxytryptamine 6 receptor,9606.0,10627,,Homo sapiens,9,16146,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618091,,3608,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,9606.0,10627,,Homo sapiens,9,17273,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618092,,3609,Inhibition against human 5-hydroxytryptamine 6 receptor,,10627,,,8,17687,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618093,,3610,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,9606.0,10627,,Homo sapiens,9,6491,,,D,B
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL618094,,3611,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,10627,,,8,16190,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618095,,3612,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,9606.0,10627,,Homo sapiens,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL875093,,3613,Binding affinity towards human 5-hydroxytryptamine 6 receptor,9606.0,10627,,Homo sapiens,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618096,,3614,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,9606.0,10627,,Homo sapiens,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618118,,3615,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,9606.0,10627,,Homo sapiens,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618119,,3616,Binding affinity against 5-hydroxytryptamine 6 receptor,9606.0,10627,,Homo sapiens,9,3555,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618120,,3617,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,,,8,5808,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618121,,3618,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,,,8,6013,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL618122,,3619,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,10627,,,8,15818,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618123,,3620,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,10627,,,8,16209,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL618124,,3621,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,10627,,,8,3935,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618125,,3622,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,,,8,15818,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL618126,,3623,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,9606.0,10627,,Homo sapiens,9,3805,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL618236,,3624,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,10627,,,8,16441,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL618237,,3625,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,10627,,,8,16441,,,H,B
BAO_0000219,Expert,,643.0,1,,,COS-7,,CHEMBL618238,,3626,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,10627,,,8,6786,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618239,,3627,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,9606.0,10627,,Homo sapiens,9,4234,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618240,,3628,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,10627,,,8,17085,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618241,,3629,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,10627,,,8,17200,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL859399,,3630,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,10627,,,8,17451,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618242,,3631,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,10627,,,8,3935,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL857991,,3632,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,10627,,,8,5033,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619951,,3633,Binding affinity against human 5-hydroxytryptamine 6 receptor,,10627,,,8,4540,,,H,B
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL619952,,3634,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,9606.0,10627,,Homo sapiens,9,4540,,,D,B
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL619953,,3635,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,9606.0,10627,,Homo sapiens,9,4540,,,D,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL619954,,3636,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,10627,,,8,17296,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL619955,,3637,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,10627,,,8,17296,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL619956,,3638,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,10627,,,8,17296,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL619957,,3639,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,10627,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL619958,,3640,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,10627,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL620627,,3641,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,10627,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL620628,,3642,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,10627,,,8,15779,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL620629,,3643,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,10627,,,8,15779,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620630,,3644,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,,,8,6166,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL620782,,3645,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,10627,,,8,17451,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620783,,3646,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,10627,,,8,15316,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620784,,3647,Binding affinity against human 5-hydroxytryptamine 6 receptor,,10627,,,8,4199,,,H,B
BAO_0000219,Expert,,308.0,1,,,HeLa,,CHEMBL620785,,3648,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,10627,,,8,15146,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL857992,,3649,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,10627,,,8,5213,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL620786,,3650,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,10627,,,8,16429,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL620787,,3651,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,10627,,,8,14818,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL620788,,3652,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,10627,,,8,4829,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL620789,,3653,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,10627,,,8,4829,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL620790,,3654,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,10627,,,8,4829,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620791,,3655,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,10628,,,8,15250,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620792,,3656,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,10628,,,8,14423,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620793,,3657,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,10628,,,8,15086,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620794,,3658,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,10628,,,8,4342,,,H,B
BAO_0000219,Autocuration,,308.0,1,,,HeLa,,CHEMBL620795,,3659,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,9606.0,10627,,Homo sapiens,9,16190,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620796,,3660,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,,,8,4820,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620797,,3661,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,10627,,,8,4639,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL620798,,3662,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,9606.0,10627,,Homo sapiens,9,17066,,,D,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620799,,3663,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,10627,,,8,6011,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620800,,3664,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,10627,,,8,17066,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620801,,3665,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,10627,,,8,17515,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL875100,,3666,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,10627,,,8,5014,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620802,,3667,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,10627,,,8,4373,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL620803,,3668,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,10627,,,8,17066,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL620804,,3669,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,10627,,,8,17066,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620805,,3670,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,10627,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620806,,3671,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,10627,,,8,4687,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620807,,3672,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,10627,,,8,16946,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620808,,3673,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,10627,,,8,16946,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620809,,3674,Binding affinities against 5-hydroxytryptamine 6 receptor,,10627,,,8,16633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620810,,3675,Binding affinities towards 5-hydroxytryptamine 6 receptor,,10627,,,8,16633,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620811,,3676,Binding affinity towards 5-hydroxytryptamine 6 receptor,9606.0,10627,,Homo sapiens,9,17066,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620812,,3677,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,10627,,,8,16700,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620813,,3678,Affinity against 5-hydroxytryptamine 6 receptor,,10627,,,8,3269,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620814,,3679,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,10627,,,8,5486,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620815,,3680,Inhibition of human 5-hydroxytryptamine 7 receptor,9606.0,10209,,Homo sapiens,9,16146,,,D,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL620816,,3681,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,10209,,,8,5014,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620817,,3682,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,10209,,,8,15463,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620818,,3683,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,10209,,,8,3805,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL620819,,3684,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,10209,,,8,5014,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620820,,3685,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,9606.0,10209,,Homo sapiens,9,6491,,,D,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620821,,3686,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,10209,,,8,16190,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620822,,3687,Binding affinity towards human 5-hydroxytryptamine 7 receptor,9606.0,10209,,Homo sapiens,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620823,,3688,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,9606.0,10209,,Homo sapiens,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620824,,3689,Binding affinity against 5-hydroxytryptamine 7 receptor,9606.0,10209,,Homo sapiens,9,3555,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL620825,,3690,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,10209,,,8,6588,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872930,,3691,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,10209,,,8,15463,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620826,,3692,Binding affinity towards 5-hydroxytryptamine 7 receptor,,10209,,,8,6013,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620827,,3693,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,10209,,,8,16209,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620828,,3694,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,10209,,,8,3935,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620829,,3695,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,10209,,,8,15818,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL620830,,3696,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,10209,,,8,5014,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL620831,,3697,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,10209,,,8,16441,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL620832,,3698,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,10209,,,8,16441,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL621548,,3699,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,9606.0,10209,,Homo sapiens,9,4234,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621549,,3700,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,10209,,,8,17085,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL621550,,3701,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,10209,,,8,17200,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL621551,,3702,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,10209,,,8,17451,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621552,,3703,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,10209,,,8,17085,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL857077,,3704,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,10209,,,8,5104,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618158,,3705,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,10209,,,8,5104,,,H,B
BAO_0000219,Expert,,643.0,1,,,COS-7,,CHEMBL618159,,3706,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,9606.0,10209,,Homo sapiens,9,5033,,,D,B
BAO_0000219,Autocuration,,643.0,1,,,COS-7,,CHEMBL875101,,3707,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,10209,,,8,5486,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL618160,,3708,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,9606.0,10209,,Homo sapiens,9,4540,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618161,,3709,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,10209,,,8,6166,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL618162,,3710,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,10209,,,8,17342,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618163,,3711,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,10209,,,8,17342,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618164,,3712,Binding affinity against 5-hydroxytryptamine 7 human receptors,,10209,,,8,17296,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL618165,,3713,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,10209,,,8,16429,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL618166,,3714,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,10209,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL857989,,3715,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,10209,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL619888,,3716,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,10209,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL619889,,3717,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,10209,,,8,15779,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL619890,,3718,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,10209,,,8,15779,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL619891,,3719,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,10209,,,8,17451,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL619892,,3720,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,10209,,,8,4199,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL619893,,3721,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,10209,,,9,4199,,,D,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL619894,,3722,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,10209,,,8,4199,,,H,B
BAO_0000219,Intermediate,,722.0,1,,,HEK293,,CHEMBL619895,,3723,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,10209,,,9,3680,,,D,B
BAO_0000357,Intermediate,,,1,,,,,CHEMBL619896,,3724,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,10209,,,9,3680,,,D,B
BAO_0000219,Autocuration,,643.0,1,,,COS-7,,CHEMBL619897,,3725,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,10209,,,8,15316,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL619898,,3726,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,10209,,,8,15146,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL619899,,3727,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,10209,,,8,5213,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL619900,,3728,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,10209,,,8,5213,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL619901,,3729,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,9606.0,10209,,Homo sapiens,9,14818,,,D,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL620580,,3730,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,10209,,,8,14818,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL620581,,3731,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,10209,,,8,14818,,,H,B
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL620733,,3732,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,10209,,,8,4829,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620734,,3733,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,9606.0,10209,,Homo sapiens,9,17200,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620735,,3734,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,10090.0,10022,,Mus musculus,9,17066,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620736,,3735,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,9986.0,10209,,Oryctolagus cuniculus,8,14025,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620737,,3736,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,11923,,,8,15250,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620738,,3737,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620739,,3738,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620740,,3739,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620741,,3740,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620742,,3741,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620743,,3742,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620744,,3743,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620745,,3744,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620746,,3745,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620747,,3746,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620748,,3747,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620749,,3748,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,11923,,,8,16372,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620750,,3749,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,11923,,,8,17066,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620751,,3750,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,10116.0,11923,,Rattus norvegicus,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620752,,3751,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,11923,,,8,17386,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL872929,,3752,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,11923,,,8,14423,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620753,,3753,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,10116.0,11923,,Rattus norvegicus,9,15874,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620754,,3754,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,10116.0,11923,,Rattus norvegicus,9,15874,,,D,B
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL620755,,3755,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,10116.0,11923,,Rattus norvegicus,9,16372,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620756,,3756,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,11923,,,8,4622,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620757,,3757,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,11923,,,8,15086,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620758,,3758,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620759,,3759,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620760,,3760,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,11923,,,8,16372,,,H,B
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL620761,,3761,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,11923,,,8,16372,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL620762,,3762,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,11923,,,8,17386,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL620763,,3763,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,11923,,,8,17386,,,H,F
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL620764,,3764,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,11923,,,8,17386,,,H,F
BAO_0000249,Expert,,,1,,,,,CHEMBL857990,,3765,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,10116.0,11923,Membranes,Rattus norvegicus,9,5831,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620765,,3766,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,11923,,,8,4342,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620766,,3767,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,11923,,,8,17319,,,H,B
BAO_0000019,Expert,,,1,,Hypothalamus,,1898.0,CHEMBL620767,,3768,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,11923,,,8,17342,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620768,,3769,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,11923,,,8,17342,,,H,B
BAO_0000249,Expert,,,1,,Hypothalamus,,1898.0,CHEMBL619051,,3770,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,11923,,,8,3680,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619052,,3771,Binding affinity towards 5-hydroxytryptamine 7 receptor,,11923,,,8,3680,,,H,B
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL619053,,3772,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,10116.0,11923,,Rattus norvegicus,9,17319,,,D,F
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL619703,,3773,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,10116.0,11923,,Rattus norvegicus,9,17319,,,D,F
BAO_0000219,Autocuration,,722.0,1,,,HEK293,,CHEMBL619704,,3774,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,10116.0,11923,,Rattus norvegicus,9,17319,,,D,F
BAO_0000357,Expert,,,1,,,,,CHEMBL619851,,3775,Binding affinity towards 5-hydroxytryptamine 7 receptor,,10209,,,8,4820,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619852,,3776,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,10209,,,8,4639,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619853,,3777,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,10209,,,8,6011,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619854,,3778,Binding affinity towards human 5-hydroxytryptamine 7 receptor,9606.0,10209,,Homo sapiens,9,17066,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619855,,3779,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,10209,,,8,17066,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619856,,3780,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,10209,,,8,17515,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619857,,3781,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,10209,,,8,4373,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619858,,3782,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,10209,,,8,17066,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619859,,3783,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,10209,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619860,,3784,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,10209,,,8,4373,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619861,,3785,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,10209,,,8,4687,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619862,,3786,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,10209,,,8,17342,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619863,,3787,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,10209,,,8,16946,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619864,,3788,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,10209,,,8,16946,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL872928,,3789,Binding affinities against 5-hydroxytryptamine 7 receptor,,10209,,,8,16633,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619865,,3790,Binding affinities towards 5-hydroxytryptamine 7 receptor,,10209,,,8,16633,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619866,,3791,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,10209,,,8,17066,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619867,,3792,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,10209,,,8,16700,,,H,B
BAO_0000221,Autocuration,,,1,,Ileum,,2116.0,CHEMBL619868,,3793,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,10209,,,8,17386,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619869,,3794,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,55,,,8,14080,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL619870,,3795,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,9606.0,55,,Homo sapiens,9,14080,,,D,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619871,,3796,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,55,,,8,409,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619872,,3797,In vitro inhibition of human recombinant lipoxygenase enzyme,,55,,,8,409,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619873,,3798,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,55,,,8,409,,,H,B
BAO_0000357,Expert,,,1,,Blood,,178.0,CHEMBL619874,,3799,Inhibition of 5-lipoxygenase in human whole blood.,,55,,,8,11090,,,H,B
BAO_0000357,Expert,,,1,,Blood,,178.0,CHEMBL619875,,3800,Inhibition of 5-lipoxygenase in human whole blood.,,55,,,8,11090,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619876,,3801,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,55,,,8,948,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619877,,3802,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,55,,,8,948,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL619878,,3803,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,55,,,8,13622,,,H,F
BAO_0000019,Autocuration,,,1,,Blood,,178.0,CHEMBL619879,,3804,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,55,,,8,13622,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619880,,3805,In vitro inhibition of 5-lipoxygenase from human polymorphs,,55,,,8,9637,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619881,,3806,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,55,,,8,11320,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619882,,3807,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,55,,,8,11320,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619883,,3808,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,55,,,8,6838,,,H,B
BAO_0000357,Expert,,,1,,Blood,,178.0,CHEMBL619884,,3809,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),9606.0,55,,Homo sapiens,9,17667,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619885,,3810,In vitro potency against human 5-Lipoxygenase,,55,,,8,12703,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619886,,3811,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,9606.0,55,,Homo sapiens,9,14312,,,D,F
BAO_0000019,Autocuration,,,1,,Blood,,178.0,CHEMBL619887,,3812,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,55,,,8,14312,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL875097,,3813,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,55,,,8,5364,,,H,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL618001,,3814,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,55,,,8,951,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL618002,,3815,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,55,,,8,951,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL618003,,3816,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,55,,,8,951,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL618004,,3817,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,55,,,8,951,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL618005,,3818,Inhibition of human 5-lipoxygenase in human cells,,55,,,8,12365,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618006,,3819,Inhibition of human neutrophil 5-lipoxygenase,,55,,,8,10603,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL875086,,3820,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,55,,,8,10501,,,H,B
BAO_0000357,Expert,,,1,,Blood,,178.0,CHEMBL618007,,3821,Inhibition of 5-lipoxygenase from human whole blood,,55,,,8,12281,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618008,,3822,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,55,,,8,2567,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL618009,,3823,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,55,,,8,2567,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618010,,3824,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,55,,,8,10193,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618011,,3825,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,55,,,8,10193,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618012,,3826,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,55,,,8,13623,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL882927,,3827,Tested against 5-lipoxygenase,,55,,,8,12780,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618013,,3828,Tested for activity against 5-Lipoxygenase (5-LO),,55,,,8,12780,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618014,,3829,Tested for activity against 5-lipoxygenase,,55,,,8,12780,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618015,,3830,Tested for inhibition of 5-HPETE production by human 5-LO,,55,,,8,11966,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618016,,3831,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,55,,,8,5364,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL618017,,3832,Inhibition of Human 5-lipoxygenase,,55,,,8,13165,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618018,,3833,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,55,,,8,5364,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL875087,,3834,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,55,,,8,11311,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL618019,,3835,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,55,,,8,11311,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618020,,3836,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,55,,,8,14863,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618021,,3837,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,55,,,8,14863,,,H,B
BAO_0000357,Autocuration,,,1,,Blood,,178.0,CHEMBL618022,,3838,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,55,,,8,11087,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618023,,3839,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,55,,,8,455,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618024,,3840,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,55,,,8,13183,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL873950,,3841,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,55,,,8,10319,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618025,,3842,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,55,,,8,10193,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL618026,,3843,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,55,,,8,951,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL618027,,3844,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,55,,,8,951,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL618028,,3845,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,55,,,8,951,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL618029,,3846,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,55,,,8,951,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618030,,3847,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,55,,,8,9859,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618031,,3848,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,55,,,8,9859,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618032,,3849,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,55,,,8,9859,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618033,,3850,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,55,,,8,2567,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618034,,3851,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,55,,,8,10193,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL875088,,3852,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,55,,,8,10193,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618035,,3853,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,55,,,8,949,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618036,,3854,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,55,,,8,949,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618037,,3855,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,55,,,8,10603,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618038,,3856,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,55,,,8,10603,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618761,,3857,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,55,,,8,10603,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL618762,,3858,Inhibition of lipoxygenase at the concentration of 0.1 uM,,55,,,8,10603,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618763,,3859,Inhibition of lipoxygenase at the concentration of 1 uM,,55,,,8,10603,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618764,,3860,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,55,,,8,10193,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618765,,3861,Inhibition of 5-Lipoxygenase (5-LOX),9606.0,55,,Homo sapiens,9,14580,,,D,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618766,,3862,Inhibition of 5-lipoxygenase in mouse macrophages.,,17087,,,8,11090,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618767,,3863,Inhibition of 5-lipoxygenase in mouse macrophages.,,17087,,,8,11090,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619380,,3864,Inhibitory activity against lipoxygenase-2 in mice,,17087,,,8,6339,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619381,,3865,Inhibitory activity against murine lipoxygenase-2.,,17087,,,8,6339,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619382,,3866,Inhibition of 5-lipoxygenase from mouse macrophage,10090.0,17087,,Mus musculus,9,12281,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619383,,3867,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,17087,,,8,11311,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619384,,3868,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,9823.0,55,,Sus scrofa,8,11089,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619385,,3869,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,9823.0,55,,Sus scrofa,8,10091,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL882928,,3870,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,9986.0,55,,Oryctolagus cuniculus,8,14352,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619386,,3871,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,10116.0,12166,,Rattus norvegicus,9,13329,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619387,,3872,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,12166,,,8,13329,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619388,,3873,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,12166,,,8,13329,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619389,,3874,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,12166,,,8,13329,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619390,,3875,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,12166,,,8,13329,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619391,,3876,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,12166,,,8,13329,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619392,,3877,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,12166,,,8,13329,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619393,,3878,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,12166,,,8,11311,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619394,,3879,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,12166,,,8,11311,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619395,,3880,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,12166,,,8,105,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619396,,3881,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,12166,,,8,105,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619397,,3882,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,12166,,,8,9138,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619398,,3883,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,12166,,,8,9138,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619399,,3884,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,12166,,,8,9138,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619400,,3885,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,12166,,,8,14427,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619401,,3886,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,12166,,,8,13329,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619402,,3887,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,12166,,,8,13329,,,H,B
BAO_0000219,Expert,,663.0,1,,,RBL-2H3,,CHEMBL619403,,3888,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,10116.0,12166,,Rattus norvegicus,9,14427,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619404,,3889,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,12166,,,8,14427,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619405,,3890,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,12166,,,8,14427,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619406,,3891,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,12166,,,8,10293,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619407,,3892,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,10116.0,12166,,Rattus norvegicus,9,338,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619408,,3893,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,12166,,,8,303,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619409,,3894,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,12166,,,8,303,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619410,,3895,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,12166,,,8,9247,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619753,,3896,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,12166,,,8,9247,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619754,,3897,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,12166,,,8,137,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619903,,3898,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,12166,,,8,11481,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619904,,3899,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,12166,,,8,11481,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619905,,3900,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,12166,,,8,9029,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619906,,3901,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,12166,,,8,1701,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619907,,3902,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,12166,,,8,1701,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619908,,3903,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,12166,,,8,1701,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619909,,3904,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,12166,,,8,1701,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619910,,3905,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,12166,,,8,13358,,,H,F
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL882929,,3906,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,12166,,,8,1175,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619911,,3907,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,12166,,,8,8797,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619912,,3908,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,12166,,,8,8797,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619913,,3909,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,10116.0,12166,,Rattus norvegicus,9,577,,,D,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619914,,3910,In vitro inhibitory activity against RBL-1 5-LO,,12166,,,8,9295,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619915,,3911,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,12166,,,8,9295,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619916,,3912,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,12166,,,8,9295,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619917,,3913,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,12166,,,8,9295,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619918,,3914,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,12166,,,8,9295,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619919,,3915,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,12166,,,8,216,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL883710,,3916,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,12166,,,8,11090,,,H,B
BAO_0000019,Autocuration,,,1,,Blood,,178.0,CHEMBL619920,,3917,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,12166,,,8,11090,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619921,,3918,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,12166,,,8,10091,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619922,,3919,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,12166,,,8,10274,,,H,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL619923,,3920,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,12166,,,8,13622,,,H,F
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619924,,3921,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,12166,,,8,12118,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619925,,3922,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,12166,,,8,12576,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619926,,3923,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,12166,,,8,9546,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619927,,3924,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,12166,,,8,9521,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619928,,3925,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,12166,,,8,10626,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619929,,3926,In vitro inhibition of RBL-1 5-lipoxygenase,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL875089,,3927,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619930,,3928,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619931,,3929,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619932,,3930,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619933,,3931,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619934,,3932,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619935,,3933,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619936,,3934,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619937,,3935,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619938,,3936,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619939,,3937,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619940,,3938,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL875090,,3939,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619941,,3940,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619942,,3941,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL883711,,3942,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619943,,3943,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619944,,3944,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619945,,3945,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619946,,3946,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619947,,3947,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619948,,3948,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,12166,,,8,9225,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619949,,3949,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,12166,,,8,9225,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619950,,3950,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,12166,,,8,9401,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618050,,3951,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,12166,,,8,10325,,,H,B
BAO_0000219,Expert,,663.0,1,,,RBL-2H3,,CHEMBL875091,,3952,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,12166,,,8,1556,,,H,F
BAO_0000219,Expert,,663.0,1,,,RBL-2H3,,CHEMBL618051,,3953,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,12166,,,8,1556,,,H,F
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL618052,,3954,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,10116.0,12166,,Rattus norvegicus,9,961,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618053,,3955,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,12166,,,8,6838,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL618054,,3956,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,12166,,,8,10325,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL618055,,3957,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,10116.0,12166,,Rattus norvegicus,9,9209,,,D,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL618056,,3958,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,12166,,,8,11520,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618057,,3959,In vitro inhibitory activity against 5-lipoxygenase was determined,,12166,,,8,137,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618058,,3960,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,12166,,,8,4717,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL618059,,3961,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,12166,,,8,10636,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL618060,,3962,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,10116.0,12166,,Rattus norvegicus,9,14312,,,D,F
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618061,,3963,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,12166,,,8,1203,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618062,,3964,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,12166,,,8,1203,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL618063,,3965,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,12166,,,8,13622,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618064,,3966,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,12166,,,8,9793,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL618065,,3967,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,10116.0,12166,,Rattus norvegicus,9,1143,,,D,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL618066,,3968,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,10116.0,12166,,Rattus norvegicus,9,11854,,,D,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618067,,3969,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,12166,,,8,3595,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618068,,3970,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,12166,,,8,3595,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL618069,,3971,Inhibition of 5-lipoxygenase in rat RBL-1 cells,10116.0,12166,,Rattus norvegicus,9,10501,,,D,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL618070,,3972,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12166,,,8,12526,,,H,B
BAO_0000019,Autocuration,,,1,,Limbic system,,349.0,CHEMBL618071,,3973,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,Limbic system,,349.0,CHEMBL619247,,3974,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,10825,,,8,10034,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619248,,3975,Approximate dose levels for a half maximal reduction of 5-HTP levels,,10825,,,8,10034,,,H,F
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL619249,,3976,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10576,,,8,10046,,,H,B
BAO_0000221,Autocuration,,,1,,Hippocampus,,10000000.0,CHEMBL619250,,3977,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10576,,,8,10046,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619251,,3978,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,10577,,,8,10046,,,H,B
BAO_0000019,Autocuration,,,1,,Blood,,178.0,CHEMBL619252,,3979,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,9615.0,55,,Canis lupus familiaris,8,12079,,,H,F
BAO_0000019,Autocuration,,,1,,Blood,,178.0,CHEMBL619253,,3980,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,55,,,8,12079,,,H,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL619254,,3981,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,12166,,,8,11311,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL619255,,3982,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,17140,,,8,12338,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL619256,,3983,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,17140,,,8,12143,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL875418,,3984,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,17140,,,8,12143,,,H,B
BAO_0000219,Expert,,,1,,,,,CHEMBL619257,,3985,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,17140,,,8,12143,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL619258,,3986,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,17140,,,8,12143,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619259,,3987,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,17140,,,8,12365,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619260,,3988,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,17140,,,8,13500,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619261,,3989,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619263,,3990,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619264,,3991,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619265,,3992,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619266,,3993,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619902,,3994,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620058,,3995,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620059,,3996,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620060,,3997,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620061,,3998,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620062,,3999,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620063,,4000,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620064,,4001,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620065,,4002,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620066,,4003,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620067,,4004,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620068,,4005,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620069,,4006,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620070,,4007,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620071,,4008,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620072,,4009,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620036,,4010,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL857702,,4011,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620037,,4012,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620038,,4013,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620039,,4014,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620040,,4015,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620041,,4016,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620042,,4017,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620043,,4018,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620044,,4019,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620045,,4020,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620046,,4021,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620047,,4022,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620048,,4023,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL857703,,4024,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620049,,4025,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620050,,4026,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL620051,,4027,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619213,,4028,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619214,,4029,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619804,,4030,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619805,,4031,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619806,,4032,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619807,,4033,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,Blood,,178.0,CHEMBL619808,,4034,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,55,,Canis lupus familiaris,8,12832,,,H,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619809,,4035,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,9615.0,55,,Canis lupus familiaris,8,3595,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619810,,4036,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,9615.0,55,,Canis lupus familiaris,8,3595,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619811,,4037,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,9615.0,55,,Canis lupus familiaris,8,3595,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620769,,4038,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,9615.0,55,,Canis lupus familiaris,8,3595,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620770,,4039,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,9615.0,55,,Canis lupus familiaris,8,3595,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620771,,4040,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,9615.0,55,,Canis lupus familiaris,8,3595,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620772,,4041,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,9615.0,55,,Canis lupus familiaris,8,3595,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620773,,4042,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,9615.0,55,,Canis lupus familiaris,8,3595,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620774,,4043,Ability to inhibit 5-lipoxygenase in guinea pig,10141.0,55,,Cavia porcellus,8,9203,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620775,,4044,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),10141.0,55,,Cavia porcellus,8,82,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620776,,4045,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,10141.0,55,,Cavia porcellus,8,11090,,,H,B
BAO_0000218,Autocuration,,,1,,Blood,,178.0,CHEMBL620777,,4046,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",10141.0,55,,Cavia porcellus,8,12832,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620778,,4047,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,10141.0,55,,Cavia porcellus,8,1065,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620779,,4048,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,10141.0,55,,Cavia porcellus,8,1065,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL621500,,4049,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,10141.0,55,,Cavia porcellus,8,12832,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL621501,,4050,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,10141.0,55,,Cavia porcellus,8,12832,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618098,,4051,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,10141.0,55,,Cavia porcellus,8,12832,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618099,,4052,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,10141.0,55,,Cavia porcellus,8,10504,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618100,,4053,Inhibitory activity against 5-lipoxygenase,10141.0,55,,Cavia porcellus,8,7788,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618101,,4054,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,10141.0,55,,Cavia porcellus,8,10001,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618102,,4055,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,10141.0,55,,Cavia porcellus,8,10193,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618103,,4056,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,10141.0,55,,Cavia porcellus,8,13243,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618104,,4057,Inhibitory activity uM,10141.0,55,,Cavia porcellus,8,13243,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL883712,,4058,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,10141.0,55,,Cavia porcellus,8,969,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618105,,4059,Inhibitory activity against 5-lipoxygenase at 10 uM,10141.0,55,,Cavia porcellus,8,10001,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618106,,4060,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,10141.0,55,,Cavia porcellus,8,7788,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618107,,4061,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,10141.0,55,,Cavia porcellus,8,10001,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618108,,4062,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,10141.0,55,,Cavia porcellus,8,10193,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618109,,4063,Inhibitory activity uM,10141.0,55,,Cavia porcellus,8,13243,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618110,,4064,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,10141.0,55,,Cavia porcellus,8,13243,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618111,,4065,Inhibitory activity uM,10141.0,55,,Cavia porcellus,8,13243,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618112,,4066,Inhibitory activity uM,10141.0,55,,Cavia porcellus,8,13243,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618113,,4067,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,10141.0,55,,Cavia porcellus,8,10504,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618114,,4068,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,10141.0,55,,Cavia porcellus,8,7788,,,H,B
BAO_0000221,Expert,,,1,,Ileum,,2116.0,CHEMBL620871,,4069,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,10141.0,55,,Cavia porcellus,8,10546,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620872,,4070,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,55,,,8,13183,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620873,,4071,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,55,,,8,13183,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620874,,4072,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,55,,,8,2578,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620875,,4073,In vitro inhibition of human 5-Lipoxygenase.,,55,,,8,12780,,,H,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620876,,4074,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620877,,4075,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL857854,,4076,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620878,,4077,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620879,,4078,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620880,,4079,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620881,,4080,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620882,,4081,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620883,,4082,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620884,,4083,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620885,,4084,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620886,,4085,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620887,,4086,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618039,,4087,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618040,,4088,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618041,,4089,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618216,,4090,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618217,,4091,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618218,,4092,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618219,,4093,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618220,,4094,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618221,,4095,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618222,,4096,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618223,,4097,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618224,,4098,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618225,,4099,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618226,,4100,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618227,,4101,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618228,,4102,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618229,,4103,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618230,,4104,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618231,,4105,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618232,,4106,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618233,,4107,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618234,,4108,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618235,,4109,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618115,,4110,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618116,,4111,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618117,,4112,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619968,,4113,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619969,,4114,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619970,,4115,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619971,,4116,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619972,,4117,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619973,,4118,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619974,,4119,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619975,,4120,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,,,,CHEMBL619976,,4121,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619977,,4122,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619978,,4123,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619979,,4124,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619980,,4125,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619981,,4126,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL619982,,4127,In vitro inhibition of 7226/S myeloma cancer cell line,9606.0,80433,,Homo sapiens,1,10797,,,N,F
BAO_0000219,Intermediate,,993.0,1,,,BEL-7404 tumor cell line,,CHEMBL619983,,4128,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),9606.0,80698,,Homo sapiens,1,6881,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL620031,,4129,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,9606.0,80640,,Homo sapiens,1,3838,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL620032,,4130,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,9606.0,80640,,Homo sapiens,1,3838,,,N,F
BAO_0000219,Expert,,505.0,1,,,V79,,CHEMBL620033,,4131,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,10029.0,81264,,Cricetulus griseus,1,12981,,,N,F
BAO_0000219,Expert,,505.0,1,,,V79,,CHEMBL620034,,4132,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,10029.0,81264,,Cricetulus griseus,1,12981,,,N,F
BAO_0000219,Intermediate,,1119.0,1,,,7800C1 cell line,,CHEMBL620035,,4133,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,10116.0,80635,,Rattus norvegicus,1,7653,,,N,F
BAO_0000219,Intermediate,,1119.0,1,,,7800C1 cell line,,CHEMBL618318,,4134,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,10116.0,80635,,Rattus norvegicus,1,7653,,,N,F
BAO_0000219,Intermediate,,1119.0,1,,,7800C1 cell line,,CHEMBL618319,,4135,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,10116.0,80635,,Rattus norvegicus,1,7653,,,N,F
BAO_0000219,Intermediate,,1119.0,1,,,7800C1 cell line,,CHEMBL618320,,4136,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,10116.0,80635,,Rattus norvegicus,1,7653,,,N,F
BAO_0000219,Intermediate,,1119.0,1,,,7800C1 cell line,,CHEMBL618321,,4137,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,10116.0,80635,,Rattus norvegicus,1,7653,,,N,F
BAO_0000219,Intermediate,,1119.0,1,,,7800C1 cell line,,CHEMBL883118,,4138,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,10116.0,80635,,Rattus norvegicus,1,7653,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL883795,,4139,In vitro antitumor activity against renal 786-0 tumor cell lines,9606.0,80640,,Homo sapiens,1,17229,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL618322,,4140,Cytotoxic activity against 786-0 Renal cancer cell line,9606.0,80640,,Homo sapiens,1,12858,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL618323,,4141,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,9606.0,80640,,Homo sapiens,1,16325,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL618324,,4142,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,9606.0,80640,,Homo sapiens,1,16325,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL618325,,4143,In vitro antitumor activity against human renal 786-0 cell line,9606.0,80640,,Homo sapiens,1,5858,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL875416,,4144,Inhibition of Renal cancer in 786-0 cancer cell lines,9606.0,80640,,Homo sapiens,1,16325,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL618326,,4145,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,9606.0,80640,,Homo sapiens,1,14696,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL618327,,4146,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,9606.0,80640,,Homo sapiens,1,3786,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619215,,4147,inhibition of the growth of renal cancer(786-0) cell line,9606.0,80640,,Homo sapiens,1,14696,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619216,,4148,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),9606.0,80640,,Homo sapiens,1,14769,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619217,,4149,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,9606.0,80640,,Homo sapiens,1,15354,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619218,,4150,The IC50 value was measured on 786-0 cell line in ovarian tumor,9606.0,80640,,Homo sapiens,1,14255,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619219,,4151,The IC50 value was measured on 786-0 cell line in ovarian tumor t,9606.0,80640,,Homo sapiens,1,14255,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619220,,4152,The IC50 value was measured on 786-0 cell line in renal tumor type.,9606.0,80640,,Homo sapiens,1,14255,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619221,,4153,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,9606.0,80640,,Homo sapiens,1,14696,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619222,,4154,Tested for cytotoxic activity against renal cancer 786-0 cell line,9606.0,80640,,Homo sapiens,1,12016,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL857454,,4155,Compound was tested for growth inhibitory activity against 786-0 cell line,9606.0,80640,,Homo sapiens,1,2597,,,N,F
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619223,,4156,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,12166,,,8,12526,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619224,,4157,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,12166,,,8,12526,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619225,,4158,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,12166,,,8,14799,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619226,,4159,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,12166,,,8,3595,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619227,,4160,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,12166,,,8,3595,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619228,,4161,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,12166,,,8,12767,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL619229,,4162,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,12166,,,8,10997,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619230,,4163,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,12166,,,8,11388,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619231,,4164,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,12166,,,8,167,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619232,,4165,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,12166,,,8,167,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619233,,4166,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,12166,,,8,13744,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619234,,4167,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,12166,,,8,1630,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619235,,4168,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,12166,,,8,1630,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619236,,4169,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",10116.0,12166,,Rattus norvegicus,9,969,,,D,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619237,,4170,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,12166,,,8,13621,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619238,,4171,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,12166,,,8,10089,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL619239,,4172,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,12166,,,8,10193,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619240,,4173,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,12166,,,8,11966,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL875417,,4174,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,12166,,,8,12251,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619241,,4175,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,12166,,,8,211,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619242,,4176,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,12166,,,8,12251,,,H,F
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL883796,,4177,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,12166,,,8,12495,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619243,,4178,Tested for its inhibitory activity against 5-lipoxygenase,,12166,,,8,414,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL619244,,4179,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,12166,,,8,414,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619245,,4180,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,12166,,,8,10325,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619246,,4181,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,12166,,,8,11966,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619984,,4182,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,12166,,,8,165,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619985,,4183,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,12166,,,8,165,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619986,,4184,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,12166,,,8,165,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL619987,,4185,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,12166,,,8,165,,,H,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619988,,4186,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,12166,,,8,11311,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619989,,4187,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,12166,,,8,11311,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL619990,,4188,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,12166,,,8,11311,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL619991,,4189,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,12166,,,8,11311,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL619992,,4190,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,12166,,,8,11311,,,H,B
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619993,,4191,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,12166,,,8,11311,,,H,B
BAO_0000219,Autocuration,,663.0,1,,,RBL-2H3,,CHEMBL619994,,4192,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,12166,,,8,11311,,,H,F
BAO_0000219,Autocuration,,663.0,1,,,RBL-2H3,,CHEMBL619995,,4193,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,12166,,,8,11311,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619996,,4194,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,12166,,,8,11311,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619997,,4195,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,12166,,,8,11732,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619998,,4196,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,12166,,,8,11732,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619999,,4197,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,12166,,,8,11087,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620000,,4198,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,12166,,,8,11087,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620001,,4199,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,12166,,,8,11087,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620002,,4200,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,10116.0,12166,,Rattus norvegicus,9,11087,,,D,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620003,,4201,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,12166,,,8,496,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL620004,,4202,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,12166,,,8,13986,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL874063,,4203,Compound was evaluated for the inhibition of 5-lipoxygenase,,12166,,,8,11520,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620005,,4204,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,12166,,,8,10293,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620006,,4205,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,12166,,,8,303,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620007,,4206,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,12166,,,8,303,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620008,,4207,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,12166,,,8,9247,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL620009,,4208,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,10116.0,12166,,Rattus norvegicus,9,9247,,,D,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620010,,4209,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,12166,,,8,9247,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620011,,4210,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,12166,,,8,9247,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620677,,4211,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,12166,,,8,9247,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620678,,4212,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,12166,,,8,9247,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620679,,4213,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,12166,,,8,9247,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620680,,4214,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,12166,,,8,9247,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620838,,4215,Inhibitory activity against 5-lipoxygenase at 10 uM,10116.0,12166,,Rattus norvegicus,9,11481,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620839,,4216,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,12166,,,8,105,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620840,,4217,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,12166,,,8,9029,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL620841,,4218,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,12166,,,8,1175,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620842,,4219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,12166,,,8,12118,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620843,,4220,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,12166,,,8,12118,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620844,,4221,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,12166,,,8,12118,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620845,,4222,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,12166,,,8,9225,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620846,,4223,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,12166,,,8,9401,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL873951,,4224,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,12166,,,8,137,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620847,,4225,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,12166,,,8,137,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620848,,4226,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,12166,,,8,4717,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620849,,4227,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,12166,,,8,3595,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620850,,4228,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,12166,,,8,10501,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620851,,4229,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,12166,,,8,10501,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620852,,4230,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,12166,,,8,10501,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL875098,,4231,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12166,,,8,12526,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL620853,,4232,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,10116.0,12166,,Rattus norvegicus,9,14799,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620854,,4233,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,12166,,,8,14799,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620855,,4234,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,12166,,,8,3595,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL839884,,4235,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,12166,,,8,3595,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620856,,4236,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12166,,,8,12526,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620857,,4237,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12166,,,8,12526,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620858,,4238,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,12166,,,8,10193,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620859,,4239,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,12166,,,8,10193,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620860,,4240,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,12166,,,8,10193,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620861,,4241,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,12166,,,8,10193,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL620862,,4242,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,12166,,,8,9138,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620863,,4243,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,12166,,,8,9138,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620864,,4244,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,12166,,,8,11966,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620865,,4245,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,12166,,,8,165,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620866,,4246,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,12166,,,8,165,,,H,B
BAO_0000219,Autocuration,,663.0,1,,,RBL-2H3,,CHEMBL620867,,4247,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,12166,,,8,11311,,,H,B
BAO_0000219,Autocuration,,663.0,1,,,RBL-2H3,,CHEMBL620868,,4248,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,12166,,,8,11311,,,H,B
BAO_0000219,Autocuration,,663.0,1,,,RBL-2H3,,CHEMBL620869,,4249,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,12166,,,8,11311,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL873952,,4250,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,12166,,,8,11311,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL875099,,4251,The compound was tested for inhibition of isolated 5-lipoxygenase,,12166,,,8,11311,,,H,B
BAO_0000219,Autocuration,,663.0,1,,,RBL-2H3,,CHEMBL620870,,4252,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,12166,,,8,11311,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618261,,4253,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,12166,,,8,11087,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618262,,4254,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,12166,,,8,11087,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619428,,4255,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,12166,,,8,11087,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619429,,4256,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,12166,,,8,11087,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619430,,4257,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,12166,,,8,11087,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620017,,4258,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,12166,,,8,496,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620018,,4259,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,12166,,,8,496,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620019,,4260,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,12166,,,8,13986,,,H,F
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620020,,4261,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,12166,,,8,13986,,,H,F
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620021,,4262,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,12166,,,8,13986,,,H,F
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620022,,4263,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,12166,,,8,13986,,,H,F
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620023,,4264,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,12166,,,8,13986,,,H,F
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620024,,4265,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,12166,,,8,13986,,,H,F
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620025,,4266,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,12166,,,8,13986,,,H,F
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620026,,4267,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,12166,,,8,13986,,,H,F
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL620027,,4268,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,12166,,,8,13986,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL620028,,4269,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,10116.0,12166,,Rattus norvegicus,9,13986,,,D,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620029,,4270,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,12166,,,8,10193,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620030,,4271,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,12166,,,8,9295,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL875415,,4272,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,12166,,,8,4717,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618256,,4273,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,12166,,,8,4717,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618257,,4274,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,12166,,,8,11854,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618258,,4275,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,12166,,,8,11854,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618259,,4276,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,12166,,,8,11854,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618260,,4277,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,12166,,,8,10193,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618215,,4278,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,12166,,,8,9295,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618390,,4279,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,12166,,,8,9295,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618391,,4280,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,12166,,,8,9295,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618392,,4281,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,12166,,,8,9295,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618393,,4282,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,12166,,,8,165,,,H,B
BAO_0000219,Autocuration,,,1,,,,,CHEMBL618394,,4283,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,12166,,,8,11311,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL618395,,4284,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),9606.0,12166,,Homo sapiens,8,10489,,,H,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL618396,,4285,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),10116.0,12166,,Rattus norvegicus,9,10489,,,D,B
BAO_0000219,Expert,,702.0,1,,,RBL-1,,CHEMBL858253,,4286,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),10116.0,12166,,Rattus norvegicus,9,10489,,,D,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618397,,4287,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,10116.0,12166,,Rattus norvegicus,9,14799,,,D,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618398,,4288,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),3847.0,12054,,Glycine max,8,9295,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618399,,4289,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,22226,,,0,16811,,,U,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618400,,4290,In vitro inhibition of 5-Lipoxygenase; Inactive.,,55,,,8,168,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618401,,4291,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,55,,,8,6309,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618402,,4292,Inhibitory concentration against 5-lipoxygenase; No inhibition,,55,,,8,6309,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL876400,,4293,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,55,,,8,3092,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618403,,4294,Inhibitory activity against 5-lipoxygenase.,,55,,,8,168,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618404,,4295,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,55,,,8,168,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618405,,4296,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,55,,,8,168,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618406,,4297,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,55,,,8,168,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL618407,,4298,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,55,,,8,12338,,,H,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618408,,4299,Tested for the inhibitory activity against 5-lipoxygenase,,55,,,8,4501,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618409,,4300,Compound was tested for its inhibitory activity against 5-lipoxygenase,,55,,,8,1132,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618410,,4301,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,55,,,8,2117,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618411,,4302,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,55,,,8,168,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618412,,4303,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,55,,,8,168,,,H,B
BAO_0000219,Autocuration,,702.0,1,,,RBL-1,,CHEMBL618413,,4304,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,12166,,,8,13575,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618414,,4305,,,12166,,,8,11089,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618415,,4306,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,10102,,,8,216,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618416,,4307,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,10102,,,8,13165,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL876401,,4308,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,10102,,,8,3278,,,H,B
BAO_0000357,Expert,,,1,,,,,CHEMBL618417,,4309,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,10102,,,8,3278,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618418,,4310,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,10102,,,8,11966,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618419,,4311,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,10102,,,8,175,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618420,,4312,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,10102,,,8,175,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618421,,4313,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,10102,,,8,13449,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618422,,4314,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,11238,,,8,12014,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618423,,4315,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,11238,,,8,12014,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618424,,4316,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,11238,,,8,12014,,,H,B
BAO_0000220,Intermediate,,,1,,,,,CHEMBL618425,,4317,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,100284,,,2,99,,,S,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618426,,4318,The dark toxicity against 543 human galactophore carcinoma cells,9606.0,22226,,Homo sapiens,0,4349,,,U,F
BAO_0000219,Expert,,390.0,1,,,Panel (56 tumour cell lines),,CHEMBL618427,,4319,Tested in vitro for cytotoxicity against 56 human tumor cell lines,9606.0,80623,,Homo sapiens,1,4071,,,N,F
BAO_0000219,Expert,,345.0,1,,,5637,,CHEMBL618428,,4320,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,9606.0,80008,,Homo sapiens,1,17589,,,N,F
BAO_0000219,Intermediate,,345.0,1,,,5637,,CHEMBL618429,,4321,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,9606.0,80008,,Homo sapiens,1,15002,,,N,F
BAO_0000219,Intermediate,,345.0,1,,,5637,,CHEMBL618430,,4322,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",9606.0,80008,,Homo sapiens,1,13958,,,N,F
BAO_0000219,Expert,,345.0,1,,,5637,,CHEMBL618431,,4323,Growth inhibition against human 5637 cell lines,9606.0,80008,,Homo sapiens,1,17589,,,N,F
BAO_0000219,Expert,,345.0,1,,,5637,,CHEMBL883799,,4324,Antitumor activity against human bladder carcinoma 5637 cells.,9606.0,80008,,Homo sapiens,1,16748,,,N,F
BAO_0000219,Intermediate,,345.0,1,,,5637,,CHEMBL618432,,4325,Antitumor activity against human bladder carcinoma 5637 cells,9606.0,80008,,Homo sapiens,1,16747,,,N,F
BAO_0000219,Intermediate,,345.0,1,,,5637,,CHEMBL618433,,4326,Antitumor activity against human bladder carcinoma 5637 cells,9606.0,80008,,Homo sapiens,1,16747,,,N,F
BAO_0000357,Expert,,,1,,,,,CHEMBL618434,,4327,In vitro inhibition of bovine trypsin(Trp).,9913.0,10443,,Bos taurus,9,15285,,,D,B
BAO_0000219,Expert,,407.0,1,,,CV-1,,CHEMBL618435,,4328,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,9527.0,240,,Cercopithecidae,8,3726,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL876402,,4329,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,10577,,,8,5033,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618436,,4330,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,104698,,,6,11756,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618437,,4331,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,22226,,,0,11953,,,U,F
BAO_0000357,Intermediate,,,1,,,,,CHEMBL618438,,4332,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,10141.0,20033,,Cavia porcellus,9,5033,,,D,B
BAO_0000251,Expert,,,1,,,,,CHEMBL883800,,4333,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,10116.0,17045,Microsomes,Rattus norvegicus,8,11347,,,H,A
BAO_0000251,Expert,,,1,,,,,CHEMBL618439,,4334,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,10116.0,17045,Microsomes,Rattus norvegicus,8,11347,,,H,A
BAO_0000019,Intermediate,,,1,,,,,CHEMBL618440,,4335,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,22226,,,0,1229,,,U,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL618441,,4336,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,22226,,,0,1229,,,U,F
BAO_0000019,Expert,,,1,,,,,CHEMBL618442,,4337,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,5691.0,11938,,Trypanosoma brucei,8,17588,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618443,,4338,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,5691.0,11938,,Trypanosoma brucei,8,17588,,,H,B
BAO_0000019,Expert,,,1,,,,,CHEMBL619158,,4339,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,9940.0,11938,,Ovis aries,8,17588,,,H,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620974,,4340,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,9940.0,11938,,Ovis aries,8,17588,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620975,,4341,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,11938,,,8,16485,,,H,B
BAO_0000019,Intermediate,,,1,,,,,CHEMBL620976,,4342,Average inhibitory concentration against 60 human cell lines was reported,9606.0,22226,,Homo sapiens,0,4337,,,U,F
BAO_0000019,Expert,,,1,,,,,CHEMBL620977,,4343,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,9606.0,22226,,Homo sapiens,0,4112,,,U,F
BAO_0000219,Intermediate,,542.0,1,,,Panel NCI-60 (60 carcinoma cell lines),,CHEMBL620978,,4344,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,9606.0,80315,,Homo sapiens,1,16160,,,N,F
BAO_0000219,Intermediate,,542.0,1,,,Panel NCI-60 (60 carcinoma cell lines),,CHEMBL620979,,4345,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,9606.0,80315,,Homo sapiens,1,16160,,,N,F
BAO_0000219,Expert,,542.0,1,,,Panel NCI-60 (60 carcinoma cell lines),,CHEMBL620980,,4346,In vitro mean growth inhibitory activity against 60-cell panel,,80315,,,1,17376,,,N,F
BAO_0000219,Expert,,542.0,1,,,Panel NCI-60 (60 carcinoma cell lines),,CHEMBL620981,,4347,In vitro mean growth lethal concentration against 60-cell panel,,80315,,,1,17376,,,N,F
BAO_0000219,Expert,,542.0,1,,,Panel NCI-60 (60 carcinoma cell lines),,CHEMBL620982,,4348,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,80315,,,1,17376,,,N,F
BAO_0000219,Expert,,542.0,1,,,Panel NCI-60 (60 carcinoma cell lines),,CHEMBL620983,,4349,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,80315,,,1,17376,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620984,,4350,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,104775,,,4,3241,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620985,,4351,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,104775,,,4,3241,,,H,F
BAO_0000357,Expert,,,1,,,,,CHEMBL620986,,4352,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,275,,,8,3725,,,H,B
BAO_0000218,Expert,,,1,,,,,CHEMBL620987,,4353,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,5833.0,50425,,Plasmodium falciparum,1,10805,,,N,F
BAO_0000218,Expert,,,1,,,,,CHEMBL620988,,4354,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,5833.0,50425,,Plasmodium falciparum,1,10805,,,N,F
BAO_0000218,Expert,,,1,,,,,CHEMBL620989,,4355,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,5833.0,50425,,Plasmodium falciparum,1,10805,,,N,F
BAO_0000218,Expert,,,1,,,,,CHEMBL620990,,4356,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,5833.0,50425,,Plasmodium falciparum,1,10805,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620991,,4357,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,5833.0,50425,,Plasmodium falciparum,1,10805,,,N,F
BAO_0000218,Intermediate,,850.0,1,,,6C3HED,,CHEMBL620992,,4358,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,10090.0,80628,,Mus musculus,1,10144,,,N,F
BAO_0000218,Intermediate,,850.0,1,,,6C3HED,,CHEMBL620993,,4359,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,10090.0,80628,,Mus musculus,1,10144,,,N,F
BAO_0000218,Intermediate,,850.0,1,,,6C3HED,,CHEMBL620994,,4360,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,10090.0,80628,,Mus musculus,1,10144,,,N,F
BAO_0000218,Intermediate,,850.0,1,,,6C3HED,,CHEMBL620995,,4361,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,10090.0,80628,,Mus musculus,1,10144,,,N,F
BAO_0000218,Intermediate,,850.0,1,,,6C3HED,,CHEMBL620996,,4362,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,10090.0,80628,,Mus musculus,1,10144,,,N,F
BAO_0000218,Intermediate,,850.0,1,,,6C3HED,,CHEMBL875581,,4363,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,10090.0,80628,,Mus musculus,1,10144,,,N,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620997,,4364,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620998,,4365,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620999,,4366,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621000,,4367,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621001,,4368,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621002,,4369,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621003,,4370,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621004,,4371,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621005,,4372,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621006,,4373,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621007,,4374,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL621008,,4375,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,10090.0,22224,,Mus musculus,0,10144,,,U,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL621009,,4376,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,10090.0,22224,,Mus musculus,0,10144,,,U,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL857705,,4377,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,10090.0,22224,,Mus musculus,0,10144,,,U,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619828,,4378,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,10090.0,22224,,Mus musculus,0,10144,,,U,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619829,,4379,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619830,,4380,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619831,,4381,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619832,,4382,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,10090.0,22224,,Mus musculus,0,10685,,,U,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619833,,4383,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,10090.0,22224,,Mus musculus,0,10685,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619834,,4384,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,10090.0,22224,,Mus musculus,0,10685,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619835,,4385,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,10090.0,22224,,Mus musculus,0,10685,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619836,,4386,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,10090.0,22224,,Mus musculus,0,10685,,,U,A
BAO_0000218,Intermediate,,850.0,1,,,6C3HED,,CHEMBL619837,,4387,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",10090.0,80628,,Mus musculus,1,8831,,,N,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619838,,4388,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,22224,,,0,11704,,,U,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619839,,4389,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,10090.0,50594,,Mus musculus,1,11704,,,N,A
BAO_0000218,Intermediate,In vivo,850.0,1,,,6C3HED,,CHEMBL619840,,4390,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,10090.0,80628,,Mus musculus,1,10685,,,N,F
BAO_0000218,Intermediate,In vivo,850.0,1,,,6C3HED,,CHEMBL619841,,4391,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,10090.0,80628,,Mus musculus,1,10685,,,N,F
BAO_0000218,Expert,,850.0,1,,,6C3HED,,CHEMBL857704,,4392,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),10090.0,80628,,Mus musculus,1,11368,,,N,F
BAO_0000218,Intermediate,,850.0,1,,,6C3HED,,CHEMBL619842,,4393,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),10090.0,80628,,Mus musculus,1,11368,,,N,F
BAO_0000218,Expert,,850.0,1,,,6C3HED,,CHEMBL619843,,4394,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),10090.0,80628,,Mus musculus,1,11368,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619844,,4395,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",1280.0,22226,,Staphylococcus aureus,0,17763,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL857855,,4396,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619845,,4397,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619846,,4398,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619847,,4399,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619848,,4400,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620893,,4401,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620894,,4402,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620895,,4403,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620896,,4404,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620897,,4405,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620898,,4406,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620899,,4407,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,10116.0,22226,Microsomes,Rattus norvegicus,0,7411,,,U,B
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL620900,,4408,The apparent total plasma clearance in monkey,9527.0,22224,,Cercopithecidae,0,347,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620901,,4409,Compound was evaluated for Hepatic clearance in monkey,9527.0,22224,,Cercopithecidae,0,3341,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620902,,4410,Lower clearance in monkey (i.v.) at 0.5 mpk,9527.0,22224,,Cercopithecidae,0,17853,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620903,,4411,Plasma clearance in rhesus monkey,9527.0,22224,,Cercopithecidae,0,4514,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620904,,4412,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,9527.0,22224,,Cercopithecidae,0,6062,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620905,,4413,Plasma clearance of compound was determined in monkey,9527.0,22224,,Cercopithecidae,0,6821,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620906,,4414,Plasma clearance was calculated in rhesus monkey,9527.0,22224,,Cercopithecidae,0,6057,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL875420,,4415,Plasma clearance in rhesus monkey,9527.0,22224,,Cercopithecidae,0,5145,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620907,,4416,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),9527.0,22224,,Cercopithecidae,0,6641,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620908,,4417,Plasma clearance was evaluated in rhesus,9527.0,22224,,Cercopithecidae,0,5472,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620909,,4418,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,9527.0,22224,,Cercopithecidae,0,4257,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620910,,4419,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,9527.0,22224,,Cercopithecidae,0,5546,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620911,,4420,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),9527.0,22224,,Cercopithecidae,0,5334,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620912,,4421,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),9527.0,22224,,Cercopithecidae,0,5334,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620913,,4422,Cmax 24 hr after 2 mg/kg oral administration in monkeys,9527.0,22224,,Cercopithecidae,0,17509,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620914,,4423,Cmax in monkey after administration of 1 mg/kg iv,9527.0,22224,,Cercopithecidae,0,6535,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620915,,4424,Cmax was determine after peroral administration at 10 mpk in Rhesus,9527.0,22224,,Cercopithecidae,0,5668,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620916,,4425,Cmax in cynomolgus monkey by iv administration,9527.0,22224,,Cercopithecidae,0,5922,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620917,,4426,Cmax in cynomolgus monkey by po administration,9527.0,22224,,Cercopithecidae,0,5922,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620918,,4427,Cmax value evaluated in monkey,9527.0,22224,,Cercopithecidae,0,6078,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620919,,4428,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,9527.0,22224,,Cercopithecidae,0,2661,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL620920,,4429,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,9527.0,22224,,Cercopithecidae,0,3249,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL620921,,4430,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,9527.0,22224,,Cercopithecidae,0,3249,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL620922,,4431,Maximal plasma concentration in squirrel monkeys,9527.0,22224,,Cercopithecidae,0,5553,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620923,,4432,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,9527.0,22224,,Cercopithecidae,0,1916,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL620924,,4433,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,9527.0,22224,,Cercopithecidae,0,6227,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620925,,4434,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),9527.0,22224,,Cercopithecidae,0,4809,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620926,,4435,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620927,,4436,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620928,,4437,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620929,,4438,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL620930,,4439,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,9527.0,22224,,Cercopithecidae,0,6221,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620931,,4440,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,9527.0,22224,,Cercopithecidae,0,167,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620932,,4441,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,9527.0,22224,,Cercopithecidae,0,167,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620933,,4442,Absolute bioavailability was evaluated in monkey,9443.0,22224,,monkey,0,4257,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620934,,4443,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,9443.0,22224,,monkey,0,6221,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620935,,4444,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,9443.0,22224,,monkey,0,17667,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620936,,4445,Bioavailability of compound was determined in rhesus monkey,9544.0,22224,,Macaca mulatta,0,17267,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620937,,4446,Bioavailability determined after oral administration in marmoset,38020.0,22224,,marmosets,0,4256,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620938,,4447,Oral bioavailability in cynomolgus monkey,9541.0,22224,,Macaca fascicularis,0,4256,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620939,,4448,Bioavailability in monkey (p.o.) at 2.0 mpk,9443.0,22224,,monkey,0,17853,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620940,,4449,Bioavailability was evaluated after oral administration in monkey,9443.0,22224,,monkey,0,16365,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620941,,4450,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,9541.0,22224,,Macaca fascicularis,0,1916,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620942,,4451,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),9544.0,22224,,Macaca mulatta,0,5334,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620943,,4452,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),9544.0,22224,,Macaca mulatta,0,5334,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620944,,4453,Bioavailability of the compound was determined in monkey,9443.0,22224,,monkey,0,17592,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620945,,4454,Bioavailability in squirrel monkey (dose 5 mg/kg),9521.0,22224,,Saimiri sciureus,0,1399,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620946,,4455,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),9443.0,22224,,monkey,0,4809,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620947,,4456,Oral bioavailability in monkey,9443.0,22224,,monkey,0,3341,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620948,,4457,Compound was tested for bioavailability in squirrel monkey,9521.0,22224,,Saimiri sciureus,0,64,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620949,,4458,Oral bioavailability in Rhesus monkey,9544.0,22224,,Macaca mulatta,0,5005,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620950,,4459,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),9544.0,22224,,Macaca mulatta,0,5005,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620951,,4460,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,9541.0,22224,,Macaca fascicularis,0,5237,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620952,,4461,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,9541.0,22224,,Macaca fascicularis,0,5237,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL875421,,4462,Oral bioavailability in monkey (dose 5 mg/kg),9443.0,22224,,monkey,0,5302,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620953,,4463,Oral bioavailability of compound at 5 mg/kg in monkey,9443.0,22224,,monkey,0,17667,,,U,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL873491,,4464,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,9615.0,50588,,Canis lupus familiaris,1,6161,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620954,,4465,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,9615.0,50588,,Canis lupus familiaris,1,6161,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL620955,,4466,Plasma half life determined,9615.0,50588,,Canis lupus familiaris,1,3854,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL618097,,4467,Plasma half life in dog,9615.0,50588,,Canis lupus familiaris,1,993,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL618268,,4468,Plasma half-life in Beagle dogs,9615.0,50588,,Canis lupus familiaris,1,4514,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL618269,,4469,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),9615.0,50588,,Canis lupus familiaris,1,5334,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL618270,,4470,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),9615.0,50588,,Canis lupus familiaris,1,5334,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618271,,4471,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,9615.0,50588,,Canis lupus familiaris,1,1466,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL873493,,4472,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,9615.0,50588,,Canis lupus familiaris,1,1466,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621031,,4473,Tested for the half life period in dog,9615.0,50588,,Canis lupus familiaris,1,5313,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621032,,4474,Tested for the half life period in dog at dosage of 10 mpk,9615.0,50588,,Canis lupus familiaris,1,5313,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621033,,4475,The compound was tested for half life in dog,9615.0,50588,,Canis lupus familiaris,1,3880,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL621034,,4476,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",9615.0,50588,,Canis lupus familiaris,1,3639,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621035,,4477,The half life was determined,9615.0,50588,,Canis lupus familiaris,1,3880,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL621036,,4478,The plasma half-life in dogs,9615.0,50588,,Canis lupus familiaris,1,3918,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL621037,,4479,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619812,,4480,Half life in dog,9615.0,50588,,Canis lupus familiaris,1,17796,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619813,,4481,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,9615.0,50588,,Canis lupus familiaris,1,5983,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL873335,,4482,tmax upon peroral administration of 10.0 mg/Kg dose in dog,9615.0,50588,,Canis lupus familiaris,1,1466,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619814,,4483,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,16456,,,N,A
BAO_0000218,Expert,In vivo,,1,,,,,CHEMBL619815,,4484,Cmax in ferrets after 30 mg/kg oral dose,9669.0,50506,,Mustela putorius furo,1,6113,,,N,A
BAO_0000218,Expert,In vivo,,1,,,,,CHEMBL619816,,4485,Emesis in ferrets at 30 mg/kg oral dose,9669.0,50506,,Mustela putorius furo,1,6113,,,N,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619817,,4486,Bioavailability in cynomolgus monkey,9541.0,22224,,Macaca fascicularis,0,17796,,,U,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619818,,4487,Volume of distribution in cynomolgus,9541.0,100710,,Macaca fascicularis,1,17796,,,N,A
BAO_0000218,Autocuration,,,1,,Plasma,,1969.0,CHEMBL619819,,4488,AUC tested in guinea pig when 3 mg/kg dose was given perorally,10141.0,22224,,Cavia porcellus,0,5308,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619820,,4489,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,10141.0,22224,,Cavia porcellus,0,4877,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL875419,,4490,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",10141.0,22224,,Cavia porcellus,0,4876,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL619821,,4491,AUC in guinea pig after 3mg/kg oral dose,10141.0,22224,,Cavia porcellus,0,4878,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619822,,4492,Bioavailability in guinea pig was tested,10141.0,22224,,Cavia porcellus,0,5308,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619823,,4493,Tested for oral bioavailability in guinea pig at 5 mg/kg,10141.0,22224,,Cavia porcellus,0,4877,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619824,,4494,Tested for the oral bioavailability of the compound,10141.0,22224,,Cavia porcellus,0,4876,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619825,,4495,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,10141.0,22224,,Cavia porcellus,0,4876,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619826,,4496,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,10141.0,22224,,Cavia porcellus,0,5308,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Lung,,2048.0,CHEMBL619827,,4497,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,10141.0,22224,,Cavia porcellus,0,4877,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618167,,4498,Cmax in guinea pig after 3mg/kg oral dose,10141.0,22224,,Cavia porcellus,0,4878,,,U,A
BAO_0000019,Autocuration,,,1,,Blood,,178.0,CHEMBL618168,,4499,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,22224,,Cavia porcellus,0,5689,,,U,A
BAO_0000019,Autocuration,,,1,,Brain,,955.0,CHEMBL618169,,4500,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,22224,,Cavia porcellus,0,5689,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618170,,4501,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,22224,,Cavia porcellus,0,5689,,,U,A
BAO_0000019,Autocuration,,,1,,Intestine,,160.0,CHEMBL618171,,4502,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,22224,,Cavia porcellus,0,5689,,,U,A
BAO_0000019,Autocuration,,,1,,Kidney,,2113.0,CHEMBL618172,,4503,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,22224,,Cavia porcellus,0,5689,,,U,A
BAO_0000019,Autocuration,,,1,,Liver,,2107.0,CHEMBL618173,,4504,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,22224,,Cavia porcellus,0,5689,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618174,,4505,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,22224,,Cavia porcellus,0,5689,,,U,A
BAO_0000019,Autocuration,,,1,,Spleen,,2106.0,CHEMBL875408,,4506,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,22224,,Cavia porcellus,0,5689,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL839827,,4507,Elimination T1/2 in Guinea pig (PO dose),10141.0,22224,,Cavia porcellus,0,14465,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618175,,4508,Partition coefficient was measured as -log (counts per min ),10141.0,22224,,Cavia porcellus,0,5689,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618176,,4509,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,10141.0,22224,,Cavia porcellus,0,611,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618177,,4510,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,10141.0,22224,,Cavia porcellus,0,611,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618178,,4511,Elimination T1/2 in Guinea pig (PO dose),10141.0,22224,,Cavia porcellus,0,14465,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618179,,4512,"Tested for the half life period of the compound, intravenously",10141.0,22224,,Cavia porcellus,0,4876,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL873489,,4513,Half-life was measured,10141.0,22224,,Cavia porcellus,0,5689,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618180,,4514,The time required for onset of inotropy after addition of a single dose of delta F75,10141.0,22224,,Cavia porcellus,0,7515,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618181,,4515,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,10141.0,22224,,Cavia porcellus,0,17667,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618182,,4516,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,10141.0,22224,,Cavia porcellus,0,17667,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618183,,4517,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,10029.0,22224,,Cricetulus griseus,0,4727,,,U,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618184,,4518,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618185,,4519,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618186,,4520,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618187,,4521,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618188,,4522,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875409,,4523,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618189,,4524,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL618190,,4525,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL618191,,4526,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL618192,,4527,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL618193,,4528,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL618194,,4529,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL618195,,4530,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL618196,,4531,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL618197,,4532,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL618198,,4533,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL618199,,4534,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL618200,,4535,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL618201,,4536,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Intestine,,160.0,CHEMBL618202,,4537,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Intestine,,160.0,CHEMBL618203,,4538,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Intestine,,160.0,CHEMBL618204,,4539,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL618205,,4540,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL618206,,4541,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL618207,,4542,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL618208,,4543,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL618932,,4544,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL618933,,4545,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL618934,,4546,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL618935,,4547,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL618936,,4548,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL618937,,4549,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL618938,,4550,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL619104,,4551,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL619105,,4552,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL619106,,4553,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL619107,,4554,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL875410,,4555,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL619108,,4556,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL619109,,4557,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,10090.0,50594,,Mus musculus,1,3655,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619110,,4558,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619111,,4559,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,10090.0,50594,,Mus musculus,1,16597,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619112,,4560,MRT value at a dose of 10 mg/kg intravenous administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619113,,4561,MRT value at a dose of 10 mg/kg peroral administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619114,,4562,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619115,,4563,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619116,,4564,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,9606.0,81034,,Homo sapiens,1,3830,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619117,,4565,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,9606.0,81034,,Homo sapiens,1,3829,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619118,,4566,Compound was evaluated for cytotoxicity against A2780 cell lines.,9606.0,81034,,Homo sapiens,1,2040,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619119,,4567,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,9606.0,81034,,Homo sapiens,1,15684,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619120,,4568,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,9606.0,81034,,Homo sapiens,1,15684,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619121,,4569,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,9606.0,81034,,Homo sapiens,1,15684,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619122,,4570,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,9606.0,81034,,Homo sapiens,1,15684,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619123,,4571,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,9606.0,81034,,Homo sapiens,1,15684,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619124,,4572,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,9606.0,81034,,Homo sapiens,1,15684,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619125,,4573,Compound was evaluated for cytotoxicity against A2780 cell line,9606.0,81034,,Homo sapiens,1,2859,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL875411,,4574,In vitro inhibitory activity against human tumor cell line A2780,9606.0,81034,,Homo sapiens,1,5618,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619126,,4575,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,9606.0,81034,,Homo sapiens,1,15684,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619127,,4576,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,9606.0,81034,,Homo sapiens,1,15684,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619128,,4577,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,9606.0,81034,,Homo sapiens,1,15684,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619129,,4578,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,9606.0,81034,,Homo sapiens,1,15684,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619130,,4579,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,9606.0,81034,,Homo sapiens,1,2113,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619131,,4580,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,9606.0,81034,,Homo sapiens,1,2113,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619132,,4581,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,9606.0,81034,,Homo sapiens,1,16745,,,N,F
BAO_0000218,Expert,,478.0,1,,,A2780,,CHEMBL619133,,4582,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,9606.0,81034,,Homo sapiens,1,16597,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619134,,4583,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,9606.0,81034,,Homo sapiens,1,15684,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619135,,4584,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,9606.0,81034,,Homo sapiens,1,15684,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619136,,4585,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,9606.0,81034,,Homo sapiens,1,2040,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619137,,4586,Relative resistance factor in A2780 cisplatin-resistant line,9606.0,81034,,Homo sapiens,1,2040,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL883713,,4587,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,9606.0,81034,,Homo sapiens,1,16165,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL875412,,4588,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,9606.0,81034,,Homo sapiens,1,16165,,,N,F
BAO_0000218,Expert,,478.0,1,,,A2780,,CHEMBL619138,,4589,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,9606.0,81034,,Homo sapiens,1,16597,,,N,F
BAO_0000218,Expert,,478.0,1,,,A2780,,CHEMBL619262,,4590,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,9606.0,81034,,Homo sapiens,1,16597,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619139,,4591,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,9606.0,81034,,Homo sapiens,1,3992,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619140,,4592,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,9606.0,81034,,Homo sapiens,1,10553,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619141,,4593,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,9606.0,81034,,Homo sapiens,1,15608,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619142,,4594,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,9606.0,81034,,Homo sapiens,1,15608,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619143,,4595,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,9606.0,81034,,Homo sapiens,1,15608,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619144,,4596,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,9606.0,81034,,Homo sapiens,1,15608,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619145,,4597,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,9606.0,81034,,Homo sapiens,1,15608,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619146,,4598,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,9606.0,81034,,Homo sapiens,1,15608,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619147,,4599,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,9606.0,81034,,Homo sapiens,1,15569,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619148,,4600,Antiproliferative effect of compound on A2780/DX cell line,9606.0,81034,,Homo sapiens,1,17420,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619149,,4601,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,9606.0,81034,,Homo sapiens,1,17420,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619150,,4602,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),9606.0,81034,,Homo sapiens,1,15099,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619151,,4603,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),9606.0,81034,,Homo sapiens,1,15099,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL883794,,4604,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,9606.0,81034,,Homo sapiens,1,17672,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619152,,4605,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,9606.0,81034,,Homo sapiens,1,17672,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619153,,4606,In vitro cytotoxicity against A2780ADR cell line,9606.0,81034,,Homo sapiens,1,17270,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619154,,4607,In vitro cytotoxicity against A2780CIS cell line,9606.0,81034,,Homo sapiens,1,17270,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619155,,4608,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,9606.0,81034,,Homo sapiens,1,5574,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619156,,4609,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,9606.0,81034,,Homo sapiens,1,2113,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619157,,4610,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",9606.0,81034,,Homo sapiens,1,16913,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619797,,4611,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",9606.0,81034,,Homo sapiens,1,16913,,,N,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619798,,4612,Oral bioavailability of compound in rhesus macaques,9544.0,22224,,Macaca mulatta,0,17839,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619799,,4613,Oral bioavailability in monkey,9443.0,22224,,monkey,0,6821,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619800,,4614,Oral bioavailability evaluated in monkey,9443.0,22224,,monkey,0,6078,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619801,,4615,Oral bioavailability in monkey (dose 1 mg/kg p.o.),9443.0,22224,,monkey,0,6535,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619802,,4616,Oral bioavailability in Rhesus monkey,9544.0,22224,,Macaca mulatta,0,4449,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619803,,4617,Oral bioavailability was calculated in rhesus monkey,9544.0,22224,,Macaca mulatta,0,6057,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619965,,4618,Oral bioavailability in cynomolgus monkey,9541.0,22224,,Macaca fascicularis,0,5922,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619966,,4619,Oral bioavailability in monkey,9443.0,22224,,monkey,0,5940,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619967,,4620,Oral bioavailability in monkey,9443.0,22224,,monkey,0,6265,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620073,,4621,Oral bioavailability in monkey (dose 1 mg/kg),9443.0,22224,,monkey,0,6265,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620074,,4622,Oral bioavailability in monkey (dose 5 mg/kg),9443.0,22224,,monkey,0,6265,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620075,,4623,Oral bioavailability in monkey,9443.0,22224,,monkey,0,5940,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620076,,4624,Oral bioavailability in monkey,9443.0,22224,,monkey,0,5940,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620077,,4625,Oral bioavailability in rhesus monkey,9544.0,22224,,Macaca mulatta,0,4514,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620078,,4626,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,9544.0,22224,,Macaca mulatta,0,5546,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620079,,4627,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,9521.0,22224,,Saimiri sciureus,0,5553,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620080,,4628,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),9443.0,22224,,monkey,0,6641,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620081,,4629,Oral bioavailability in Rhesus monkey,9544.0,22224,,Macaca mulatta,0,5472,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620082,,4630,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),9544.0,22224,,Macaca mulatta,0,5668,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620083,,4631,Oral bioavailability in monkey at 10 mg/kg of the compound,9443.0,22224,,monkey,0,5711,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620084,,4632,Bioavailability in Rhesus monkey,9544.0,22224,,Macaca mulatta,0,5145,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620085,,4633,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL874595,,4634,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL873352,,4635,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,9527.0,22224,,Cercopithecidae,0,3249,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620086,,4636,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,9527.0,22224,,Cercopithecidae,0,3249,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620087,,4637,Mean residence time was determined after intravenous administration in cynomolgus monkeys,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620088,,4638,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620089,,4639,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620090,,4640,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),9527.0,22224,,Cercopithecidae,0,4809,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620091,,4641,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),9527.0,22224,,Cercopithecidae,0,4809,,,U,A
BAO_0000251,Autocuration,,,1,,,,,CHEMBL620092,,4642,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),9527.0,22224,Microsomes,Cercopithecidae,0,14294,,,U,A
BAO_0000251,Autocuration,,,1,,,,,CHEMBL620093,,4643,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),9527.0,22224,Microsomes,Cercopithecidae,0,14294,,,U,A
BAO_0000251,Autocuration,,,1,,,,,CHEMBL620094,,4644,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),9527.0,22224,Microsomes,Cercopithecidae,0,14294,,,U,A
BAO_0000251,Autocuration,,,1,,,,,CHEMBL620095,,4645,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),9527.0,22224,Microsomes,Cercopithecidae,0,14294,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620096,,4646,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620097,,4647,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620098,,4648,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620099,,4649,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620100,,4650,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620101,,4651,Elimination Half-life of compound was determined in monkey,9527.0,22224,,Cercopithecidae,0,6821,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620102,,4652,Half life of compound was determined in rhesus monkey,9527.0,22224,,Cercopithecidae,0,17267,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL620103,,4653,Half life in monkey plasma,9527.0,22224,,Cercopithecidae,0,5819,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL620104,,4654,Half life in monkey plasma; Not detected,9527.0,22224,,Cercopithecidae,0,5819,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL874596,,4655,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,9527.0,22224,,Cercopithecidae,0,1916,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL873490,,4656,Half-life 24 hr after 2 mg/kg iv administration in monkeys,9527.0,22224,,Cercopithecidae,0,17509,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620105,,4657,Terminal half life of the compound.,9527.0,22224,,Cercopithecidae,0,1399,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620780,,4658,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,9527.0,22224,,Cercopithecidae,0,1916,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620781,,4659,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),9527.0,22224,,Cercopithecidae,0,4809,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620956,,4660,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,9527.0,22224,,Cercopithecidae,0,5546,,,U,A
BAO_0000218,Autocuration,,,1,,Urine,,1088.0,CHEMBL620957,,4661,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000218,Autocuration,,,1,,Urine,,1088.0,CHEMBL620958,,4662,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620959,,4663,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,9527.0,22224,,Cercopithecidae,0,4257,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620960,,4664,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,9527.0,22224,,Cercopithecidae,0,6221,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620961,,4665,Volume of distribution was evaluated in rhesus,9527.0,22224,,Cercopithecidae,0,5472,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620962,,4666,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,10029.0,22224,,Cricetulus griseus,0,4727,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620963,,4667,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,10029.0,22224,,Cricetulus griseus,0,4727,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620964,,4668,Bioavailability in hamster was determined,10029.0,22224,,Cricetulus griseus,0,4727,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620965,,4669,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,10029.0,22224,,Cricetulus griseus,0,4727,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620966,,4670,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,10029.0,22224,,Cricetulus griseus,0,4727,,,U,A
BAO_0000221,Autocuration,,,1,,Blood,,178.0,CHEMBL620967,,4671,Half life of compound was determined in hamster blood,10029.0,22224,,Cricetulus griseus,0,4727,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620968,,4672,Michaelis-Menten constant of the compound.,9823.0,22224,,Sus scrofa,0,1452,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL874597,,4673,Vmax value was measured at 0 uM concentration of silyl ether.,9823.0,22224,,Sus scrofa,0,1452,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620969,,4674,Vmax value was measured at 10 uM concentration of silyl ether.,9823.0,22224,,Sus scrofa,0,1452,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620970,,4675,Vmax value was measured at 5 uM concentration of silyl ether.,9823.0,22224,,Sus scrofa,0,1452,,,U,A
BAO_0000357,Expert,,,1,,,,,CHEMBL620971,,4676,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,9606.0,235,,Homo sapiens,9,11706,,,D,B
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620972,,4677,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,9606.0,22224,,Homo sapiens,0,1916,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620973,,4678,Compound was evaluated for area under the curve expressed as (h*ug/ml),9606.0,22224,,Homo sapiens,0,17791,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618243,,4679,Active metabolite of ifosfamide determined in humans; A-Active,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618244,,4680,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,9606.0,22224,,Homo sapiens,0,6567,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618245,,4681,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,9606.0,22224,,Homo sapiens,0,6567,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618246,,4682,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,9606.0,22224,,Homo sapiens,0,6567,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618247,,4683,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,9606.0,22224,,Homo sapiens,0,6567,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618248,,4684,Compound was evaluated for oral bioavailability in human,9606.0,22224,,Homo sapiens,0,17791,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL618249,,4685,Metabolite of ifosfamide determined in urine; NF-Not found,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618250,,4686,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),9606.0,22224,,Homo sapiens,0,6852,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL874598,,4687,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,9606.0,22224,,Homo sapiens,0,6852,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618251,,4688,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,9606.0,22224,,Homo sapiens,0,6852,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618252,,4689,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,9606.0,22224,,Homo sapiens,0,6852,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618253,,4690,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,9606.0,22224,,Homo sapiens,0,6852,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618254,,4691,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),9606.0,22224,,Homo sapiens,0,6852,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618255,,4692,Percent of compound in healthy individuals (Group D),9606.0,22224,,Homo sapiens,0,6852,,,U,A
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL618983,,4693,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,9606.0,22224,Microsomes,Homo sapiens,0,4397,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618984,,4694,Binding towards human plasma protein at 10 uM,9606.0,22224,,Homo sapiens,0,17409,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618985,,4695,Binding towards human plasma protein at 100 uM,9606.0,22224,,Homo sapiens,0,17409,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618986,,4696,Human plasma protein binding activity was determined,9606.0,22224,,Homo sapiens,0,17176,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618987,,4697,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),9606.0,22224,,Homo sapiens,0,15444,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618988,,4698,Percent binding of compound towards human plasma protein was determined,9606.0,22224,,Homo sapiens,0,17267,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL618989,,4699,Plasma clearance in human liver microsomes,9606.0,22224,Microsomes,Homo sapiens,0,5944,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL618990,,4700,In vitro intrinsic clearance in human liver microsome,9606.0,22224,Microsomes,Homo sapiens,0,5668,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL618991,,4701,In vitro intrinsic clearance in human liver microsome,9606.0,22224,Microsomes,Homo sapiens,0,5669,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,,,,CHEMBL876725,,4702,In vitro microsome metabolism clearance in human was determined,9606.0,22224,Microsomes,Homo sapiens,0,5041,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,,,,CHEMBL618992,,4703,In vitro microsome metabolism clearance in human was determined; High,9606.0,22224,Microsomes,Homo sapiens,0,5041,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,,,,CHEMBL618993,,4704,In vitro microsome metabolism clearance in human was determined; ND denotes no data,9606.0,22224,Microsomes,Homo sapiens,0,5041,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL618994,,4705,Pharmacokinetic property (clearance) in human liver microsome,9606.0,22224,Microsomes,Homo sapiens,0,5676,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL618995,,4706,Plasma clearance in human liver microsomes,9606.0,22224,Microsomes,Homo sapiens,0,5944,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL618996,,4707,In vitro clearance in human liver microsomes,9606.0,22224,Microsomes,Homo sapiens,0,17538,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL618997,,4708,Intrinsic clearance in human liver microsomes was determined,9606.0,22224,Microsomes,Homo sapiens,0,6331,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL618998,,4709,Intrinsic clearance in human liver microsomes was determined,9606.0,22224,Microsomes,Homo sapiens,0,5948,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618999,,4710,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,9606.0,22224,,Homo sapiens,0,5965,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620223,,4711,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,9606.0,22224,,Homo sapiens,0,1916,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620224,,4712,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,9606.0,22224,,Homo sapiens,0,5965,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620225,,4713,Stability in human plasma 2 hr after incubation expressed as percent concentration,9606.0,22224,,Homo sapiens,0,1299,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620226,,4714,Stability in human plasma 4 hr after incubation expressed as percent concentration,9606.0,22224,,Homo sapiens,0,1299,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL620227,,4715,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL876726,,4716,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL620228,,4717,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL620229,,4718,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620230,,4719,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620231,,4720,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620232,,4721,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620233,,4722,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620234,,4723,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),10090.0,50594,,Mus musculus,1,14294,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620235,,4724,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),10090.0,50594,,Mus musculus,1,14294,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620236,,4725,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),10090.0,50594,,Mus musculus,1,14294,,,N,A
BAO_0000218,Intermediate,,,1,,Liver,,2107.0,CHEMBL620237,,4726,In vitro metabolic potential in mouse liver microsomes,10090.0,50594,,Mus musculus,1,6251,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620238,,4727,Ability of compound to bind to plasma protein was evaluated in HSA cells,10090.0,50594,,Mus musculus,1,17582,,,N,A
BAO_0000218,Intermediate,,,1,,Adrenal gland,,2369.0,CHEMBL620239,,4728,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),10090.0,50594,,Mus musculus,1,17811,,,N,A
BAO_0000218,Intermediate,,,1,,Brain,,955.0,CHEMBL620240,,4729,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,10090.0,50594,,Mus musculus,1,17811,,,N,A
BAO_0000218,Intermediate,,,1,,Brain,,955.0,CHEMBL620241,,4730,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,10090.0,50594,,Mus musculus,1,17811,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL876727,,4731,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),10090.0,50594,,Mus musculus,1,17811,,,N,A
BAO_0000218,Intermediate,,,1,,Kidney,,2113.0,CHEMBL620242,,4732,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),10090.0,50594,,Mus musculus,1,17811,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620243,,4733,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),10090.0,50594,,Mus musculus,1,17811,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620244,,4734,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,10090.0,50594,,Mus musculus,1,5288,,,N,A
BAO_0000218,Intermediate,,,1,,Serum,,1977.0,CHEMBL620245,,4735,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,10090.0,50594,,Mus musculus,1,2717,,,N,A
BAO_0000218,Intermediate,,,1,,Serum,,1977.0,CHEMBL620246,,4736,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,10090.0,50594,,Mus musculus,1,2717,,,N,A
BAO_0000218,Intermediate,,,1,,Serum,,1977.0,CHEMBL620247,,4737,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,10090.0,50594,,Mus musculus,1,2717,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL620248,,4738,Half life of compound was determined in plasma of mice at 24 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL873497,,4739,Half life of compound was determined in plasma of mice at 40 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL620249,,4740,Half life of compound was determined in plasma of mice at 5 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620250,,4741,Half life after intraperitoneal administration in mice at 18 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620251,,4742,Half life after intraperitoneal administration in mice at 23 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620252,,4743,Half life after intraperitoneal administration in mice at 25 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620253,,4744,Half life after intraperitoneal administration in mice at 26 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620254,,4745,Half life after intravenous administration in mice at 23 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620255,,4746,Half life after intravenous administration in mice at 24 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620256,,4747,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876728,,4748,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,10090.0,50594,,Mus musculus,1,2675,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620257,,4749,Maximum time required to reach Cp max was evaluated in mice after oral administration,10090.0,50594,,Mus musculus,1,2675,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620258,,4750,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620259,,4751,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",10090.0,50594,,Mus musculus,1,4890,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620260,,4752,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,10090.0,50594,,Mus musculus,1,429,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL620261,,4753,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,10090.0,50594,,Mus musculus,1,17837,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620262,,4754,Half life at a dose of 10 mg/kg intravenous administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620263,,4755,Half life at a dose of 10 mg/kg peroral administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620264,,4756,Half life in ob/ob mice,10090.0,50594,,Mus musculus,1,6619,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620265,,4757,Half-life at a single subcutaneous administration of 40 mg/kg in mice,10090.0,50594,,Mus musculus,1,4066,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620266,,4758,Half-life was measured in mouse,10090.0,50594,,Mus musculus,1,4239,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620267,,4759,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619364,,4760,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,10090.0,50594,,Mus musculus,1,8999,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619365,,4761,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,10090.0,50594,,Mus musculus,1,8999,,,N,A
BAO_0000218,Intermediate,,,1,,Brain,,955.0,CHEMBL619366,,4762,T2 in brain of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,,,1,,Kidney,,2113.0,CHEMBL619367,,4763,T2 in kidney of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,,,1,,Liver,,2107.0,CHEMBL619368,,4764,T2 in liver of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,,,1,,Lung,,2048.0,CHEMBL619369,,4765,T2 in lungs of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,,,1,,Spleen,,2106.0,CHEMBL876729,,4766,T2 in spleen of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619370,,4767,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619371,,4768,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",10090.0,50594,,Mus musculus,1,4890,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619372,,4769,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,10090.0,50594,,Mus musculus,1,429,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620012,,4770,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,10090.0,50594,,Mus musculus,1,429,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620013,,4771,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL620014,,4772,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",9606.0,81034,,Homo sapiens,1,16913,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL620015,,4773,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",9606.0,81034,,Homo sapiens,1,16913,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621010,,4774,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",9606.0,81034,,Homo sapiens,1,16913,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621011,,4775,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",9606.0,81034,,Homo sapiens,1,16913,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621012,,4776,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",9606.0,81034,,Homo sapiens,1,16913,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621013,,4777,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",9606.0,81034,,Homo sapiens,1,16913,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621014,,4778,In vitro cytotoxicity against A2780TAX cell line,9606.0,81034,,Homo sapiens,1,17270,,,N,F
BAO_0000219,Intermediate,,481.0,1,,,A2780cisR,,CHEMBL618154,,4779,In vitro inhibitory activity against human tumor cell line A2780cis,9606.0,80017,,Homo sapiens,1,5618,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL618155,,4780,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,9606.0,81034,,Homo sapiens,1,17777,,,N,F
BAO_0000219,Intermediate,,481.0,1,,,A2780cisR,,CHEMBL618156,,4781,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,9606.0,80017,,Homo sapiens,1,16112,,,N,F
BAO_0000219,Intermediate,,481.0,1,,,A2780cisR,,CHEMBL618157,,4782,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),9606.0,80017,,Homo sapiens,1,15748,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618328,,4783,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,9606.0,81034,,Homo sapiens,1,6633,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618329,,4784,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,9606.0,81034,,Homo sapiens,1,16930,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618330,,4785,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,9606.0,81034,,Homo sapiens,1,17496,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL618331,,4786,In vitro antitumor activity against A2780cisR cell line.,9606.0,81034,,Homo sapiens,1,12989,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618332,,4787,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),9606.0,81034,,Homo sapiens,1,4840,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL618333,,4788,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,9606.0,81034,,Homo sapiens,1,12989,,,N,F
BAO_0000219,Intermediate,,481.0,1,,,A2780cisR,,CHEMBL618334,,4789,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,9606.0,80017,,Homo sapiens,1,16745,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL618335,,4790,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,9606.0,81034,,Homo sapiens,1,16597,,,N,F
BAO_0000019,Expert,,,1,,,,,CHEMBL618336,,4791,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,10116.0,11736,,Rattus norvegicus,9,16547,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL618337,,4792,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,11736,,,8,16547,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL618338,,4793,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),10116.0,11736,,Rattus norvegicus,9,16547,,,D,F
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL618339,,4794,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,9606.0,278,,Homo sapiens,9,15856,,,D,F
BAO_0000219,Expert,,722.0,1,,,HEK293,,CHEMBL618340,,4795,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,9606.0,278,,Homo sapiens,9,15856,,,D,F
BAO_0000019,Expert,,,1,,,,,CHEMBL618341,,4796,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,10090.0,11831,,Mus musculus,9,16547,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL618342,,4797,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,11831,,,8,16547,,,H,F
BAO_0000019,Expert,,,1,,,,,CHEMBL618343,,4798,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),10090.0,11831,,Mus musculus,9,16547,,,D,F
BAO_0000357,Expert,,,1,,,,,CHEMBL621038,,4799,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,280,,,8,17402,,,H,B
BAO_0000219,Autocuration,,574.0,1,,,T-cells,,CHEMBL621039,,4800,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),9606.0,22226,,Homo sapiens,0,11746,,,U,F
BAO_0000219,Autocuration,,574.0,1,,,T-cells,,CHEMBL621040,,4801,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,9606.0,22226,,Homo sapiens,0,11746,,,U,F
BAO_0000219,Intermediate,,455.0,1,,,A-375,,CHEMBL621041,,4802,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,9606.0,80018,,Homo sapiens,1,5455,,,N,F
BAO_0000219,Intermediate,,455.0,1,,,A-375,,CHEMBL621042,,4803,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,9606.0,80018,,Homo sapiens,1,2068,,,N,F
BAO_0000219,Intermediate,,455.0,1,,,A-375,,CHEMBL621043,,4804,In vitro antitumor activity against A375cell line extracted form melanoma,9606.0,80018,,Homo sapiens,1,2683,,,N,F
BAO_0000219,Expert,,455.0,1,,,A-375,,CHEMBL621044,,4805,Inhibition of cell growth in (A375) melan cell line,9606.0,80018,,Homo sapiens,1,15313,,,N,F
BAO_0000219,Intermediate,,455.0,1,,,A-375,,CHEMBL621045,,4806,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,9606.0,80018,,Homo sapiens,1,13739,,,N,F
BAO_0000219,Intermediate,,455.0,1,,,A-375,,CHEMBL621046,,4807,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,9606.0,80018,,Homo sapiens,1,13739,,,N,F
BAO_0000219,Intermediate,,455.0,1,,,A-375,,CHEMBL621047,,4808,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,9606.0,80018,,Homo sapiens,1,14750,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL621048,,4809,Antiproliferative activity measured against A427 human lung carcinoma,9606.0,80019,,Homo sapiens,1,14777,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL883798,,4810,Antiproliferative activity measured against A427 human lung carcinoma,9606.0,80019,,Homo sapiens,1,14777,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL621049,,4811,Cytotoxicity against lung carcinoma A427 tumor cell lines,9606.0,80019,,Homo sapiens,1,17672,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL621050,,4812,Inhibition of large cell lung carcinoma (A427),9606.0,80019,,Homo sapiens,1,14368,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL621051,,4813,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,9606.0,80019,,Homo sapiens,1,14368,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL621052,,4814,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,9606.0,80019,,Homo sapiens,1,13866,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL621053,,4815,Inhibitory concentration in human lung carcinoma A427 cell line,9606.0,80019,,Homo sapiens,1,2545,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL621054,,4816,Inhibitory concentration in human lung carcinoma A427/VCR cell line,9606.0,80019,,Homo sapiens,1,2545,,,N,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621055,,4817,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,9527.0,22224,,Cercopithecidae,0,6062,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL876398,,4818,Tested for volume of distribution upon iv administration to african green monkey,9527.0,22224,,Cercopithecidae,0,4578,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621056,,4819,Volume of distribution in monkey,9527.0,22224,,Cercopithecidae,0,17592,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621057,,4820,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,9544.0,22224,,Macaca mulatta,0,5005,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621058,,4821,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,9544.0,22224,,Macaca mulatta,0,5005,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621059,,4822,Pharmacokinetic property(Vdss) in cynomolgus monkey,9527.0,22224,,Cercopithecidae,0,5922,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621060,,4823,The distribution volume after intravenous administration in cynomolgus monkeys,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621061,,4824,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621062,,4825,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621063,,4826,Volume displacement was calculated in rhesus monkey,9527.0,22224,,Cercopithecidae,0,6057,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621064,,4827,Volume of distribution in steady state was determined in rhesus monkey,9527.0,22224,,Cercopithecidae,0,5145,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621065,,4828,Volume of distribution of compound was determined in monkey,9527.0,22224,,Cercopithecidae,0,6821,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621066,,4829,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),9527.0,22224,,Cercopithecidae,0,5334,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621067,,4830,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),9527.0,22224,,Cercopithecidae,0,5334,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621068,,4831,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),9527.0,22224,,Cercopithecidae,0,6641,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL876399,,4832,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,9527.0,22224,,Cercopithecidae,0,2661,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621069,,4833,Volume distribution in monkey after administration of 1 mg/kg iv,9527.0,22224,,Cercopithecidae,0,6535,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621070,,4834,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),9527.0,22224,,Cercopithecidae,0,4809,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621071,,4835,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,9527.0,22224,,Cercopithecidae,0,6062,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621072,,4836,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618209,,4837,Oral systemic bioavailability upon iv administration to african green monkey,9527.0,22224,,Cercopithecidae,0,4578,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618210,,4838,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),9527.0,22224,,Cercopithecidae,0,4809,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618211,,4839,Baboon plasma free fraction. ,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618212,,4840,Area under the curve was calculated in rhesus monkey after iv administration,9527.0,22224,,Cercopithecidae,0,6057,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618213,,4841,Area under the curve was calculated in rhesus monkey after peroral administration,9527.0,22224,,Cercopithecidae,0,6057,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618214,,4842,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,9527.0,22224,,Cercopithecidae,0,17853,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL873492,,4843,Half life period in monkey after 5 mg/kg dose,9527.0,22224,,Cercopithecidae,0,5302,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618272,,4844,Half-life was determined in monkey after 3 mg/kg of i.v. dose,9527.0,22224,,Cercopithecidae,0,4257,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618273,,4845,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,9527.0,22224,,Cercopithecidae,0,4257,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL618274,,4846,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,9527.0,22224,,Cercopithecidae,0,13501,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618275,,4847,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,9527.0,22224,,Cercopithecidae,0,5394,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618276,,4848,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,9527.0,22224,,Cercopithecidae,0,2661,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618277,,4849,Compound was evaluated for terminal half life in monkey,9527.0,22224,,Cercopithecidae,0,3341,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618278,,4850,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,9527.0,22224,,Cercopithecidae,0,3045,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL618279,,4851,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,9544.0,22224,,Macaca mulatta,0,5005,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618280,,4852,Half life of compound was determined in squirrel monkey,9527.0,22224,,Cercopithecidae,0,4847,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618281,,4853,Half life after iv administration in cynomolgus monkey,9541.0,22224,,Macaca fascicularis,0,4256,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL618282,,4854,Half life in monkey plasma after administration of 1 mg/kg iv,9527.0,22224,,Cercopithecidae,0,6535,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618283,,4855,Half life was calculated in rhesus monkey,9527.0,22224,,Cercopithecidae,0,6057,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618284,,4856,Half life in monkey,9527.0,22224,,Cercopithecidae,0,17592,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618285,,4857,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),9527.0,22224,,Cercopithecidae,0,6641,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618286,,4858,Half life was evaluated in rhesus,9527.0,22224,,Cercopithecidae,0,5472,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618287,,4859,Half life period after oral administration (2.5 mg/kg) in monkey was determined,9527.0,22224,,Cercopithecidae,0,6221,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618288,,4860,Half life period was determine after peroral administration at 10 mpk in Rhesus,9527.0,22224,,Cercopithecidae,0,5668,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL876393,,4861,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),9527.0,22224,,Cercopithecidae,0,4809,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618289,,4862,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,9527.0,22224,,Cercopithecidae,0,5546,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618290,,4863,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,9527.0,22224,,Cercopithecidae,0,5553,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618291,,4864,Half-life was calculated in monkey,9527.0,22224,,Cercopithecidae,0,6078,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618292,,4865,Half-life in Squirrel monkey,9527.0,22224,,Cercopithecidae,0,5147,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618293,,4866,Half-life in rhesus monkey,9527.0,22224,,Cercopithecidae,0,5145,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618294,,4867,Half-life was measured in monkey after an iv dose of 1 mg/kg,9527.0,22224,,Cercopithecidae,0,6062,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618295,,4868,Half-life period after intravenous administration in cynomolgus monkeys,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618296,,4869,Half-life period after oral administration in cynomolgus monkeys,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618297,,4870,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL618298,,4871,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL618299,,4872,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL618300,,4873,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL618301,,4874,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL618302,,4875,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL876394,,4876,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL618303,,4877,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL618304,,4878,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618305,,4879,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,9606.0,22224,,Homo sapiens,0,1916,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618306,,4880,Oral bioavailability in human,9606.0,22224,,Homo sapiens,0,16643,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618307,,4881,Compound was tested for human plasma protein binding,9606.0,22224,,Homo sapiens,0,17248,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618308,,4882,Compound was tested for human plasma protein binding; Not determined,9606.0,22224,,Homo sapiens,0,17248,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618309,,4883,Protein binding activity of compound in human plasma; % Free,9606.0,22224,,Homo sapiens,0,6241,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618310,,4884,Unbound fraction (plasma),9606.0,22224,,Homo sapiens,0,17716,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL873353,,4885,Half life for the hydrolysis of compound in human blood serum,9606.0,22224,,Homo sapiens,0,17605,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618311,,4886,Half life period in human plasma using phosphate buffer (0.08 M),9606.0,22224,,Homo sapiens,0,17625,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618312,,4887,Half life period in human plasma using phosphate buffer (0.1 M),9606.0,22224,,Homo sapiens,0,17625,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618313,,4888,Half-life in human plasma was determined,9606.0,22224,,Homo sapiens,0,17747,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618314,,4889,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,9606.0,22224,,Homo sapiens,0,15613,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618315,,4890,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),9606.0,22224,,Homo sapiens,0,354,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618316,,4891,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",9606.0,22224,,Homo sapiens,0,3741,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618317,,4892,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",9606.0,22224,,Homo sapiens,0,3741,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620138,,4893,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",9606.0,22224,,Homo sapiens,0,3741,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL858280,,4894,Partition coefficient (logP),9606.0,22224,,Homo sapiens,0,17599,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620139,,4895,In vitro metabolic stability in human was measured as pmol/min/mg/protein,9606.0,22224,,Homo sapiens,0,5486,,,U,A
BAO_0000251,Autocuration,,,1,,,,,CHEMBL620140,,4896,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,9606.0,22224,Microsomes,Homo sapiens,0,5600,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620141,,4897,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),9606.0,22224,,Homo sapiens,0,14294,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620142,,4898,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),9606.0,22224,,Homo sapiens,0,14294,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620143,,4899,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),9606.0,22224,,Homo sapiens,0,14294,,,U,A
BAO_0000251,Autocuration,,,1,,,,,CHEMBL620144,,4900,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),9606.0,22224,Microsomes,Homo sapiens,0,14294,,,U,A
BAO_0000251,Autocuration,,,1,,,,,CHEMBL620145,,4901,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),9606.0,22224,Microsomes,Homo sapiens,0,14294,,,U,A
BAO_0000251,Autocuration,,,1,,,,,CHEMBL620146,,4902,Metabolism of compound in human microsomes; Trace,9606.0,22224,Microsomes,Homo sapiens,0,14294,,,U,A
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620147,,4903,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,9606.0,22224,Microsomes,Homo sapiens,0,6260,,,U,A
BAO_0000251,Autocuration,,,1,,,,,CHEMBL620148,,4904,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,9606.0,22224,Microsomes,Homo sapiens,0,6187,,,U,A
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL620149,,4905,In vitro metabolic potential in human liver microsomes,9606.0,22224,Microsomes,Homo sapiens,0,6251,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL876412,,4906,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,9606.0,22224,,Homo sapiens,0,3246,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619352,,4907,Tested for human plasma protein binding of the compound; Not tested,9606.0,22224,,Homo sapiens,0,17313,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619353,,4908,Compound was tested for percent protein binding (PB) in human,9606.0,22224,,Homo sapiens,0,6227,,,U,A
BAO_0000019,Autocuration,,,1,,Plasma,,1969.0,CHEMBL619354,,4909,Protein binding in human plasma,9606.0,22224,,Homo sapiens,0,5530,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619355,,4910,Permeability coefficient (B to A) in Caco-2 cell,9606.0,22224,,Homo sapiens,0,6108,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619356,,4911,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,9606.0,22224,,Homo sapiens,0,6108,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619357,,4912,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),9606.0,22224,,Homo sapiens,0,2774,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619358,,4913,In vitro rate of absorption observed as Caco-2 permeability in humans,9606.0,22224,,Homo sapiens,0,16643,,,U,A
BAO_0000219,Autocuration,,495.0,1,,,Caco-2,,CHEMBL619359,,4914,Cellular permeability of compound was determined in Caco-2 cells; High,9606.0,22224,,Homo sapiens,0,17582,,,U,A
BAO_0000219,Autocuration,,495.0,1,,,Caco-2,,CHEMBL619360,,4915,Permeability in Caco-2 cells of compound,9606.0,22224,,Homo sapiens,0,6838,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619361,,4916,Permeability coefficient (A to B) in Caco-2 cell,9606.0,22224,,Homo sapiens,0,6108,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619362,,4917,Permeability coefficient (B to A) in Caco-2 cell,9606.0,22224,,Homo sapiens,0,6108,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619363,,4918,Permeability coefficient (Papp) (Caco-2 cell monolayer),9606.0,22224,,Homo sapiens,0,6108,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618942,,4919,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,9606.0,22224,,Homo sapiens,0,2146,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618943,,4920,Compound was tested for protein binding in human plasma,9606.0,22224,,Homo sapiens,0,4514,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618944,,4921,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,9606.0,22224,,Homo sapiens,0,6108,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL618945,,4922,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618946,,4923,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876413,,4924,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),10090.0,50594,,Mus musculus,1,3277,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618947,,4925,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,10090.0,50594,,Mus musculus,1,3802,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL618948,,4926,Time taken to reach maximum concentration in plasma upon oral administration in mouse,10090.0,50594,,Mus musculus,1,2862,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL618949,,4927,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,10090.0,50594,,Mus musculus,1,6348,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618950,,4928,Tmax after intraperitoneal administration in mice at 23 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618951,,4929,Tmax after oral administration at 30 mg/kg in ICR mouse,10090.0,50594,,Mus musculus,1,5781,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618952,,4930,Tmax after peroral administration in mice at 2.4 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618953,,4931,Tmax at a single subcutaneous administration of 40 mg/kg in mice,10090.0,50594,,Mus musculus,1,4066,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL618954,,4932,Tmax in brain of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL618955,,4933,Tmax in kidney of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL618956,,4934,Tmax in liver of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL618957,,4935,Tmax in lungs of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618958,,4936,Tmax in mice at 18 uM/kg i.p. administration,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618959,,4937,Tmax in mice at 23 uM/kg i.v. administration,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618960,,4938,Tmax in mice at 25 uM/kg i.p. administration,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876723,,4939,Tmax in mice at 26 uM/kg i.p. administration,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL618961,,4940,Tmax in spleen of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618962,,4941,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618963,,4942,Tmax value at a dose of 10 mg/kg peroral administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618964,,4943,Tmax value in IRC mice,10090.0,50594,,Mus musculus,1,5951,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618965,,4944,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,10090.0,50594,,Mus musculus,1,5506,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618966,,4945,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,10090.0,50594,,Mus musculus,1,5506,,,N,A
BAO_0000218,Intermediate,,,1,,Urine,,1088.0,CHEMBL618967,,4946,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),10090.0,50594,,Mus musculus,1,429,,,N,A
BAO_0000218,Intermediate,,,1,,Urine,,1088.0,CHEMBL618968,,4947,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),10090.0,50594,,Mus musculus,1,429,,,N,A
BAO_0000218,Intermediate,,,1,,Urine,,1088.0,CHEMBL618969,,4948,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),10090.0,50594,,Mus musculus,1,4066,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618970,,4949,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,10090.0,50594,,Mus musculus,1,17734,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618971,,4950,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,10090.0,50594,,Mus musculus,1,17734,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618972,,4951,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,10090.0,50594,,Mus musculus,1,6062,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618973,,4952,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618974,,4953,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618975,,4954,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618976,,4955,Vd in mice,10090.0,50594,,Mus musculus,1,5980,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618977,,4956,Volume of distribution in mouse,10090.0,50594,,Mus musculus,1,17592,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876724,,4957,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,10090.0,50594,,Mus musculus,1,6348,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618978,,4958,Volume of distribution of compound in plasma was determined at 24 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618979,,4959,Volume of distribution of compound in plasma was determined at 40 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618980,,4960,Volume of distribution of compound in plasma was determined at 5 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618981,,4961,Pharmacokinetic property (vdss) was measured in mouse,10090.0,50594,,Mus musculus,1,4239,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618982,,4962,Value distribution upon iv administration in mouse,10090.0,50594,,Mus musculus,1,2862,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620150,,4963,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,10090.0,50594,,Mus musculus,1,17734,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620151,,4964,Volume of distribution was evaluated in mice after intravenous administration,10090.0,50594,,Mus musculus,1,2675,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620152,,4965,Volume of distribution was evaluated in mice after oral administration,10090.0,50594,,Mus musculus,1,2675,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620153,,4966,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,10090.0,50594,,Mus musculus,1,17837,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876395,,4967,Steady state volume of distribution was determined in mice,10090.0,50594,,Mus musculus,1,5727,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620154,,4968,Volume distribution (steady state) of compound was determined in mouse,10090.0,50594,,Mus musculus,1,17852,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620155,,4969,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620156,,4970,Vss value at a dose of 10 mg/kg intravenous administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620157,,4971,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,10090.0,50594,,Mus musculus,1,6062,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL620158,,4972,Biodistribution of compound (oxidized form) in in kidney tissue,10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL620159,,4973,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL620160,,4974,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL620161,,4975,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL620162,,4976,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,9606.0,80019,,Homo sapiens,1,10708,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL620163,,4977,Inhibition of A431 human squamous cell carcinoma cell proliferation,9606.0,80852,,Homo sapiens,1,16597,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL620833,,4978,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,9606.0,80852,,Homo sapiens,1,16062,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL876396,,4979,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,9606.0,80852,,Homo sapiens,1,16062,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL620834,,4980,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,9606.0,80852,,Homo sapiens,1,16958,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL620835,,4981,Inhibition of A431 human carcinoma cell proliferation,9606.0,80852,,Homo sapiens,1,6700,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL620836,,4982,In vitro inhibition of A431 (human carcinoma) cell basal growth.,9606.0,80852,,Homo sapiens,1,17226,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL620837,,4983,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,9606.0,80852,,Homo sapiens,1,6828,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621017,,4984,In vitro cytotoxicity against epidermoid carcinoma cell line,9606.0,80852,,Homo sapiens,1,12314,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL621018,,4985,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",9606.0,9,,Homo sapiens,9,13412,,,D,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621019,,4986,Antiproliferative activity of compound was measured on human tumor cell line A431.,9606.0,80852,,Homo sapiens,1,13299,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621020,,4987,Antiproliferative effect of compound on A431 cell line expressing mutant p53,9606.0,80852,,Homo sapiens,1,17420,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621021,,4988,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,9606.0,80852,,Homo sapiens,1,13678,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621022,,4989,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,9,,,8,14171,,,H,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621023,,4990,Tested for antiproliferative activity against human A431 cells,9606.0,80852,,Homo sapiens,1,6333,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621024,,4991,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,9606.0,9,,Homo sapiens,9,2356,,,D,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621025,,4992,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,9606.0,80852,,Homo sapiens,1,15578,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621026,,4993,Inhibition of A431 cell proliferation,9606.0,80852,,Homo sapiens,1,5126,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621027,,4994,Cytotoxic effect on A431 human epidermoid carcinoma cells,9606.0,80852,,Homo sapiens,1,6844,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL876397,,4995,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),9606.0,80852,,Homo sapiens,1,6844,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL883797,,4996,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,9606.0,80852,,Homo sapiens,1,4925,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621028,,4997,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,9606.0,80852,,Homo sapiens,1,4925,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621029,,4998,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,9606.0,80852,,Homo sapiens,1,13978,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621030,,4999,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,9606.0,80852,,Homo sapiens,1,16786,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621147,,5000,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,9,,,8,13412,,,H,F
BAO_0000218,Intermediate,,500.0,1,,,A-431,,CHEMBL621148,,5001,In vivo antiproliferative activity against A431 cell line,9606.0,80852,,Homo sapiens,1,17824,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621149,,5002,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,9606.0,9,,Homo sapiens,9,12751,,,D,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621150,,5003,Inhibition of A431 human epidermoid carcinoma cell proliferation,9606.0,80852,,Homo sapiens,1,12380,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621151,,5004,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,9606.0,9,,Homo sapiens,9,4959,,,D,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621152,,5005,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),9606.0,80852,,Homo sapiens,1,6333,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621153,,5006,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),9606.0,80852,,Homo sapiens,1,6333,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL884000,,5007,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),9606.0,80852,,Homo sapiens,1,6333,,,N,F
BAO_0000019,Expert,,,1,,,,,CHEMBL621154,,5008,Inhibition of EGFR overexpressing A431 cell proliferation,9606.0,9,,Homo sapiens,9,5296,,,D,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621155,,5009,Inhibition of A431 cell proliferation,9606.0,80852,,Homo sapiens,1,12624,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621156,,5010,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,9606.0,9,,Homo sapiens,9,14926,,,D,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621157,,5011,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",9606.0,9,,Homo sapiens,9,14926,,,D,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621158,,5012,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,9,,,8,14926,,,H,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621159,,5013,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,9606.0,80852,,Homo sapiens,1,15144,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621160,,5014,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,9606.0,80852,,Homo sapiens,1,15144,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621161,,5015,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,9606.0,80852,,Homo sapiens,1,5245,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621162,,5016,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,9606.0,80852,,Homo sapiens,1,5245,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621163,,5017,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,9606.0,80852,,Homo sapiens,1,5245,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621164,,5018,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,9606.0,80852,,Homo sapiens,1,5245,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621165,,5019,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,9606.0,80852,,Homo sapiens,1,5245,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619159,,5020,Half-life period in cynomolgus monkey,9527.0,22224,,Cercopithecidae,0,5922,,,U,A
BAO_0000366,Autocuration,In vitro,,1,,Plasma,,1969.0,CHEMBL619160,,5021,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",9527.0,22224,,Cercopithecidae,0,1116,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619161,,5022,Longer half-life in monkey (i.v.) at 0.5 mpk,9527.0,22224,,Cercopithecidae,0,17853,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL619162,,5023,Plasma half life in monkey,9527.0,22224,,Cercopithecidae,0,993,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL619163,,5024,Plasma half-life in rhesus monkey,9527.0,22224,,Cercopithecidae,0,4514,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL619164,,5025,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),9527.0,22224,,Cercopithecidae,0,5334,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL619320,,5026,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),9527.0,22224,,Cercopithecidae,0,5334,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619321,,5027,Tested for half life upon iv administration to african green monkey,9527.0,22224,,Cercopithecidae,0,4578,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL873336,,5028,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,9527.0,22224,,Cercopithecidae,0,2661,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619322,,5029,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619323,,5030,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL619324,,5031,The time for peak concentration value after oral administration in cynomolgus monkeys,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619325,,5032,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL876411,,5033,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619326,,5034,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619327,,5035,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619328,,5036,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619329,,5037,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619330,,5038,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619331,,5039,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619332,,5040,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619333,,5041,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619334,,5042,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619335,,5043,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619336,,5044,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619337,,5045,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619338,,5046,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619339,,5047,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,9527.0,22224,,Cercopithecidae,0,11271,,,U,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619340,,5048,Bioavailability in rat (cannulated) (dose 2 mg/kg),10116.0,50597,,Rattus norvegicus,1,5809,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL873496,,5049,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,10116.0,50597,,Rattus norvegicus,1,17720,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL619341,,5050,AUC value in rat after IV administration at a dose of 10 mg/kg,10116.0,50597,,Rattus norvegicus,1,3546,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL619342,,5051,AUC value in rat after oral administration at a dose of 10 mg/kg,10116.0,50597,,Rattus norvegicus,1,3546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619343,,5052,Cmax value in rat after oral administration at a dose of 10 mg/kg,10116.0,50597,,Rattus norvegicus,1,3546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619344,,5053,Bioavailability in rat after oral administration at a dose of 10 mg/kg,10116.0,50597,,Rattus norvegicus,1,3546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619345,,5054,Tmax value in rat after oral administration at a dose of 10 mg/kg,10116.0,50597,,Rattus norvegicus,1,3546,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619346,,5055,Vc value in rat after IV administration at a dose of 10 mg/kg,10116.0,50597,,Rattus norvegicus,1,3546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619347,,5056,Half life period in rat after IV administration at a dose of 10 mg/kg,10116.0,50597,,Rattus norvegicus,1,3546,,,N,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619348,,5057,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,9557.0,22224,,Papio hamadryas,0,10625,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619349,,5058,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),9557.0,22224,,Papio hamadryas,0,10625,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619350,,5059,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),9557.0,22224,,Papio hamadryas,0,10625,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619351,,5060,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,9557.0,22224,,Papio hamadryas,0,10625,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL875953,,5061,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,9557.0,22224,,Papio hamadryas,0,10625,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621716,,5062,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,9557.0,22224,,Papio hamadryas,0,10625,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621717,,5063,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,9557.0,22224,,Papio hamadryas,0,10625,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621718,,5064,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,9557.0,22224,,Papio hamadryas,0,10625,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621719,,5065,Area under curve after 1 mpk peroral administration to beagles,9615.0,22224,,beagle,0,3510,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621720,,5066,Area under curve after 2 mpk peroral administration to beagles,9615.0,22224,,beagle,0,3510,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621721,,5067,Cmax value after 1 mpk peroral administration to beagles,9615.0,22224,,beagle,0,3510,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL621722,,5068,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL621723,,5069,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL621724,,5070,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL623443,,5071,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL623444,,5072,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL623445,,5073,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000019,Autocuration,,,1,,Urine,,1088.0,CHEMBL623446,,5074,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,9606.0,22224,,Homo sapiens,0,7766,,,U,A
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL623447,,5075,Metabolic stability observed at 30 min after administration in human liver microsomes,9606.0,22224,Microsomes,Homo sapiens,0,16643,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623448,,5076,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,9606.0,22224,,Homo sapiens,0,6852,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623449,,5077,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,9606.0,22224,,Homo sapiens,0,6852,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623450,,5078,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,9606.0,22224,,Homo sapiens,0,6852,,,U,A
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL623451,,5079,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",9606.0,22224,Microsomes,Homo sapiens,0,6567,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623452,,5080,Metabolic stability (% remaining at 30 mins) in human S9.,9606.0,22224,,Homo sapiens,0,6570,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623453,,5081,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,9606.0,22224,,Homo sapiens,0,6570,,,U,A
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL623454,,5082,Percent parent compound remaining after 20 min incubation with human liver microsomes,9606.0,22224,Microsomes,Homo sapiens,0,5237,,,U,A
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL623455,,5083,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,9606.0,22224,Microsomes,Homo sapiens,0,5237,,,U,A
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL624371,,5084,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,9606.0,22224,Microsomes,Homo sapiens,0,5237,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL624372,,5085,First pass metabolism and metabolic bioavailability using human hepatic microsomes,9606.0,22224,,Homo sapiens,0,5202,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL624373,,5086,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,9606.0,22224,,Homo sapiens,0,5481,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL624374,,5087,Percent remaining in human plasma after incubation for 60 min at 37 C.,9606.0,22224,,Homo sapiens,0,5481,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL624556,,5088,The percent remaining in human plasma after 30 min was determined,9606.0,22224,,Homo sapiens,0,3956,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL624557,,5089,Conversion rate of the prodrug in human plasma,9606.0,22224,,Homo sapiens,0,5074,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL624558,,5090,Conversion rate of the prodrug in human plasma; ND means no data,9606.0,22224,,Homo sapiens,0,5074,,,U,A
BAO_0000221,Autocuration,,,1,,Blood,,178.0,CHEMBL624559,,5091,Half life of compound was determined in human blood,9606.0,22224,,Homo sapiens,0,4727,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL624560,,5092,Half life of compound was determined in man with once daily dosing,9606.0,22224,,Homo sapiens,0,5965,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,,,,CHEMBL624561,,5093,Half life in human microsomes,9606.0,22224,Microsomes,Homo sapiens,0,5732,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL624562,,5094,Half life in human plasma,9606.0,22224,,Homo sapiens,0,5819,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL624563,,5095,Half life in human plasma; Not detected,9606.0,22224,,Homo sapiens,0,5819,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL624564,,5096,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,9606.0,22224,,Homo sapiens,0,1916,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL624565,,5097,Half-life for oxidative metabolic stability was determined using rat liver microsomes,9606.0,22224,Microsomes,Homo sapiens,0,6597,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL875152,,5098,Half-life in human plasma,9606.0,22224,,Homo sapiens,0,5229,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL624566,,5099,Half-life of the parent prodrug in plasma,9606.0,22224,,Homo sapiens,0,5229,,,U,A
BAO_0000366,Autocuration,In vitro,,1,,Plasma,,1969.0,CHEMBL873805,,5100,In vitro half life in human plasma was determined,9606.0,22224,,Homo sapiens,0,2192,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL624567,,5101,The compound was tested In Vitro for half life in human liver microsomes.,9606.0,22224,Microsomes,Homo sapiens,0,3032,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL624568,,5102,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,9606.0,22224,,Homo sapiens,0,1916,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL624569,,5103,Observed volume of distribution,9606.0,22224,,Homo sapiens,0,17716,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL624570,,5104,Oral bioavailability in human,9606.0,22224,,Homo sapiens,0,15778,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL624571,,5105,Tested for human plasma protein binding of the compound,9606.0,22224,,Homo sapiens,0,17313,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL624572,,5106,"First order rate constant, k was determined in human plasma",9606.0,22224,,Homo sapiens,0,4231,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL624573,,5107,Observed rate constant in 80% human plasma at 37 degree Centigrade,9606.0,22224,,Homo sapiens,0,4755,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL875153,,5108,Observed rate constant in 80% human plasma at 37 degree Centigrade,9606.0,22224,,Homo sapiens,0,4755,,,U,A
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL624574,,5109,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,9606.0,22224,Microsomes,Homo sapiens,0,16907,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL624575,,5110,The compound was tested for the plasma binding in human,9606.0,22224,,Homo sapiens,0,10839,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL624576,,5111,Plasma protein binding (human),9606.0,22224,,Homo sapiens,0,10839,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL624577,,5112,Compound was evaluated for half-life in human liver microsomes,9606.0,22224,Microsomes,Homo sapiens,0,3199,,,U,A
BAO_0000221,Autocuration,In vitro,,1,,Blood,,178.0,CHEMBL624578,,5113,Half life measured in vitro for its stability in human blood,9606.0,22224,,Homo sapiens,0,1345,,,U,A
BAO_0000019,Autocuration,,,1,,Serum,,1977.0,CHEMBL622796,,5114,Half life in human serum,9606.0,22224,,Homo sapiens,0,4297,,,U,A
BAO_0000019,Autocuration,,,1,,Serum,,1977.0,CHEMBL622797,,5115,Half life in human serum; ND=not determined,9606.0,22224,,Homo sapiens,0,4297,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL622798,,5116,Half life were determined in CEM-SS cell extract in decomposition step 1,9606.0,22224,,Homo sapiens,0,4297,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL622799,,5117,Half life were determined in CEM-SS cell extract in decomposition step 2,9606.0,22224,,Homo sapiens,0,4297,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL622800,,5118,Half life of the in human plasma,9606.0,22224,,Homo sapiens,0,4231,,,U,A
BAO_0000220,Autocuration,In vitro,,1,,,,,CHEMBL622801,,5119,Half life period in human hepatic S9 fraction was determined,9606.0,22224,S9,Homo sapiens,0,5633,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL622802,,5120,Half life period in human liver microsome was determined,9606.0,22224,Microsomes,Homo sapiens,0,5633,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL622803,,5121,Half life period was determined; 6-7,9606.0,22224,,Homo sapiens,0,17791,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL875154,,5122,Half life period was evaluated in human,9606.0,22224,,Homo sapiens,0,17791,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL622804,,5123,Half life time in human plasma,9606.0,22224,,Homo sapiens,0,3160,,,U,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL622805,,5124,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL622611,,5125,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL622612,,5126,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL875160,,5127,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL622613,,5128,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL622614,,5129,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL622615,,5130,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL622616,,5131,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL622617,,5132,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL622618,,5133,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL622619,,5134,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL622620,,5135,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL622621,,5136,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL622622,,5137,Biodistribution of compound (oxidized form) in blood tissue,10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL622623,,5138,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL622624,,5139,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL622625,,5140,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL622626,,5141,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL622627,,5142,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL622628,,5143,Biodistribution of compound (oxidized form) in brain tissue of mice,10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL622629,,5144,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL622630,,5145,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL622631,,5146,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL622632,,5147,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL622633,,5148,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL622634,,5149,Biodistribution of compound (oxidized form) in heart tissue of mice,10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL622635,,5150,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL875161,,5151,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL622636,,5152,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL623335,,5153,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL623336,,5154,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623337,,5155,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623338,,5156,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623339,,5157,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623524,,5158,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623525,,5159,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL623526,,5160,Biodistribution of compound (oxidized form) in liver tissue,10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL623527,,5161,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL623528,,5162,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",10090.0,50594,,Mus musculus,1,16438,,,N,A
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL624615,,5163,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,9606.0,80852,,Homo sapiens,1,5245,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621672,,5164,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,9606.0,80852,,Homo sapiens,1,5245,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL621673,,5165,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,80852,,,1,16289,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL621674,,5166,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,80852,,,1,16289,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL884002,,5167,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9606.0,9,,Homo sapiens,9,16093,,,D,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621850,,5168,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",9606.0,80852,,Homo sapiens,1,16825,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL621851,,5169,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,9606.0,80852,,Homo sapiens,1,4848,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621852,,5170,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,9606.0,9,,Homo sapiens,9,14827,,,D,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL621853,,5171,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,9606.0,9,,Homo sapiens,9,14827,,,D,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL621854,,5172,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,80852,,,1,16289,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL621855,,5173,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,80852,,,1,16289,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL623724,,5174,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,80852,,,1,16289,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL623725,,5175,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,80852,,,1,16289,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL623726,,5176,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,80852,,,1,16289,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL623727,,5177,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",9606.0,9,,Homo sapiens,9,16289,,,D,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL623728,,5178,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,9,,,8,16289,,,H,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL623729,,5179,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,80852,,,1,16289,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL623730,,5180,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,80852,,,1,16289,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL623731,,5181,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,80852,,,1,16289,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL623732,,5182,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",10090.0,80852,,Mus musculus,1,14555,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL623733,,5183,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",10090.0,80852,,Mus musculus,1,14555,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL623734,,5184,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",10090.0,80852,,Mus musculus,1,14555,,,N,F
BAO_0000218,Expert,,500.0,1,,,A-431,,CHEMBL623735,,5185,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",10090.0,80852,,Mus musculus,1,14555,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL623736,,5186,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,9606.0,80852,,Homo sapiens,1,1937,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL623737,,5187,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,9606.0,80852,,Homo sapiens,1,13739,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL623738,,5188,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,9606.0,80852,,Homo sapiens,1,3558,,,N,F
BAO_0000219,Intermediate,,500.0,1,,,A-431,,CHEMBL875168,,5189,Dose giving a 50% decrease in the living cell number (A437 cells),9606.0,80852,,Homo sapiens,1,3558,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL623739,,5190,In vitro inhibitory concentration against proliferation of A459 cell line.,9606.0,80682,,Homo sapiens,1,17686,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623740,,5191,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,9606.0,80682,,Homo sapiens,1,5305,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624424,,5192,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,9606.0,80682,,Homo sapiens,1,3614,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624425,,5193,In vitro antitumor activity against renal A498 tumor cell lines,9606.0,80021,,Homo sapiens,1,17229,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624426,,5194,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",9606.0,80021,,Homo sapiens,1,15935,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624427,,5195,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",9606.0,80021,,Homo sapiens,1,15935,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624428,,5196,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,9606.0,80021,,Homo sapiens,1,15560,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624429,,5197,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,9606.0,80021,,Homo sapiens,1,13891,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624620,,5198,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,9606.0,80021,,Homo sapiens,1,13891,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624621,,5199,Cytotoxicity on kidney carcinoma (A-498) cell line,9606.0,80021,,Homo sapiens,1,13788,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624622,,5200,Compound was evaluated against Human cell line renal A498,9606.0,80021,,Homo sapiens,1,15403,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624623,,5201,Compound was tested for inhibition of A498 human renal cancer cell line,9606.0,80021,,Homo sapiens,1,1009,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL874365,,5202,Growth inhibitory activity against A498 human cancer cell line,9606.0,80021,,Homo sapiens,1,1043,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624624,,5203,In vitro antitumor activity against human renal A498 cell line,9606.0,80021,,Homo sapiens,1,5858,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624625,,5204,In vitro cytotoxic activity against renal (A498) cell line,9606.0,80021,,Homo sapiens,1,5958,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624626,,5205,In vitro cytotoxic activity against human renal cancer (A498) cell line,9606.0,80021,,Homo sapiens,1,5506,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624627,,5206,Tested for cytostatic activity against renal A498 cell line,9606.0,80021,,Homo sapiens,1,12781,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL883157,,5207,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,9606.0,80021,,Homo sapiens,1,14399,,,N,F
BAO_0000219,Expert,,624.0,1,,,A498,,CHEMBL624628,,5208,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,9606.0,80021,,Homo sapiens,1,5958,,,N,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL624629,,5209,Cmax value after 2 mpk peroral administration to beagles,9615.0,22224,,beagle,0,3510,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL623551,,5210,Bioavailability,9615.0,22224,,Canis lupus familiaris,0,3510,beagle,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL623552,,5211,Bioavailability after 1 mpk peroral administration to beagles,9615.0,22224,,Canis lupus familiaris,0,3510,beagle,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL623553,,5212,Bioavailability after 2 mpk peroral administration to beagles,9615.0,22224,,Canis lupus familiaris,0,3510,beagle,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623554,,5213,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,9913.0,22224,,Bos taurus,0,3085,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623555,,5214,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,9913.0,22224,,Bos taurus,0,3085,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623556,,5215,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,9913.0,22224,,Bos taurus,0,3085,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623557,,5216,Solubility against bovine alpha-chymotrypsin,9913.0,22224,,Bos taurus,0,9372,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623558,,5217,Rate constant of the bovine serum albumin catalyzed reaction of the compound,9913.0,22224,,Bos taurus,0,3085,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623559,,5218,Rate constant of the bovine serum albumin catalyzed reaction of the compound,9913.0,22224,,Bos taurus,0,3085,,,U,A
BAO_0000221,Autocuration,,,1,,Spleen,,2106.0,CHEMBL623560,,5219,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,9913.0,22224,,Bos taurus,0,1469,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623561,,5220,Half life in culture medium containing 10% of heat inactivated foetal calf serum,9913.0,22224,,Bos taurus,0,4297,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623562,,5221,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,9913.0,22224,,Bos taurus,0,4297,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623563,,5222,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,9913.0,22224,,Bos taurus,0,17585,,,U,A
BAO_0000221,Autocuration,,,1,,Spleen,,2106.0,CHEMBL623564,,5223,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,9913.0,22224,,Bos taurus,0,1336,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL873806,,5224,Half life in presence of 2 mg/mL BSA at pH 8.8,9913.0,22224,,Bos taurus,0,3085,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623565,,5225,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,9913.0,22224,,Bos taurus,0,2857,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623566,,5226,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,9913.0,22224,,Bos taurus,0,2857,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623567,,5227,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,9913.0,22224,,Bos taurus,0,2857,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623568,,5228,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),9913.0,22224,,Bos taurus,0,1540,,,U,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL623569,,5229,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6316,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL623570,,5230,AUC after administration at 100 mg/kg/day in dogs,9615.0,50588,,Canis lupus familiaris,1,17594,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL624254,,5231,AUC in dog at 0-24 hr by peroral administration at 3 mpk,9615.0,50588,,Canis lupus familiaris,1,4953,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL624255,,5232,AUC value after 15 mg/kg iv dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL624256,,5233,AUC value after 30 mg/kg po dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL624257,,5234,AUC value after administration of 4 mg/Kg oral dose in dog,9615.0,50588,,Canis lupus familiaris,1,2959,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL624258,,5235,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,9615.0,50588,,Canis lupus familiaris,1,17594,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL875277,,5236,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,9615.0,50588,,Canis lupus familiaris,1,5356,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622667,,5237,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,9615.0,50588,,Canis lupus familiaris,1,16807,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622668,,5238,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,4527,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622669,,5239,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,4527,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622670,,5240,Area under curve determined in dogs after intravenous administration of 3 mg/kg,9615.0,50588,,Canis lupus familiaris,1,15660,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622671,,5241,Area under curve determined in dogs after oral administration of 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,15660,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622672,,5242,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,9615.0,50588,,Canis lupus familiaris,1,5802,,,N,A
BAO_0000218,Expert,,,1,,,,,CHEMBL622673,,5243,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3598,,,N,A
BAO_0000218,Expert,,,1,,,,,CHEMBL622674,,5244,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3598,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622675,,5245,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5944,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622676,,5246,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,9615.0,50588,,Canis lupus familiaris,1,5944,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622677,,5247,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5944,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622678,,5248,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,9615.0,50588,,Canis lupus familiaris,1,5944,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622679,,5249,Area under curve in dog after administration of 20 mg/kg dose through peroral route,9615.0,50588,,Canis lupus familiaris,1,4186,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622680,,5250,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5007,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622681,,5251,Area under curve was determine after peroral administration at 10 mpk in dog,9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL875278,,5252,Area under curve was determine after peroral administration at 5 mpk in dog,9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622682,,5253,Area under curve was determined,9615.0,50588,,Canis lupus familiaris,1,5006,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622683,,5254,Area under curve in dogs,9615.0,50588,,Canis lupus familiaris,1,5006,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622684,,5255,Area under curve in dogs at 10 mg/kg dose fo oral administration,9615.0,50588,,Canis lupus familiaris,1,3771,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622685,,5256,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),9615.0,50588,,Canis lupus familiaris,1,3771,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622686,,5257,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,9615.0,50588,,Canis lupus familiaris,1,3771,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618344,,5258,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,9615.0,50588,,Canis lupus familiaris,1,1916,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL875582,,5259,Area under curve value in dog at a dose of 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5302,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618345,,5260,Area under curve was determined after 0.1 mg/kg iv administration in dog,9615.0,50588,,Canis lupus familiaris,1,5600,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618346,,5261,Area under curve was determined after 0.3 mg/kg po administration in dog,9615.0,50588,,Canis lupus familiaris,1,5600,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618347,,5262,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17764,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618348,,5263,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4368,,,N,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618349,,5264,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,9606.0,22224,,Homo sapiens,0,5318,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618350,,5265,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,9606.0,22224,,Homo sapiens,0,5318,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618351,,5266,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,9606.0,22224,,Homo sapiens,0,5318,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618352,,5267,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,9606.0,22224,,Homo sapiens,0,5318,,,U,A
BAO_0000221,Autocuration,,,1,,Blood,,178.0,CHEMBL873494,,5268,Time taken to reduce 50% of the concentration of compound in blood plasma,9606.0,22224,,Homo sapiens,0,14518,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618353,,5269,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",9606.0,22224,,Homo sapiens,0,2209,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618354,,5270,Half life in human plasma,9606.0,22224,,Homo sapiens,0,6787,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL875583,,5271,Half life in human plasma was reported,9606.0,22224,,Homo sapiens,0,4898,,,U,A
BAO_0000019,Autocuration,,,1,,Serum,,1977.0,CHEMBL618355,,5272,Half life in human serum,9606.0,22224,,Homo sapiens,0,6072,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618356,,5273,Half life upon exposure to human plasma,9606.0,22224,,Homo sapiens,0,16907,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,,,,CHEMBL618357,,5274,t1/2 in human microsomes,9606.0,22224,Microsomes,Homo sapiens,0,5656,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618358,,5275,Half life period in 80% human plasma at 37 degree Centigrade,9606.0,22224,,Homo sapiens,0,4755,,,U,A
BAO_0000221,Autocuration,,,1,,Zone of skin,,14.0,CHEMBL618359,,5276,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),9606.0,22224,,Homo sapiens,0,17503,,,U,A
BAO_0000366,Autocuration,In vitro,,1,,Plasma,,1969.0,CHEMBL618360,,5277,Half-life measured in in vitro Cathepsin B assay in human plasma,9606.0,22224,,Homo sapiens,0,12357,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618361,,5278,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,9606.0,22224,,Homo sapiens,0,3076,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL618362,,5279,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,9606.0,22224,Microsomes,Homo sapiens,0,6410,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618363,,5280,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",9606.0,22224,,Homo sapiens,0,3741,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618364,,5281,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",9606.0,22224,,Homo sapiens,0,3741,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL875584,,5282,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",9606.0,22224,,Homo sapiens,0,3741,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618365,,5283,Half-life in the CEM cell extracts,9606.0,22224,,Homo sapiens,0,1540,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL873495,,5284,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,9606.0,22224,,Homo sapiens,0,2905,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618366,,5285,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,9606.0,22224,,Homo sapiens,0,2905,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618367,,5286,Half-life was determined,9606.0,22224,,Homo sapiens,0,5523,,,U,A
BAO_0000221,Autocuration,,,1,,Blood,,178.0,CHEMBL618368,,5287,Half-life (human blood stability),9606.0,22224,,Homo sapiens,0,1499,,,U,A
BAO_0000221,Autocuration,,,1,,Blood,,178.0,CHEMBL618369,,5288,Half-life (human blood stability); no data,9606.0,22224,,Homo sapiens,0,1499,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618370,,5289,Half-life in human plasma,9606.0,22224,,Homo sapiens,0,17065,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618371,,5290,CYP3A4 metabolism half-life (t1/2),9606.0,22224,,Homo sapiens,0,6861,,,U,A
BAO_0000221,Autocuration,,,1,,Blood,,178.0,CHEMBL618372,,5291,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),9606.0,22224,,Homo sapiens,0,1499,,,U,A
BAO_0000366,Autocuration,In vitro,,1,,Plasma,,1969.0,CHEMBL618373,,5292,In vitro half life in human plasma,9606.0,22224,,Homo sapiens,0,530,,,U,A
BAO_0000366,Autocuration,In vitro,,1,,Plasma,,1969.0,CHEMBL618374,,5293,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",9606.0,22224,,Homo sapiens,0,1116,,,U,A
BAO_0000366,Autocuration,In vitro,,1,,Plasma,,1969.0,CHEMBL618375,,5294,In vitro hydrolysis in human plasma,9606.0,22224,,Homo sapiens,0,6695,,,U,A
BAO_0000366,Autocuration,In vitro,,1,,Plasma,,1969.0,CHEMBL618376,,5295,In vitro hydrolysis in human plasma; no data,9606.0,22224,,Homo sapiens,0,6695,,,U,A
BAO_0000251,Autocuration,In vitro,,1,,Liver,,2107.0,CHEMBL618377,,5296,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,9606.0,22224,Microsomes,Homo sapiens,0,10,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618378,,5297,Plasma half life in human,9606.0,22224,,Homo sapiens,0,993,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618379,,5298,Stability after incubation with human plasma (at 37 degree C),9606.0,22224,,Homo sapiens,0,15429,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618380,,5299,T1/2 was evaluated in human plasma,9606.0,22224,,Homo sapiens,0,1675,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618381,,5300,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",9606.0,22224,,Homo sapiens,0,2209,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL618382,,5301,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",9606.0,22224,,Homo sapiens,0,2209,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618383,,5302,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,9606.0,22224,,Homo sapiens,0,5318,,,U,A
BAO_0000019,Autocuration,In vitro,,1,,,,,CHEMBL618384,,5303,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,9606.0,22224,,Homo sapiens,0,2412,,,U,A
BAO_0000019,Autocuration,In vitro,,1,,,,,CHEMBL618385,,5304,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,9606.0,22224,,Homo sapiens,0,2412,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL619099,,5305,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,9606.0,22224,,Homo sapiens,0,2906,,,U,A
BAO_0000366,Autocuration,,,1,,Plasma,,1969.0,CHEMBL619100,,5306,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,9606.0,22224,,Homo sapiens,0,2906,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619101,,5307,Time taken for 50% to be consumed by serum PON1 was determined,9606.0,22224,,Homo sapiens,0,5495,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL619102,,5308,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,9606.0,22224,,Homo sapiens,0,5495,,,U,A
BAO_0000251,Autocuration,,,1,,Liver,,2107.0,CHEMBL619103,,5309,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,9606.0,22224,Microsomes,Homo sapiens,0,4397,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619268,,5310,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619269,,5311,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619270,,5312,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619271,,5313,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL875585,,5314,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL619272,,5315,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619273,,5316,Compound tested for growth inhibition of renal cancer cell line 786-0,9606.0,80640,,Homo sapiens,1,6058,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619274,,5317,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,9606.0,80640,,Homo sapiens,1,17708,,,N,F
BAO_0000219,Expert,,391.0,1,,,786-0,,CHEMBL619275,,5318,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,9606.0,80640,,Homo sapiens,1,14017,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619276,,5319,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",9606.0,80640,,Homo sapiens,1,16818,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619277,,5320,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",9606.0,80640,,Homo sapiens,1,16818,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619278,,5321,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",9606.0,80640,,Homo sapiens,1,16818,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619279,,5322,Tested for cytotoxicity against 786-0 cell lines in renal cancer,9606.0,80640,,Homo sapiens,1,11970,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL858458,,5323,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,9606.0,80640,,Homo sapiens,1,12400,,,N,F
BAO_0000219,Expert,,391.0,1,,,786-0,,CHEMBL619280,,5324,Cytotoxic effect on renal cancer line 786-0,9606.0,80640,,Homo sapiens,1,12888,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619281,,5325,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,9606.0,80640,,Homo sapiens,1,15300,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619282,,5326,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),9606.0,80640,,Homo sapiens,1,14769,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619283,,5327,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",9606.0,80640,,Homo sapiens,1,15895,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619284,,5328,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,9606.0,80640,,Homo sapiens,1,17376,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619285,,5329,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,9606.0,80640,,Homo sapiens,1,14882,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619286,,5330,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),9606.0,80640,,Homo sapiens,1,14882,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619287,,5331,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,9606.0,80640,,Homo sapiens,1,15176,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL857455,,5332,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,9606.0,80640,,Homo sapiens,1,12696,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL883801,,5333,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),9606.0,80640,,Homo sapiens,1,2496,,,N,F
BAO_0000219,Intermediate,,972.0,1,,,791T cell line,,CHEMBL619288,,5334,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,9606.0,80641,,Homo sapiens,1,11831,,,N,F
BAO_0000219,Intermediate,,972.0,1,,,791T cell line,,CHEMBL619289,,5335,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),9606.0,80641,,Homo sapiens,1,11831,,,N,F
BAO_0000219,Intermediate,,972.0,1,,,791T cell line,,CHEMBL619290,,5336,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,9606.0,80641,,Homo sapiens,1,11831,,,N,F
BAO_0000219,Intermediate,,972.0,1,,,791T cell line,,CHEMBL619291,,5337,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),9606.0,80641,,Homo sapiens,1,11831,,,N,F
BAO_0000219,Intermediate,,972.0,1,,,791T cell line,,CHEMBL619292,,5338,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),9606.0,80641,,Homo sapiens,1,11831,,,N,F
BAO_0000219,Intermediate,,972.0,1,,,791T cell line,,CHEMBL619293,,5339,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,9606.0,80641,,Homo sapiens,1,11831,,,N,F
BAO_0000219,Intermediate,,972.0,1,,,791T cell line,,CHEMBL619294,,5340,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),9606.0,80641,,Homo sapiens,1,11831,,,N,F
BAO_0000219,Intermediate,,972.0,1,,,791T cell line,,CHEMBL619295,,5341,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),9606.0,80641,,Homo sapiens,1,11831,,,N,F
BAO_0000219,Intermediate,,972.0,1,,,791T cell line,,CHEMBL619296,,5342,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),9606.0,80641,,Homo sapiens,1,11831,,,N,F
BAO_0000219,Intermediate,,972.0,1,,,791T cell line,,CHEMBL619297,,5343,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,9606.0,80641,,Homo sapiens,1,11831,,,N,F
BAO_0000219,Intermediate,,391.0,1,,,786-0,,CHEMBL619298,,5344,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,9606.0,80640,,Homo sapiens,1,12782,,,N,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL619299,,5345,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,22226,,,0,1229,,,U,F
BAO_0000219,Expert,,741.0,1,,,RPMI-8226,,CHEMBL619300,,5346,Inhibition of cell growth in drug resistant 8226 myeloma cell line,9606.0,80433,,Homo sapiens,1,15313,,,N,F
BAO_0000219,Expert,,741.0,1,,,RPMI-8226,,CHEMBL619301,,5347,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,9606.0,80433,,Homo sapiens,1,15313,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL619302,,5348,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,9606.0,80433,,Homo sapiens,1,11544,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL619303,,5349,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL619304,,5350,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL857706,,5351,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL619305,,5352,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL619306,,5353,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL619307,,5354,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL619308,,5355,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL619309,,5356,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL619310,,5357,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619311,,5358,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),9606.0,80021,,Homo sapiens,1,14769,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619312,,5359,Compound was tested for the growth inhibition of A498 renal tumor cell line,9606.0,80021,,Homo sapiens,1,15354,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619313,,5360,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),9606.0,80021,,Homo sapiens,1,17445,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619314,,5361,In vitro inhibitory concentration against renal cancer cell line A498,9606.0,80021,,Homo sapiens,1,4337,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619959,,5362,Cytotoxicity against A 498 tumor cell line,9606.0,80021,,Homo sapiens,1,15277,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619960,,5363,In vitro antitumor activity against A498 human cancer cell line,9606.0,80021,,Homo sapiens,1,4812,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619961,,5364,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),9606.0,80021,,Homo sapiens,1,4812,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619962,,5365,Inhibitory dose required against A498 human tumor cell lines,9606.0,80021,,Homo sapiens,1,4995,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL875586,,5366,Anticancer activity against one renal cancer (A498 cell line),9606.0,80021,,Homo sapiens,1,5847,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619963,,5367,In vitro cytotoxicity against melanoma A498 cell line,9606.0,80021,,Homo sapiens,1,6557,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619964,,5368,Compound was tested for growth inhibitory activity against A498 cell line,9606.0,80021,,Homo sapiens,1,2597,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL620108,,5369,Compound tested for growth inhibition of renal cancer cell line A498,9606.0,80021,,Homo sapiens,1,6058,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL620109,,5370,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,9606.0,80021,,Homo sapiens,1,17708,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL620110,,5371,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,9606.0,80021,,Homo sapiens,1,15176,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL620111,,5372,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,9606.0,80021,,Homo sapiens,1,15300,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL620112,,5373,Tested for cytotoxicity against A498 cell lines in renal cancer,9606.0,80021,,Homo sapiens,1,11970,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL620113,,5374,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,9606.0,80021,,Homo sapiens,1,12400,,,N,F
BAO_0000219,Expert,,624.0,1,,,A498,,CHEMBL620114,,5375,Cytotoxic effect on renal cancer lines A498,9606.0,80021,,Homo sapiens,1,12888,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL620115,,5376,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,9606.0,80021,,Homo sapiens,1,3030,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL620116,,5377,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),9606.0,80021,,Homo sapiens,1,14769,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL620117,,5378,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,9606.0,80021,,Homo sapiens,1,17376,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL620118,,5379,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,9606.0,80021,,Homo sapiens,1,16558,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL620119,,5380,Cytotoxicity against human kidney carcinoma cell lines A4982LM,9606.0,80021,,Homo sapiens,1,5194,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL620120,,5381,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,9606.0,80021,,Homo sapiens,1,10708,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620121,,5382,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,9606.0,80682,,Homo sapiens,1,16880,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620122,,5383,Antitumor activity against A549 human lung carcinoma cell line,9606.0,80682,,Homo sapiens,1,10196,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620123,,5384,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,9606.0,80682,,Homo sapiens,1,10196,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620124,,5385,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,9606.0,80682,,Homo sapiens,1,10196,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620125,,5386,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",9606.0,80682,,Homo sapiens,1,12083,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620126,,5387,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,9606.0,80682,,Homo sapiens,1,16464,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL883027,,5388,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,9606.0,80682,,Homo sapiens,1,16464,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620127,,5389,In vitro cytotoxic activity against human lung A549 cell line,9606.0,80682,,Homo sapiens,1,16470,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620128,,5390,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),9606.0,80682,,Homo sapiens,1,16470,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620129,,5391,In vitro cytotoxic activity against human lung A549 cell line),9606.0,80682,,Homo sapiens,1,16470,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620130,,5392,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,9606.0,80682,,Homo sapiens,1,16470,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620131,,5393,In vitro cytotoxicity against human non small-cell-lung cell line A549.,9606.0,80682,,Homo sapiens,1,16582,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620132,,5394,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",9606.0,80682,,Homo sapiens,1,15935,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620133,,5395,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",9606.0,80682,,Homo sapiens,1,15935,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620134,,5396,Inhibition of A549 human lung carcinoma cell proliferation,9606.0,80682,,Homo sapiens,1,16597,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620135,,5397,Inhibitory activity against A549 lung adenocarcinoma cell line,9606.0,80682,,Homo sapiens,1,17376,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620136,,5398,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,9606.0,80682,,Homo sapiens,1,16496,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620137,,5399,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,9606.0,80682,,Homo sapiens,1,16152,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620268,,5400,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,9606.0,80682,,Homo sapiens,1,16152,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620269,,5401,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,9606.0,80682,,Homo sapiens,1,16464,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620270,,5402,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,9606.0,80682,,Homo sapiens,1,2288,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620271,,5403,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,9606.0,80682,,Homo sapiens,1,17350,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620272,,5404,Inhibition of A549 cancer cell proliferation,9606.0,80682,,Homo sapiens,1,4090,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620273,,5405,Inhibition of A549 cancer cell proliferation (Not tested),9606.0,80682,,Homo sapiens,1,4090,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620274,,5406,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,9606.0,80682,,Homo sapiens,1,17350,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620275,,5407,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,9606.0,80682,,Homo sapiens,1,4197,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620276,,5408,Antiproliferative potency determined as inhibitory concentration against A549 cells,9606.0,80682,,Homo sapiens,1,17072,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620277,,5409,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,9606.0,80682,,Homo sapiens,1,17072,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620278,,5410,Cytotoxicity against Renal cell lines A549 was determined,9606.0,80682,,Homo sapiens,1,5194,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620279,,5411,Area under curve was determined in dog after a 3 mg/kg of oral dose,9615.0,50588,,Canis lupus familiaris,1,4257,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620280,,5412,Area under curve was determined in dog after oral administration at 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6123,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620281,,5413,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,9615.0,50588,,Canis lupus familiaris,1,1337,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620282,,5414,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,9615.0,50588,,Canis lupus familiaris,1,1337,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621134,,5415,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),9615.0,50588,,Canis lupus familiaris,1,8833,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621135,,5416,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),9615.0,50588,,Canis lupus familiaris,1,8833,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621136,,5417,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),9615.0,50588,,Canis lupus familiaris,1,8833,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621137,,5418,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),9615.0,50588,,Canis lupus familiaris,1,8833,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL621138,,5419,Area under plasma concentration time curve in dog upon oral administration,9615.0,50588,,Canis lupus familiaris,1,17657,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL875587,,5420,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17650,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621139,,5421,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,9615.0,50588,,Canis lupus familiaris,1,1977,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621140,,5422,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,9615.0,50588,,Canis lupus familiaris,1,1977,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621141,,5423,Area under the curve for the compound was obtained when tested in dog,9615.0,50588,,Canis lupus familiaris,1,3132,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621142,,5424,Area under the curve at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5473,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621143,,5425,Area under the curve at a dose of 1 mg/kg (oral),9615.0,50588,,Canis lupus familiaris,1,5474,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621144,,5426,Area under the curve at i.v. dose of 0.2 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5474,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621145,,5427,Area under the curve was measured in dog after an iv dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6062,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621146,,5428,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4709,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622567,,5429,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,9615.0,50588,,Canis lupus familiaris,1,2652,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622568,,5430,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,9615.0,50588,,Canis lupus familiaris,1,2652,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622569,,5431,Compound was evaluated for area under the curve in dog blood.,9615.0,50588,,Canis lupus familiaris,1,2877,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622570,,5432,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,9615.0,50588,,Canis lupus familiaris,1,5444,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL622571,,5433,AUC in dog after oral dose (1 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5130,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622572,,5434,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6265,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622573,,5435,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",9615.0,50588,,Canis lupus familiaris,1,4657,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622574,,5436,Pharmacokinetic parameter AUC after intravenous administration to dogs,9615.0,50588,,Canis lupus familiaris,1,16367,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622575,,5437,Pharmacokinetic parameter AUC after oral administration to dogs,9615.0,50588,,Canis lupus familiaris,1,16367,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622576,,5438,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,9615.0,50588,,Canis lupus familiaris,1,9579,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622577,,5439,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,9615.0,50588,,Canis lupus familiaris,1,9579,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622578,,5440,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,9615.0,50588,,Canis lupus familiaris,1,5983,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622579,,5441,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6241,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622580,,5442,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",9615.0,50588,,Canis lupus familiaris,1,5313,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622581,,5443,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",9615.0,50588,,Canis lupus familiaris,1,5313,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622582,,5444,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),9615.0,50588,,Canis lupus familiaris,1,6642,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622583,,5445,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),9615.0,50588,,Canis lupus familiaris,1,6642,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622584,,5446,Oral AUCN in dog (dosed at 0.5 mpk iv ),9615.0,50588,,Canis lupus familiaris,1,6641,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622585,,5447,Oral AUCN in dog (dosed at 0.5 mpk iv ),9615.0,50588,,Canis lupus familiaris,1,6642,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622586,,5448,Compound was evaluated for oral bioavailability in dog; 90-100,9615.0,50588,,Canis lupus familiaris,1,17791,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623281,,5449,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,9615.0,50588,,Canis lupus familiaris,1,17655,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623282,,5450,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,9615.0,50588,,Canis lupus familiaris,1,17655,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623283,,5451,PAPP (membrane permeability) in dog kidney cell monolayer assay,9615.0,50588,,Canis lupus familiaris,1,6596,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623284,,5452,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,3880,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623285,,5453,Bioavailability administered orally at a dose of 10 mg/kg to dogs,9615.0,50588,,Canis lupus familiaris,1,16367,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL623463,,5454,Plasma protein binding towards dog plasma at 10 uM,9615.0,50588,,Canis lupus familiaris,1,17409,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL875952,,5455,Plasma protein binding towards dog plasma at 100 uM,9615.0,50588,,Canis lupus familiaris,1,17409,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621705,,5456,Bioavailability in dog (dose 4 mg/kg p.o.),9615.0,50588,,Canis lupus familiaris,1,2959,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621706,,5457,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,9615.0,50588,,Canis lupus familiaris,1,13501,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621707,,5458,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,4527,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621708,,5459,Bioavailability in dogs,9615.0,50588,,Canis lupus familiaris,1,15145,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621709,,5460,Bioavailability,9615.0,50588,,Canis lupus familiaris,1,4219,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621710,,5461,Oral bioavailability in dog (dose 10 mg/kg),9615.0,50588,,Canis lupus familiaris,1,17538,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621711,,5462,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,9615.0,50588,,Canis lupus familiaris,1,17538,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621712,,5463,Bioavailability in dog (dose 10.0 mg/kg p.o.),9615.0,50588,,Canis lupus familiaris,1,1466,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621713,,5464,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17650,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621714,,5465,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,9615.0,50588,,Canis lupus familiaris,1,3132,,,N,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL621715,,5466,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,Liver,,2107.0,CHEMBL623717,,5467,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,Liver,,2107.0,CHEMBL623718,,5468,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,Liver,,2107.0,CHEMBL623719,,5469,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL623720,,5470,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL623721,,5471,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,Muscle tissue,,2385.0,CHEMBL623722,,5472,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,Muscle tissue,,2385.0,CHEMBL623723,,5473,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,Muscle tissue,,2385.0,CHEMBL618543,,5474,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,Spleen,,2106.0,CHEMBL618544,,5475,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,Spleen,,2106.0,CHEMBL875155,,5476,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618545,,5477,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618546,,5478,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL623529,,5479,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL623530,,5480,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL621764,,5481,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,22224,,Mus sp.,0,2413,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621765,,5482,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),9527.0,22224,,Cercopithecidae,0,17827,,,U,A
BAO_0000019,Autocuration,,,1,,Cerebellum,,2037.0,CHEMBL621766,,5483,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),9527.0,22224,,Cercopithecidae,0,17827,,,U,A
BAO_0000019,Autocuration,,,1,,Frontal cortex,,1870.0,CHEMBL621767,,5484,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),9527.0,22224,,Cercopithecidae,0,17827,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621768,,5485,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),9527.0,22224,,Cercopithecidae,0,17827,,,U,A
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL621769,,5486,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),9527.0,22224,,Cercopithecidae,0,17827,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621770,,5487,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),9527.0,22224,,Cercopithecidae,0,17827,,,U,A
BAO_0000019,Autocuration,,,1,,Cerebellum,,2037.0,CHEMBL621771,,5488,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),9527.0,22224,,Cercopithecidae,0,17827,,,U,A
BAO_0000019,Autocuration,,,1,,Frontal cortex,,1870.0,CHEMBL621772,,5489,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),9527.0,22224,,Cercopithecidae,0,17827,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621773,,5490,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),9527.0,22224,,Cercopithecidae,0,17827,,,U,A
BAO_0000019,Autocuration,,,1,,Striatum,,2435.0,CHEMBL621774,,5491,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),9527.0,22224,,Cercopithecidae,0,17827,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL621775,,5492,Compound was evaluated for oral bioavailability in rats,9527.0,22224,,Cercopithecidae,0,17791,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL621776,,5493,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,9527.0,22224,,Cercopithecidae,0,17667,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621777,,5494,Half life period was evaluated in monkey,9527.0,22224,,Cercopithecidae,0,17791,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL875162,,5495,Half-life in rhesus monkeys by intravenous administration of dose,9527.0,22224,,Cercopithecidae,0,110,,,U,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL621778,,5496,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,10090.0,50594,,Mus musculus,1,5781,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL621779,,5497,AUC after intraperitoneal administration of 100 mg/kg in mice,10090.0,50594,,Mus musculus,1,17734,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL622479,,5498,AUC value was determined after oral administration,10090.0,50594,,Mus musculus,1,17718,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622480,,5499,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,10090.0,50594,,Mus musculus,1,4573,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622481,,5500,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),10090.0,50594,,Mus musculus,1,3277,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622482,,5501,Area under curve by ioral administration in mouse,10090.0,50594,,Mus musculus,1,2862,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622483,,5502,Area under curve by iv administration in mouse,10090.0,50594,,Mus musculus,1,2862,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622484,,5503,Area under curve at 0-8 hr in IRC mice after peroral administration,10090.0,50594,,Mus musculus,1,5951,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622641,,5504,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17729,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622642,,5505,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,10090.0,50594,,Mus musculus,1,17728,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622643,,5506,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,10090.0,50594,,Mus musculus,1,17728,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622644,,5507,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,10090.0,50594,,Mus musculus,1,17729,,,N,A
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL622645,,5508,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL622646,,5509,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL621238,,5510,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL621239,,5511,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL621240,,5512,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL621241,,5513,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL621242,,5514,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620350,,5515,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620351,,5516,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620352,,5517,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620353,,5518,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620354,,5519,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620355,,5520,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620356,,5521,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620357,,5522,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620358,,5523,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Expert,,741.0,1,,,RPMI-8226,,CHEMBL620359,,5524,In vitro inhibition of human 8226 myeloma tumor cell line growth.,9606.0,80433,,Homo sapiens,1,9424,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620360,,5525,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,9606.0,80433,,Homo sapiens,1,11544,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620361,,5526,Cytotoxicity of compound against 8226/DOX1V cells,9606.0,80433,,Homo sapiens,1,17378,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620362,,5527,Cytotoxicity of compound against 8226/S cells,9606.0,80433,,Homo sapiens,1,17378,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620363,,5528,Inhibitory concentration against 8226 myeloma cancer cell line,9606.0,80433,,Homo sapiens,1,17079,,,N,F
BAO_0000219,Intermediate,,741.0,1,,,RPMI-8226,,CHEMBL620364,,5529,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,9606.0,80433,,Homo sapiens,1,17079,,,N,F
BAO_0000219,Intermediate,,854.0,1,,,833K,,CHEMBL620365,,5530,Inhibition of cell growth was studied in human teratocarcinoma (833K).,9606.0,80647,,Homo sapiens,1,13466,,,N,F
BAO_0000219,Intermediate,,854.0,1,,,833K,,CHEMBL620366,,5531,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',9606.0,80647,,Homo sapiens,1,13466,,,N,F
BAO_0000219,Expert,,854.0,1,,,833K,,CHEMBL620367,,5532,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,9606.0,80647,,Homo sapiens,1,2392,,,N,F
BAO_0000219,Intermediate,,854.0,1,,,833K,,CHEMBL620368,,5533,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,9606.0,80647,,Homo sapiens,1,2392,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620369,,5534,Inhibitory activity against caspase-1,,22226,,,0,6608,,,U,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620370,,5535,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,1351.0,45,,Enterococcus faecalis,8,10199,,,H,B
BAO_0000219,Intermediate,,705.0,1,,,8701-BC,,CHEMBL620371,,5536,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,9606.0,80648,,Homo sapiens,1,17749,,,N,F
BAO_0000219,Intermediate,,705.0,1,,,8701-BC,,CHEMBL620372,,5537,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,9606.0,80648,,Homo sapiens,1,17749,,,N,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL876492,,5538,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,22226,,,0,1229,,,U,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL620373,,5539,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,22226,,,0,1229,,,U,F
BAO_0000019,Intermediate,,,1,,,,,CHEMBL620374,,5540,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,22226,,,0,1229,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620375,,5541,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,22226,,,0,6390,,,U,B
BAO_0000019,Autocuration,,,1,,,,,CHEMBL857902,,5542,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,1314.0,22226,,Streptococcus pyogenes,0,16219,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620376,,5543,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,1314.0,22226,,Streptococcus pyogenes,0,16219,,,U,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620377,,5544,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,11922,,,8,17043,,,H,B
BAO_0000219,Intermediate,,324.0,1,,,KB ,,CHEMBL620378,,5545,Tested for in vitro cytotoxic potency of compound in 9KB assay,9606.0,81115,,Homo sapiens,1,6929,,,N,F
BAO_0000219,Intermediate,,324.0,1,,,KB ,,CHEMBL620379,,5546,Tested for in vitro cytotoxic potency of compound in 9KB assay,9606.0,81115,,Homo sapiens,1,6929,,,N,A
BAO_0000219,Autocuration,,,1,,,,,CHEMBL620380,,5547,In vitro cytotoxicity of compound was tested against 9KB cells.,9606.0,22226,,Homo sapiens,0,7083,,,U,F
BAO_0000219,Intermediate,,392.0,1,,,9L,,CHEMBL884006,,5548,Cytotoxic concentration against 9L cells was determined on day 3,10116.0,80653,,Rattus norvegicus,1,12446,,,N,F
BAO_0000219,Expert,,392.0,1,,,9L,,CHEMBL620381,,5549,Tested in vitro for anticancer activity against 9L cells,10116.0,80653,,Rattus norvegicus,1,15345,,,N,F
BAO_0000219,Expert,,392.0,1,,,9L,,CHEMBL620382,,5550,Tested in vitro for anticancer activity against 9L cells; Not determined,10116.0,80653,,Rattus norvegicus,1,15345,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620383,,5551,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,9606.0,80682,,Homo sapiens,1,6301,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL876493,,5552,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,9606.0,80682,,Homo sapiens,1,4833,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620384,,5553,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,9606.0,80682,,Homo sapiens,1,4833,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620385,,5554,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,9606.0,80682,,Homo sapiens,1,4833,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620386,,5555,Cytotoxicity against human lung carcinoma A549 cell line,9606.0,80682,,Homo sapiens,1,13330,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620387,,5556,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,9606.0,25,,Homo sapiens,9,17517,,,D,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621404,,5557,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",9606.0,25,,Homo sapiens,9,17517,,,D,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621405,,5558,"In vitro growth inhibition of A549, lung carcinoma",9606.0,80682,,Homo sapiens,1,14425,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621406,,5559,"In vitro growth inhibition of A549, lung carcinoma.",9606.0,80682,,Homo sapiens,1,14425,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621407,,5560,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,9606.0,80682,,Homo sapiens,1,5228,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621408,,5561,Cytotoxic activity against human lung cancer A549 cell line was determined,9606.0,80682,,Homo sapiens,1,5351,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL885345,,5562,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,9606.0,80682,,Homo sapiens,1,12198,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621409,,5563,Cytotoxicity concentration against human lung carcinoma A-549 cell line,9606.0,80682,,Homo sapiens,1,13891,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL876034,,5564,Cytotoxicity in A549 (human carcinoma) cell line.,9606.0,80682,,Homo sapiens,1,5677,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621410,,5565,Cytotoxicity on lung carcinoma (A-549) cell line,9606.0,80682,,Homo sapiens,1,13788,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621411,,5566,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,9606.0,80682,,Homo sapiens,1,13384,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621412,,5567,Effective dose of compound against replication of A549 cell line was evaluated,9606.0,80682,,Homo sapiens,1,6726,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621413,,5568,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,9606.0,80682,,Homo sapiens,1,3455,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621414,,5569,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),9606.0,80682,,Homo sapiens,1,5726,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621415,,5570,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,9606.0,80682,,Homo sapiens,1,5726,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621416,,5571,The compound was evaluated for antiproliferative activity against A549 cell line,9606.0,80682,,Homo sapiens,1,3936,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621417,,5572,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,9606.0,80682,,Homo sapiens,1,14991,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621418,,5573,Concentration required for growth inhibition of human lung carcinoma cell line A549,9606.0,80682,,Homo sapiens,1,5243,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621419,,5574,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,9606.0,80682,,Homo sapiens,1,12858,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621420,,5575,Growth inhibition against A549 cell line was evaluated,9606.0,80682,,Homo sapiens,1,6776,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL875823,,5576,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,9606.0,80682,,Homo sapiens,1,16558,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621421,,5577,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,9606.0,80682,,Homo sapiens,1,4583,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621422,,5578,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,9606.0,80682,,Homo sapiens,1,13514,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL884014,,5579,Chemosensitivity against DT-diaphorase rich A549 cell lines,9606.0,80682,,Homo sapiens,1,15166,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621423,,5580,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,9606.0,80682,,Homo sapiens,1,13873,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621424,,5581,In vitro cytotoxicity against human A549 (lung cancer) cell line.,9606.0,80682,,Homo sapiens,1,6447,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621425,,5582,In vitro antitumor activity against A549 (lung) human tumor cell lines.,9606.0,80682,,Homo sapiens,1,2068,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621426,,5583,In vitro cytotoxic activity against human lung carcinoma A549 cell line,9606.0,80682,,Homo sapiens,1,1863,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621427,,5584,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,9606.0,80682,,Homo sapiens,1,13873,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621428,,5585,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,9606.0,80682,,Homo sapiens,1,13873,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621429,,5586,Tested against A549 lung carcinoma in the sulforhodamine B assay.,9606.0,80682,,Homo sapiens,1,13873,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621430,,5587,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),9606.0,80682,,Homo sapiens,1,579,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621431,,5588,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,9606.0,80682,,Homo sapiens,1,579,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621432,,5589,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,9606.0,80682,,Homo sapiens,1,4584,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621433,,5590,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,9606.0,80682,,Homo sapiens,1,5421,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL875824,,5591,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,9606.0,80682,,Homo sapiens,1,5421,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621434,,5592,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,9606.0,80682,,Homo sapiens,1,5421,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621435,,5593,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,9606.0,80682,,Homo sapiens,1,5421,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621436,,5594,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,9606.0,80682,,Homo sapiens,1,14188,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621437,,5595,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,9606.0,80682,,Homo sapiens,1,14188,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621438,,5596,Compound was tested for the growth inhibition of A549 lung tumor cell line,9606.0,80682,,Homo sapiens,1,15354,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621439,,5597,Growth inhibition of human non-small-lung carcinoma (A549) cell line,9606.0,80682,,Homo sapiens,1,14253,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621440,,5598,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,9606.0,80682,,Homo sapiens,1,13873,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621441,,5599,Oral bioavailability in dog (conscious),9615.0,50588,,Canis lupus familiaris,1,3043,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621442,,5600,Compound was evaluated for the oral bioavailability after oral administration in dog.,9615.0,50588,,Canis lupus familiaris,1,3045,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621443,,5601,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,9615.0,50588,,Canis lupus familiaris,1,3022,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621444,,5602,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,4453,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625133,,5603,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,1696,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625134,,5604,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5045,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625135,,5605,Oral bioavailability in dog (fasted),9615.0,50588,,Canis lupus familiaris,1,5356,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625136,,5606,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625137,,5607,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6448,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625138,,5608,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,1475,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625139,,5609,Percent bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,3788,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL872264,,5610,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,9615.0,50588,,Canis lupus familiaris,1,3639,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625140,,5611,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,13397,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624436,,5612,The compound was evaluated for bioavailability in dogs; 34-44,9615.0,50588,,Canis lupus familiaris,1,2137,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624437,,5613,Bioavailability in dog (dose 4 mg/kg p.o.),9615.0,50588,,Canis lupus familiaris,1,2959,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL872261,,5614,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6448,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624438,,5615,8 hour trough Blood level in dog was measured after administration of compound,9615.0,50588,,Canis lupus familiaris,1,6084,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL624439,,5616,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,9615.0,50588,,Canis lupus familiaris,1,3639,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624440,,5617,C24 after oral administration at 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6316,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624441,,5618,Clearance after oral and iv dosing in dogs,9615.0,50588,,Canis lupus familiaris,1,5238,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL624442,,5619,Clearance of the drug was measured in the plasma of dog,9615.0,50588,,Canis lupus familiaris,1,17796,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624443,,5620,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,9615.0,50588,,Canis lupus familiaris,1,2652,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624444,,5621,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5654,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624445,,5622,Clearance of compound was determined in dogs,9615.0,50588,,Canis lupus familiaris,1,6621,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624446,,5623,Clearance on i.v. administration of 2 mg/kg was measured in dog,9615.0,50588,,Canis lupus familiaris,1,6505,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624447,,5624,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,9615.0,50588,,Canis lupus familiaris,1,5802,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624448,,5625,Plasma clearance in dog was determined,9615.0,50588,,Canis lupus familiaris,1,17267,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624449,,5626,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,9615.0,50588,,Canis lupus familiaris,1,4521,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624450,,5627,Plasma clearance in dog after administration of 0.25 mg/kg iv,9615.0,50588,,Canis lupus familiaris,1,6535,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875942,,5628,Plasma clearance in dog after administration of 1 mg/kg iv,9615.0,50588,,Canis lupus familiaris,1,6535,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624451,,5629,Plasma clearance in dogs,9615.0,50588,,Canis lupus familiaris,1,6535,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624452,,5630,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5542,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624453,,5631,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,9615.0,50588,,Canis lupus familiaris,1,5199,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624454,,5632,Plasma clearance after 15 mg/kg iv dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624455,,5633,Plasma clearance after 30 mg/kg po dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624456,,5634,Plasma administration to dogs,9615.0,50588,,Canis lupus familiaris,1,16367,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624457,,5635,Plasma clearance was determined,9615.0,50588,,Canis lupus familiaris,1,5505,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624458,,5636,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,9615.0,50588,,Canis lupus familiaris,1,6215,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624459,,5637,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,9615.0,50588,,Canis lupus familiaris,1,1466,,,N,A
BAO_0000251,Intermediate,In vitro,,1,,Liver,,2107.0,CHEMBL624460,,5638,Intrinsic clearance in human liver microsomes,9606.0,102164,Microsomes,Homo sapiens,2,5007,,,S,A
BAO_0000251,Intermediate,In vitro,,1,,Liver,,2107.0,CHEMBL624461,,5639,Intrinsic clearance in human liver microsomes,9606.0,102164,Microsomes,Homo sapiens,2,5007,,,S,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875943,,5640,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624462,,5641,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624463,,5642,Clearance in dog (dose 1 mg/kg i.v.),9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624464,,5643,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,9615.0,50588,,Canis lupus familiaris,1,6221,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624465,,5644,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5007,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624466,,5645,Plasma clearance after peroral administration at 10 mpk in dog,9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624467,,5646,Plasma clearance after peroral administration at 5 mpk in dog,9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624468,,5647,Plasma clearance after peroral administration at 5 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624469,,5648,Plasma clearance was measured in dog,9615.0,50588,,Canis lupus familiaris,1,15660,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624470,,5649,Plasma clearance was measured in dog,9615.0,50588,,Canis lupus familiaris,1,15660,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624471,,5650,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,9615.0,50588,,Canis lupus familiaris,1,5983,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624472,,5651,Total clearance was determined after 0.1 mg/kg iv administration in dog,9615.0,50588,,Canis lupus familiaris,1,5600,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622775,,5652,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622776,,5653,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,6039,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622777,,5654,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,6039,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622778,,5655,Clearance after peroral administration of 0.2 mg/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,6039,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622779,,5656,Clearance by intravenous administration of 1.2 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4368,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622780,,5657,Clearance by iv administration in dogs at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,4305,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL622781,,5658,Clearance value was evaluated in dog plasma,9615.0,50588,,Canis lupus familiaris,1,1918,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622782,,5659,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6005,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL622783,,5660,Compound was tested for plasma clearance in dog,9615.0,50588,,Canis lupus familiaris,1,4839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622784,,5661,Pharmacokinetic property (Plasma clearance) was measured in dog,9615.0,50588,,Canis lupus familiaris,1,4239,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622785,,5662,Area under curve when injected perorally in mice at a dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17729,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622786,,5663,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17728,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622787,,5664,Area under curve value in mouse at a dose of 10 mg/kg,10090.0,50594,,Mus musculus,1,5302,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL875949,,5665,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,10090.0,50594,,Mus musculus,1,5506,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622788,,5666,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,10090.0,50594,,Mus musculus,1,5506,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622789,,5667,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622790,,5668,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622791,,5669,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622792,,5670,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622793,,5671,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622794,,5672,Area under curve was determined for the compound at 24 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622795,,5673,Area under curve was determined for the compound at 40 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621803,,5674,Area under curve was determined for the compound at 5 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621804,,5675,Area under the curve for the compound is obtained at dose 25 mg/kg,10090.0,50594,,Mus musculus,1,3132,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621805,,5676,Area under the curve for the compound was obtained when tested in mouse,10090.0,50594,,Mus musculus,1,3132,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621806,,5677,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,10090.0,50594,,Mus musculus,1,17837,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621807,,5678,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,10090.0,50594,,Mus musculus,1,17837,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621808,,5679,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,10090.0,50594,,Mus musculus,1,6062,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621809,,5680,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,10090.0,50594,,Mus musculus,1,4066,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621810,,5681,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL875164,,5682,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,10090.0,50594,,Mus musculus,1,14239,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621811,,5683,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,10090.0,50594,,Mus musculus,1,14239,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621812,,5684,"Compound was evaluated for the pharmacokinetic parameter, area under curve",10090.0,50594,,Mus musculus,1,4890,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621813,,5685,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),10090.0,50594,,Mus musculus,1,429,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621814,,5686,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),10090.0,50594,,Mus musculus,1,429,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621815,,5687,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621816,,5688,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621817,,5689,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621818,,5690,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,10090.0,50594,,Mus musculus,1,6091,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621819,,5691,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,10090.0,50594,,Mus musculus,1,6091,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621820,,5692,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,10090.0,50594,,Mus musculus,1,6091,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621821,,5693,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,10090.0,50594,,Mus musculus,1,6091,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621822,,5694,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,10090.0,50594,,Mus musculus,1,6178,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619474,,5695,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,10090.0,50594,,Mus musculus,1,6178,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619475,,5696,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",10090.0,50594,,Mus musculus,1,6619,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619476,,5697,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",10090.0,50594,,Mus musculus,1,6619,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619477,,5698,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",10090.0,50594,,Mus musculus,1,3760,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619478,,5699,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",10090.0,50594,,Mus musculus,1,3760,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619479,,5700,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",10090.0,50594,,Mus musculus,1,3760,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619480,,5701,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",10090.0,50594,,Mus musculus,1,3760,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619481,,5702,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,10090.0,50594,,Mus musculus,1,3192,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619482,,5703,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,10090.0,50594,,Mus musculus,1,3192,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619483,,5704,Area under the curve was evaluated in mice after intravenous administration,10090.0,50594,,Mus musculus,1,2675,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619484,,5705,Area under the curve was evaluated in mice after oral administration,10090.0,50594,,Mus musculus,1,2675,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL619485,,5706,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL619486,,5707,AUC total value at a dose of 10 mg/kg peroral administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619487,,5708,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619488,,5709,AUMC after intraperitoneal administration of 100 mg/kg in mice,10090.0,50594,,Mus musculus,1,17734,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL620106,,5710,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000219,Intermediate,,392.0,1,,,9L,,CHEMBL620107,,5711,The compound was tested in vitro for anticancer activity against 9L cells,,80653,,,1,15345,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620283,,5712,Anti proliferation activity determined; Weak effect,10116.0,22226,,Rattus norvegicus,0,2181,,,U,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL875176,,5713,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,10116.0,22226,,Rattus norvegicus,0,2181,,,U,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL620284,,5714,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,10116.0,22226,,Rattus norvegicus,0,2181,,,U,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL623515,,5715,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,10116.0,22226,,Rattus norvegicus,0,2181,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623516,,5716,The cytotoxic activity was in vitro tested by 9PS assay method,10090.0,22226,,Mus musculus,0,10486,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623517,,5717,The cytotoxic activity was in vitro tested by 9PS assay method.,10090.0,22226,,Mus musculus,0,10486,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL857878,,5718,Partition coefficient (logD6.5),,22224,,,0,15508,,,U,A
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL623518,,5719,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,9606.0,81034,,Homo sapiens,1,5242,,,N,F
BAO_0000219,Intermediate,,455.0,1,,,A-375,,CHEMBL624195,,5720,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),9606.0,80018,,Homo sapiens,1,16167,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL624196,,5721,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,9606.0,80852,,Homo sapiens,1,4782,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL624197,,5722,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9606.0,9,,Homo sapiens,9,16093,,,D,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL624198,,5723,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,9606.0,80021,,Homo sapiens,1,2596,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL621287,,5724,in vitro cytotoxicity against A 498 cancer cell line,9606.0,80021,,Homo sapiens,1,2596,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL621288,,5725,In vitro cytotoxic activity against renal (A 498) cancer cell line.,9606.0,80021,,Homo sapiens,1,3239,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL876496,,5726,Cytotoxic activity against A 498 renal cancer cell lines.,9606.0,80021,,Homo sapiens,1,1847,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL621289,,5727,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,9606.0,80021,,Homo sapiens,1,10553,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621290,,5728,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,1280.0,22226,,Staphylococcus aureus,0,16219,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621291,,5729,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,1280.0,22226,,Staphylococcus aureus,0,16219,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621292,,5730,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,1280.0,22226,,Staphylococcus aureus,0,16219,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621293,,5731,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,1280.0,22226,,Staphylococcus aureus,0,16219,,,U,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621294,,5732,Inhibitory concentration required against A 549 lung cancer cell line,9606.0,80682,,Homo sapiens,1,4782,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621295,,5733,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,9606.0,80682,,Homo sapiens,1,11805,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL884007,,5734,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,9606.0,80682,,Homo sapiens,1,11805,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621296,,5735,In vitro cytotoxicity against lung cancer A 549 cell lines,9606.0,80682,,Homo sapiens,1,2007,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621297,,5736,Compound was tested for its cytotoxicity against A 549 cell line,9606.0,80682,,Homo sapiens,1,4594,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL839828,,5737,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",9606.0,80682,,Homo sapiens,1,6018,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620397,,5738,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",9606.0,80682,,Homo sapiens,1,6018,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620398,,5739,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,9606.0,80682,,Homo sapiens,1,3599,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620399,,5740,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,9606.0,80682,,Homo sapiens,1,2551,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620400,,5741,In vitro inhibition of A549 (human lung cancer) cell growth.,9606.0,80682,,Homo sapiens,1,16132,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620401,,5742,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,9606.0,80682,,Homo sapiens,1,16132,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620402,,5743,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,9606.0,80682,,Homo sapiens,1,2551,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620403,,5744,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),9606.0,80682,,Homo sapiens,1,2551,,,N,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL620404,,5745,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,22226,,,0,11913,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620405,,5746,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,104694,,,4,12621,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620406,,5747,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,104694,,,4,12621,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620407,,5748,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,104694,,,4,12621,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620408,,5749,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,104694,,,4,12621,,,H,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620409,,5750,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,104694,,,4,12621,,,H,F
BAO_0000219,Expert,,624.0,1,,,A498,,CHEMBL620410,,5751,Inhibition of A-498 human Renal cell proliferation,9606.0,80021,,Homo sapiens,1,3600,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620411,,5752,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",10116.0,22226,,Rattus norvegicus,0,1796,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620412,,5753,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",10116.0,22226,,Rattus norvegicus,0,1796,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL876596,,5754,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",10116.0,22226,,Rattus norvegicus,0,1796,,,U,F
BAO_0000219,Expert,,622.0,1,,,A 172,,CHEMBL620413,,5755,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,9606.0,80012,,Homo sapiens,1,16464,,,N,F
BAO_0000219,Intermediate,,622.0,1,,,A 172,,CHEMBL620414,,5756,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,9606.0,80012,,Homo sapiens,1,16464,,,N,F
BAO_0000219,Intermediate,,622.0,1,,,A 172,,CHEMBL620415,,5757,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,9606.0,80012,,Homo sapiens,1,16464,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620416,,5758,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,9606.0,80682,,Homo sapiens,1,13617,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620417,,5759,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,9606.0,80682,,Homo sapiens,1,4584,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620418,,5760,Cytotoxic activity evaluated against A549 tumor cells,9606.0,80682,,Homo sapiens,1,13799,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620419,,5761,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,9606.0,80682,,Homo sapiens,1,16726,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620420,,5762,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,9606.0,80682,,Homo sapiens,1,16109,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620421,,5763,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,9606.0,80682,,Homo sapiens,1,16109,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620422,,5764,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,9606.0,80682,,Homo sapiens,1,15474,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620423,,5765,Cytotoxicity of compound against A549 cell line,9606.0,80682,,Homo sapiens,1,6851,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620424,,5766,Cytotoxicity against human lung cell carcinoma A549 cell line,9606.0,80682,,Homo sapiens,1,17534,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620425,,5767,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,9606.0,80682,,Homo sapiens,1,2621,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620426,,5768,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,9606.0,80682,,Homo sapiens,1,830,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620427,,5769,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,9606.0,80682,,Homo sapiens,1,14255,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620428,,5770,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,9606.0,80682,,Homo sapiens,1,14255,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620429,,5771,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,9606.0,80682,,Homo sapiens,1,1590,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620430,,5772,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,9606.0,80682,,Homo sapiens,1,6146,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL839887,,5773,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,9606.0,80682,,Homo sapiens,1,17427,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620431,,5774,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,9606.0,80682,,Homo sapiens,1,5280,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL884010,,5775,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,9606.0,80682,,Homo sapiens,1,16786,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620538,,5776,In vitro cytotoxicity against A549 (human lung cancer),9606.0,80682,,Homo sapiens,1,5895,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620539,,5777,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,9606.0,80682,,Homo sapiens,1,14297,,,N,F
BAO_0000218,Intermediate,,646.0,1,,,A549,,CHEMBL623373,,5778,In vivo antiproliferative activity against A549 cell line,9606.0,80682,,Homo sapiens,1,17824,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623374,,5779,Inhibition of non-small-cell lung adenocarcinoma (A549),9606.0,80682,,Homo sapiens,1,14368,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623375,,5780,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,9606.0,80682,,Homo sapiens,1,14368,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623376,,5781,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,9606.0,80682,,Homo sapiens,1,14254,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623377,,5782,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),9606.0,80682,,Homo sapiens,1,15897,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623378,,5783,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,9606.0,80682,,Homo sapiens,1,13866,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623379,,5784,Inhibitory activity of compound against human A549 lung carcinoma cell line.,9606.0,80682,,Homo sapiens,1,13370,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623380,,5785,Inhibitory activity against A549 lung cancer cell line,9606.0,80682,,Homo sapiens,1,4862,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623381,,5786,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,9606.0,80682,,Homo sapiens,1,4862,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623382,,5787,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,9606.0,80682,,Homo sapiens,1,4862,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623383,,5788,Inhibitory concentration against A549 (lung cancer) cell line,9606.0,80682,,Homo sapiens,1,15970,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL623384,,5789,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,9606.0,80682,,Homo sapiens,1,17713,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623385,,5790,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,9606.0,80682,,Homo sapiens,1,4833,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL623386,,5791,Activity against A549 cancer cell line.,9606.0,80682,,Homo sapiens,1,13736,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL884105,,5792,The compound was evaluated for cytotoxicity against A549 cell line,9606.0,80682,,Homo sapiens,1,4312,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623387,,5793,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,9606.0,80682,,Homo sapiens,1,5421,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621568,,5794,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,9606.0,80682,,Homo sapiens,1,5421,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621569,,5795,Growth inhibitory activity was measured for human A549 tumor cell line.,9606.0,80682,,Homo sapiens,1,14717,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621570,,5796,Inhibitory activity against A549 lung cancer cell line,9606.0,80682,,Homo sapiens,1,4634,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621571,,5797,Inhibitory activity against A549 cell line; inactive,9606.0,80682,,Homo sapiens,1,1149,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621572,,5798,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,9606.0,80682,,Homo sapiens,1,5421,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621573,,5799,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,9606.0,80682,,Homo sapiens,1,5421,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621574,,5800,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,9606.0,80682,,Homo sapiens,1,5421,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621575,,5801,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),9606.0,80682,,Homo sapiens,1,3320,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621576,,5802,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),9606.0,80682,,Homo sapiens,1,3320,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621577,,5803,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),9606.0,80682,,Homo sapiens,1,3320,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621578,,5804,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),9606.0,80682,,Homo sapiens,1,3320,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621579,,5805,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),9606.0,80682,,Homo sapiens,1,3320,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621580,,5806,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,9606.0,80682,,Homo sapiens,1,5726,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621581,,5807,Plasma clearance (in vivo) in mongrel dogs was determined,9615.0,50588,,Canis lupus familiaris,1,17800,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621582,,5808,Plasma clearance was measured in dog,9615.0,50588,,Canis lupus familiaris,1,5985,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621583,,5809,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5530,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621584,,5810,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5530,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL621585,,5811,Tested for plasma clearance in dog,9615.0,50588,,Canis lupus familiaris,1,4839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621586,,5812,The compound was tested for clearance in dog plasma.,9615.0,50588,,Canis lupus familiaris,1,3639,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875835,,5813,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",9615.0,50588,,Canis lupus familiaris,1,4838,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621587,,5814,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,9615.0,50588,,Canis lupus familiaris,1,4137,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL621588,,5815,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5017,,,N,A
BAO_0000218,Intermediate,In vitro,,1,,Liver,,2107.0,CHEMBL621589,,5816,In vitro clearance in dog liver microsomes,9615.0,50588,Microsomes,Canis lupus familiaris,1,17538,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621590,,5817,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,9615.0,50588,,Canis lupus familiaris,1,6161,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621591,,5818,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,9615.0,50588,,Canis lupus familiaris,1,6161,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621592,,5819,Plasma clearance in dog,9615.0,50588,,Canis lupus familiaris,1,1696,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621593,,5820,Clearance rate in dog,9615.0,50588,,Canis lupus familiaris,1,6762,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL621594,,5821,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,9615.0,50588,,Canis lupus familiaris,1,5932,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621595,,5822,Clearance in dogs,9615.0,50588,,Canis lupus familiaris,1,6305,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621596,,5823,Plasma clearance in dogs,9615.0,50588,,Canis lupus familiaris,1,4942,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621597,,5824,Plasma clearance was determined,9615.0,50588,,Canis lupus familiaris,1,4219,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621598,,5825,Lower clearance in dog (i.v.) at 0.5 mpk,9615.0,50588,,Canis lupus familiaris,1,17853,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621599,,5826,Plasma clearance in Beagle dogs,9615.0,50588,,Canis lupus familiaris,1,4514,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875836,,5827,Plasma clearance (Clp) in dog,9615.0,50588,,Canis lupus familiaris,1,6448,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621600,,5828,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621601,,5829,Plasma clearance (pharmacokinetic parameter) in dog was determined,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618474,,5830,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6062,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618475,,5831,Plasma clearance of compound was determined in dog,9615.0,50588,,Canis lupus familiaris,1,6821,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624524,,5832,Plasma clearance after intravenous administration of 1 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4709,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624525,,5833,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,9615.0,50588,,Canis lupus familiaris,1,4521,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624526,,5834,Plasma clearance in dog was determined,9615.0,50588,,Canis lupus familiaris,1,5374,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624527,,5835,Plasma clearance was calculated in dog,9615.0,50588,,Canis lupus familiaris,1,6057,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624528,,5836,Plasma clearance at the dose of 2 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4727,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624529,,5837,Plasma clearance in dog,9615.0,50588,,Canis lupus familiaris,1,5145,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624530,,5838,Plasma clearance in dog,9615.0,50588,,Canis lupus familiaris,1,17657,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624531,,5839,Plasma clearance in dog; Unable to calculate,9615.0,50588,,Canis lupus familiaris,1,17657,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624532,,5840,Plasma clearance in rhesus monkey,9615.0,50588,,Canis lupus familiaris,1,5145,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624533,,5841,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),9615.0,50588,,Canis lupus familiaris,1,6642,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624534,,5842,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),9615.0,50588,,Canis lupus familiaris,1,6641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624535,,5843,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),9615.0,50588,,Canis lupus familiaris,1,6642,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624536,,5844,Plasma clearance was evaluated in dog,9615.0,50588,,Canis lupus familiaris,1,5472,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624537,,5845,Plasma clearance was evaluated in dog; Not tested,9615.0,50588,,Canis lupus familiaris,1,5472,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624538,,5846,Plasma clearance was evaluated in rhesus,9615.0,50588,,Canis lupus familiaris,1,5472,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624539,,5847,Plasma clearance was evaluated in rhesus; Not tested,9615.0,50588,,Canis lupus familiaris,1,5472,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624540,,5848,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,9615.0,50588,,Canis lupus familiaris,1,4257,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624541,,5849,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,9615.0,50588,,Canis lupus familiaris,1,6679,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624542,,5850,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,9615.0,50588,,Canis lupus familiaris,1,5546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624543,,5851,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,9615.0,50588,,Canis lupus familiaris,1,6348,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624544,,5852,Clearance value at a dose of 0.2 mg/kg i.v.,9615.0,50588,,Canis lupus familiaris,1,5474,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL624545,,5853,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6316,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624546,,5854,Cmax after oral dose of compound at 3 mg/kg in dogs,9615.0,50588,,Canis lupus familiaris,1,17594,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875957,,5855,Cmax after single intravenous bolus of 1 mg/kg in dogs,9615.0,50588,,Canis lupus familiaris,1,17594,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624547,,5856,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,9615.0,50588,,Canis lupus familiaris,1,5802,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624548,,5857,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,9615.0,50588,,Canis lupus familiaris,1,6535,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624549,,5858,Cmax in dog after administration of 1 mg/kg iv,9615.0,50588,,Canis lupus familiaris,1,6535,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL624550,,5859,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,9615.0,50588,,Canis lupus familiaris,1,1466,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621613,,5860,Cmax on p.o. administration of 10 mg/kg was measured in dog,9615.0,50588,,Canis lupus familiaris,1,6505,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621614,,5861,Cmax was determine after peroral administration at 10 mpk in dog,9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623431,,5862,Cmax was determine after peroral administration at 5 mpk in dog,9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623432,,5863,Cmax was determine after peroral administration at 5 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623433,,5864,Cmax after 0.3 mg/kg po administration in dog,9615.0,50588,,Canis lupus familiaris,1,5600,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623434,,5865,Cmax after peroral administration in dogs at 2.4 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623435,,5866,Cmax in dog after oral administration at 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6123,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623436,,5867,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,9615.0,50588,,Canis lupus familiaris,1,6123,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875958,,5868,Cmax upon oral administration in male Beagle dog at 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6757,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623437,,5869,Cmax value after 15 mg/kg iv dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL623438,,5870,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL623439,,5871,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL623440,,5872,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL623441,,5873,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL623442,,5874,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623469,,5875,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623470,,5876,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623471,,5877,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL623472,,5878,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL623473,,5879,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL623474,,5880,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623475,,5881,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623476,,5882,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623477,,5883,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Intestine,,160.0,CHEMBL621896,,5884,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Intestine,,160.0,CHEMBL621897,,5885,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Intestine,,160.0,CHEMBL621898,,5886,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL621899,,5887,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL621900,,5888,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL621901,,5889,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL621902,,5890,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL621903,,5891,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL622587,,5892,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL620285,,5893,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL875285,,5894,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL620286,,5895,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620287,,5896,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620288,,5897,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620289,,5898,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Intestine,,160.0,CHEMBL620290,,5899,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Intestine,,160.0,CHEMBL620291,,5900,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Intestine,,160.0,CHEMBL620292,,5901,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL620293,,5902,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL620294,,5903,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL618614,,5904,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL618615,,5905,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL618616,,5906,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000219,Expert,,622.0,1,,,A 172,,CHEMBL618617,,5907,Cytotoxicity against A-172 human tumor cell lines,9606.0,80012,,Homo sapiens,1,2036,,,N,F
BAO_0000219,Intermediate,,622.0,1,,,A 172,,CHEMBL618618,,5908,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,9606.0,80012,,Homo sapiens,1,2357,,,N,F
BAO_0000219,Intermediate,,623.0,1,,,A204,,CHEMBL618619,,5909,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,9606.0,80014,,Homo sapiens,1,1457,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618620,,5910,Tested for antiproliferative activity against A-2780 tumoral cell line,9606.0,81034,,Homo sapiens,1,4379,,,N,F
BAO_0000219,Intermediate,,455.0,1,,,A-375,,CHEMBL618621,,5911,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,9606.0,80018,,Homo sapiens,1,1093,,,N,F
BAO_0000219,Intermediate,,455.0,1,,,A-375,,CHEMBL618622,,5912,Tested in vitro against A-375 cell line human melanoma,9606.0,80018,,Homo sapiens,1,12152,,,N,F
BAO_0000219,Expert,,797.0,1,,,A-427,,CHEMBL618623,,5913,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,9606.0,80019,,Homo sapiens,1,16464,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL618624,,5914,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,9606.0,80019,,Homo sapiens,1,16464,,,N,F
BAO_0000219,Expert,,797.0,1,,,A-427,,CHEMBL618625,,5915,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,9606.0,80019,,Homo sapiens,1,16582,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL618626,,5916,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,9606.0,80019,,Homo sapiens,1,16464,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL618627,,5917,Antitumor activity on A-427 lung carcinoma cell lines,9606.0,80019,,Homo sapiens,1,10413,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL618628,,5918,Cytotoxic activity against human A-427 lung tumor cell line,9606.0,80019,,Homo sapiens,1,6418,,,N,F
BAO_0000219,Expert,,797.0,1,,,A-427,,CHEMBL618629,,5919,In vitro antitumor effects against human A-427 cell lines.,9606.0,80019,,Homo sapiens,1,17134,,,N,F
BAO_0000219,Expert,,797.0,1,,,A-427,,CHEMBL618630,,5920,In vitro inhibition of A-427 (human lung cancer) cell growth.,9606.0,80019,,Homo sapiens,1,16132,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL618631,,5921,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,9606.0,80019,,Homo sapiens,1,16132,,,N,F
BAO_0000219,Intermediate,,797.0,1,,,A-427,,CHEMBL618632,,5922,Cytotoxic activity of compound against A-427 lung human tumor cell line,9606.0,80019,,Homo sapiens,1,16780,,,N,F
BAO_0000219,Expert,,500.0,1,,,A-431,,CHEMBL618633,,5923,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,9606.0,80852,,Homo sapiens,1,4085,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619315,,5924,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,9606.0,80021,,Homo sapiens,1,1276,,,N,F
BAO_0000219,Expert,,624.0,1,,,A498,,CHEMBL619316,,5925,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,9606.0,80021,,Homo sapiens,1,3498,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619317,,5926,Cytotoxicity against human kidney carcinoma A-498cell lines,9606.0,80021,,Homo sapiens,1,1169,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619318,,5927,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,9606.0,80021,,Homo sapiens,1,4450,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619319,,5928,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,9606.0,80021,,Homo sapiens,1,3311,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619739,,5929,Antitumor cytotoxic activity against A-498 cell line was determined,9606.0,80021,,Homo sapiens,1,4461,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619740,,5930,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,9606.0,80021,,Homo sapiens,1,3311,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL883158,,5931,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,9606.0,80021,,Homo sapiens,1,3311,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL884012,,5932,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,9606.0,80021,,Homo sapiens,1,1457,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619741,,5933,In vitro inhibitory activity against A-498 ovarian cancer cell lines,9606.0,80021,,Homo sapiens,1,3664,,,N,F
BAO_0000219,Intermediate,,624.0,1,,,A498,,CHEMBL619742,,5934,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",9606.0,80021,,Homo sapiens,1,15895,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL876610,,5935,Inhibition of growth lung non-small cell carcinoma A-549 cell line,9606.0,80682,,Homo sapiens,1,11843,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619743,,5936,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,9606.0,80682,,Homo sapiens,1,11843,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619744,,5937,In vitro antiproliferative activity against human A-549 NSCL cell line,9606.0,80682,,Homo sapiens,1,17705,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619745,,5938,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,9606.0,80682,,Homo sapiens,1,17705,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619746,,5939,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,9606.0,80682,,Homo sapiens,1,4369,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619747,,5940,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,9606.0,80682,,Homo sapiens,1,4369,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619748,,5941,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,9606.0,80682,,Homo sapiens,1,4369,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619749,,5942,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,9606.0,80682,,Homo sapiens,1,4369,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619750,,5943,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,9606.0,80682,,Homo sapiens,1,4369,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624014,,5944,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,9606.0,80682,,Homo sapiens,1,4369,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624015,,5945,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,9606.0,80682,,Homo sapiens,1,4369,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL885344,,5946,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,9606.0,80682,,Homo sapiens,1,4787,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623224,,5947,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,9606.0,80682,,Homo sapiens,1,4787,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL623225,,5948,Cytotoxic activity against A-549 cell line,9606.0,80682,,Homo sapiens,1,6513,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622698,,5949,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,9606.0,80682,,Homo sapiens,1,6690,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622699,,5950,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,9606.0,80682,,Homo sapiens,1,6690,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL622700,,5951,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",9606.0,80682,,Homo sapiens,1,12263,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622701,,5952,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),9606.0,80682,,Homo sapiens,1,1054,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622702,,5953,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),9606.0,80682,,Homo sapiens,1,1359,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622703,,5954,Cytotoxic activity against human lung carcinoma (A-549) cell line,9606.0,80682,,Homo sapiens,1,3547,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL622704,,5955,Cytotoxic activity towards A-549 cells,9606.0,80682,,Homo sapiens,1,5771,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622705,,5956,"In vitro percent inhibition of A549, lung carcinoma.",9606.0,80682,,Homo sapiens,1,14425,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622706,,5957,"In vitro percent inhibition of A549, lung carcinoma",9606.0,80682,,Homo sapiens,1,14425,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622707,,5958,"In vitro percent inhibition of A549, lung carcinoma.",9606.0,80682,,Homo sapiens,1,14425,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622708,,5959,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",9606.0,80682,,Homo sapiens,1,14425,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622709,,5960,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,9606.0,80682,,Homo sapiens,1,5280,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622710,,5961,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,9606.0,80682,,Homo sapiens,1,15176,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622711,,5962,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,9606.0,80682,,Homo sapiens,1,15300,,,N,F
BAO_0000218,Intermediate,,646.0,1,,,A549,,CHEMBL622712,,5963,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",9606.0,80682,,Homo sapiens,1,17824,,,N,F
BAO_0000218,Intermediate,,646.0,1,,,A549,,CHEMBL622713,,5964,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",9606.0,80682,,Homo sapiens,1,17824,,,N,F
BAO_0000218,Intermediate,,646.0,1,,,A549,,CHEMBL622714,,5965,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",9606.0,80682,,Homo sapiens,1,17824,,,N,F
BAO_0000218,Intermediate,,646.0,1,,,A549,,CHEMBL622715,,5966,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",9606.0,80682,,Homo sapiens,1,17824,,,N,F
BAO_0000218,Intermediate,,646.0,1,,,A549,,CHEMBL622716,,5967,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",9606.0,80682,,Homo sapiens,1,17824,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622717,,5968,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",9606.0,80682,,Homo sapiens,1,17824,,,N,F
BAO_0000218,Intermediate,,646.0,1,,,A549,,CHEMBL622718,,5969,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),9606.0,80682,,Homo sapiens,1,17528,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL622719,,5970,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,9606.0,80682,,Homo sapiens,1,6870,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622720,,5971,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,9606.0,80682,,Homo sapiens,1,6870,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622721,,5972,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,9606.0,80682,,Homo sapiens,1,6870,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622722,,5973,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,9606.0,80682,,Homo sapiens,1,6870,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL876030,,5974,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,9606.0,80682,,Homo sapiens,1,16726,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620206,,5975,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",9606.0,80682,,Homo sapiens,1,6170,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620207,,5976,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,9606.0,80682,,Homo sapiens,1,6583,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620208,,5977,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,9606.0,80682,,Homo sapiens,1,6583,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620209,,5978,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,9606.0,80682,,Homo sapiens,1,6583,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620210,,5979,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,9606.0,80682,,Homo sapiens,1,6583,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621639,,5980,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,9606.0,80682,,Homo sapiens,1,6583,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621640,,5981,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,9606.0,80682,,Homo sapiens,1,17321,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621641,,5982,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,9606.0,80682,,Homo sapiens,1,17528,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL621642,,5983,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,9606.0,80682,,Homo sapiens,1,12888,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621643,,5984,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,9606.0,80682,,Homo sapiens,1,4312,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621644,,5985,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,9606.0,80682,,Homo sapiens,1,4312,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621645,,5986,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,9606.0,80682,,Homo sapiens,1,4312,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621646,,5987,In vitro antiproliferative activity against A549 cell line,10090.0,80682,,Mus musculus,1,17737,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621647,,5988,Synergism with indomethacin in A549 cells,,80682,,,1,6630,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621648,,5989,Synergism with tolmetin in A549 cells,,80682,,,1,6630,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621649,,5990,Synergism with sulindac in A549 cells,,80682,,,1,6630,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621650,,5991,Antagonism of indomethacin in A549 cells,,80682,,,1,6630,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621651,,5992,Antagonism of sulindac in A549 cells,,80682,,,1,6630,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621652,,5993,Antagonism of tolmetin in A549 cells,,80682,,,1,6630,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621653,,5994,Synergism with indomethacin in A549 cells,,80682,,,1,6630,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621654,,5995,Synergism with sulindac in A549 cells,,80682,,,1,6630,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL621655,,5996,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,80682,,,1,6630,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621656,,5997,Cmax value after 30 mg/kg po dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621657,,5998,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5944,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621658,,5999,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,9615.0,50588,,Canis lupus familiaris,1,5944,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621659,,6000,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5944,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621660,,6001,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,9615.0,50588,,Canis lupus familiaris,1,5944,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621661,,6002,Cmax value after administration of 4 mg/Kg oral dose in dog,9615.0,50588,,Canis lupus familiaris,1,2959,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621662,,6003,Cmax value in dog,9615.0,50588,,Canis lupus familiaris,1,6241,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621663,,6004,Cmax value in dogs after oral administration at 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6241,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621664,,6005,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,9615.0,50588,,Canis lupus familiaris,1,2652,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL621665,,6006,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,9615.0,50588,,Canis lupus familiaris,1,1806,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL621666,,6007,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,9615.0,50588,,Canis lupus familiaris,1,1806,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621667,,6008,Concentration maxima after oral dosing in dogs,9615.0,50588,,Canis lupus familiaris,1,1021,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876738,,6009,Concentration maxima after oral dosing in dogs; not available,9615.0,50588,,Canis lupus familiaris,1,1021,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621668,,6010,Concentration maxima after oral dosing in dogs; not available,9615.0,50588,,Canis lupus familiaris,1,1021,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621669,,6011,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,9615.0,50588,,Canis lupus familiaris,1,5444,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621670,,6012,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,9615.0,50588,,Canis lupus familiaris,1,5444,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621671,,6013,In vivo maximal concentration was calculated at 1 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,5444,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622360,,6014,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,9615.0,50588,,Canis lupus familiaris,1,5444,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622361,,6015,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,9615.0,50588,,Canis lupus familiaris,1,5444,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL622362,,6016,Cmax in dog plasma after oral dose (1 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5130,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL622363,,6017,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3249,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL622364,,6018,Maximal plasma concentration at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5473,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL622365,,6019,Maximal plasma concentration at a dose of 1 mg/kg (oral),9615.0,50588,,Canis lupus familiaris,1,5474,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL622533,,6020,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,9615.0,50588,,Canis lupus familiaris,1,4657,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622534,,6021,Maximum concentration of compound in dog was evaluated.,9615.0,50588,,Canis lupus familiaris,1,3031,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622535,,6022,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,4527,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876739,,6023,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,9615.0,50588,,Canis lupus familiaris,1,4186,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622536,,6024,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5007,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL622537,,6025,Maximum concentration obtained in dog plasma was determined,9615.0,50588,,Canis lupus familiaris,1,3132,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622538,,6026,Maximum concentration was determined,9615.0,50588,,Canis lupus familiaris,1,5006,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL627867,,6027,Maximum concentration at the dose of 2 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4727,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL627868,,6028,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,9615.0,50588,,Canis lupus familiaris,1,1916,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627869,,6029,Maximum concentration was evaluated in dog plasma,9615.0,50588,,Canis lupus familiaris,1,1918,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL627870,,6030,Maximum concentration was evaluated after 75 min after administration in dog,9615.0,50588,,Canis lupus familiaris,1,3045,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627871,,6031,Maximum plasma concentration determined in dog after oral administration of 17b,9615.0,50588,,Canis lupus familiaris,1,9579,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627872,,6032,Maximum plasma concentration determined in dog after oral administration of 2b,9615.0,50588,,Canis lupus familiaris,1,9579,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627873,,6033,Maximum plasma concentration in dog,9615.0,50588,,Canis lupus familiaris,1,933,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627874,,6034,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,17839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627875,,6035,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,9615.0,50588,,Canis lupus familiaris,1,17839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627876,,6036,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,9615.0,50588,,Canis lupus familiaris,1,17839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627877,,6037,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,17839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627878,,6038,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,9615.0,50588,,Canis lupus familiaris,1,6348,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627879,,6039,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,16367,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL875355,,6040,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,9615.0,50588,,Canis lupus familiaris,1,1337,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627880,,6041,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,9615.0,50588,,Canis lupus familiaris,1,1337,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627881,,6042,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,9615.0,50588,,Canis lupus familiaris,1,5199,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627882,,6043,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17650,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL627883,,6044,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,9615.0,50588,,Canis lupus familiaris,1,6679,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL628526,,6045,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,9615.0,50588,,Canis lupus familiaris,1,5356,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL628527,,6046,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,9615.0,50588,,Canis lupus familiaris,1,5356,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL628528,,6047,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL628529,,6048,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL628530,,6049,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL625243,,6050,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Expert,In vivo,,1,,Plasma,,1969.0,CHEMBL625244,,6051,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3598,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625245,,6052,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4368,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625246,,6053,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6265,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL625247,,6054,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Urine,,1088.0,CHEMBL625248,,6055,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Urine,,1088.0,CHEMBL625249,,6056,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Urine,,1088.0,CHEMBL625250,,6057,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,10090.0,50594,,Mus musculus,1,7767,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625251,,6058,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,10090.0,50594,,Mus musculus,1,17811,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL875356,,6059,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,10090.0,50594,,Mus musculus,1,17811,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625252,,6060,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,Blood,,178.0,CHEMBL625253,,6061,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625254,,6062,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625255,,6063,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625256,,6064,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,Blood,,178.0,CHEMBL625257,,6065,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,Blood,,178.0,CHEMBL625258,,6066,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625259,,6067,Compound was evaluated for washout rate in mice (Radiolabeled compound),10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625260,,6068,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625261,,6069,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625262,,6070,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622639,,6071,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622640,,6072,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,10090.0,50594,,Mus musculus,1,17257,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622812,,6073,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,10090.0,50594,,Mus musculus,1,17257,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622813,,6074,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,10090.0,50594,,Mus musculus,1,17257,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622814,,6075,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,10090.0,50594,,Mus musculus,1,17257,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622815,,6076,Time at maximum activity in mice (Radiolabeled compound),10090.0,50594,,Mus musculus,1,17827,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625342,,6077,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,10090.0,50594,,Mus musculus,1,3760,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625343,,6078,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,10090.0,50594,,Mus musculus,1,3760,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL877591,,6079,Binding towards mouse plasma protein at 10 uM,10090.0,50594,,Mus musculus,1,17409,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625344,,6080,Binding towards mouse plasma protein at 100 uM,10090.0,50594,,Mus musculus,1,17409,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625345,,6081,Bioavailability was evaluated in mice after intravenous administration,10090.0,50594,,Mus musculus,1,2675,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625346,,6082,Bioavailability was evaluated in mice after oral administration,10090.0,50594,,Mus musculus,1,2675,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625347,,6083,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,10090.0,50594,,Mus musculus,1,3132,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625348,,6084,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,10090.0,50594,,Mus musculus,1,3132,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625349,,6085,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625350,,6086,Oral bioavailability in mouse,10090.0,50594,,Mus musculus,1,2862,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL882952,,6087,Oral bioavailability after intravenous administration in mice at 24 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL625351,,6088,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL625352,,6089,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL877592,,6090,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL625353,,6091,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL625354,,6092,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL626019,,6093,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL626020,,6094,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL626021,,6095,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL626022,,6096,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL626192,,6097,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL626193,,6098,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),9606.0,80682,,Homo sapiens,1,1276,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL626194,,6099,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,9606.0,80682,,Homo sapiens,1,3498,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL626195,,6100,Cytotoxicity against human lung carcinoma A-549 cell lines,9606.0,80682,,Homo sapiens,1,1169,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL626196,,6101,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,9606.0,80682,,Homo sapiens,1,4450,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL626197,,6102,In vitro cytotoxicity against human lung carcinoma cell line A-549,9606.0,80682,,Homo sapiens,1,358,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL626198,,6103,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,9606.0,80682,,Homo sapiens,1,358,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL626199,,6104,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,9606.0,80682,,Homo sapiens,1,358,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL626200,,6105,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,9606.0,80682,,Homo sapiens,1,358,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL626201,,6106,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,9606.0,80682,,Homo sapiens,1,358,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL626202,,6107,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,9606.0,80682,,Homo sapiens,1,358,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL626203,,6108,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,9606.0,80682,,Homo sapiens,1,358,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL626204,,6109,In vitro cytotoxicity against A-549 human lung cancer cells,9606.0,80682,,Homo sapiens,1,15167,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624701,,6110,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,9606.0,80682,,Homo sapiens,1,4139,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624702,,6111,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,9606.0,80682,,Homo sapiens,1,833,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL624703,,6112,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,9606.0,80682,,Homo sapiens,1,15718,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624704,,6113,Tested in vitro for cytotoxicity against A-549 lung cancer cells,9606.0,80682,,Homo sapiens,1,12373,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624705,,6114,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,9606.0,80682,,Homo sapiens,1,637,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL624706,,6115,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,9606.0,80682,,Homo sapiens,1,14867,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624707,,6116,Antitumor cytotoxic activity against A-549 cell line was determined,9606.0,80682,,Homo sapiens,1,4461,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624708,,6117,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",9606.0,80682,,Homo sapiens,1,5406,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624709,,6118,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,9606.0,80682,,Homo sapiens,1,4457,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL884107,,6119,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,9606.0,80682,,Homo sapiens,1,1386,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624710,,6120,Antitumoral activity was assayed against A-549 cell line,9606.0,80682,,Homo sapiens,1,3265,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624711,,6121,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,9606.0,80682,,Homo sapiens,1,2359,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624712,,6122,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,9606.0,80682,,Homo sapiens,1,4457,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL624713,,6123,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,9606.0,80682,,Homo sapiens,1,12454,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624714,,6124,Compound was tested for inhibition of cell growth of A-549 cells,9606.0,80682,,Homo sapiens,1,1481,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624715,,6125,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,9606.0,80682,,Homo sapiens,1,1750,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624716,,6126,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,9606.0,80682,,Homo sapiens,1,5065,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619505,,6127,In vitro cytotoxicity against A549-human lung carcinoma cells.,9606.0,80682,,Homo sapiens,1,808,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619506,,6128,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,9606.0,80682,,Homo sapiens,1,16364,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619507,,6129,Cytotoxic activity against A-549 cell lines.,9606.0,80682,,Homo sapiens,1,1847,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619508,,6130,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,9606.0,80682,,Homo sapiens,1,1747,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619509,,6131,Cytotoxicity against human A549 non small cell lung cell lines,9606.0,80682,,Homo sapiens,1,1003,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619510,,6132,Inhibition of cell growth in (A-549) lung cell line,9606.0,80682,,Homo sapiens,1,15313,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619511,,6133,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,9606.0,80682,,Homo sapiens,1,3122,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619512,,6134,In vitro antitumor activity against A-549 tumor cells.,9606.0,80682,,Homo sapiens,1,16049,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619513,,6135,In vitro antitumor effects against human A-549 cell lines.,9606.0,80682,,Homo sapiens,1,17134,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619514,,6136,In vitro cytotoxic activity of compound against A-549 cell line,9606.0,80682,,Homo sapiens,1,6406,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619515,,6137,In vitro cytotoxicity against human lung carcinoma A-549 cell line,9606.0,80682,,Homo sapiens,1,627,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619516,,6138,In vitro cytotoxicity against human non-small cell lung carcinoma A549,9606.0,80682,,Homo sapiens,1,12307,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL884005,,6139,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,9606.0,80682,,Homo sapiens,1,17861,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619517,,6140,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,9606.0,80682,,Homo sapiens,1,6682,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619518,,6141,Inhibitory concentration of compound against A-549 cell line,9606.0,80682,,Homo sapiens,1,6663,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619519,,6142,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,9606.0,80682,,Homo sapiens,1,2454,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL876489,,6143,cytotoxic activity against leukemia (A-549) cancer cell line,9606.0,80682,,Homo sapiens,1,14709,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619520,,6144,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,9606.0,80682,,Homo sapiens,1,15718,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619521,,6145,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,9606.0,80682,,Homo sapiens,1,15718,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619522,,6146,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),9606.0,80682,,Homo sapiens,1,17130,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619523,,6147,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),9606.0,80682,,Homo sapiens,1,17130,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619524,,6148,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),9606.0,80682,,Homo sapiens,1,17130,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619525,,6149,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),9606.0,80682,,Homo sapiens,1,17130,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619526,,6150,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,80682,,,1,6630,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619527,,6151,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,9606.0,80682,,Homo sapiens,1,16726,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619528,,6152,Cytotoxicity against A549 cells; No cytotoxicity,9606.0,80682,,Homo sapiens,1,17846,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619529,,6153,Cytotoxicity against human lung carcinoma (A549) cell lines,9606.0,80682,,Homo sapiens,1,3415,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619530,,6154,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,9606.0,80682,,Homo sapiens,1,3415,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL876490,,6155,In vitro anticancer activity against human lung (A549) cell line,9606.0,80682,,Homo sapiens,1,5609,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619531,,6156,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619532,,6157,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619533,,6158,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619534,,6159,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620164,,6160,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620165,,6161,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620166,,6162,Inhibition of A549 human lung tumor cell proliferation,9606.0,80682,,Homo sapiens,1,16295,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620167,,6163,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",9606.0,80682,,Homo sapiens,1,16825,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL620168,,6164,In vitro cytotoxicity against human tumor cell line A549,9606.0,80682,,Homo sapiens,1,3439,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620338,,6165,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,9606.0,80682,,Homo sapiens,1,10870,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620339,,6166,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,9606.0,80682,,Homo sapiens,1,4845,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620340,,6167,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,9606.0,80682,,Homo sapiens,1,5822,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620341,,6168,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,9606.0,80682,,Homo sapiens,1,5822,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL876491,,6169,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,9606.0,80682,,Homo sapiens,1,5822,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620342,,6170,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,9606.0,80682,,Homo sapiens,1,16381,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620343,,6171,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,9606.0,80682,,Homo sapiens,1,16381,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620344,,6172,% inhibition against A549 cells (lung cancer) at 4 ug/mL,9606.0,80682,,Homo sapiens,1,16381,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620345,,6173,In vitro anticancer activity against human lung (A549) cell line,9606.0,80682,,Homo sapiens,1,5609,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620346,,6174,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,9606.0,80682,,Homo sapiens,1,4644,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620347,,6175,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,9606.0,80682,,Homo sapiens,1,4644,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620348,,6176,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,9606.0,80682,,Homo sapiens,1,4644,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620349,,6177,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,9606.0,80682,,Homo sapiens,1,4644,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL618667,,6178,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,9606.0,80682,,Homo sapiens,1,5822,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL618668,,6179,Percentage inhibition of human lung carcinoma (A549) cell lines,9606.0,80682,,Homo sapiens,1,3415,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL876031,,6180,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,9606.0,80682,,Homo sapiens,1,16726,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL618759,,6181,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL618760,,6182,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619000,,6183,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619001,,6184,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619002,,6185,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619003,,6186,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619597,,6187,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619598,,6188,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619599,,6189,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619600,,6190,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619601,,6191,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,9606.0,80682,,Homo sapiens,1,16726,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619602,,6192,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619603,,6193,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619604,,6194,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619605,,6195,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619606,,6196,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,9615.0,50588,,Canis lupus familiaris,1,6084,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876032,,6197,Pharmacokinetic activity (Cmax) in dog,9615.0,50588,,Canis lupus familiaris,1,6084,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619607,,6198,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),9615.0,50588,,Canis lupus familiaris,1,4809,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619608,,6199,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5983,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619609,,6200,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6251,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL619610,,6201,Cmax in dog plasma after 30mg/kg oral dose,9615.0,50588,,Canis lupus familiaris,1,5932,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL619611,,6202,Tested for the peak blood level in dog,9615.0,50588,,Canis lupus familiaris,1,4273,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619612,,6203,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",9615.0,50588,,Canis lupus familiaris,1,5313,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619613,,6204,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",9615.0,50588,,Canis lupus familiaris,1,5313,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL619614,,6205,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,9615.0,50588,,Canis lupus familiaris,1,6221,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619615,,6206,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4709,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619616,,6207,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,9615.0,50588,,Canis lupus familiaris,1,167,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL619617,,6208,Final plasma concentration in dogs after oral administration at 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6241,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619618,,6209,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,9615.0,50588,,Canis lupus familiaris,1,344,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL876033,,6210,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,9615.0,50588,,Canis lupus familiaris,1,344,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619619,,6211,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,9615.0,50588,,Canis lupus familiaris,1,344,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619620,,6212,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,9615.0,50588,,Canis lupus familiaris,1,2189,,,N,A
BAO_0000218,Intermediate,,,1,,Urine,,1088.0,CHEMBL619621,,6213,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,9615.0,50588,,Canis lupus familiaris,1,2189,,,N,A
BAO_0000218,Intermediate,,,1,,Urine,,1088.0,CHEMBL619622,,6214,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,9615.0,50588,,Canis lupus familiaris,1,2189,,,N,A
BAO_0000218,Intermediate,,,1,,Urine,,1088.0,CHEMBL618874,,6215,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,9615.0,50588,,Canis lupus familiaris,1,2189,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618875,,6216,Absolute bioavailability was evaluated in dog,9615.0,50588,,Canis lupus familiaris,1,4257,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618876,,6217,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,9615.0,50588,,Canis lupus familiaris,1,6221,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618877,,6218,Bioavailability after peroral administration (1 mg/kg) was determined in dog,9615.0,50588,,Canis lupus familiaris,1,6215,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618878,,6219,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,17267,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618879,,6220,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6621,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618880,,6221,Bioavailability after intravenous administration in dogs,9615.0,50588,,Canis lupus familiaris,1,3854,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618881,,6222,Bioavailability after peroral administration in dogs,9615.0,50588,,Canis lupus familiaris,1,3854,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618882,,6223,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),9615.0,50588,,Canis lupus familiaris,1,5007,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624226,,6224,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,9615.0,50588,,Canis lupus familiaris,1,4333,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL624227,,6225,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,9615.0,50588,,Canis lupus familiaris,1,4333,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624228,,6226,Bioavailability,9615.0,50588,,Canis lupus familiaris,1,5006,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624229,,6227,Bioavailability,9615.0,50588,,Canis lupus familiaris,1,5199,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624230,,6228,Bioavailability by intravenous administration of 1.2 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4368,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624231,,6229,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,3771,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624232,,6230,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,4953,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625127,,6231,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5064,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625128,,6232,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,17657,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621675,,6233,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,17796,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621676,,6234,Bioavailability in dog (p.o.) at 2.0 mpk,9615.0,50588,,Canis lupus familiaris,1,17853,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621677,,6235,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),9615.0,50588,,Canis lupus familiaris,1,4521,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621678,,6236,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,9615.0,50588,,Canis lupus familiaris,1,4521,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621679,,6237,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5006,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621680,,6238,Bioavailability was evaluated after oral administration in dog,9615.0,50588,,Canis lupus familiaris,1,16365,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621681,,6239,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,9615.0,50588,,Canis lupus familiaris,1,1916,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876740,,6240,Bioavailability was evaluated in dog,9615.0,50588,,Canis lupus familiaris,1,1918,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621682,,6241,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,4239,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621683,,6242,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6505,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621684,,6243,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),9615.0,50588,,Canis lupus familiaris,1,5334,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621685,,6244,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),9615.0,50588,,Canis lupus familiaris,1,5334,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621686,,6245,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),9615.0,50588,,Canis lupus familiaris,1,4809,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621687,,6246,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,9615.0,50588,,Canis lupus familiaris,1,6348,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621688,,6247,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6005,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621689,,6248,Bioavailability of compound in dog was determined after peroral administration,9615.0,50588,,Canis lupus familiaris,1,17804,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621690,,6249,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,3184,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621691,,6250,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,9615.0,50588,,Canis lupus familiaris,1,1806,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875941,,6251,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,9615.0,50588,,Canis lupus familiaris,1,1806,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621692,,6252,Compound was evaluated for oral bioavailability in dogs; 37-38 %,9615.0,50588,,Canis lupus familiaris,1,1806,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621693,,6253,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,4839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621694,,6254,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),9615.0,50588,,Canis lupus familiaris,1,5017,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL621695,,6255,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL621696,,6256,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL621697,,6257,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL621698,,6258,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623420,,6259,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623421,,6260,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623422,,6261,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623423,,6262,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL623424,,6263,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL623425,,6264,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL623426,,6265,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL623427,,6266,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL623428,,6267,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL875947,,6268,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL623429,,6269,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL623430,,6270,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL622588,,6271,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL622589,,6272,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL622751,,6273,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL622752,,6274,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,10090.0,50594,,Mus musculus,1,846,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL622753,,6275,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL622647,,6276,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL875163,,6277,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL622648,,6278,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL622649,,6279,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Brain,CCRF S-180,955.0,CHEMBL622650,,6280,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Brain,CCRF S-180,955.0,CHEMBL622651,,6281,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Brain,CCRF S-180,955.0,CHEMBL622652,,6282,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Brain,CCRF S-180,955.0,CHEMBL622653,,6283,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Brain,CCRF S-180,955.0,CHEMBL622654,,6284,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Heart,CCRF S-180,948.0,CHEMBL622655,,6285,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Heart,CCRF S-180,948.0,CHEMBL622656,,6286,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Heart,CCRF S-180,948.0,CHEMBL622657,,6287,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Heart,CCRF S-180,948.0,CHEMBL622658,,6288,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Heart,CCRF S-180,948.0,CHEMBL622659,,6289,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Kidney,CCRF S-180,2113.0,CHEMBL624630,,6290,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Kidney,CCRF S-180,2113.0,CHEMBL624631,,6291,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Kidney,CCRF S-180,2113.0,CHEMBL624632,,6292,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624633,,6293,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,9606.0,80682,,Homo sapiens,1,17130,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624634,,6294,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,9606.0,80682,,Homo sapiens,1,17130,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624635,,6295,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),9606.0,80682,,Homo sapiens,1,17130,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624636,,6296,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),9606.0,80682,,Homo sapiens,1,17130,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL857055,,6297,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,9606.0,80682,,Homo sapiens,1,3263,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL624637,,6298,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,9606.0,80682,,Homo sapiens,1,6663,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL624638,,6299,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,9606.0,80682,,Homo sapiens,1,6663,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL874366,,6300,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,9606.0,80682,,Homo sapiens,1,6663,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL624639,,6301,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,9606.0,80682,,Homo sapiens,1,6663,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL624640,,6302,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,9606.0,80682,,Homo sapiens,1,6663,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624641,,6303,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,9606.0,80682,,Homo sapiens,1,6663,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624642,,6304,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,9606.0,80682,,Homo sapiens,1,6663,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624643,,6305,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,9606.0,80682,,Homo sapiens,1,6663,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624644,,6306,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,9606.0,80682,,Homo sapiens,1,6663,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL624645,,6307,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,9606.0,80682,,Homo sapiens,1,6663,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619445,,6308,The compound was evaluated for its cytotoxic potency against A-549 cell line,9606.0,80682,,Homo sapiens,1,3983,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL839886,,6309,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,9606.0,80682,,Homo sapiens,1,11141,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619446,,6310,Cytotoxic activity of compound against A-549 tumor cell line.,9606.0,80682,,Homo sapiens,1,5076,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619447,,6311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,9606.0,80682,,Homo sapiens,1,3311,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619448,,6312,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,9606.0,80682,,Homo sapiens,1,3311,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619449,,6313,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,9606.0,80682,,Homo sapiens,1,3311,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619450,,6314,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,9606.0,80682,,Homo sapiens,1,5076,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619451,,6315,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),9606.0,80682,,Homo sapiens,1,4150,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619452,,6316,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,9606.0,80682,,Homo sapiens,1,2150,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619453,,6317,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,9606.0,80682,,Homo sapiens,1,4644,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL874367,,6318,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,9606.0,80682,,Homo sapiens,1,263,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619454,,6319,Cytotoxic concentration against A-549 tumor cells.,9606.0,80682,,Homo sapiens,1,11333,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619455,,6320,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,9606.0,80682,,Homo sapiens,1,11333,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619456,,6321,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",9606.0,80682,,Homo sapiens,1,15895,,,N,F
BAO_0000218,Expert,,,1,,,,,CHEMBL619457,,6322,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,470.0,50191,,Acinetobacter baumannii,1,16677,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619458,,6323,Activity against Acinetobacter calcoaceticus (AC54),471.0,50192,,Acinetobacter calcoaceticus,1,10624,,,N,F
BAO_0000218,Expert,,,1,,,,,CHEMBL619459,,6324,In vitro antifungal activity against Aspergillus flavus CM74,5059.0,50274,,Aspergillus flavus,1,16717,,,N,F
BAO_0000218,Expert,,,1,,,,,CHEMBL619460,,6325,In vitro antifungal activity against Aspergillus flavus CM74,5059.0,50274,,Aspergillus flavus,1,16717,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619461,,6326,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,746128.0,50416,,Aspergillus fumigatus,1,5513,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619462,,6327,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),746128.0,50416,,Aspergillus fumigatus,1,15962,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620388,,6328,Antimicrobial activity against Aspergillus fumigatus (MIC),746128.0,50416,,Aspergillus fumigatus,1,15962,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620389,,6329,Antimicrobial activity against Aspergillus fumigatus (MIC),746128.0,50416,,Aspergillus fumigatus,1,15962,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620390,,6330,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),746128.0,50416,,Aspergillus fumigatus,1,15962,,,N,F
BAO_0000218,Expert,,,1,,,,,CHEMBL620391,,6331,In vitro antifungal activity against Aspergillus fumigatus 48238E,746128.0,50416,,Aspergillus fumigatus,1,16717,,,N,F
BAO_0000218,Expert,,,1,,,,,CHEMBL621073,,6332,In vitro antifungal activity against Aspergillus fumigatus 48238E,746128.0,50416,,Aspergillus fumigatus,1,16717,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621074,,6333,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,1655.0,50296,,Actinomyces naeslundii,1,8117,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621075,,6334,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,1656.0,50366,,Actinomyces viscosus,1,8117,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619554,,6335,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),6277.0,50535,,Acanthocheilonema viteae,1,15472,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619555,,6336,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),6277.0,50535,,Acanthocheilonema viteae,1,15472,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619556,,6337,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,714.0,50169,,Aggregatibacter actinomycetemcomitans,1,16443,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619557,,6338,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,714.0,50169,,Aggregatibacter actinomycetemcomitans,1,16443,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619558,,6339,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,714.0,50169,,Aggregatibacter actinomycetemcomitans,1,16443,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619559,,6340,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619560,,6341,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619561,,6342,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,9606.0,80682,,Homo sapiens,1,16381,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619562,,6343,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,9606.0,80682,,Homo sapiens,1,16381,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619563,,6344,% inhibition against A549 cells (lung cancer) at 4 ug/mL,9606.0,80682,,Homo sapiens,1,16381,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL857457,,6345,GI values against A549 cells (lung cancer),9606.0,80682,,Homo sapiens,1,16381,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619564,,6346,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,9606.0,80682,,Homo sapiens,1,17206,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619565,,6347,Inhibitory activity against A549 human adenocarcinoma,9606.0,80682,,Homo sapiens,1,16325,,,N,F
BAO_0000218,Intermediate,,646.0,1,,,A549,,CHEMBL619566,,6348,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,9606.0,80682,,Homo sapiens,1,10708,,,N,F
BAO_0000218,Intermediate,,646.0,1,,,A549,,CHEMBL619567,,6349,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,9606.0,80682,,Homo sapiens,1,10708,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619568,,6350,Inhibitory activity against A549 lung adenocarcinoma cell line,9606.0,80682,,Homo sapiens,1,17376,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619569,,6351,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,9606.0,80682,,Homo sapiens,1,17376,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619570,,6352,Cytotoxicity against human A549 lung cells,9606.0,80682,,Homo sapiens,1,17488,,,N,F
BAO_0000218,Intermediate,,646.0,1,,,A549,,CHEMBL619571,,6353,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,9606.0,80682,,Homo sapiens,1,17404,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619572,,6354,Growth inhibition of A549 (human lung carcinoma) cell line.,9606.0,80682,,Homo sapiens,1,10958,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619573,,6355,Effective dose required for inhibitory activity against A549 human tumor cell line.,9606.0,80682,,Homo sapiens,1,17099,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619574,,6356,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,9606.0,80682,,Homo sapiens,1,17099,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619575,,6357,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,9606.0,80682,,Homo sapiens,1,4096,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL619576,,6358,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,9606.0,80682,,Homo sapiens,1,4096,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619577,,6359,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,9606.0,80682,,Homo sapiens,1,4096,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619578,,6360,In vitro inhibitory activity against A549 tumor cell culture,9606.0,80682,,Homo sapiens,1,2525,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL884009,,6361,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,9606.0,80682,,Homo sapiens,1,2525,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619579,,6362,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),9606.0,80682,,Homo sapiens,1,5302,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619580,,6363,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,9606.0,80682,,Homo sapiens,1,16325,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619581,,6364,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,9606.0,80682,,Homo sapiens,1,16939,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619582,,6365,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,9606.0,80682,,Homo sapiens,1,17229,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619583,,6366,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,9606.0,80682,,Homo sapiens,1,17380,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL876502,,6367,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,9606.0,80682,,Homo sapiens,1,17380,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619584,,6368,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,9606.0,80682,,Homo sapiens,1,1903,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619585,,6369,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,9606.0,80682,,Homo sapiens,1,3838,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619586,,6370,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,9606.0,80682,,Homo sapiens,1,14696,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619587,,6371,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,9606.0,80682,,Homo sapiens,1,3838,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619588,,6372,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,9606.0,80682,,Homo sapiens,1,1522,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619589,,6373,Tested in vitro for cytotoxicity in A549/ATCC cell lines,9606.0,80682,,Homo sapiens,1,12400,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619590,,6374,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,9606.0,80682,,Homo sapiens,1,14696,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619591,,6375,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),9606.0,80682,,Homo sapiens,1,14769,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619592,,6376,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,9606.0,80682,,Homo sapiens,1,14696,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL619593,,6377,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,9606.0,80682,,Homo sapiens,1,1888,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620217,,6378,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,9606.0,80682,,Homo sapiens,1,12016,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620218,,6379,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,9606.0,80682,,Homo sapiens,1,6058,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620219,,6380,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,9606.0,80682,,Homo sapiens,1,17708,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL620220,,6381,Antitumor activity against A549/ATCC cell line,9606.0,80682,,Homo sapiens,1,12301,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL625141,,6382,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,9606.0,80682,,Homo sapiens,1,11970,,,N,F
BAO_0000219,Expert,,646.0,1,,,A549,,CHEMBL625142,,6383,In vitro cytotoxicity against A549/ATCC cell line.,9606.0,80682,,Homo sapiens,1,11818,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL625143,,6384,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,9606.0,80682,,Homo sapiens,1,12400,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL625144,,6385,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,9606.0,80682,,Homo sapiens,1,3381,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL622474,,6386,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,9606.0,80682,,Homo sapiens,1,17376,,,N,F
BAO_0000219,Intermediate,,646.0,1,,,A549,,CHEMBL884104,,6387,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,9606.0,80682,,Homo sapiens,1,10708,,,N,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL622475,,6388,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,9606.0,22226,,Homo sapiens,0,2964,,,U,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622476,,6389,Compound was tested for oral bioavailability in dogs,9615.0,22224,,Canis lupus familiaris,0,5005,,,U,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875831,,6390,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,9615.0,50588,,Canis lupus familiaris,1,6229,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622477,,6391,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,9615.0,50588,,Canis lupus familiaris,1,6229,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622478,,6392,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5374,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623172,,6393,Compound was tested for the oral bioavailability in dog; No availability,9615.0,50588,,Canis lupus familiaris,1,5374,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623173,,6394,Oral bioavailability in dog (dose 5 mg/kg),9615.0,50588,,Canis lupus familiaris,1,6265,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623174,,6395,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,9615.0,50588,,Canis lupus familiaris,1,5654,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623175,,6396,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,9615.0,50588,,Canis lupus familiaris,1,5654,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623340,,6397,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),9615.0,50588,,Canis lupus familiaris,1,16456,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623341,,6398,Oral bioavailability in dog (dose 5 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5302,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623342,,6399,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),9615.0,50588,,Canis lupus familiaris,1,3624,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623343,,6400,Oral bioavailability of active FTIs in dogs,9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623344,,6401,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),9615.0,50588,,Canis lupus familiaris,1,5802,,,N,A
BAO_0000218,Expert,In vivo,,1,,,,,CHEMBL623345,,6402,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3598,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875832,,6403,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,17839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623346,,6404,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6762,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623347,,6405,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6821,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623348,,6406,Oral bioavailability of compound was determined in dog; Not tested,9615.0,50588,,Canis lupus familiaris,1,6821,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623349,,6407,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5210,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623350,,6408,Oral bioavailability (10 mg/kg) was determined in dog,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623351,,6409,Oral bioavailability,9615.0,50588,,Canis lupus familiaris,1,761,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623352,,6410,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),9615.0,50588,,Canis lupus familiaris,1,761,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623353,,6411,Oral bioavailability administered in solution in rats,9615.0,50588,,Canis lupus familiaris,1,761,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875833,,6412,Oral bioavailability after 30 mg/kg po dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623354,,6413,Oral bioavailability at a dose of 1 mg/kg in dogs,9615.0,50588,,Canis lupus familiaris,1,5474,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623355,,6414,Oral bioavailability in dog (dose 1 mg/kg p.o.),9615.0,50588,,Canis lupus familiaris,1,6535,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623356,,6415,Oral bioavailability in Dog; ND = not determined,9615.0,50588,,Canis lupus familiaris,1,6535,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623357,,6416,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,3352,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623358,,6417,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6168,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623359,,6418,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5988,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623360,,6419,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,4942,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623361,,6420,Oral bioavailability in dogs; No data,9615.0,50588,,Canis lupus familiaris,1,4942,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623362,,6421,Oral bioavailability measured in dogs,9615.0,50588,,Canis lupus familiaris,1,14541,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623363,,6422,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,4449,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623364,,6423,Oral bioavailability was calculated in dog,9615.0,50588,,Canis lupus familiaris,1,6057,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875834,,6424,Oral bioavailability after 0.3 mg/kg po administration in dog,9615.0,50588,,Canis lupus familiaris,1,5600,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623365,,6425,Oral bioavailability in dog (i.v. dosing),9615.0,50588,,Canis lupus familiaris,1,5542,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623366,,6426,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5542,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623367,,6427,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,9615.0,50588,,Canis lupus familiaris,1,5546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623368,,6428,Oral bioavailability in Beagle dogs,9615.0,50588,,Canis lupus familiaris,1,4514,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623369,,6429,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,3624,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623370,,6430,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,3854,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623371,,6431,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5836,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623372,,6432,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5940,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621351,,6433,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6168,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621352,,6434,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621353,,6435,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6251,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621354,,6436,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6448,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621355,,6437,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6647,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621356,,6438,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5940,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621357,,6439,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,933,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621358,,6440,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5210,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621359,,6441,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),9615.0,50588,,Canis lupus familiaris,1,6642,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621360,,6442,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),9615.0,50588,,Canis lupus familiaris,1,6641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621361,,6443,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),9615.0,50588,,Canis lupus familiaris,1,6642,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621362,,6444,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5472,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621363,,6445,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5985,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621364,,6446,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,15660,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621166,,6447,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),9615.0,50588,,Canis lupus familiaris,1,5530,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621167,,6448,Oral bioavailability in dog (dose 1 mg/kg i.v.),9615.0,50588,,Canis lupus familiaris,1,5530,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621168,,6449,Oral bioavailability (F) in dogs,9615.0,50588,,Canis lupus familiaris,1,6305,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621169,,6450,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5210,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875950,,6451,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5238,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621170,,6452,Oral bioavailability in dog (dose 10 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621171,,6453,Oral bioavailability after peroral administration at 5 mpk in Dog,9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621172,,6454,Oral bioavailability in dog (dose 5 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621173,,6455,Oral bioavailability in dog (dose 10 mg/kg),9615.0,50588,,Canis lupus familiaris,1,6084,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Kidney,CCRF S-180,2113.0,CHEMBL621174,,6456,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Kidney,CCRF S-180,2113.0,CHEMBL621175,,6457,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Liver,CCRF S-180,2107.0,CHEMBL621176,,6458,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Liver,CCRF S-180,2107.0,CHEMBL621177,,6459,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Liver,CCRF S-180,2107.0,CHEMBL621178,,6460,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Liver,CCRF S-180,2107.0,CHEMBL621179,,6461,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Liver,CCRF S-180,2107.0,CHEMBL621180,,6462,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Lung,CCRF S-180,2048.0,CHEMBL875951,,6463,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Lung,CCRF S-180,2048.0,CHEMBL621181,,6464,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Lung,CCRF S-180,2048.0,CHEMBL621182,,6465,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Lung,CCRF S-180,2048.0,CHEMBL621183,,6466,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Lung,CCRF S-180,2048.0,CHEMBL621184,,6467,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621185,,6468,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621186,,6469,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621187,,6470,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621188,,6471,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621189,,6472,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Spleen,CCRF S-180,2106.0,CHEMBL621190,,6473,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Spleen,CCRF S-180,2106.0,CHEMBL618520,,6474,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Spleen,CCRF S-180,2106.0,CHEMBL621739,,6475,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Spleen,CCRF S-180,2106.0,CHEMBL621740,,6476,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Spleen,CCRF S-180,2106.0,CHEMBL621741,,6477,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621742,,6478,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621743,,6479,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621744,,6480,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621745,,6481,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621746,,6482,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621747,,6483,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621748,,6484,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621749,,6485,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621750,,6486,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL621751,,6487,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Heart,CCRF S-180,948.0,CHEMBL621752,,6488,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Heart,CCRF S-180,948.0,CHEMBL621753,,6489,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Heart,CCRF S-180,948.0,CHEMBL875955,,6490,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Heart,CCRF S-180,948.0,CHEMBL621754,,6491,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Heart,CCRF S-180,948.0,CHEMBL621755,,6492,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Liver,CCRF S-180,2107.0,CHEMBL621756,,6493,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Liver,CCRF S-180,2107.0,CHEMBL624199,,6494,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Liver,CCRF S-180,2107.0,CHEMBL624200,,6495,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Liver,CCRF S-180,2107.0,CHEMBL624375,,6496,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Liver,CCRF S-180,2107.0,CHEMBL624376,,6497,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Lung,CCRF S-180,2048.0,CHEMBL624377,,6498,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Lung,CCRF S-180,2048.0,CHEMBL624378,,6499,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL857901,,6500,Compound tested for the antimicrobial activity against Acinetobacter anitratus,107673.0,50067,,aeinetobacter anitrotap,1,12269,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL875274,,6501,Compound tested for the antimicrobial activity against Acinetobacter anitratus,107673.0,50067,,Acinetobacter calcoaceticus subsp. anitratus,1,12269,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624379,,6502,Compound tested for the antimicrobial activity against Acinetobacter anitratus,107673.0,50067,,Acinetobacter calcoaceticus subsp. anitratus,1,12269,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624380,,6503,Compound tested for the antimicrobial activity against Acinetobacter anitratus,107673.0,50067,,aeinetobacter anitrotap,1,12269,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624381,,6504,Activity against Acinetobacter calcoaceticus (AC54),471.0,50192,,Acinetobacter calcoaceticus,1,10624,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624382,,6505,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,28377.0,50714,,Anolis carolinensis,1,17216,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624383,,6506,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,28377.0,50714,,Anolis carolinensis,1,17216,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624384,,6507,Chlorohexidine coefficient for Actinomyces naeslundii 631,1655.0,50296,,Actinomyces naeslundii,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624385,,6508,Chlorohexidine coefficient for Actinomyces naeslundii B74,1655.0,50296,,Actinomyces naeslundii,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624386,,6509,Chlorohexidine coefficient for Actinomyces naeslundii N/3,1655.0,50296,,Actinomyces naeslundii,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624387,,6510,Chlorohexidine coefficient for Actinomyces naeslundii N/9,1655.0,50296,,Actinomyces naeslundii,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624388,,6511,Plaque bactericidal index against Actinomyces naeslundii 631,1655.0,50296,,Actinomyces naeslundii,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624389,,6512,Plaque bactericidal index against Actinomyces naeslundii N/9,1655.0,50296,,Actinomyces naeslundii,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624390,,6513,Plaque bactericidal index against Actinomyces naeslundii B74,1655.0,50296,,Actinomyces naeslundii,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL875275,,6514,Plaque bactericidal index against Actinomyces naeslundii N/3,1655.0,50296,,Actinomyces naeslundii,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624391,,6515,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,85549.0,50056,,Artemia salina,1,114,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623636,,6516,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",85549.0,50056,,Artemia salina,1,114,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623637,,6517,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,6253.0,50532,,Ascaris suum,1,10841,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623638,,6518,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,6253.0,50532,,Ascaris suum,1,10841,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623639,,6519,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,6253.0,50532,,Ascaris suum,1,10841,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623640,,6520,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,6253.0,50532,,Ascaris suum,1,10841,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623641,,6521,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,6253.0,50532,,Ascaris suum,1,10841,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623642,,6522,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,6253.0,50532,,Ascaris suum,1,10841,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623643,,6523,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,6253.0,50532,,Ascaris suum,1,10841,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623644,,6524,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,6253.0,50532,,Ascaris suum,1,10841,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623645,,6525,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,6253.0,50532,,Ascaris suum,1,10841,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623646,,6526,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,6253.0,50532,,Ascaris suum,1,10841,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623647,,6527,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,6253.0,50532,,Ascaris suum,1,10841,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623648,,6528,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,6253.0,50532,,Ascaris suum,1,10841,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623649,,6529,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1656.0,50366,,Actinomyces viscosus,1,8117,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623650,,6530,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1656.0,50366,,Actinomyces viscosus,1,8117,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623651,,6531,Chlorohexidine coefficient for Actinomyces viscosus 8A06,1656.0,50366,,Actinomyces viscosus,1,9560,,,N,F
BAO_0000218,Expert,,,1,,,,,CHEMBL623652,,6532,Chlorohexidine coefficient for Actinomyces viscosus M-100,1656.0,50366,,Actinomyces viscosus,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623653,,6533,Chlorohexidine coefficient for Actinomyces viscosus M-626,1656.0,50366,,Actinomyces viscosus,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623654,,6534,Chlorohexidine coefficient for Actinomyces viscosus T14V,1656.0,50366,,Actinomyces viscosus,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623655,,6535,Plaque bactericidal index against Actinomyces viscosus 8A06,1656.0,50366,,Actinomyces viscosus,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623656,,6536,Plaque bactericidal index against Actinomyces viscosus M-100,1656.0,50366,,Actinomyces viscosus,1,9560,,,N,F
BAO_0000218,Expert,,,1,,,,,CHEMBL623657,,6537,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,1656.0,50366,,Actinomyces viscosus,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623658,,6538,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1656.0,50366,,Actinomyces viscosus,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623659,,6539,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1656.0,50366,,Actinomyces viscosus,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623660,,6540,Plaque bactericidal index against Actinomyces viscosus 626,1656.0,50366,,Actinomyces viscosus,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623661,,6541,Plaque bactericidal index against Actinomyces viscosus T14V,1656.0,50366,,Actinomyces viscosus,1,9560,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL875281,,6542,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,6277.0,50535,,Acanthocheilonema viteae,1,10986,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623662,,6543,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,6277.0,50535,,Acanthocheilonema viteae,1,10986,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623663,,6544,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,6277.0,50535,,Acanthocheilonema viteae,1,10986,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623664,,6545,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,6277.0,50535,,Acanthocheilonema viteae,1,10986,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623665,,6546,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,6277.0,50535,,Acanthocheilonema viteae,1,10986,,,N,F
BAO_0000219,Intermediate,,165.0,1,,,A673,,CHEMBL621856,,6547,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,9606.0,80023,,Homo sapiens,1,10708,,,N,F
BAO_0000219,Intermediate,,645.0,1,,,A704,,CHEMBL620432,,6548,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,9606.0,80661,,Homo sapiens,1,10708,,,N,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL620433,,6549,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,10116.0,22226,,Rattus norvegicus,0,416,,,U,F
BAO_0000219,Intermediate,,625.0,1,,,A9,,CHEMBL620434,,6550,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,10090.0,80024,,Mus musculus,1,14354,,,N,F
BAO_0000219,Intermediate,,625.0,1,,,A9,,CHEMBL620435,,6551,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,10090.0,80024,,Mus musculus,1,14354,,,N,F
BAO_0000219,Intermediate,,625.0,1,,,A9,,CHEMBL620436,,6552,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,9606.0,80024,,Homo sapiens,1,5116,,,N,F
BAO_0000219,Intermediate,,625.0,1,,,A9,,CHEMBL876597,,6553,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,9606.0,80024,,Homo sapiens,1,5116,,,N,F
BAO_0000219,Expert,,874.0,1,,,Human ovarian carcinoma cell line,,CHEMBL620437,,6554,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,9606.0,81037,,Homo sapiens,1,15694,,,N,F
BAO_0000219,Expert,,625.0,1,,,A9,,CHEMBL620438,,6555,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",10090.0,80024,,Mus musculus,1,13038,,,N,F
BAO_0000219,Expert,,625.0,1,,,A9,,CHEMBL620439,,6556,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,10090.0,80024,,Mus musculus,1,13038,,,N,F
BAO_0000219,Expert,,625.0,1,,,A9,,CHEMBL619657,,6557,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,10090.0,80024,,Mus musculus,1,10923,,,N,F
BAO_0000219,Intermediate,,625.0,1,,,A9,,CHEMBL619658,,6558,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,10090.0,80024,,Mus musculus,1,10923,,,N,F
BAO_0000219,Intermediate,,625.0,1,,,A9,,CHEMBL619659,,6559,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,10090.0,80024,,Mus musculus,1,10923,,,N,F
BAO_0000019,Expert,,,1,,,,,CHEMBL619660,,6560,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,10649,,,8,10923,,,H,F
BAO_0000219,Intermediate,,625.0,1,,,A9,,CHEMBL619661,,6561,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,10090.0,80024,,Mus musculus,1,10923,,,N,F
BAO_0000219,Intermediate,,625.0,1,,,A9,,CHEMBL619662,,6562,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,10090.0,80024,,Mus musculus,1,10923,,,N,F
BAO_0000219,Intermediate,,975.0,1,,,AA6,,CHEMBL619663,,6563,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,10029.0,80663,,Cricetulus griseus,1,8158,,,N,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL619664,,6564,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,9606.0,22226,,Homo sapiens,0,15494,,,U,F
BAO_0000219,Autocuration,,,1,,,,,CHEMBL619665,,6565,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",9606.0,22226,,Homo sapiens,0,15494,,,U,F
BAO_0000219,Intermediate,,974.0,1,,,AA5,,CHEMBL883244,,6566,Anti -HIV activity was measured against AA5/HIV-1(IIIB),9606.0,80662,,Homo sapiens,1,12348,,,N,F
BAO_0000219,Intermediate,,974.0,1,,,AA5,,CHEMBL884011,,6567,Cytotoxicity was measured against AA5/HIV-1(IIIB),9606.0,80662,,Homo sapiens,1,12348,,,N,F
BAO_0000219,Intermediate,,974.0,1,,,AA5,,CHEMBL619666,,6568,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,9606.0,80662,,Homo sapiens,1,2726,,,N,F
BAO_0000219,Intermediate,,379.0,1,,,U-937,,CHEMBL619667,,6569,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,9606.0,80566,,Homo sapiens,1,2726,,,N,F
BAO_0000219,Intermediate,,274.0,1,,,UV4,,CHEMBL619668,,6570,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,10029.0,80578,,Cricetulus griseus,1,10747,,,N,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL619669,,6571,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",10029.0,80089,,Cricetulus griseus,1,11005,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL876608,,6572,Average intracellular compound concentration when the hypoxic SER=1.6,10029.0,80089,,Cricetulus griseus,1,12687,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL619670,,6573,Average intracellular compound concentration when the hypoxic SER=1.6.,10029.0,80089,,Cricetulus griseus,1,12687,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL619671,,6574,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,10029.0,80089,,Cricetulus griseus,1,12687,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL619672,,6575,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,10029.0,80089,,Cricetulus griseus,1,12687,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL619673,,6576,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,10029.0,80089,,Cricetulus griseus,1,12687,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL619674,,6577,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",10029.0,80089,,Cricetulus griseus,1,13436,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL619675,,6578,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",10029.0,80089,,Cricetulus griseus,1,13435,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL619676,,6579,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,10029.0,80089,,Cricetulus griseus,1,13302,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL619677,,6580,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,10029.0,80089,,Cricetulus griseus,1,12687,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL619678,,6581,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,10029.0,80089,,Cricetulus griseus,1,12687,,,N,A
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL619679,,6582,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,10029.0,80089,,Cricetulus griseus,1,12687,,,N,A
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL619680,,6583,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,10029.0,80089,,Cricetulus griseus,1,12878,,,N,A
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL621457,,6584,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,10029.0,80089,,Cricetulus griseus,1,12878,,,N,A
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL876609,,6585,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,10029.0,80089,,Cricetulus griseus,1,14367,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL621458,,6586,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,10029.0,80089,,Cricetulus griseus,1,14367,,,N,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL621459,,6587,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,36483.0,80089,,hampster,1,12398,,,N,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL621460,,6588,Aerobic growth inhibition in Chinese hamster cell line AA8,10029.0,80089,,Cricetulus griseus,1,12878,,,N,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL621461,,6589,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,10029.0,80089,,Cricetulus griseus,1,13820,,,N,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL621462,,6590,Inhibition of growth under aerobic conditions in AA8 cells,10029.0,80089,,Cricetulus griseus,1,13436,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621463,,6591,Oral bioavailability in dog (dose 10 mg/kg),9615.0,50588,,Canis lupus familiaris,1,6084,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621464,,6592,Oral bioavailability in dog at 10 mg/kg of the compound,9615.0,50588,,Canis lupus familiaris,1,5711,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621465,,6593,Oral bioavailability in dog (dose 5 uM/kg),9615.0,50588,,Canis lupus familiaris,1,4353,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621466,,6594,Oral bioavailability in dog (dose 5 uM/kg),9615.0,50588,,Canis lupus familiaris,1,4353,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621467,,6595,Oral bioavailability in dog (mongrel),9615.0,50588,,Canis lupus familiaris,1,17800,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621468,,6596,Oral bioavailability in dog (dose 10 mg/kg),9615.0,50588,,Canis lupus familiaris,1,3994,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876734,,6597,Oral bioavailability in dog (dose 10 mg/kg),9615.0,50588,,Canis lupus familiaris,1,3994,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618476,,6598,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,5145,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618477,,6599,Bioavailability in dog (dose 1 mg/kg i.v.),9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618478,,6600,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618479,,6601,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5983,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618480,,6602,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,4273,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618481,,6603,Bioavailability in dog (dose 3-10 mg/kg),9615.0,50588,,Canis lupus familiaris,1,12500,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL618482,,6604,The compound was tested for bioavailability of compound in plasma of dog; Complete,9615.0,50588,,Canis lupus familiaris,1,12500,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618483,,6605,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,3639,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618484,,6606,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,3880,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618485,,6607,Bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,4838,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618486,,6608,oral bioavailability was measured in dogs,9615.0,50588,,Canis lupus familiaris,1,15600,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618487,,6609,Compound was tested for plasma protein binding in dog; Not determined,9615.0,50588,,Canis lupus familiaris,1,17248,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618488,,6610,Compound was tested for plasma protein binding of dog,9615.0,50588,,Canis lupus familiaris,1,17248,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL876735,,6611,Compound was tested for plasma protein binding of dog; Not determined,9615.0,50588,,Canis lupus familiaris,1,17248,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618489,,6612,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,9615.0,50588,,Canis lupus familiaris,1,17443,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618490,,6613,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,9615.0,50588,,Canis lupus familiaris,1,4186,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618491,,6614,Half life was determined,9615.0,50588,,Canis lupus familiaris,1,3749,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618492,,6615,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3249,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL873354,,6616,Half life was evaluated in dog,9615.0,50588,,Canis lupus familiaris,1,3022,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618493,,6617,Half life was determined,9615.0,50588,,Canis lupus familiaris,1,3749,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618494,,6618,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),9615.0,50588,,Canis lupus familiaris,1,2517,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL618495,,6619,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),9615.0,50588,,Canis lupus familiaris,1,2517,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL618496,,6620,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),9615.0,50588,,Canis lupus familiaris,1,2517,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL618497,,6621,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),9615.0,50588,,Canis lupus familiaris,1,2517,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL618498,,6622,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),9615.0,50588,,Canis lupus familiaris,1,2517,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL618499,,6623,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),9615.0,50588,,Canis lupus familiaris,1,2517,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL876736,,6624,LogP in dog,9615.0,50588,,Canis lupus familiaris,1,3639,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618500,,6625,Partition coefficient (logP),9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL857831,,6626,Partition coefficient in dog,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618501,,6627,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618502,,6628,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),9615.0,50588,,Canis lupus familiaris,1,4809,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618503,,6629,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,9615.0,50588,,Canis lupus familiaris,1,5600,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618504,,6630,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),9615.0,50588,,Canis lupus familiaris,1,14294,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618505,,6631,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),9615.0,50588,,Canis lupus familiaris,1,14294,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618506,,6632,Metabolism of compound in dog S9 microsomes; Trace,9615.0,50588,,Canis lupus familiaris,1,14294,,,N,A
BAO_0000218,Intermediate,,,1,,Liver,,2107.0,CHEMBL618507,,6633,In vitro metabolic potential in dog liver microsomes,9615.0,50588,,Canis lupus familiaris,1,6251,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876737,,6634,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,9615.0,50588,,Canis lupus familiaris,1,3748,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618508,,6635,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,2713,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618509,,6636,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6512,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618510,,6637,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,9615.0,50588,,Canis lupus familiaris,1,6679,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618511,,6638,The compound was tested for bioavailability in dogs,9615.0,50588,,Canis lupus familiaris,1,3749,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618512,,6639,The compound was tested for oral bioavailability in dogs,9615.0,50588,,Canis lupus familiaris,1,3749,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618513,,6640,Oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,6742,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618514,,6641,Compound was tested for percent protein binding (PB) in dog,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620052,,6642,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,9615.0,50588,,Canis lupus familiaris,1,6874,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL620053,,6643,Compound was evaluated for plasma clearance.,9615.0,50588,,Canis lupus familiaris,1,2877,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL620054,,6644,The compound was tested for plasma clearance in dog,9615.0,50588,,Canis lupus familiaris,1,12500,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL620055,,6645,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,9615.0,50588,,Canis lupus familiaris,1,12500,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL620056,,6646,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4709,,,N,A
BAO_0000218,Intermediate,,,1,,Liver,,2107.0,CHEMBL620057,,6647,In vitro relative rate of metabolism was determined in dog liver microsomes,9615.0,50588,,Canis lupus familiaris,1,5542,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618939,,6648,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,9615.0,50588,,Canis lupus familiaris,1,17594,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618940,,6649,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,9615.0,50588,,Canis lupus familiaris,1,2652,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618941,,6650,Half life after intravenous administration in dogs at 1.2 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17764,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Lung,CCRF S-180,2048.0,CHEMBL624473,,6651,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Lung,CCRF S-180,2048.0,CHEMBL624474,,6652,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,Lung,CCRF S-180,2048.0,CHEMBL624475,,6653,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL624476,,6654,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL623478,,6655,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL623479,,6656,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL623480,,6657,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,42.0,1,,,CCRF S-180,,CHEMBL623481,,6658,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,10090.0,50594,,Mus musculus,1,6599,,,N,A
BAO_0000218,Intermediate,,,1,,Brain,,955.0,CHEMBL623482,,6659,C2 in brain of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,,,1,,Kidney,,2113.0,CHEMBL623483,,6660,C2 in kidney of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,,,1,,Liver,,2107.0,CHEMBL623484,,6661,C2 in liver of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,,,1,,Lung,,2048.0,CHEMBL623485,,6662,C2 in lungs of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,,,1,,Spleen,,2106.0,CHEMBL623486,,6663,C2 in spleen of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623487,,6664,Plasma clearance in mouse,10090.0,50594,,Mus musculus,1,17852,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623488,,6665,Clearance of compound after intravenous administration in mice at 24 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623489,,6666,Clearance from mouse blood following i.v. administration of 10 mg/kg,10090.0,50594,,Mus musculus,1,17837,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875157,,6667,Clearance was evaluated in mice after intravenous administration,10090.0,50594,,Mus musculus,1,2675,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623490,,6668,Clearance was evaluated in mice after oral administration,10090.0,50594,,Mus musculus,1,2675,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623491,,6669,Pharmacokinetic property (Plasma clearance) was measured in mouse,10090.0,50594,,Mus musculus,1,4239,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623492,,6670,Plasma clearance of compound was determined at 40 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623493,,6671,Plasma clearance of at 24 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623494,,6672,Plasma clearance at 24 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623495,,6673,Plasma clearance at 5 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623496,,6674,Plasma clearance in mice,10090.0,50594,,Mus musculus,1,5727,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623497,,6675,Plasma clearance value upon iv administration in mouse,10090.0,50594,,Mus musculus,1,2862,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623498,,6676,Total plasma clearance in mice,10090.0,50594,,Mus musculus,1,5980,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623499,,6677,Clearance in mouse,10090.0,50594,,Mus musculus,1,17592,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623500,,6678,Clearance value was determined,10090.0,50594,,Mus musculus,1,17718,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623501,,6679,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000100,Intermediate,,,1,,,,,CHEMBL875158,,6680,Calculated partition coefficient (clogP),,22229,,,0,17384,,,U,P
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623502,,6681,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,10090.0,50594,,Mus musculus,1,6062,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623503,,6682,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,10090.0,50594,,Mus musculus,1,17734,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623504,,6683,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,10090.0,50594,,Mus musculus,1,6348,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623505,,6684,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623506,,6685,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623507,,6686,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623508,,6687,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623509,,6688,Cmax after oral administration at 30 mg/kg in ICR mouse,10090.0,50594,,Mus musculus,1,5781,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875159,,6689,Cmax after peroral administration in mice at 2.4 uM/kg,10090.0,50594,,Mus musculus,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL623510,,6690,Cmax in brain of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL623511,,6691,Cmax in kidney of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL623512,,6692,Cmax in liver of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL623513,,6693,Cmax in lungs of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623514,,6694,Cmax in mice at 18 uM/kg i.p. administration,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622609,,6695,Cmax in mice at 23 uM/kg i.v. administration,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622610,,6696,Cmax in mice at 24 uM/kg i.p. administration,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621823,,6697,Cmax in mice at 25 uM/kg i.p. administration,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621824,,6698,Cmax in mice at 26 uM/kg i.p. administration,10090.0,50594,,Mus musculus,1,17764,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL621825,,6699,Cmax in spleen of mice at the oral dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621826,,6700,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621827,,6701,Cmax value at a dose of 10 mg/kg peroral administration in mice.,10090.0,50594,,Mus musculus,1,16597,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621828,,6702,Cmax value was determined,10090.0,50594,,Mus musculus,1,5727,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621829,,6703,Cmax value in IRC mice,10090.0,50594,,Mus musculus,1,5951,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621830,,6704,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,10090.0,50594,,Mus musculus,1,5506,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621831,,6705,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,10090.0,50594,,Mus musculus,1,5506,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL621832,,6706,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,10090.0,50594,,Mus musculus,1,14239,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL624579,,6707,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",10090.0,50594,,Mus musculus,1,4890,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624580,,6708,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,10090.0,50594,,Mus musculus,1,429,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624581,,6709,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,6277.0,50535,,Acanthocheilonema viteae,1,10986,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624582,,6710,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,6277.0,50535,,Acanthocheilonema viteae,1,10986,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624583,,6711,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,6277.0,50535,,Acanthocheilonema viteae,1,10986,,,N,F
BAO_0000219,Intermediate,,455.0,1,,,A-375,,CHEMBL624584,,6712,Inhibitory activity against human tumor cell line A0375 melanoma.,9606.0,80018,,Homo sapiens,1,13227,,,N,F
BAO_0000249,Expert,,,1,,,,,CHEMBL624585,,6713,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,10116.0,12512,Brain membranes,Rattus norvegicus,9,4481,,,D,B
BAO_0000019,Expert,,,1,,,,,CHEMBL875165,,6714,Forskolin-induced cAMP production at human A1 adenosine receptor,9606.0,114,,Homo sapiens,9,16931,,,D,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL619490,,6715,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,114,,,8,3850,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL619491,,6716,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,114,,,8,3850,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL619492,,6717,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,114,,,8,3850,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL619493,,6718,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,114,,,8,3850,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL619494,,6719,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,114,,,8,3850,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL619495,,6720,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,114,,,8,3850,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL619496,,6721,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,114,,,8,3850,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL619497,,6722,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,9606.0,114,,Homo sapiens,9,3850,,,D,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL619498,,6723,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,114,,,8,3850,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL619499,,6724,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,114,,,8,3850,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL619500,,6725,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,114,,,8,3850,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL619501,,6726,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,114,,,8,3850,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL619502,,6727,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,114,,,8,3850,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL619503,,6728,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,114,,,8,3850,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL619504,,6729,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,114,,,8,3850,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL621298,,6730,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,114,,,8,3850,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL621299,,6731,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,114,,,8,3850,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL621300,,6732,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,114,,,8,3850,,,H,F
BAO_0000219,Autocuration,,449.0,1,,,CHO,,CHEMBL621301,,6733,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,114,,,8,3850,,,H,F
BAO_0000219,Expert,,449.0,1,,,CHO,,CHEMBL621302,,6734,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,114,,,8,3850,,,H,F
BAO_0000219,Intermediate,,164.0,1,,,A10,,CHEMBL621303,,6735,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,9986.0,80013,,Oryctolagus cuniculus,1,12680,,,N,F
BAO_0000219,Autocuration,,164.0,1,,,A10,,CHEMBL621304,,6736,In vitro potassium channel opening activity in A10 (smooth muscle) cells,10116.0,22226,,Rattus norvegicus,0,1313,,,U,F
BAO_0000219,Autocuration,,164.0,1,,,A10,,CHEMBL621305,,6737,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,10116.0,22226,,Rattus norvegicus,0,1313,,,U,F
BAO_0000219,Intermediate,,164.0,1,,,A10,,CHEMBL621306,,6738,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,10116.0,80013,,Rattus norvegicus,1,17567,,,N,F
BAO_0000219,Intermediate,,164.0,1,,,A10,,CHEMBL618444,,6739,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,10116.0,80013,,Rattus norvegicus,1,17567,,,N,F
BAO_0000219,Intermediate,,164.0,1,,,A10,,CHEMBL618445,,6740,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,10116.0,80013,,Rattus norvegicus,1,11819,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL618446,,6741,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,10029.0,80089,,Cricetulus griseus,1,13436,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL618447,,6742,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,10029.0,80089,,Cricetulus griseus,1,12687,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL618448,,6743,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,10029.0,80089,,Cricetulus griseus,1,12651,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL618449,,6744,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,10029.0,80089,,Cricetulus griseus,1,13300,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL618637,,6745,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,10029.0,80089,,Cricetulus griseus,1,15296,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL618638,,6746,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",10029.0,80089,,Cricetulus griseus,1,15328,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL618639,,6747,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),10029.0,80089,,Cricetulus griseus,1,13302,,,N,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL618640,,6748,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",10029.0,80089,,Cricetulus griseus,1,14367,,,N,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL618641,,6749,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,10029.0,80089,,Cricetulus griseus,1,17002,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL618642,,6750,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,10029.0,80089,,Cricetulus griseus,1,13436,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL618643,,6751,Inhibitory activity against aerobic growth of AA8 cells.,10029.0,80089,,Cricetulus griseus,1,13435,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL884013,,6752,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,10029.0,80089,,Cricetulus griseus,1,10503,,,N,A
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL622723,,6753,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,10029.0,80089,,Cricetulus griseus,1,10503,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL622724,,6754,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,10029.0,80089,,Cricetulus griseus,1,10503,,,N,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL622725,,6755,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,10029.0,80089,,Cricetulus griseus,1,15090,,,N,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL622726,,6756,Cytotoxicity against AA8 cell line,10029.0,80089,,Cricetulus griseus,1,10368,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL622727,,6757,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),10029.0,80089,,Cricetulus griseus,1,12651,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL622728,,6758,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),10029.0,80089,,Cricetulus griseus,1,12687,,,N,A
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL622729,,6759,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),10029.0,80089,,Cricetulus griseus,1,12687,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL622730,,6760,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),10029.0,80089,,Cricetulus griseus,1,12687,,,N,A
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL622731,,6761,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,10029.0,80089,,Cricetulus griseus,1,1890,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL622732,,6762,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,10029.0,80089,,Cricetulus griseus,1,10747,,,N,F
BAO_0000219,Intermediate,,185.0,1,,,CHO-AA8,,CHEMBL622733,,6763,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,10029.0,80089,,Cricetulus griseus,1,10747,,,N,F
BAO_0000218,Autocuration,,,1,,,,,CHEMBL622734,,6764,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),10029.0,22224,,Cricetulus griseus,0,11616,,,U,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL622735,,6765,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,10029.0,80089,,Cricetulus griseus,1,11616,,,N,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL618746,,6766,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,10029.0,22224,,Cricetulus griseus,0,3471,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL618747,,6767,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,10029.0,22224,,Cricetulus griseus,0,3471,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL620540,,6768,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,10029.0,22224,,Cricetulus griseus,0,3471,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL620541,,6769,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,10029.0,22224,,Cricetulus griseus,0,3471,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL620542,,6770,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,10029.0,22224,,Cricetulus griseus,0,3471,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL620543,,6771,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,10029.0,22224,,Cricetulus griseus,0,3471,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL618832,,6772,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,10029.0,22224,,Cricetulus griseus,0,3471,,,U,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL618833,,6773,Concentration required to reduce AA8 cell survival by 10%,10029.0,80089,,Cricetulus griseus,1,11616,,,N,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL618834,,6774,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",10029.0,22224,,Cricetulus griseus,0,2656,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL618835,,6775,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,10029.0,22224,,Cricetulus griseus,0,10518,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL618836,,6776,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,10029.0,22224,,Cricetulus griseus,0,10518,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL618837,,6777,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,10029.0,22224,,Cricetulus griseus,0,10518,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL618838,,6778,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,10029.0,22224,,Cricetulus griseus,0,10518,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL618839,,6779,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,10029.0,22224,,Cricetulus griseus,0,16156,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL618840,,6780,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,10029.0,22224,,Cricetulus griseus,0,2656,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618841,,6781,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",10029.0,22224,,Cricetulus griseus,0,11005,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL618842,,6782,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,10029.0,22224,,Cricetulus griseus,0,11942,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL618843,,6783,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,10029.0,22224,,Cricetulus griseus,0,2128,,,U,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618844,,6784,Half life period after 15 mg/kg iv dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618845,,6785,Half life period after 30 mg/kg po dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618846,,6786,Half life was measured after oral 2b administration (tested in 6 dogs),9615.0,50588,,Canis lupus familiaris,1,9579,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618847,,6787,Half life was measured in dog after oral 17b administration,9615.0,50588,,Canis lupus familiaris,1,9579,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618848,,6788,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,9615.0,50588,,Canis lupus familiaris,1,9579,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618849,,6789,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,9615.0,50588,,Canis lupus familiaris,1,9579,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618850,,6790,Tmax value after 15 mg/kg iv dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618851,,6791,Tmax value after 30 mg/kg po dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL873815,,6792,Compound was evaluated for its half life when administered intravenously in dog,9615.0,50588,,Canis lupus familiaris,1,3184,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL618852,,6793,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5017,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618853,,6794,Elimination Half-life of compound was determined in dog,9615.0,50588,,Canis lupus familiaris,1,6821,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618854,,6795,Half life of compound in dog following oral administration,9615.0,50588,,Canis lupus familiaris,1,17839,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618855,,6796,Half life of compound was determined in dog,9615.0,50588,,Canis lupus familiaris,1,17267,,,N,A
BAO_0000218,Intermediate,,,1,,Blood,,178.0,CHEMBL618856,,6797,Half life of compound was determined in dog blood,9615.0,50588,,Canis lupus familiaris,1,4727,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875827,,6798,Half life after oral and iv dosing in dogs,9615.0,50588,,Canis lupus familiaris,1,5238,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618857,,6799,Half life in dogs in hours,9615.0,50588,,Canis lupus familiaris,1,4942,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618858,,6800,Half life on i.v. administration of 2 mg/kg was measured in dog,9615.0,50588,,Canis lupus familiaris,1,6505,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618859,,6801,t1/2 in dog after oral dose (1 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5130,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618860,,6802,Half life was evaluated in dog,9615.0,50588,,Canis lupus familiaris,1,1475,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618861,,6803,Half life period of compound was determined after intravenous administration at 2 mg/kg,9615.0,50588,,Canis lupus familiaris,1,17804,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622539,,6804,Half life period of compound was determined after peroral administration at 2 mg/kg,9615.0,50588,,Canis lupus familiaris,1,17804,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622540,,6805,Half life period (10 mg/kg) was determined in dog,9615.0,50588,,Canis lupus familiaris,1,6084,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL873803,,6806,Half life period (10 mg/kg) was determined in dog,9615.0,50588,,Canis lupus familiaris,1,6084,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL873804,,6807,Half life period by iv administration in dog at a dose of 0.3 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5542,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624311,,6808,Half life period by po administration in dog at a dose of 0.3 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5542,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624312,,6809,Half life period in dog,9615.0,50588,,Canis lupus familiaris,1,6084,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624313,,6810,Half life period in dogs after oral administration at 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6241,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624314,,6811,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,9615.0,50588,,Canis lupus familiaris,1,1916,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624315,,6812,Half-life of compound was determined in dogs,9615.0,50588,,Canis lupus familiaris,1,6621,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL624316,,6813,Half-life in dog plasma,9615.0,50588,,Canis lupus familiaris,1,1696,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624317,,6814,Half-life in mongrel dogs was determined,9615.0,50588,,Canis lupus familiaris,1,17800,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624318,,6815,Half-life in dog upon oral administration,9615.0,50588,,Canis lupus familiaris,1,17657,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624319,,6816,Half-life in dog upon oral administration; Unable to calculate,9615.0,50588,,Canis lupus familiaris,1,17657,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624496,,6817,Half-life was measured in dog,9615.0,50588,,Canis lupus familiaris,1,4239,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624497,,6818,Half-life was measured in dog,9615.0,50588,,Canis lupus familiaris,1,5985,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624498,,6819,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,9615.0,50588,,Canis lupus familiaris,1,9932,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624499,,6820,Oral half life was determined,9615.0,50588,,Canis lupus familiaris,1,5199,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL624500,,6821,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,9615.0,50588,,Canis lupus familiaris,1,5199,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL624501,,6822,Plasma half life was evaluated,9615.0,50588,,Canis lupus familiaris,1,1475,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL623666,,6823,Plasma half life was evaluated in Dog,9615.0,50588,,Canis lupus familiaris,1,1475,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL623667,,6824,Plasma half life was evaluated in dog,9615.0,50588,,Canis lupus familiaris,1,1475,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623668,,6825,T1/2 (Half-life) was after oral administration at 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6316,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623669,,6826,Tested for the half life value in dog,9615.0,50588,,Canis lupus familiaris,1,4883,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623670,,6827,Maximum time at the dose of 2 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4727,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623671,,6828,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,9615.0,50588,,Canis lupus familiaris,1,1916,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL875945,,6829,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,9615.0,50588,,Canis lupus familiaris,1,1337,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL623672,,6830,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,9615.0,50588,,Canis lupus familiaris,1,1337,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623673,,6831,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6265,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623674,,6832,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),9615.0,50588,,Canis lupus familiaris,1,4809,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623675,,6833,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,9615.0,50588,,Canis lupus familiaris,1,5983,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL872526,,6834,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",9615.0,50588,,Canis lupus familiaris,1,5313,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623676,,6835,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",9615.0,50588,,Canis lupus familiaris,1,5313,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623677,,6836,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17650,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623678,,6837,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,9615.0,50588,,Canis lupus familiaris,1,5199,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL623679,,6838,Time taken for maximum plasma concentration in dog,9615.0,50588,,Canis lupus familiaris,1,933,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623680,,6839,Time to reach Cmax after oral administration to dogs,9615.0,50588,,Canis lupus familiaris,1,16367,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623681,,6840,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,9615.0,50588,,Canis lupus familiaris,1,6348,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623682,,6841,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6316,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623683,,6842,Tmax after peroral administration (1 mg/kg) was determined in dog,9615.0,50588,,Canis lupus familiaris,1,6215,,,N,A
BAO_0000218,Expert,In vivo,,1,,,,,CHEMBL623684,,6843,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3598,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622745,,6844,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,4527,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622746,,6845,Tmax after peroral administration in dogs at 2.4 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622747,,6846,In vivo Cmax in mice at dose of 100 mg/kg,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622748,,6847,In vivo Cmax in mice at dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,5969,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622749,,6848,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,10090.0,50594,,Mus musculus,1,4573,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL622750,,6849,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),10090.0,50594,,Mus musculus,1,3277,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623411,,6850,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,10090.0,50594,,Mus musculus,1,17734,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL875946,,6851,Maximum concentration obtained in mouse plasma was determined,10090.0,50594,,Mus musculus,1,3132,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623412,,6852,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,10090.0,50594,,Mus musculus,1,3132,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623413,,6853,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,10090.0,50594,,Mus musculus,1,6348,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623414,,6854,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17729,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623415,,6855,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,10090.0,50594,,Mus musculus,1,17729,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623416,,6856,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,10090.0,50594,,Mus musculus,1,17729,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623417,,6857,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,10090.0,50594,,Mus musculus,1,17728,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623418,,6858,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,10090.0,50594,,Mus musculus,1,17728,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623419,,6859,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,10090.0,50594,,Mus musculus,1,17728,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622816,,6860,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,10090.0,50594,,Mus musculus,1,4066,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623313,,6861,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,10090.0,50594,,Mus musculus,1,6178,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623314,,6862,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,10090.0,50594,,Mus musculus,1,6178,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876788,,6863,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,10090.0,50594,,Mus musculus,1,3760,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623315,,6864,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,10090.0,50594,,Mus musculus,1,3760,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623316,,6865,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,10090.0,50594,,Mus musculus,1,3760,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623317,,6866,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,10090.0,50594,,Mus musculus,1,3760,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623319,,6868,Cmax in male mice after 2 mg/kg oral dose,10090.0,50594,,Mus musculus,1,5961,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623320,,6869,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,10090.0,50594,,Mus musculus,1,6137,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623321,,6870,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,10090.0,50594,,Mus musculus,1,3802,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623322,,6871,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,10090.0,50594,,Mus musculus,1,3535,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623323,,6872,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,10090.0,50594,,Mus musculus,1,3535,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623324,,6873,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,10090.0,50594,,Mus musculus,1,3535,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623325,,6874,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,10090.0,50594,,Mus musculus,1,3535,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623326,,6875,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,10090.0,50594,,Mus musculus,1,3535,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL623327,,6876,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,10090.0,50594,,Mus musculus,1,3535,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL623328,,6877,Maximum concentration in plasma upon oral administration in mouse,10090.0,50594,,Mus musculus,1,2862,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL623329,,6878,Maximum plasma concentration was evaluated in mice after oral administration,10090.0,50594,,Mus musculus,1,2675,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL623330,,6879,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,10090.0,50594,,Mus musculus,1,2675,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL876789,,6880,Dose at which the compound induced fecal excretion in mice,10090.0,50594,,Mus musculus,1,5399,,,N,A
BAO_0000219,Expert,,164.0,1,,,A10,,CHEMBL623333,,6893,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,10116.0,80013,,Rattus norvegicus,1,11819,,,N,F
BAO_0000219,Expert,,164.0,1,,,A10,,CHEMBL623334,,6894,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,10116.0,80013,,Rattus norvegicus,1,11819,,,N,F
BAO_0000219,Expert,,164.0,1,,,A10,,CHEMBL627536,,6895,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,10116.0,80013,,Rattus norvegicus,1,11819,,,N,F
BAO_0000219,Expert,,164.0,1,,,A10,,CHEMBL627537,,6896,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,10116.0,80013,,Rattus norvegicus,1,11819,,,N,F
BAO_0000219,Intermediate,,164.0,1,,,A10,,CHEMBL627538,,6897,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),10116.0,80013,,Rattus norvegicus,1,16361,,,N,F
BAO_0000219,Intermediate,,393.0,1,,,A121,,CHEMBL884106,,6898,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,9606.0,80655,,Homo sapiens,1,2288,,,N,F
BAO_0000219,Intermediate,,393.0,1,,,A121,,CHEMBL625294,,6899,Anticancer activity against human ovarian carcinoma A121 cells,9606.0,80655,,Homo sapiens,1,10404,,,N,F
BAO_0000219,Intermediate,,393.0,1,,,A121,,CHEMBL625295,,6900,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,9606.0,80655,,Homo sapiens,1,14790,,,N,F
BAO_0000219,Intermediate,,393.0,1,,,A121,,CHEMBL625296,,6901,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,9606.0,80655,,Homo sapiens,1,14790,,,N,F
BAO_0000219,Expert,,393.0,1,,,A121,,CHEMBL625297,,6902,Growth inhibition of human ovarian carcinoma (A121) cell line,9606.0,80655,,Homo sapiens,1,14253,,,N,F
BAO_0000219,Expert,,393.0,1,,,A121,,CHEMBL625298,,6903,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,9606.0,80655,,Homo sapiens,1,13617,,,N,F
BAO_0000219,Intermediate,,393.0,1,,,A121,,CHEMBL625960,,6904,Cytotoxicity against human A121 ovarian cells,9606.0,80655,,Homo sapiens,1,1003,,,N,F
BAO_0000219,Intermediate,,393.0,1,,,A121,,CHEMBL625961,,6905,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,9606.0,80655,,Homo sapiens,1,830,,,N,F
BAO_0000219,Intermediate,,393.0,1,,,A121,,CHEMBL625962,,6906,In vitro cytotoxicity against human ovarian carcinoma A21,9606.0,80655,,Homo sapiens,1,12307,,,N,F
BAO_0000219,Intermediate,,393.0,1,,,A121,,CHEMBL624717,,6907,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,9606.0,80655,,Homo sapiens,1,14254,,,N,F
BAO_0000219,Intermediate,,393.0,1,,,A121,,CHEMBL624718,,6908,Inhibitory activity of compound against human A121 ovarian cell line.,9606.0,80655,,Homo sapiens,1,13370,,,N,F
BAO_0000219,Intermediate,,393.0,1,,,A121,,CHEMBL624719,,6909,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,9606.0,80655,,Homo sapiens,1,14790,,,N,F
BAO_0000219,Intermediate,,393.0,1,,,A121,,CHEMBL624720,,6910,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,9606.0,80655,,Homo sapiens,1,3614,,,N,F
BAO_0000219,Intermediate,,622.0,1,,,A 172,,CHEMBL624721,,6911,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,9606.0,80012,,Homo sapiens,1,2664,,,N,F
BAO_0000219,Expert,,622.0,1,,,A 172,,CHEMBL624722,,6912,In vitro cytotoxicity against A172 human tumor cell lines.,9606.0,80012,,Homo sapiens,1,2037,,,N,F
BAO_0000219,Intermediate,,622.0,1,,,A 172,,CHEMBL877597,,6913,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,9606.0,80012,,Homo sapiens,1,14539,,,N,F
BAO_0000219,Intermediate,,622.0,1,,,A 172,,CHEMBL624723,,6914,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,9606.0,80012,,Homo sapiens,1,2836,,,N,F
BAO_0000219,Intermediate,,622.0,1,,,A 172,,CHEMBL624724,,6915,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,9606.0,80012,,Homo sapiens,1,10708,,,N,F
BAO_0000224,Autocuration,,,1,,,,,CHEMBL624725,,6916,Association constant against A2 adenosine receptor,9615.0,104729,,Canis lupus familiaris,4,8975,,,H,B
BAO_0000219,Intermediate,,1085.0,1,,,A2,,CHEMBL624726,,6917,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,80656,,fish,1,7645,,,N,F
BAO_0000224,Autocuration,,,1,,,,,CHEMBL857535,,6918,Ratio of Ki for adenosine A2 and A1 receptor binding,10116.0,104713,,Rattus norvegicus,5,11377,,,D,B
BAO_0000219,Expert,,623.0,1,,,A204,,CHEMBL624727,,6919,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,9606.0,80014,,Homo sapiens,1,13528,,,N,F
BAO_0000219,Expert,,623.0,1,,,A204,,CHEMBL624728,,6920,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,9606.0,80014,,Homo sapiens,1,10160,,,N,F
BAO_0000219,Intermediate,,404.0,1,,,A2058,,CHEMBL624729,,6921,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,9606.0,80015,,Homo sapiens,1,15144,,,N,F
BAO_0000219,Intermediate,,973.0,1,,,A253 cell line,,CHEMBL624730,,6922,Growth inhibition against Human squamous cell line(A 253),9606.0,80657,,Homo sapiens,1,13160,,,N,F
BAO_0000219,Intermediate,,973.0,1,,,A253 cell line,,CHEMBL624731,,6923,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,9606.0,80657,,Homo sapiens,1,12898,,,N,F
BAO_0000219,Intermediate,,973.0,1,,,A253 cell line,,CHEMBL624732,,6924,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,9606.0,80657,,Homo sapiens,1,13069,,,N,F
BAO_0000219,Intermediate,,973.0,1,,,A253 cell line,,CHEMBL883245,,6925,Growth inhibition of A253 cell lines.,9606.0,80657,,Homo sapiens,1,15984,,,N,F
BAO_0000219,Intermediate,,973.0,1,,,A253 cell line,,CHEMBL624733,,6926,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),9606.0,80657,,Homo sapiens,1,15564,,,N,F
BAO_0000219,Intermediate,,973.0,1,,,A253 cell line,,CHEMBL624734,,6927,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,9606.0,80657,,Homo sapiens,1,15564,,,N,F
BAO_0000219,Intermediate,,973.0,1,,,A253 cell line,,CHEMBL624735,,6928,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,9606.0,80657,,Homo sapiens,1,15564,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621780,,6929,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,9606.0,81034,,Homo sapiens,1,4720,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL877598,,6930,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,9606.0,81034,,Homo sapiens,1,16112,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL621781,,6931,Cytotoxic activity against A2780 human ovarian carcinoma cell line,9606.0,81034,,Homo sapiens,1,16597,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621782,,6932,Cytotoxicity against human cancer cell lines A2780 (ovarian),9606.0,81034,,Homo sapiens,1,16378,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL621783,,6933,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,9606.0,81034,,Homo sapiens,1,16085,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621784,,6934,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,9606.0,81034,,Homo sapiens,1,16317,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621785,,6935,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),9606.0,81034,,Homo sapiens,1,15748,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL621968,,6936,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,9606.0,81034,,Homo sapiens,1,16597,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL621969,,6937,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,9606.0,81034,,Homo sapiens,1,16597,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL621970,,6938,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,9606.0,81034,,Homo sapiens,1,16597,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621971,,6939,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,9606.0,81034,,Homo sapiens,1,15608,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621972,,6940,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,9606.0,81034,,Homo sapiens,1,15608,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL884108,,6941,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,9606.0,81034,,Homo sapiens,1,15608,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623826,,6942,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,10029.0,22224,,Cricetulus griseus,0,15296,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL623827,,6943,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,10029.0,22224,,Cricetulus griseus,0,10251,,,U,A
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL623828,,6944,Evaluated for growth inhibition of AA8 cells under aerobic conditions,10029.0,22224,,Cricetulus griseus,0,10251,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL623829,,6945,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,10029.0,22224,,Cricetulus griseus,0,10251,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL623830,,6946,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),10029.0,22224,,Cricetulus griseus,0,10251,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623831,,6947,Growth inhibition against CHO-derived cell line AA8,10029.0,22224,,Cricetulus griseus,0,11858,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL623832,,6948,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],10029.0,22224,,Cricetulus griseus,0,11858,,,U,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL623833,,6949,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,36483.0,80089,,hampster,1,11616,,,N,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL623834,,6950,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,10029.0,80089,,Cricetulus griseus,1,11616,,,N,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL623835,,6951,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,10029.0,22224,,Cricetulus griseus,0,10518,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL623836,,6952,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,10029.0,22224,,Cricetulus griseus,0,11396,,,U,F
BAO_0000219,Autocuration,,185.0,1,,,CHO-AA8,,CHEMBL623837,,6953,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,10029.0,22224,,Cricetulus griseus,0,10518,,,U,F
BAO_0000219,Expert,,185.0,1,,,CHO-AA8,,CHEMBL623838,,6954,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,10029.0,80089,,Cricetulus griseus,1,11616,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623839,,6955,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,12675,,,8,14837,,,H,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL623840,,6956,Number of binding sites (n) of isolated serum protein AAG,,12675,,,8,14837,,,H,F
BAO_0000225,Intermediate,,,1,,,,,CHEMBL623841,,6957,Association constant for binding to AATT duplex,,22222,,,3,16037,,,M,B
BAO_0000219,Expert,,416.0,1,,,ABAE,,CHEMBL623842,,6958,Inhibition of ABAE human fibroblast cell proliferation,9606.0,100090,,Homo sapiens,1,16597,,,N,F
BAO_0000218,Intermediate,,1064.0,1,,,AC755,,CHEMBL623843,,6959,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",10090.0,80668,,Mus musculus,1,8831,,,N,F
BAO_0000218,Expert,,,1,,,,,CHEMBL618669,,6960,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,9986.0,102444,,Oryctolagus cuniculus,9,13419,,,D,F
BAO_0000218,Expert,In vivo,,1,,,,,CHEMBL618670,,6961,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,9986.0,102444,,Oryctolagus cuniculus,9,13419,,,D,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618671,,6962,Inhibitory activity against angiotensin-converting enzyme (ACE).,,69,,,8,15778,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL618672,,6963,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,69,,,8,15778,,,H,B
BAO_0000219,Intermediate,,978.0,1,,,ACH-2 cell line,,CHEMBL618673,,6964,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,9606.0,80669,,Homo sapiens,1,12988,,,N,F
BAO_0000219,Intermediate,,978.0,1,,,ACH-2 cell line,,CHEMBL618674,,6965,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),9606.0,80669,,Homo sapiens,1,12988,,,N,F
BAO_0000219,Autocuration,,998.0,1,,,T cell line,,CHEMBL618675,,6966,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,11676.0,22224,,Human immunodeficiency virus 1,0,12988,,,U,F
BAO_0000219,Autocuration,,998.0,1,,,T cell line,,CHEMBL618676,,6967,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),11676.0,22224,,Human immunodeficiency virus 1,0,12988,,,U,F
BAO_0000219,Autocuration,,998.0,1,,,T cell line,,CHEMBL618677,,6968,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),11676.0,22224,,Human immunodeficiency virus 1,0,12988,,,U,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL618678,,6969,Inhibition of growth of renal cancer ACHN cell line,9606.0,80025,,Homo sapiens,1,11843,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL618679,,6970,Inhibition of growth of ACHN renal cancer cell line,9606.0,80025,,Homo sapiens,1,16939,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL618680,,6971,Inhibitory concentration required against ACHN renal cancer cell line,9606.0,80025,,Homo sapiens,1,4782,,,N,F
BAO_0000219,Expert,,626.0,1,,,ACHN,,CHEMBL618681,,6972,Concentration required to inhibit growth of human renal (ACHN) cell line,9606.0,80025,,Homo sapiens,1,6310,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL618682,,6973,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,9606.0,80025,,Homo sapiens,1,6310,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL618683,,6974,Cytotoxic activity against ACHN Renal cancer cell line,9606.0,80025,,Homo sapiens,1,12858,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL618684,,6975,Cytotoxicity evaluation against ACHN renal cancer cells,9606.0,80025,,Homo sapiens,1,17380,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL618685,,6976,In vitro antitumor activity against human renal ACHN cell line,9606.0,80025,,Homo sapiens,1,5858,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL876499,,6977,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,9606.0,80025,,Homo sapiens,1,3838,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL618686,,6978,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,9606.0,80025,,Homo sapiens,1,3838,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL618687,,6979,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",9606.0,80025,,Homo sapiens,1,5406,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL618688,,6980,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,9606.0,80025,,Homo sapiens,1,4071,,,N,F
BAO_0000219,Expert,,626.0,1,,,ACHN,,CHEMBL618689,,6981,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,9606.0,80025,,Homo sapiens,1,4071,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL618690,,6982,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,9606.0,80025,,Homo sapiens,1,4071,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL618691,,6983,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,9606.0,80025,,Homo sapiens,1,15002,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL619373,,6984,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),9606.0,80025,,Homo sapiens,1,14769,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL884008,,6985,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",9606.0,80025,,Homo sapiens,1,13958,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL619374,,6986,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,9606.0,80025,,Homo sapiens,1,1665,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL619375,,6987,Compound was tested for the growth inhibition of ACHN renal tumor cell line,9606.0,80025,,Homo sapiens,1,15354,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL619376,,6988,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,9606.0,80025,,Homo sapiens,1,15354,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL619377,,6989,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,9606.0,80025,,Homo sapiens,1,13978,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL619378,,6990,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,9606.0,80025,,Homo sapiens,1,6798,,,N,F
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL872527,,6991,Tmax value after administration of 4 mg/Kg oral dose in dog,9615.0,50588,,Canis lupus familiaris,1,2959,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL876500,,6992,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",9615.0,50588,,Canis lupus familiaris,1,9932,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619379,,6993,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,9615.0,50588,,Canis lupus familiaris,1,5546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619538,,6994,Volume distribution after 15 mg/kg iv dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619539,,6995,Volume distribution after 30 mg/kg po dose in Dogs,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619540,,6996,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,9615.0,50588,,Canis lupus familiaris,1,4257,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619541,,6997,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,4305,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619542,,6998,Volume of distribution was evaluated in dog,9615.0,50588,,Canis lupus familiaris,1,5472,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619543,,6999,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6062,,,N,A
BAO_0000218,Expert,,,1,,,,,CHEMBL619544,,7000,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3598,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619545,,7001,The compound was tested for volume of distribution in dog,9615.0,50588,,Canis lupus familiaris,1,12500,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619546,,7002,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,9615.0,50588,,Canis lupus familiaris,1,12500,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619547,,7003,Vd (1 mg/kg) was determined in dog (in vivo),9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619548,,7004,Vd in dog,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619549,,7005,Volume distribution was determined,9615.0,50588,,Canis lupus familiaris,1,4219,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619550,,7006,Volume of distribution in dog,9615.0,50588,,Canis lupus familiaris,1,1696,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876501,,7007,Volume of distribution by as 4 fold increase by iv administration in dogs,9615.0,50588,,Canis lupus familiaris,1,5542,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619551,,7008,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,9615.0,50588,,Canis lupus familiaris,1,5199,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619552,,7009,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,9615.0,50588,,Canis lupus familiaris,1,6348,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619553,,7010,Volume distribution at the dose of 2 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4727,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618722,,7011,Steady state volume of distribution was determined,9615.0,50588,,Canis lupus familiaris,1,16367,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618723,,7012,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,9615.0,50588,,Canis lupus familiaris,1,2652,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618724,,7013,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618725,,7014,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618726,,7015,Bioavailability in dog (dose 1 mg/kg i.v.),9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618727,,7016,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),9615.0,50588,,Canis lupus familiaris,1,5334,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624233,,7017,Pharmacokinetic property (vdss) was measured in dog,9615.0,50588,,Canis lupus familiaris,1,4239,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624234,,7018,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4709,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624235,,7019,Vdss was determined after iv 0.1 mg/kg administration in dog,9615.0,50588,,Canis lupus familiaris,1,5600,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624236,,7020,Volume displacement was calculated in dog,9615.0,50588,,Canis lupus familiaris,1,6057,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624237,,7021,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5654,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624238,,7022,Volume distribution constant was determined,9615.0,50588,,Canis lupus familiaris,1,5505,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624239,,7023,Volume distribution at a dose of 1 uM/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,4527,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875829,,7024,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,9615.0,50588,,Canis lupus familiaris,1,4521,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624240,,7025,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,9615.0,50588,,Canis lupus familiaris,1,4521,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624241,,7026,Volume distribution (Vdss) was measured in dog,9615.0,50588,,Canis lupus familiaris,1,15660,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624242,,7027,Volume distribution (Vdss) was measured in dog,9615.0,50588,,Canis lupus familiaris,1,15660,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624243,,7028,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,9615.0,50588,,Canis lupus familiaris,1,6679,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624244,,7029,Volume of distribution in steady state was determined in dog,9615.0,50588,,Canis lupus familiaris,1,5145,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624245,,7030,Volume of distribution of compound was determined in dog,9615.0,50588,,Canis lupus familiaris,1,6821,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624246,,7031,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,9615.0,50588,,Canis lupus familiaris,1,4137,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624247,,7032,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),9615.0,50588,,Canis lupus familiaris,1,5334,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624248,,7033,Volume of distribution (Vdss) was measured in dog,9615.0,50588,,Canis lupus familiaris,1,15660,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624249,,7034,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),9615.0,50588,,Canis lupus familiaris,1,6642,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624250,,7035,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),9615.0,50588,,Canis lupus familiaris,1,6641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624251,,7036,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),9615.0,50588,,Canis lupus familiaris,1,6642,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624252,,7037,Maximum rate of depolarization of the upstroke of the action potential,9615.0,50588,,Canis lupus familiaris,1,11659,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624253,,7038,Steady state volume distribution in dog,9615.0,50588,,Canis lupus familiaris,1,6448,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624950,,7039,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,9615.0,50588,,Canis lupus familiaris,1,5474,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624951,,7040,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,9615.0,50588,,Canis lupus familiaris,1,1466,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875830,,7041,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,9615.0,50588,,Canis lupus familiaris,1,6535,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624952,,7042,Volume distribution in dog after administration of 1 mg/kg iv,9615.0,50588,,Canis lupus familiaris,1,6535,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624953,,7043,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17764,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624954,,7044,Vss after intravenous administration (0.5 mg/kg) was determined in dog,9615.0,50588,,Canis lupus familiaris,1,6215,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624955,,7045,Vss on i.v. administration of 2 mg/kg was measured in dog,9615.0,50588,,Canis lupus familiaris,1,6505,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624956,,7046,Vss was determined,9615.0,50588,,Canis lupus familiaris,1,3639,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625129,,7047,Vss in dog,9615.0,50588,,Canis lupus familiaris,1,3639,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625130,,7048,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6062,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625131,,7049,Volume distribution in dogs,9615.0,50588,,Canis lupus familiaris,1,4942,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625132,,7050,Volume of distribution in dog,9615.0,50588,,Canis lupus familiaris,1,17796,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL872263,,7051,Tested for the oral bioavailability in dog,9615.0,50588,,Canis lupus familiaris,1,4883,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624336,,7060,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,10090.0,50594,,Mus musculus,1,17837,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624337,,7061,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,10090.0,50594,,Mus musculus,1,17729,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624338,,7062,Bioavailability after peroral administration of 50 mg/kg of dose in mice,10090.0,50594,,Mus musculus,1,17729,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624339,,7063,Bioavailability was measured in mouse,10090.0,50594,,Mus musculus,1,4239,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624340,,7064,Bioavailability in mouse,10090.0,50594,,Mus musculus,1,17592,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624341,,7065,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,10090.0,50594,,Mus musculus,1,6348,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624342,,7066,Bioavailability in mouse,10090.0,50594,,Mus musculus,1,2801,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624343,,7067,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,10090.0,50594,,Mus musculus,1,2801,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624344,,7068,Oral bioavailability in mouse,10090.0,50594,,Mus musculus,1,17718,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624345,,7069,Oral availability at 50 mg/kg po in male mice,10090.0,50594,,Mus musculus,1,5727,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624346,,7070,Oral bioavailability in mouse (dose 10 mg/kg),10090.0,50594,,Mus musculus,1,5302,,,N,A
BAO_0000218,Expert,In vivo,,1,,,,,CHEMBL624347,,7071,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,10090.0,50594,,Mus musculus,1,3598,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624348,,7072,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",10090.0,50594,,Mus musculus,1,5961,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622754,,7074,Oral bioavailability in mouse,10090.0,50594,,Mus musculus,1,6091,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622755,,7075,Oral bioavailability in vivo in mice;ND=Not determined,10090.0,50594,,Mus musculus,1,6091,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622756,,7076,Oral bioavailability in mouse at 10 mg/kg of the compound,10090.0,50594,,Mus musculus,1,5711,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622757,,7077,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),10090.0,50594,,Mus musculus,1,17728,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622758,,7078,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),10090.0,50594,,Mus musculus,1,17728,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622759,,7079,Tested for bioavailability of the compound,10090.0,50594,,Mus musculus,1,3802,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622760,,7080,Tested for half life at the dose of 10 mg/kg when administered intravenously,10090.0,50594,,Mus musculus,1,3802,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL622761,,7081,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,10090.0,50594,,Mus musculus,1,14029,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL622762,,7082,The plasma half life of compound was determined on heparin prepared by human plasma. ,10090.0,50594,,Mus musculus,1,14029,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL622763,,7083,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,10090.0,50594,,Mus musculus,1,14029,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL622764,,7084,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,10090.0,50594,,Mus musculus,1,14029,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL622765,,7085,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,10090.0,50594,,Mus musculus,1,14029,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622766,,7086,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622767,,7087,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL622768,,7088,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,10090.0,50594,,Mus musculus,1,17753,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL875948,,7089,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL622769,,7090,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL622770,,7091,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL622771,,7092,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL622772,,7093,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL622773,,7094,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL622774,,7095,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL621725,,7096,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL621726,,7097,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621727,,7098,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,9606.0,81034,,Homo sapiens,1,15608,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL622413,,7099,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,9606.0,81034,,Homo sapiens,1,3290,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622414,,7100,Compound was evaluated for cytotoxicity against A2780 cell line,9606.0,81034,,Homo sapiens,1,2859,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL622415,,7101,Inhibition of A2780 cell clonogenic assay,9606.0,81034,,Homo sapiens,1,15688,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL884001,,7102,Cytotoxic effect on ovarian cancer cell line (A2780),9606.0,81034,,Homo sapiens,1,5642,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622416,,7103,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,9606.0,81034,,Homo sapiens,1,6633,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622417,,7104,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",9606.0,81034,,Homo sapiens,1,3906,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL622590,,7105,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,9606.0,81034,,Homo sapiens,1,6788,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL622591,,7106,Antiproliferative activity against human A2780 cells,9606.0,81034,,Homo sapiens,1,17582,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL622592,,7107,Inhibition of human A2780 cell proliferation,9606.0,81034,,Homo sapiens,1,17764,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL622593,,7108,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,9606.0,81034,,Homo sapiens,1,17764,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL622594,,7109,Inhibition of human A2780 cell proliferation (No data),9606.0,81034,,Homo sapiens,1,17764,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622595,,7110,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,9606.0,81034,,Homo sapiens,1,2815,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622596,,7111,Compound was evaluated against human Ovarian carcinoma cell line A2780,9606.0,81034,,Homo sapiens,1,16930,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL622597,,7112,Growth inhibition against A2780 wild-type ovarian cell lines,9606.0,81034,,Homo sapiens,1,17777,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622598,,7113,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,9606.0,81034,,Homo sapiens,1,17777,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL622599,,7114,Inhibition of tubulin polymerization in human ovarian cancer cell lines,9606.0,104766,,Homo sapiens,5,16936,,,D,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622600,,7115,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,9606.0,81034,,Homo sapiens,1,13759,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622601,,7116,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,9606.0,81034,,Homo sapiens,1,13759,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622602,,7117,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,9606.0,81034,,Homo sapiens,1,13759,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622603,,7118,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,9606.0,81034,,Homo sapiens,1,13759,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622604,,7119,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,9606.0,81034,,Homo sapiens,1,15292,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622605,,7120,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,9606.0,81034,,Homo sapiens,1,15292,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL622606,,7121,In vitro inhibition of human ovarian cell line A2780,9606.0,81034,,Homo sapiens,1,15069,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL619463,,7122,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",9606.0,81034,,Homo sapiens,1,15069,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619464,,7123,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),9606.0,81034,,Homo sapiens,1,14073,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL619465,,7124,Concentration required to inhibit A2780-cell growth by 50%,9606.0,81034,,Homo sapiens,1,14553,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL619466,,7125,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,9606.0,81034,,Homo sapiens,1,13040,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL619467,,7126,Cytotoxic effect on human ovarian (A2780) cancer cell line,9606.0,81034,,Homo sapiens,1,6891,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619468,,7127,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,9606.0,81034,,Homo sapiens,1,15569,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL619469,,7128,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,9606.0,81034,,Homo sapiens,1,14190,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL619470,,7129,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,9606.0,81034,,Homo sapiens,1,15014,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619471,,7130,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,9606.0,81034,,Homo sapiens,1,15014,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619472,,7131,Cytotoxicity against human ovarian carcinoma A2780 cell line,9606.0,81034,,Homo sapiens,1,17496,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL619473,,7132,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",9606.0,81034,,Homo sapiens,1,13617,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL874368,,7133,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",9606.0,81034,,Homo sapiens,1,13617,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL884003,,7134,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",9606.0,81034,,Homo sapiens,1,13617,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622690,,7135,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",9606.0,81034,,Homo sapiens,1,13617,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622691,,7136,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,9606.0,81034,,Homo sapiens,1,17672,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL622692,,7137,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,9606.0,81034,,Homo sapiens,1,4544,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL623406,,7138,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,9606.0,81034,,Homo sapiens,1,4544,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL884004,,7139,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",9606.0,81034,,Homo sapiens,1,16317,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL623407,,7140,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,9606.0,81034,,Homo sapiens,1,15099,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL623408,,7141,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,9606.0,81034,,Homo sapiens,1,13978,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL623409,,7142,In vitro antitumor activity against A2780 cell line.,9606.0,81034,,Homo sapiens,1,12989,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL623410,,7143,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,9606.0,81034,,Homo sapiens,1,5574,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL623576,,7144,In vitro cytotoxicity against A2780 human ovarian cancer cell line,9606.0,81034,,Homo sapiens,1,13528,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623577,,7145,Inhibitory activity against kidney A-CHN tumor cell growth in culture,9606.0,80025,,Homo sapiens,1,12782,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623578,,7146,The IC50 value was measured on ACHN cell line in renal tumor type.,9606.0,80025,,Homo sapiens,1,14255,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623579,,7147,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,9606.0,80025,,Homo sapiens,1,16364,,,N,F
BAO_0000219,Expert,,626.0,1,,,ACHN,,CHEMBL623580,,7148,In vitro lethal concentration against most sensitive ACHN cell line,9606.0,80025,,Homo sapiens,1,17376,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623581,,7149,Tested for cytotoxic activity against renal cancer ACHN cell line,9606.0,80025,,Homo sapiens,1,12016,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL857456,,7150,Compound tested for growth inhibition of renal cancer cell line ACHN,9606.0,80025,,Homo sapiens,1,6058,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623582,,7151,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,9606.0,80025,,Homo sapiens,1,17708,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623583,,7152,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,9606.0,80025,,Homo sapiens,1,15176,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623584,,7153,In vitro anticancer activity against ACHN renal cancer cell line,9606.0,80025,,Homo sapiens,1,2806,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623585,,7154,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,9606.0,80025,,Homo sapiens,1,15300,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623586,,7155,Percent selectivity was evaluated in renal ACHN cell lines,9606.0,80025,,Homo sapiens,1,16364,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623587,,7156,In vitro inhibitory activity against renal ACHN cancer cell line,9606.0,80025,,Homo sapiens,1,13859,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL875279,,7157,Tested for cytotoxicity against ACHN cell lines in renal cancer,9606.0,80025,,Homo sapiens,1,11970,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623588,,7158,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,9606.0,80025,,Homo sapiens,1,2450,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623589,,7159,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,9606.0,80025,,Homo sapiens,1,12696,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623590,,7160,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,9606.0,80025,,Homo sapiens,1,12400,,,N,F
BAO_0000219,Expert,,626.0,1,,,ACHN,,CHEMBL623591,,7161,Cytotoxic effect on renal cancer line ACHN,9606.0,80025,,Homo sapiens,1,12888,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623592,,7162,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,9606.0,80025,,Homo sapiens,1,3156,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623593,,7163,In vitro inhibition of Renal Cancer ACHN cell lines,9606.0,80025,,Homo sapiens,1,3381,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL623594,,7164,Antitumor activity against human renal adenocarcinoma ACHN cells,9606.0,80025,,Homo sapiens,1,16747,,,N,F
BAO_0000219,Expert,,626.0,1,,,ACHN,,CHEMBL621833,,7165,Antitumor activity against human renal adenocarcinoma ACHN cells.,9606.0,80025,,Homo sapiens,1,16748,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL621834,,7166,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,9606.0,80025,,Homo sapiens,1,12062,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL621835,,7167,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),9606.0,80025,,Homo sapiens,1,14769,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL621836,,7168,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",9606.0,80025,,Homo sapiens,1,15895,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL621837,,7169,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,9606.0,80025,,Homo sapiens,1,17376,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL875280,,7170,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,9606.0,80025,,Homo sapiens,1,14882,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL621838,,7171,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,9606.0,80025,,Homo sapiens,1,14882,,,N,F
BAO_0000219,Intermediate,,626.0,1,,,ACHN,,CHEMBL621839,,7172,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,9606.0,80025,,Homo sapiens,1,15661,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621840,,7173,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,22224,,,0,9680,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621841,,7174,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,10647,,,8,14579,,,H,F
BAO_0000218,Expert,,468.0,1,,,HEL,,CHEMBL622979,,7175,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,10358.0,50529,,Cytomegalovirus,1,17290,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL876595,,7176,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,10358.0,50529,,Cytomegalovirus,1,17290,,,N,F
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620221,,7177,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,12159,,,8,15891,,,H,B
BAO_0000357,Autocuration,,,1,,,,,CHEMBL620222,,7178,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,12159,,,8,15890,,,H,B
BAO_0000219,Intermediate,,979.0,1,,,ADDP cell line,,CHEMBL620506,,7179,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,9913.0,80670,,Bos taurus,1,3801,,,N,F
BAO_0000219,Intermediate,,980.0,1,,,ADJ/PC6,,CHEMBL620507,,7180,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,10090.0,80671,,Mus musculus,1,9222,,,N,F
BAO_0000219,Intermediate,,980.0,1,,,ADJ/PC6,,CHEMBL620508,,7181,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,10090.0,80671,,Mus musculus,1,9222,,,N,F
BAO_0000219,Intermediate,,980.0,1,,,ADJ/PC6,,CHEMBL620509,,7182,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",10090.0,80671,,Mus musculus,1,7257,,,N,F
BAO_0000219,Intermediate,,980.0,1,,,ADJ/PC6,,CHEMBL620510,,7183,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,10090.0,80671,,Mus musculus,1,7257,,,N,F
BAO_0000219,Intermediate,,980.0,1,,,ADJ/PC6,,CHEMBL620511,,7184,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,10090.0,80671,,Mus musculus,1,7257,,,N,A
BAO_0000219,Intermediate,,980.0,1,,,ADJ/PC6,,CHEMBL620512,,7185,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,10090.0,80671,,Mus musculus,1,8084,,,N,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620513,,7186,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,10090.0,22224,,Mus musculus,0,14943,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620514,,7187,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,10090.0,22224,,Mus musculus,0,14943,,,U,F
BAO_0000019,Autocuration,,,1,,,,,CHEMBL620515,,7188,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,10090.0,22224,,Mus musculus,0,14943,,,U,F
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL620516,,7189,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1423.0,22224,,Bacillus subtilis,0,10524,,,U,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL620517,,7190,AUC value in dog after IV administration at a dose of 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3546,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL620518,,7191,AUC value in dog after oral administration at a dose of 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL620519,,7192,Cmax value in dog after oral administration at a dose of 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621386,,7193,Bioavailability in dog after oral administration at a dose of 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621387,,7194,Tmax value in dog after oral administration at a dose of 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621388,,7195,Compound was evaluated for its clearance when administered intravenously in dog,9615.0,50588,,Canis lupus familiaris,1,3184,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621389,,7196,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,16456,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621390,,7197,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),9615.0,50588,,Canis lupus familiaris,1,4809,,,N,A
BAO_0000100,Intermediate,,,1,,,,,CHEMBL621391,,7198,Calculated partition coefficient (clogP),,22229,,,0,4219,,,U,P
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621392,,7199,Half life in dog,9615.0,50588,,Canis lupus familiaris,1,3748,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621393,,7200,Time taken for EC90 was determined when tested in dog,9615.0,50588,,Canis lupus familiaris,1,3132,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621394,,7201,Half life (iv) was determined,9615.0,50588,,Canis lupus familiaris,1,4219,,,N,A
BAO_0000218,Intermediate,,,1,,Liver,,2107.0,CHEMBL621395,,7202,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621396,,7203,Area under the curve was calculated in dog after iv administration,9615.0,50588,,Canis lupus familiaris,1,6057,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621397,,7204,Area under the curve was calculated in dog after peroral administration,9615.0,50588,,Canis lupus familiaris,1,6057,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621398,,7205,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,9615.0,50588,,Canis lupus familiaris,1,17853,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618818,,7206,pKa was evaluated in dog,9615.0,50588,,Canis lupus familiaris,1,3639,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618819,,7207,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,9615.0,50588,,Canis lupus familiaris,1,14541,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618820,,7208,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,16456,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL873810,,7209,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,16456,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876606,,7210,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,9615.0,50588,,Canis lupus familiaris,1,2652,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618821,,7211,Compound was evaluated for the half-life (t 1/2) in hours,9615.0,50588,,Canis lupus familiaris,1,3624,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL618822,,7212,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,9615.0,50588,,Canis lupus familiaris,1,1337,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL618823,,7213,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,9615.0,50588,,Canis lupus familiaris,1,1337,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618824,,7214,Half life after intravenous administration of 1 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4709,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618825,,7215,Half life was measured in dog,9615.0,50588,,Canis lupus familiaris,1,15660,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618826,,7216,Half life period in dog after 5 mg/kg dose,9615.0,50588,,Canis lupus familiaris,1,5302,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618827,,7217,Half life period was evaluated in dog; 4-4.8,9615.0,50588,,Canis lupus familiaris,1,17791,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618828,,7218,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,9615.0,50588,,Canis lupus familiaris,1,6348,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL618829,,7219,Half-life was determined in dog after a3 mg/kg of iv dose,9615.0,50588,,Canis lupus familiaris,1,4257,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618830,,7220,Half-life was determined,9615.0,50588,,Canis lupus familiaris,1,3771,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL618831,,7221,Half life in dogs,9615.0,50588,,Canis lupus familiaris,1,6305,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL619489,,7222,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,9615.0,50588,,Canis lupus familiaris,1,13501,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619649,,7223,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,9615.0,50588,,Canis lupus familiaris,1,17594,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876607,,7224,Compound was evaluated for the half life period after iv administration in Beagle dog.,9615.0,50588,,Canis lupus familiaris,1,3045,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619650,,7225,Compound was evaluated for the half life period after oral administration in conscious dog.,9615.0,50588,,Canis lupus familiaris,1,3043,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619651,,7226,Compound was tested for half life in dog,9615.0,50588,,Canis lupus familiaris,1,4839,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619652,,7227,Compound was tested for its half life in dog,9615.0,50588,,Canis lupus familiaris,1,4839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619653,,7228,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,9615.0,50588,,Canis lupus familiaris,1,5802,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619654,,7229,Half life of compound in dog was determined,9615.0,50588,,Canis lupus familiaris,1,17839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619655,,7230,Half life (iv) was determined,9615.0,50588,,Canis lupus familiaris,1,4219,,,N,A
BAO_0000218,Intermediate,,,1,,Blood,,178.0,CHEMBL619656,,7231,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),9615.0,50588,,Canis lupus familiaris,1,13966,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL873812,,7232,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,9615.0,50588,,Canis lupus familiaris,1,3994,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL621365,,7233,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,9615.0,50588,,Canis lupus familiaris,1,3994,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621366,,7234,Half life in dog,9615.0,50588,,Canis lupus familiaris,1,4453,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL621367,,7235,Half life in dog plasma,9615.0,50588,,Canis lupus familiaris,1,6535,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL621368,,7236,Half life in dog plasma after administration of 0.25 mg/kg iv,9615.0,50588,,Canis lupus familiaris,1,6535,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL621369,,7237,Half life in dog plasma after administration of 1 mg/kg iv,9615.0,50588,,Canis lupus familiaris,1,6535,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL621370,,7238,Half life in dog plasma was determined at dose 10 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3132,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621371,,7239,Half life in dog was determined,9615.0,50588,,Canis lupus familiaris,1,5374,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621372,,7240,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),9615.0,50588,,Canis lupus familiaris,1,5007,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL621373,,7241,Half life upon exposure to human plasma,9615.0,50588,,Canis lupus familiaris,1,16907,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621374,,7242,Half life was calculated in dog,9615.0,50588,,Canis lupus familiaris,1,6057,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621375,,7243,Half life was determined,9615.0,50588,,Canis lupus familiaris,1,5006,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621376,,7244,Half life was determined,9615.0,50588,,Canis lupus familiaris,1,5473,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619624,,7245,Half life by intravenous administration of 1.2 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,4368,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL875840,,7246,Half life in dog,9615.0,50588,,Canis lupus familiaris,1,6448,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619625,,7247,Half life in dog after intra venous administration of the compound,9615.0,50588,,Canis lupus familiaris,1,4353,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619626,,7248,Half life in dog after intra venous administration of the compound; ND means Not determined,9615.0,50588,,Canis lupus familiaris,1,4353,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619627,,7249,Half life in dog after po administration of the compound,9615.0,50588,,Canis lupus familiaris,1,4353,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL873817,,7250,Half life in dog after po administration of the compound; ND means Not determined,9615.0,50588,,Canis lupus familiaris,1,4353,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619628,,7251,Half life in dog at the single oral dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6265,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619629,,7252,Half life in dogs,9615.0,50588,,Canis lupus familiaris,1,5006,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619630,,7253,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,9615.0,50588,,Canis lupus familiaris,1,5356,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL619631,,7254,Half life in rat,9615.0,50588,,Canis lupus familiaris,1,405,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL619632,,7255,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),9615.0,50588,,Canis lupus familiaris,1,6642,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL619633,,7256,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL875841,,7257,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL619634,,7258,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL619635,,7259,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL619636,,7260,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Gut,,10000004.0,CHEMBL619637,,7261,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Gut,,10000004.0,CHEMBL619638,,7262,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Gut,,10000004.0,CHEMBL619639,,7263,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Gut,,10000004.0,CHEMBL619640,,7264,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Gut,,10000004.0,CHEMBL619641,,7265,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Gut,,10000004.0,CHEMBL619642,,7266,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Gut,,10000004.0,CHEMBL619643,,7267,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL619644,,7268,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL621112,,7269,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL621113,,7270,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL621114,,7271,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL621115,,7272,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL621116,,7273,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL621117,,7274,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL621118,,7275,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL621119,,7276,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL621120,,7277,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL621757,,7278,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL621758,,7279,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL621759,,7280,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Kidney,,2113.0,CHEMBL621760,,7281,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL621761,,7282,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL621762,,7283,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL621763,,7284,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL624502,,7285,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL624503,,7286,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL624504,,7287,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Liver,,2107.0,CHEMBL624505,,7288,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL624506,,7289,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL624507,,7290,In vitro cytotoxicity against A2780 (human ovarian cancer),9606.0,81034,,Homo sapiens,1,5895,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL624508,,7291,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,9606.0,81034,,Homo sapiens,1,6338,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL624509,,7292,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,9606.0,81034,,Homo sapiens,1,15163,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL624510,,7293,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,9606.0,81034,,Homo sapiens,1,15163,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL875956,,7294,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,9606.0,81034,,Homo sapiens,1,15000,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL839885,,7295,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,9606.0,81034,,Homo sapiens,1,15000,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL624511,,7296,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,9606.0,81034,,Homo sapiens,1,14729,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL624512,,7297,In vitro cytotoxicity against A2780 cell line,9606.0,81034,,Homo sapiens,1,17270,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL624513,,7298,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,9606.0,81034,,Homo sapiens,1,5685,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL624514,,7299,In vitro inhibitory activity against human ovarian cancer A2780 cell line,9606.0,81034,,Homo sapiens,1,3563,,,N,F
BAO_0000218,Intermediate,,478.0,1,,,A2780,,CHEMBL618547,,7300,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,9606.0,81034,,Homo sapiens,1,17753,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618548,,7301,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",9606.0,81034,,Homo sapiens,1,16317,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618549,,7302,Inhibition of tubulin polymerization in analogy of ca.,9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618550,,7303,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,9606.0,81034,,Homo sapiens,1,3801,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL618551,,7304,Cytotoxic effect in ovarian cancer cell line (A2780),9606.0,81034,,Homo sapiens,1,6181,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618552,,7305,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,9606.0,81034,,Homo sapiens,1,5318,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618553,,7306,Tested for the cytotoxicity in A2780 ovarian cell line,9606.0,81034,,Homo sapiens,1,4840,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618554,,7307,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),9606.0,81034,,Homo sapiens,1,15748,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618555,,7308,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,9606.0,81034,,Homo sapiens,1,15748,,,N,F
BAO_0000219,Intermediate,,481.0,1,,,A2780cisR,,CHEMBL618556,,7309,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,80017,,,1,15748,,,N,F
BAO_0000219,Intermediate,,481.0,1,,,A2780cisR,,CHEMBL618557,,7310,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,80017,,,1,15748,,,N,F
BAO_0000219,Intermediate,,481.0,1,,,A2780cisR,,CHEMBL618558,,7311,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,80017,,,1,15748,,,N,F
BAO_0000219,Intermediate,,481.0,1,,,A2780cisR,,CHEMBL618559,,7312,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,80017,,,1,15748,,,N,F
BAO_0000218,Intermediate,,478.0,1,,,A2780,,CHEMBL618560,,7313,In vivo log of cells killed after administration of compound in A2780 cell line,9606.0,81034,,Homo sapiens,1,17753,,,N,F
BAO_0000218,Intermediate,In vivo,478.0,1,,,A2780,,CHEMBL618561,,7314,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,9606.0,81034,,Homo sapiens,1,17753,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618562,,7315,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618563,,7316,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618564,,7317,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618565,,7318,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000218,Intermediate,,478.0,1,,,A2780,,CHEMBL618566,,7319,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),9606.0,81034,,Homo sapiens,1,17528,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL618567,,7320,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,9606.0,81034,,Homo sapiens,1,6633,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL618568,,7321,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,9606.0,81034,,Homo sapiens,1,15000,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL618569,,7322,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,9606.0,81034,,Homo sapiens,1,17528,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621857,,7323,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621858,,7324,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621859,,7325,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621860,,7326,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621861,,7327,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL621862,,7328,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621863,,7329,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621864,,7330,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621865,,7331,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),9606.0,81034,,Homo sapiens,1,16936,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621866,,7332,In vitro antiproliferative activity against A2780 cell line,10090.0,81034,,Mus musculus,1,17737,,,N,F
BAO_0000219,Expert,,478.0,1,,,A2780,,CHEMBL621867,,7333,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,10090.0,81034,,Mus musculus,1,17764,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL621868,,7334,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,9606.0,81034,,Homo sapiens,1,3830,,,N,F
BAO_0000219,Intermediate,,478.0,1,,,A2780,,CHEMBL875282,,7335,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,9606.0,81034,,Homo sapiens,1,3829,,,N,F
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621869,,7336,Vc value in dog after IV administration at a dose of 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621870,,7337,Half life period in dog after IV administration at a dose of 5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,3546,,,N,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621871,,7338,Area under curve was determine after peroral administration at 10 mpk in Rhesus,9527.0,22224,,Cercopithecidae,0,5668,,,U,A
BAO_0000218,Autocuration,,,1,,Plasma,,1969.0,CHEMBL621243,,7339,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000218,Autocuration,,,1,,Plasma,,1969.0,CHEMBL621244,,7340,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621245,,7341,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,9541.0,22224,,Macaca fascicularis,0,4256,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621246,,7342,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,9541.0,22224,,Macaca fascicularis,0,4256,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621247,,7343,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,9541.0,22224,,Macaca fascicularis,0,4256,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618386,,7344,Oral Bioavailability in rat,10116.0,22224,,Rattus norvegicus,0,4256,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618387,,7345,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,9527.0,22224,,Cercopithecidae,0,1916,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618388,,7346,Area under curve value in monkey at a dose of 5 mg/kg,9527.0,22224,,Cercopithecidae,0,5302,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618389,,7347,Area under curve was determined in monkey after a 3 mg/kg of oral dose,9527.0,22224,,Cercopithecidae,0,4257,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618574,,7348,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618575,,7349,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618576,,7350,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618577,,7351,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,9527.0,22224,,Cercopithecidae,0,6078,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL876487,,7352,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,9527.0,22224,,Cercopithecidae,0,6078,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618578,,7353,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,9527.0,22224,,Cercopithecidae,0,6062,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618579,,7354,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,9527.0,22224,,Cercopithecidae,0,2661,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618580,,7355,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,9527.0,22224,,Cercopithecidae,0,2661,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618581,,7356,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,9527.0,22224,,Cercopithecidae,0,5394,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618582,,7357,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,9527.0,22224,,Cercopithecidae,0,4397,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618583,,7358,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,9527.0,22224,,Cercopithecidae,0,17509,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618584,,7359,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,9527.0,22224,,Cercopithecidae,0,17509,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618585,,7360,Oral AUCN in monkey (dosed at 0.5 mpk iv ),9527.0,22224,,Cercopithecidae,0,6641,,,U,A
BAO_0000218,Autocuration,,,1,,,,,CHEMBL618586,,7361,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618587,,7362,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618588,,7363,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,22224,,Cercopithecidae,0,3443,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618589,,7364,Binding towards monkey plasma protein at 10 uM,9527.0,22224,,Cercopithecidae,0,17409,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL618590,,7365,Binding towards monkey plasma protein at 100 uM,9527.0,22224,,Cercopithecidae,0,17409,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL872262,,7366,Apparent bioavailability in squirrel monkey was determined,9527.0,22224,,Cercopithecidae,0,1052,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618591,,7367,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,9527.0,22224,,Cercopithecidae,0,13501,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618592,,7368,Bioavailability in monkey (dose 2 mg/kg),9443.0,22224,,monkey,0,17509,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL876488,,7369,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,9527.0,22224,,Cercopithecidae,0,5394,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618593,,7370,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,9527.0,22224,,Cercopithecidae,0,2661,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618594,,7371,Bioavailability in monkey (i.d. dosing),9443.0,22224,,monkey,0,11219,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL618595,,7372,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,9527.0,22224,,Cercopithecidae,0,3045,,,U,A
BAO_0000019,Autocuration,,,1,,,,,CHEMBL621469,,7373,Clearance of the drug was measured in cynomolgus,9527.0,22224,,Cercopithecidae,0,17796,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621470,,7374,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,9527.0,22224,,Cercopithecidae,0,1399,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621471,,7375,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,9527.0,22224,,Cercopithecidae,0,2661,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,Plasma,,1969.0,CHEMBL621472,,7376,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,9544.0,22224,,Macaca mulatta,0,5005,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621473,,7377,Plasma clearance in rhesus monkey was determined,9527.0,22224,,Cercopithecidae,0,17267,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621474,,7378,Plasma clearance in monkey after administration of 1 mg/kg iv,9527.0,22224,,Cercopithecidae,0,6535,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621475,,7379,Plasma clearance in cynomolgus monkey,9527.0,22224,,Cercopithecidae,0,5922,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL621476,,7380,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,9527.0,22224,,Cercopithecidae,0,6221,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL624290,,7381,Plasma clearance after peroral administration at 10 mpk in Rhesus,9527.0,22224,,Cercopithecidae,0,5668,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL624291,,7382,The total clearance was determined after intravenous administration in cynomolgus monkeys,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL624292,,7383,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL624293,,7384,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,9527.0,22224,,Cercopithecidae,0,5355,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL624294,,7385,Tested for Clearance upon iv administration to african green monkey,9527.0,22224,,Cercopithecidae,0,4578,,,U,A
BAO_0000218,Autocuration,In vivo,,1,,,,,CHEMBL624295,,7386,Clearance in monkey,9527.0,22224,,Cercopithecidae,0,17592,,,U,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624296,,7387,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),9615.0,50588,,Canis lupus familiaris,1,6641,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624297,,7388,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),9615.0,50588,,Canis lupus familiaris,1,6642,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624298,,7389,Half life was evaluated after intravenous administration to dogs,9615.0,50588,,Canis lupus familiaris,1,16367,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624299,,7390,Half life was evaluated in dog,9615.0,50588,,Canis lupus familiaris,1,5472,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624300,,7391,Half life was evaluated in dog,9615.0,50588,,Canis lupus familiaris,1,5474,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624301,,7392,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5654,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624302,,7393,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876026,,7394,Half life period after intravenous administration in dog,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624303,,7395,Half life period after oral administration (2.5 mg/kg) in dog was determined,9615.0,50588,,Canis lupus familiaris,1,6221,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624304,,7396,Half life period at a dose of 1 uM/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,4527,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624305,,7397,Half life period was determine after peroral administration at 10 mpk in dog,9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624306,,7398,Half life period was determine after peroral administration at 5 mpk in dog,9615.0,50588,,Canis lupus familiaris,1,5668,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624307,,7399,Half life period was determined,9615.0,50588,,Canis lupus familiaris,1,3854,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624308,,7400,Half life period was determined,9615.0,50588,,Canis lupus familiaris,1,5505,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624309,,7401,Half life period by iv administration in dog at a dose of 6 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6251,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624310,,7402,Half life period was evaluated in dog,9615.0,50588,,Canis lupus familiaris,1,1918,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625003,,7403,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,9615.0,50588,,Canis lupus familiaris,1,5546,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625004,,7404,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),9615.0,50588,,Canis lupus familiaris,1,4809,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625005,,7405,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,9615.0,50588,,Canis lupus familiaris,1,6215,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL873813,,7406,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,4527,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625006,,7407,Half-life after oral dose of compound at 3 mg/kg in dogs,9615.0,50588,,Canis lupus familiaris,1,17594,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625007,,7408,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,9615.0,50588,,Canis lupus familiaris,1,17839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL876027,,7409,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,9615.0,50588,,Canis lupus familiaris,1,17839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625008,,7410,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,9615.0,50588,,Canis lupus familiaris,1,17839,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL625009,,7411,Half-life of compound in dog following p.o. administration of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,17839,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL625010,,7412,Half-life of compound in plasma of dog was determined,9615.0,50588,,Canis lupus familiaris,1,5210,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL625011,,7413,Half-life of compound was determined in dogs,9615.0,50588,,Canis lupus familiaris,1,5210,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621553,,7414,Half-life after administration of 4 mg/Kg oral dose in dog,9615.0,50588,,Canis lupus familiaris,1,2959,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621554,,7415,Half-life after intravenous administration of 1 mg/kg/h in dog,9615.0,50588,,Canis lupus familiaris,1,4137,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621555,,7416,Half-life in Dog,9615.0,50588,,Canis lupus familiaris,1,5064,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621556,,7417,Half-life in Dog,9615.0,50588,,Canis lupus familiaris,1,5147,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621557,,7418,Half-life in dog,9615.0,50588,,Canis lupus familiaris,1,5145,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621558,,7419,Half-life in dog after oral administration at 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6123,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621559,,7420,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,9615.0,50588,,Canis lupus familiaris,1,6123,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL621560,,7421,Half-life in dogs,9615.0,50588,,Canis lupus familiaris,1,4333,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL876028,,7422,Half-life in dogs; ND indicates not determined,9615.0,50588,,Canis lupus familiaris,1,4333,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL621561,,7423,Half-life in plasma of dog,9615.0,50588,,Canis lupus familiaris,1,12500,,,N,A
BAO_0000218,Intermediate,,,1,,Plasma,,1969.0,CHEMBL621562,,7424,Half-life in plasma of dog at dose of 3-10 mgkg,9615.0,50588,,Canis lupus familiaris,1,12500,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621563,,7425,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6005,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621564,,7426,Half-life was measured in dog after an iv dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,6062,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621565,,7427,Half-life was measured in dogs after an oral dose of 10 uM/kg,9615.0,50588,,Canis lupus familiaris,1,17650,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621566,,7428,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5530,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL621567,,7429,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,9615.0,50588,,Canis lupus familiaris,1,5530,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL622978,,7430,Half-life of the compound after 0.3 mg/kg po administration in dog,9615.0,50588,,Canis lupus familiaris,1,5600,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL873814,,7431,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,6039,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623219,,7432,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,6039,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624477,,7433,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,9615.0,50588,,Canis lupus familiaris,1,6039,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624478,,7434,t1/2 in dog,9615.0,50588,,Canis lupus familiaris,1,6227,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624479,,7435,Half-life period measured in dogs,9615.0,50588,,Canis lupus familiaris,1,14541,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624480,,7436,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,9615.0,50588,,Canis lupus familiaris,1,4521,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623595,,7437,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,9615.0,50588,,Canis lupus familiaris,1,4521,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623596,,7438,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,9615.0,50588,,Canis lupus familiaris,1,6679,,,N,A
BAO_0000218,Intermediate,In vitro,,1,,Plasma,,1969.0,CHEMBL623597,,7439,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",9615.0,50588,,Canis lupus familiaris,1,1116,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623598,,7440,In vivo half life period was calculated at 1 mg/kg in dog,9615.0,50588,,Canis lupus familiaris,1,5444,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623599,,7441,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,9615.0,50588,,Canis lupus familiaris,1,5444,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623600,,7442,Longer half-life in dog (i.v.) at 0.5 mpk,9615.0,50588,,Canis lupus familiaris,1,17853,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623601,,7443,Oral bioavailability in dog (dose 5 uM/kg),9615.0,50588,,Canis lupus familiaris,1,4353,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623602,,7444,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623603,,7445,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL623604,,7446,Bioavailability in dog (dose 1 mg/kg i.v.),9615.0,50588,,Canis lupus familiaris,1,16452,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL623605,,7447,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL623606,,7448,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL623607,,7449,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL623608,,7450,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL623609,,7451,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Lung,,2048.0,CHEMBL623610,,7452,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL623611,,7453,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL623612,,7454,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL623613,,7455,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL623614,,7456,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL623615,,7457,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL623616,,7458,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Muscle tissue,,2385.0,CHEMBL623617,,7459,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Zone of skin,,14.0,CHEMBL875944,,7460,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Zone of skin,,14.0,CHEMBL623618,,7461,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Zone of skin,,14.0,CHEMBL623619,,7462,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Zone of skin,,14.0,CHEMBL623620,,7463,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Zone of skin,,14.0,CHEMBL623621,,7464,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Zone of skin,,14.0,CHEMBL623622,,7465,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Zone of skin,,14.0,CHEMBL623623,,7466,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL623624,,7467,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL618521,,7468,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL618522,,7469,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL618523,,7470,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL618524,,7471,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL618525,,7472,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Spleen,,2106.0,CHEMBL624586,,7473,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL624587,,7474,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL624588,,7475,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL624589,,7476,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL624590,,7477,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL624591,,7478,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL624592,,7479,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Stomach,,945.0,CHEMBL624593,,7480,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,50594,,Mus musculus,1,10107,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624594,,7481,Oral bioavailability in rat,10116.0,50597,,Rattus norvegicus,1,4689,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624595,,7482,Tested for the bioavailability in rat,10116.0,50597,,Rattus norvegicus,1,4950,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624596,,7483,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),10116.0,50597,,Rattus norvegicus,1,5328,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624597,,7484,Bioavailability in rat,10116.0,50597,,Rattus norvegicus,1,406,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624598,,7485,Bioavailability in rat,10116.0,50597,,Rattus norvegicus,1,12500,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624599,,7486,Bioavailability in rat (dose 3-10 mg/kg),10116.0,50597,,Rattus norvegicus,1,12500,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL875166,,7487,Bioavailability in rat,10116.0,50597,,Rattus norvegicus,1,5247,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL624600,,7488,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,10116.0,50597,,Rattus norvegicus,1,4186,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL624601,,7489,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,10116.0,50597,,Rattus norvegicus,1,4186,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624602,,7490,Half life after oral administration was determined in rats at 6 mg/kg,10116.0,50597,,Rattus norvegicus,1,6647,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624603,,7491,Half life was determined,10116.0,50597,,Rattus norvegicus,1,6484,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,,,,CHEMBL624604,,7492,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,10116.0,50597,,Rattus norvegicus,1,3249,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Plasma,,1969.0,CHEMBL624605,,7493,Plasma half life in rat at oral dose 2.8 mg/mk body weight,10116.0,50597,,Rattus norvegicus,1,6281,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624606,,7494,Half life in rats,10116.0,50597,,Rattus norvegicus,1,3307,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL624607,,7495,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,10116.0,50597,,Rattus norvegicus,1,12058,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624608,,7496,Hill coefficient of the compound,10116.0,50597,,Rattus norvegicus,1,8833,,,N,A
BAO_0000218,Intermediate,,,1,,Blood,,178.0,CHEMBL624609,,7497,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,10116.0,50597,,Rattus norvegicus,1,3193,,,N,A
BAO_0000218,Intermediate,,,1,,Blood,,178.0,CHEMBL624610,,7498,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,10116.0,50597,,Rattus norvegicus,1,3193,,,N,A
BAO_0000218,Intermediate,,,1,,Blood,,178.0,CHEMBL624611,,7499,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,10116.0,50597,,Rattus norvegicus,1,3193,,,N,A
BAO_0000218,Intermediate,,,1,,Blood,,178.0,CHEMBL624612,,7500,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,10116.0,50597,,Rattus norvegicus,1,3193,,,N,A
BAO_0000218,Intermediate,,,1,,Blood,,178.0,CHEMBL875167,,7501,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,10116.0,50597,,Rattus norvegicus,1,3193,,,N,A
BAO_0000218,Intermediate,,,1,,Blood,,178.0,CHEMBL624613,,7502,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,10116.0,50597,,Rattus norvegicus,1,3193,,,N,A
BAO_0000218,Intermediate,,,1,,Blood,,178.0,CHEMBL624614,,7503,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",10116.0,50597,,Rattus norvegicus,1,3193,,,N,A
BAO_0000218,Intermediate,,,1,,,,,CHEMBL624392,,7504,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,10116.0,50597,,Rattus norvegicus,1,5960,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL624393,,7505,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,10116.0,50597,,Rattus norvegicus,1,13950,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL624394,,7506,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,10116.0,50597,,Rattus norvegicus,1,13950,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL624395,,7507,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,10116.0,50597,,Rattus norvegicus,1,13950,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL624396,,7508,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,10116.0,50597,,Rattus norvegicus,1,13950,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Brain,,955.0,CHEMBL624397,,7509,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,10116.0,50597,,Rattus norvegicus,1,13950,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Thyroid gland,,2046.0,CHEMBL624398,,7510,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,10116.0,50597,,Rattus norvegicus,1,13950,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Thyroid gland,,2046.0,CHEMBL624399,,7511,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,10116.0,50597,,Rattus norvegicus,1,13950,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Thyroid gland,,2046.0,CHEMBL624400,,7512,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,10116.0,50597,,Rattus norvegicus,1,13950,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Thyroid gland,,2046.0,CHEMBL624401,,7513,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,10116.0,50597,,Rattus norvegicus,1,13950,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Thyroid gland,,2046.0,CHEMBL624402,,7514,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,10116.0,50597,,Rattus norvegicus,1,13950,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL624403,,7515,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,10116.0,50597,,Rattus norvegicus,1,9866,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL624404,,7516,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,10116.0,50597,,Rattus norvegicus,1,9866,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Blood,,178.0,CHEMBL624405,,7517,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,10116.0,50597,,Rattus norvegicus,1,9866,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL624406,,7518,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,10116.0,50597,,Rattus norvegicus,1,9866,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL624407,,7519,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,10116.0,50597,,Rattus norvegicus,1,9866,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Bone,,10000001.0,CHEMBL624408,,7520,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,10116.0,50597,,Rattus norvegicus,1,9866,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL618644,,7521,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,10116.0,50597,,Rattus norvegicus,1,9866,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL618645,,7522,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,10116.0,50597,,Rattus norvegicus,1,9866,,,N,A
BAO_0000218,Intermediate,In vivo,,1,,Heart,,948.0,CHEMBL618646,,7523,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,10116.0,50597,,Rattus norvegicus,1,9866,,,N,A
